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Abstract 
The point of no return in the intrinsic apoptosis pathway is the loss of outer mitochondrial 
membrane integrity. Protein complexes, such as the PT-pore, have been implicated in 
mediating mitochondrial disintegration via the induction of mitochondrial permeability 
transition (MPT). My study provides evidence that the mitochondrial creatine kinase CKMT1 
is a key regulator of MPT through a complex distinct from the “classical” PT-pore. 
Overexpression of CKMT1 confers resistance against mitochondrial depolarization and 
apoptosis – an effect that is independent of its kinase activity. Furthermore, CKMT1 is a 
functionally necessary gatekeeper of MPT, as its depletion universally induces mitochondrial 
depolarization and apoptotic cell death in transformed and primary cells. This cannot be 
abrogated by the supplementation with phosphocreatine, the end product of the enzymatic 
reaction catalysed by CKMT1, but can efficiently be inhibited by bongkrekic acid – a 
pharmacological agent inhibiting mitochondrial membrane channels. My studies highlight 
that CKMT1 determines cellular fate and thus could be a promising therapeutic target as 
altered CKMT1 expression has been described in tumours and neurodegenerative disease. 
The second part of this thesis describes the intricate challenges of CKMT1 RNAi validation 
techniques and offers a detailed examination of the human CKMT1 locus. 
The third part addresses the effect of mitochondrial IκΒα in apoptosis. I reveal a 
fundamentally new function of the NF-κB target gene IκΒα, which is distinct from its well-
established NF-κB inhibition. It potently represses apoptosis when targeted specifically to 
the outer mitochondrial membrane where its N-terminus interacts with and its anti-apoptotic 
property depends on VDAC1. Therefore, IκΒα regulates the intricate balance of cell survival 
and cell death via contributing to canonical NF-κB signalling and the “classical” PT-pore, 
respectively. Considering that NF-κB dysregulation is a major culprit in disease formation, 
the biological implications of my results could be crucial in understanding and targeting the 
underlying pathological mechanisms. 
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List of Commonly Used Abbreviations 
aa : Amino Acid 
   
ADP  
:
  
Adenosine Diphosphate  
   
AIF  
:
  
Apoptosis Inducing Factor  
   
ANT  
:
  
Adenine Nucleotide Translocator  
   
APAF1  
:
  
Apoptotic Protease Activating Factor 1  
   
ATP  
:
  
Adenosine Triphosphate  
   
BA  
:
  
Bongkrekic Acid  
   
Bcl-2  
:
  
B-cell Lymphoma 2  
   
BclXL : B-cell Lymphoma-extra Large 
   
Bgal : Beta-galactosidase 
   
BH Domain  
:
  
Bcl-2 Homology Domain  
   
Bp  
:
  
Base Pairs  
   
BSA  
:
  
Bovine Serum Albumin  
   
CKMT1 : Mitochondrial Creatine Kinase 1 
   
CsA : Cyclosporin A 
   
CypD : Cyclophilin D 
   
CytC : Cytochrome C 
   
kDa : Kilo-Dalton 
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DAPI : 4,6-Diamidino-2-Phenylindole 
   
DIABLO : Direct IAP Binding Protein with Low PI 
   
DIDS : 4,4'-Diisothiocyanatostilbene-2,2'-disulfonate 
   
DiOC6 : 3,3-Dihexyloxacarbocyanine Iodide 
   
DMEM : Dulbecco’s Modified Eagle Medium 
   
DMSO : Dimethylsulfoxide 
   
EDTA : Ethylenediaminetetraacetic Acid 
   
EGTA : 
Ethylene Glycol-bis(2-aminoethylether)-N-N-N-N-tetraacetic 
acid 
   
ER : Endoplasmatic Reticulum 
   
FACS : Fluorescent Activated Cell Sorting 
   
FAS : TNF Receptor Superfamily, Member 6 
   
Gag : Group Antigen 
   
GFP : Green Fluorescent Protein 
   
HBS : HEPES Buffered Saline 
   
HEPES : 4-(2-Hydroexyethyl)-1-Piperazineethanesulfonic Acid 
   
HRP : Horse Radish Peroxidase 
   
ΙκBα : 
Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in 
B-cells Inhibitor 
   
ΙΚΚ : IκB kinase 
   
IMM : Inner Mitochondrial Membrane 
   
IMS : Inter-membrane Space 
   
IP : Immunoprecipitation 
   
JC1 : 
5,5’,6,6’-Tetrachloro-1,1’,3,3’ 
Tetraethylbenzimidazolylcarbocyanine Iodide 
   
MOMP : Mitochondrial Outer Membrane Permeabilisation  
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MPT : Mitochondrial Permeability Transition 
   
mRNA : Messenger RNA 
   
NF-κB  : 
Nuclear factor Kappa Light Chain Enhancer of Activated B 
Cells 
   
NLS : Nuclear Localisation Signal 
   
OMM : Outer Mitochondrial Membrane 
   
PAGE : Polyacrylamide Gel Electrophoresis  
   
PARP : Poly ADP-Ribose Polymerase 
   
PCD  Programmed Cell Death 
   
PCR : Polymerase Chain Reaction 
   
PI : Propidium Iodide 
   
Pol : Reverse Transcriptase 
   
PT-pore : Permeability Transition Pore 
   
PVDF : Polyvinylidene Difluoride 
   
Rev : Reverse Transcriptase 
   
RIP : Receptor Interaction Protein 
   
RNAi : RNA interference 
   
ROS : Reactive Oxygen Species 
   
RT : Room Temperature 
   
Sc : Scramble 
   
S.D. : Standard Deviation  
   
SDS : Sodium Dodecyl Sulfate 
   
SfA : Sanglifehrin A 
   
shRNA : Short Hairpin RNA 
   
Smac : Second Mitochondria Derived Activator of Caspase 
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STS : Staurosporine 
   
TMRE : TetraMethylRhodamine Ethyl Ester 
   
TNF : Tumour Necrosis Factor 
   
TRAIL : TNF-related Apoptosis Inducing Ligand 
   
VDAC : Voltage Dependent Anion Channel 
   
VSVG : Vesicular Stomatitis Virus Glycoprotein  
   
WT : Wild Type 
   
zVAD : Benzyloxycarbonyl-Val-Ala-Asp Fluoromethyl Ketone 
   
ΔΨm : Mitochondrial Electrochemical Proton Gradient 
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A. INTRODUCTION 
A.1 Cell Death 
Multicellular organisms depend on a dynamic interplay of cell growth and death for 
maintaining tissue integrity and establishing organ function. In order to achieve a 
relative state of equilibrium within their internal environment - commonly referred 
to as tissue homeostasis – living organisms depend on a plethora of tightly 
controlled homeostatic processes. These enable the organism to stabilize vital 
parameters and perform fundamental functions. In the context of multicellular 
organisms, the dynamic balance of the cellular turnover is achieved by processes, 
which add new cells to the system on the one hand, or result in cellular demise on 
the other hand. Based on morphological and biochemical criteria, three major 
distinct modes of cellular demise can be defined: apoptotic, necrotic and autophagic 
cell death(Kroemer, Galluzzi et al. 2009). 
 
A.1.1 Apoptotic, Necrotic and Autophagic Cell Death 
 
A.1.1.1 Apoptosis 
Apoptosis is an evolutionary conserved, precisely choreographed suicide mechanism 
of the cell occurring both in a physiological as well as a pathological setting. It plays 
a pivotal role in development(Brill, Torchinsky et al. 1999), immunity(Cohen, Duke 
et al. 1992) and in the maintenance of cellular homeostasis in multicellular 
organisms(Henson and Hume 2006). The morphological distinction between 
apoptotic and necrotic cell death was first described by Kerr et al.(Kerr, Wyllie et al. 
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1972) and is reviewed in a schematic representation in Fig.A.1. Accordingly, 
apoptosis is the route of programmed cell death (PCD) that is accompanied by the 
rounding-up of the cell, retraction of pseudopodia, reduction of the cellular volume 
(pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and 
plasma membrane blebbing (Fig.A.2 and Fig.A.3). Classically, little or no 
ultrastructural modifications of cytoplasmic organelles can be observed. Apoptosis 
results in the fragmentation of the cell into compact membrane-enclosed structures. 
These so-called ‘apoptotic bodies’ are rapidly phagocytosed by neighbouring or 
recruited cells and thus are removed from the tissue without causing an 
inflammatory response. 
Biochemically, apoptosis is characterized by distinct energy-dependent mechanisms. 
including protein cleavage, perturbance of mitochondrial function, DNA breakdown, 
and signals for phagocytic recognition(Elmore 2007). The mitochondrial membrane 
potential and the integrity of mitochondrial architecture is lost, leading to the shut-
down of ATP (adenosine triphosphate) production and the rupture of the outer 
mitochondrial membrane. This, in turn, releases proapoptotic factors from the 
mitochondrial intermembrane space and activates a cascade of inducer and effector 
proteases. A family of cysteine-dependent aspartate directed proteases, so-called 
Caspases, is – once activated – responsible for the proteolytic cleavage of diverse 
cellular substrates(Martin and Green 1995). Another feature of apoptosis is an 
increase in the cytoplasmic calcium concentration (Fig.A.4). 
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Fig.A.1: Schematic Representation of Apoptosis and Necrosis. A) The two 
fundamental pathways of cell death as described by Kerr et al. 1972. B) Transmission 
electron microscopy of necrotic and apoptotic cells. B1) Necrotic cell undergoing organelle 
swelling, cell lysis and release of intracellular contents into the surrounding environment. 
B2) Apoptotic cell with diverse membrane enclosed vesicles. B3) Engulfment of an 
apoptotic cell for clearing (Microscopic pictures were taken from the thesis Dr. A-L Mahul-
Mellier). 
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Fig.A.2: Transmission Electron Micrograph of 
Thymus Lymphocytes. 2A) Normal thymic tissue with 
closely packed lymphocytes displays large nuclei and 
scant cytoplasm. 2B) Early apoptotic thymic lymphocytes 
showing irregular cellular outline and condensed 
chromatin; the arrow indicates a fragmented part of the 
nucleus and the arrowhead marks an apoptotic body. 2C) 
The arrow indicates a late apoptotic lymphocyte in the 
process of extrusion of membrane-bound cytoplasm 
(“budding”). Once detached, this will form an apoptotic 
body which can subsequently be engulfed and cleared by 
surrounding cells or infiltrating phagocytic cells. 2D) 
Section of the thymus showing lymphocytes in various 
stages of apoptosis, e.g. late stage of apoptosis 
displaying nuclear fragmentation (arrowhead). The centre 
of the picture shows a macrophage which has engulfed 
several apoptotic bodies for phagocytic clearance. 
Pictures were taken from (Elmore 2007). 
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Fig.A.3: Morphological Features of Apoptosis Visualized by Time Lapse 
Fluorescence Microscopy. HeLa cells expressing GFP were captured over a time 
period of 8 hours. Cells undergoing spontaneous apoptosis are shown in the series 
above: Normal cells (top left) show a uniform cytoplasmic GFP signal. Apoptosis 
induction results in the gradual formation of discrete spherical structures, which 
reflects the retraction of pseudopodia, reduction of cellular volume and the formation 
of membrane blebs and apoptotic bodies (middle panel). Eventually, cells round up 
and lose anchorage (lower panel). Pictures were taken in collaboration with Dr. R. 
Iwasawa and Dr. B. Lin. 
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A) 
B) C) 
Fig.A.4: Biochemical Features of Apoptosis – Increase of Cytosolic Calcium 
Concentration and Caspase Activation. A) HeLa were transfected with the 
cytosolic calcium indicator YC3.6 and treated with doxorubicin. Staining with 
CaspaTag caspase 3/7 sulforhodamine was used to visualise the activation of 
Caspases 3 and 7 and time lapse fluorescence images were acquired using a Leica 
confocal microscope. The panels on the top show apoptosis results in an increase of 
the cytosolic calcium concentration as indicated by the increase in green fluorescence 
and the quantitative histogram below (B) and subsequent activation of caspases as 
indicated by the increase in red staining and quantitative histogram below (C). 
Images were taken in collaboration with Dr. R. Iwasawa. 
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Another biochemical feature of apoptotic cells is the expression of cell surface 
markers that flag up the cell for phagocytic recognition by adjacent cells or for 
clearance through phagocytes. One of the best studied processes in this regard is 
the externalisation of phosphatidylserine, i.e. the normally inwardly facing 
phosphatidylserine of the cell’s lipid bilayer is transferred to the outer layer of the 
plasma membrane(Bratton, Fadok et al. 1997). Other apoptosis-induced surface 
molecules that demark the cell for phagocytic engulfment include Annexin I(Arur, 
Uche et al. 2003; Lim and Pervaiz 2007) and Calreticulin(Gardai, McPhillips et al. 
2005). Biochemical and morphological features of apoptosis are summarized in 
Table A.1. 
 
Table A.1: Morphological and Biochemical Features of Apoptosis. 
Morphological Features Biochemical Features 
Cell shrinkage Free [Ca
+2
]
c 
 rise 
Chromatin condensation DNA degradation 
Nuclear fragmentation Caspase activation 
Membrane blebbing  Loss of mitochondrial membrane potential 
Cell detachment Phosphatidylserine externalisation 
Production of apoptotic bodies 
 
Phagocytosis of cell corpses 
 
  
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |30 
 
As mentioned above, apoptosis is a crucial process for development, immunity, and 
the maintenance of cellular homeostasis in multicellular organisms. During 
development, many cells are produced in excess and their controlled removal 
through apoptosis contributes to organogenesis and tissue architecture(Meier, Finch 
et al. 2000). The most classical example of morphogenic apoptosis during 
development is the removal of the excess interdigital webs during hand formation; 
however, apoptosis is also crucially involved in the development of the neuronal 
networks of the central and peripheral nervous system by selective attrition of 
unnecessary neurons. Failure in the execution of apoptosis during development 
causes fatality in severe cases or birth defects in less severe cases, for example 
syndactyly, i.e. the condition where two or more digits are fused together(Malik 
2012). 
Another example illustrating the fundamental importance of apoptosis in adult 
vertebrae is the immune system(Pinkoski, Waterhouse et al. 2006): Immune cells, 
in particular lymphocytes need to respond to an innumerable repertoire of foreign 
antigens yet tolerate auto-antigens. Apoptosis, in this scenario, serves two main 
functions – first, the negative selection of totally non-reactive leukocyte precursors 
and second, the negative selection of thymocytes that show reactivity against 
antigens of the own body, i.e. lymphocytes displaying auto-reactivity in the thymus 
are induced to undergo apoptosis in order to prevent auto-immunity. Physiological 
levels of apoptosis are also required for maintaining the stability in cell number and 
architecture in dynamic tissues, as well as re-establishing these upon injury through 
tissue repair. Tissue healing involves a series of fast changes in cell populations 
responsible for wound repair, the deposition of new matrices and the maturation of 
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the wound. As progression to the next phase of healing depends on the elimination 
of specific cell types, apoptosis eliminates these populations without causing further 
tissue damage or an inflammatory response(Greenhalgh 1998). Furthermore, 
apoptotic cell death eliminates cells that impose a potential threat to the organism. 
Virally infected cells, supernumerary, misplaced cells or damaged cells (e.g. DNA 
damage) can be induced to undergo apoptosis(Norbury and Hickson 2001) – the 
defect cells are eliminated in order to ensure the survival and functioning of the 
“normal” cells. 
These examples demonstrate how vital a precisely tuned apoptosis regulation is for 
the living organism. Consequently, the dysregulation of apoptosis is associated with 
the pathogenesis of a wide array of diseases(Hetts 1998): excessive apoptosis can 
be causally linked to neurodegeneration as the gradual loss of neuronal subtypes 
from the central nervous system is the hallmark of a variety of neurodegenerative 
disorders including Parkinson disease, Alzheimer disease, spinal muscular atrophy 
and amyotrophic lateral sclerosis(Thompson 1995). Excessive molecular mediators 
of apoptosis have also been found in the failing human heart raising the hypothesis 
that excessive apoptosis could be causally linked to heart disease. Excessive 
apoptosis of certain cell types can also result in the progression of infectious 
disease, e.g. the acquired immunodeficiency syndrome (AIDS) through inevitable 
apoptosis of CD4T cells infected with the Human Immunodeficiency Virus 
(HIV)(Cummins and Badley 2010). As opposed to apoptosis excesses, apoptosis 
deficiencies can lead to autoimmunity, graft rejection or cancer (cancer formation 
and progression in the context of apoptosis will be discussed separately in the next 
chapter). Autoimmunity results from the lack of negative selection of immune cells 
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in the thymus, i.e. a lack of apoptosis induction cells that are reactive against auto-
antigens. Allografts (tissue transplants from a genetically non-identical person) and 
xenografts (tissue transplants from another species) are usually recognised by the 
host’s immune system and eliminated via induction of apoptosis. 
 
Considering the fundamental importance of apoptosis for the organism, genes and 
gene products involved in the regulation and execution of apoptosis are potentially 
excellent targets for diagnosis of and therapeutic intervention against a wide range 
of disease states. Therapeutic intervention can be targeted at both, reinstating the 
defective apoptotic programme on the one hand, or suppression of excessive 
apoptosis in order to restore functionality on the other hand. 
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A.1.1.2 Necrosis 
In contrast to apoptotic cell death, necrosis is often described as a passive process 
that occurs as a result of acute, non-physiological injury. Morphologically, necrosis 
is characterized by an increase in cell volume (oncosis), swelling of organelles, 
plasma membrane rupture and subsequent release of intracellular contents into the 
extracellular milieu. This results in the damage of surrounding cells and a strong 
inflammatory response in the corresponding tissue(Leist and Jaattela 2001).  
As describe above, necrotic cell death is induced by extreme external factors, e.g. 
temperature extremes, poisons or mechanical injury. Affected cells can be described 
as passive victims that follow an energy-independent and uncontrolled mode of 
death. Functionally, necrosis is generally considered as a pathological uncontrolled 
type of cell death. However, recent studies(Festjens, Vanden Berghe et al. 2006; 
Golstein and Kroemer 2007) point to the possibility that the execution of necrotic 
cell death might also be regulated by cellular signal transduction pathways.  
Although the cell death modalities of apoptosis and necrosis as outlined above 
appear to be totally distinct, this distinction has been questioned by introducing the 
term “apoptosis-necrosis continuum”(Zeiss 2003). Accordingly, typical apoptosis 
and necrosis are two extremes, while the real situation is more complex: Necrosis 
and apoptosis are distinct morphologic modalities of partly shared biochemical 
networks; and apoptotic stimuli can be converted into necrotic processes by 
changing the physiologic milieu. For example, decreasing the availability of caspases 
or intracellular ATP can transform an apoptotic process into necrosis(Denecker, 
Vercammen et al. 2001). While these experiments link apotosis and necrosis, it has 
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yet to be established whether such conversions could occur within physiological 
settings. 
In conclusion, the mode of cell death is determined in part by the nature and 
strength of the death stimulus, the tissue type, the developmental stage of the 
tissue, and the surrounding environment. 
 
 
A.1.1.3 Autophagy 
The third type of cell death, termed autophagy, is characterized by the 
sequestration of cytoplasmic material within autophagosomes and subsequent 
degradation by lysosomes(Levine and Klionsky 2004; Baehrecke 2005; Levine and 
Kroemer 2008); this process can be described as an act of self-cannibalization. 
Autophagic vacuolization occurs in response to nutritional starvation and stress 
conditions in which the degradation of intracellular organelles and proteins provides 
a source of amino acids, nucleotides and fatty acids(Levine and Yuan 2005). During 
autophagy, vesicular compartments invaginate and sequester cytoplasmatic 
organelles including mitochondria, endoplasmic reticulum and ribosomes. These 
autophagosomes fuse with the lysosome (in mammalian cells) or the vacuole (in 
yeast and plant cells) in order to degrade and recycle the sequestered material. All 
cells show a low basal level of autophagy, which is necessary to perform 
homeostatic functions; however, this autophagy is massively upregulated during 
starvation or trophic factor withdrawal, architectural changes (e.g. developmental 
processes) or the turnover of damaged cytoplasmic organelles (e.g. during oxidative 
stress or infections). In contrast to necrosis, and similar to apoptosis, autophagic 
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cell death does not result in the induction of a tissue inflammatory response; 
ultrastructural examples of cells undergoing autophagy or apoptosis are depicted in 
Fig.A.5. In contrast to apoptosis, DNA fragmentation and caspase activation are 
only detected in very late (if at all) stages of autophagy. 
One controversially discussed question is whether autophagy is a death execution 
mechanism or whether autophagic activity in dying cells is actually a survival 
strategy intended to prevent cell death(Tsujimoto and Shimizu 2005): On the one 
hand it seems logical that excessive autophagy leads to cell death, but there is 
accumulating evidence from genetic knock-out models that limited autophagy also 
plays a prominent role as a pro-survival pathway: suppression of autophagy by 
knock-out of essential autophagy genes in fact did in some cases not inhibit cell 
death, but rather accelerated its pace(Galluzzi, Vicencio et al. 2008). Accordingly, 
RNA interference (RNAi) against the crucial autophagy-mediating genes beclin1, 
atg5, atg10 and atg12 enhanced starvation-induced cell death in HeLa cells(Boya, 
Gonzalez-Polo et al. 2005). Presumably, the autolysosomal degradation of 
cytoplasmic constituents provides fatty acids and amino acids that can be recycled 
to fuel ATP energy production within mitochondria and ribosomal protein synthesis, 
thus sustaining life during starvation. 
However, there is also evidence supporting the theory that autophagy is a mode of 
cell death execution: Pharmacologic inhibition of autophagy partially inhibits cell 
death in a variety of settings, e.g. the in anti-estrogen treated human mammary 
carcinoma cells(Bursch, Ellinger et al. 1996) or in nerve growth deprived 
sympathetic neurons(Xue, Fletcher et al. 1999). And genetic inhibiton of autophagy 
by RNAi against autophagy genes including atg7, atg5 and beclin1(Yu, Alva et al. 
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2004) blocked cell death under certain circumstances (inhibition of normal apoptotic 
pathways). 
 
 
 
The subsequent parts of this thesis focus on apoptotic cell death, its significance in 
cancer research and its functional key players. Special attention will be given to 
aspects of apoptosis that connect molecular signalling pathways to clinical disease, 
especially cancer. 
  
Fig.A.5: Ultrastructural Examples of Apoptotic and Autophagic Cell Death. 
Transmission electron micrographs of FasL-treated Jurkat cells undergoing apoptotic 
cell death (A) and MCF7 human breast carcinoma cell line undergoing cell death with 
autophagic features after treatment with tamoxifen (B). Apoptosis in this micrograph 
is characterized by chromatin condensation and cytoplasmic vacuolization, whereas 
numerous autophagosomes are present. Pictures are taken from(Levine and Yuan 
2005). 
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A.1.2 Apoptosis and Cancer 
Cancer is a disease that results from the aberrant uncontrolled accumulation of 
atypical cells. Until recently, models of tumour formation and progression mainly 
focussed on the role of excess proliferation in neoplastic diseases. While it holds 
true that tumour development partly relies on an aberrant proliferation of cells, 
insufficient apoptosis or a combination of both are equally detrimental(Hetts 1998). 
And in fact, defects in the programmed suicide machinery of the cell characterize all 
tumours and are relevant for malignant transformation, tumour formation, tumour 
progression and therapeutic outcome(Cotter 2009). Hanahan and 
Weinberg(Hanahan and Weinberg 2000) described certain acquired characteristics 
(‘hallmarks’) that provide cancer cells with a survival and growth advantage during 
tumourigenesis (Fig.A.6). According to them, acquired resistance towards apoptosis 
induction is a major hallmark of most or probably all types of cancer. The ability of 
cells to evade apoptosis arises from the dysregulation of both, the cellular 
machinery involved in sensing relevant intracellular and extracellular stimuli as well 
as the signalling pathways involved in the actual execution of apoptosis. For 
example, one molecule that has been the topic of extensive investigations in this 
context is p53. The tumor suppressor protein p53 has been shown to be critical for 
the pathogenesis of cancer, the aggressiveness of the tumours as well as their 
likelihood of resistance to conventional anti-proliferative chemotherapy(Fisher 1994; 
Levine 1997). Accordingly, mutations in the p53 gene are occurring in 
approximately 55% to 70% of human cancers(Levine and Oren 2009). 
Physiologically, p53 and its modulator mdm2 (murine double minute) are 
responsible for inducing cell cycle arrest in response to DNA damage and activate 
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DNA repair functions. Thus, mutations in p53 lead to genomic instability and 
inefficient cell cycle arrest in response to DNA damage. p53 acts as a transcription 
factor and activates the expression of diverse apoptosis-inducing genes. These 
include the expression of genes generating free radicals or the upregulation of pro-
apoptotic Bcl-2 family members(Polyak, Xia et al. 1997) and thus result in apoptosis 
induction via the mitochondrial pathway (see chapter A.2.2 for a detailed description 
of the mitochondrial apoptosis pathway). Transcription-independent mechanisms of 
apoptosis induction by p53 have also been described, such as the induction of outer 
mitochondrial membrane permeabilisation by forming complexes with the protective 
Bcl-2 family proteins(Mihara, Erster et al. 2003). Another discovery linking 
dysregulated apoptosis induction to cancer formation is the ability of diverse 
oncogenes, such as Bcl-2 or Myc(Strasser, Harris et al. 1990), to inhibit apoptosis. 
 
In conclusion, the inherent blockade of cell death programs (required for 
oncogenesis and tumour progression) on the one hand, and the therapeutic need of 
reactivating such programs on the other hand, presents a formidable challenge in 
clinical oncology(Thompson 1995). Mutations in genes directly or indirectly involved 
in reducing apoptosis are correlated with poor prognosis as the effectiveness of 
most anti-neoplastic agents relies on triggering apoptosis in cancer cells: For 
example, the anti-tumour compounds 5-fluorouracil(Armstrong, Isaacs et al. 1992), 
cis-platin(Barry, Behnke et al. 1990; Eastman 1990) and etoposide(Kaufmann 
1989; Walker, Smith et al. 1991), exert their therapeutic effect by inducing 
apoptosis in cancer cells(Mow, Blajeski et al. 2001). This also implies that during 
anti-cancer treatment, tumour cells potentially get selected for repressing the 
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apoptosis program. This selection results in acquired chemotherapy resistance, 
which poses a huge challenge in the clinical management of drug-resistant recurrent 
disease(Pommier, Sordet et al. 2004). Thus, the elucidation of the role of molecular 
players of apoptosis, the signalling pathways involved and the understanding of 
their mechanism of action can be harnessed for improving the efficacy of cancer 
therapy in diverse stages of the clinical presentation. 
 
 
  
Fig.A.6: Acquired Characteristics of 
Tumour Cells. The key characteristics 
allowing cells to form a tumour 
comprise self-sufficiency in growth 
signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, 
limitless replicative potential, sustained 
angiogenesis and evading apoptosis. 
Cancer cells acquire these 
characteristics during tumourigenesis 
and tumour progression; figure after 
(Hanahan and Weinberg 2000). 
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A.2 Apoptotic Pathways 
Apoptosis can be induced via two main routes involving either the activation of 
death receptors on the cell surface (the extrinsic pathway)(Ashkenazi and Dixit 
1998) or the mitochondria (the intrinsic pathway)(Green and Reed 1998). These 
two principal pathways of apoptosis induction are illustrated in Fig.A.7 and 
introduced separately in the following chapters. 
 
Both pathways involve signalling cascades that can be divided into an initiation 
phase, an integration phase, and a cell death execution phase. While the initiation 
phase and the integration phase are highly variable comparing these two pathways, 
the execution pathway is overlapping. In essence, the extrinsic apoptotic pathway is 
triggered by an external ligand binding to its cognate death receptor on the surface 
of the cell and subsequent formation of an intracellular signalling complex. As 
opposed to an external signal, the damage of an intracellular organelle (e.g. 
nucleus, endoplasmic reticulum, lysosome, Golgi apparatus or mitochondria) 
initiates the intrinsic apoptosis pathway, which is mediated in a mitochondria-
dependent manner. The integration phase involves the processing of the stimulus 
and a complex signalling machinery is responsible for deciding whether the so-called 
“point of no return” for cell death commitment is reached. 
Ultimately, both pathways converge in the execution phase by activating proteases 
called ‘caspases’. These proteases are the final executioners of cell death by 
proteolytic cleavage of diverse vital cellular substrates including nuclear 
lamins(Lazebnik, Takahashi et al. 1995), DNA repair enzymes such as PARP (poly-
ADP-ribose-polymerase)(Lazebnik, Kaufmann et al. 1994) and cytoskeletal 
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proteins(Mashima, Naito et al. 1995). However, it should be noted that caspase-
independent forms of apoptosis have been reported as well(Leist and Jaattela 
2001).  
Fig.A.7: Two Principal Pathways of Apoptotic Cell Death: Death Receptor and 
Mitochondria-mediated Apoptosis. Apoptosis can be induced by external stimuli such as 
inflammation, withdrawal of growth factors, or drugs. These signals can eventually cause 
binding of specific ligands to death receptors. The downstream signal transduction pathway 
involves the formation of a death-inducing signal complex (DISC) consisting of Fas, FADD 
(Fas-associated death domain), and Procaspase 8. Consequently, active Caspase 8 is 
generated by autocatalytic proteolytic processing and can in turn activate Procaspase 3. 
Caspase 8 can also cleave Bid to tBid, which leads to mitochondrial release of proapoptotic 
peptides such as Cytochrome c, AIF (Apoptosis inducing factor), Endonuclease G, 
Smac/Diablo (second mitochondria-derived activator of caspases/direct IAP-associated 
binding protein with low pI) and Omi/HtrA2 (high temperature requirement A2). Internal 
stimuli emanating from cellular damage sensors (e.g. p53) or developmental stimuli activate 
mitochondrial apoptosis. The key event in mitochondrial apoptosis is the rupture of the outer 
mitochondrial membrane and the subsequent release of proapoptotic proteins into the 
cytoplasm. This activates Procaspase 3, which results in the final execution of apoptosis. 
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A.2.1 The Extrinsic Apoptosis Pathway 
The extrinsic pathway is activated when a pro-apoptotic ligand binds to a “death 
receptor”. Death receptors are plasma membrane proteins belonging to the TNF 
(tumour necrosis factor) receptor superfamily, which trigger apoptosis upon ligand 
binding. The death receptor gene family consist of over 20 proteins and regulates a 
wide range of biological functions including cell death and survival, differentiation or 
immune regulation(Walczak and Krammer 2000; Ashkenazi 2002). Members of the 
TNF receptor family are characterized by cysteine-rich extracellular domains and a 
conserved cytoplasmic domain of about 80 amino acid – the “death domain” (DD), 
which integrates the death signal from the surface of the cell to elicit an intracellular 
signalling pathway. Although the focus in this thesis will be placed on apoptosis 
pathways, it is important to note that signalling through the TNF receptor family can 
trigger signalling cascades leading to both, cell death or a pro-survival response. 
Among the best characterized death receptors are Fas(Dhein, Walczak et al. 1995), 
TNF receptor 1(Tartaglia, Rothe et al. 1993), TRAMP(Kitson, Raven et al. 1996; 
Bodmer, Burns et al. 1997) and TRAIL receptor 1 and 2(MacFarlane, Ahmad et al. 
1997; Pan, O'Rourke et al. 1997). Their cognate death receptor ligands are 
expressed as transmembrane proteins displayed on the cell surface, but can be 
released into the extracellular milieu to function as soluble cytokines upon cleavage 
by metalloproteases. Association of the ligand (Fas, TNFα, lymphotoxin, Tweak and 
Trail) with the respective receptor initiates the trimerization of receptor-ligand 
complexes. The resulting conformational change of the intracellular domain reveals 
the intracellular “death domain”, allows for the binding of adaptor proteins (e.g. 
FADD - Fas-associated death domain) and the recruitment of pro-caspase 8. Once 
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assembled, this so-called “death receptor induced signaling complex” (DISC) 
initiates apoptosis by activating Caspase 8 via autoproteolytic processing(Smith, 
Farrah et al. 1994; Boldin, Mett et al. 1995; Chinnaiyan, O'Rourke et al. 1995; 
Ashkenazi and Dixit 1998; Thorburn 2004). Caspase 8 in turn proteolytically actives 
the downstream cascade of effector caspases including Caspase 3, 6 and 7. 
 
 
A.2.1.1 The TNF Receptor-Mediated Extrinsic Apoptosis Pathway 
The TNF receptor mediated extrinsic apoptosis pathway is initiated by an external 
ligand, either TNFα or TNFβ (also known as lymphotoxin) binding to the death 
receptors TNF Receptor 1 (TNFR1) or TNF Receptor 2 (TNFR2) on the plasma 
membrane. TNFR1 is widely expressed in all human tissues and is the main receptor 
for TNFα, whereas TNFR2 expression is mostly restricted to cells of the immune 
system and binds to both, TNFα and TNFβ. 
TNFα is a pleiotropic proinflammatory cytokine involved in various physiological and 
pathological processes including cell proliferation, differentiation, apoptosis, 
modulation of immune responses and inflammation(Baud and Karin 2001). In the 
human body, it is produced by diverse cell types such as macrophages, 
lymphocytes, fibroblasts or keratinocytes, mostly in response to environmental 
stresses, e.g infections. As mentioned above, it exerts its function by binding to 
TNFR1 and TNFR2 to activate multiple downstream signalling pathways that are 
either pro-apoptotic or pro-survival(Gupta 2001). TNFR1 contains the DD in the 
cytoplasmic tail of the transmembrane protein, whereas TNFR2 lacks this domain 
and thus primarily mediates a cell survival signal. 
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Upon binding of TNFα, TNFR1 trimerizes, which brings the intracellular DD domains 
in close proximity and facilitates the recruitment of an adapter protein - TNFR-
associated death domain (TRADD), which in turn recruits other adapter molecules. 
Following the binding of TRADD to TNFR1 complex, the set of recruited adapter 
proteins and subsequent complex formation determines the activation of several 
downstream signalling cascades(Micheau and Tschopp 2003). Thus, TNFR1 ligation 
can result in cell survival or cell death; however the exact mechanism determining 
these two opposing responses is not fully understood. The current model suggests 
that the contribution of 2 distinct signalling complexes and their downstream 
effectors determines the outcome: An initial plasma membrane bound multiprotein 
complex termed “complex I” results in pro-survival signalling mainly through MAP 
(Mitogen-activated protein) kinase pathway activation and NF-κB pathway 
activation(Baud and Karin 2001). Secondary recruitment of a different subset of 
adapter proteins results in the formation of a cytoplasmic complex, the so-called 
“complex II”, which induces a signalling cascade resulting in cell death 
induction(Micheau and Tschopp 2003). 
 
Survival and Activation Signalling Through TNFR1 Complex I 
TNFα induces a survival and activation signal, which involves signalling through a 
specific set of adapter proteins and transcription factors. In this scenario, the DD of 
TRADD recruits the receptor interaction protein 1 (RIP1) and the TNF receptor 
associated factor 2 (TRAF2)(Hsu, Shu et al. 1996; Chen and Goeddel 2002). The 
resulting protein complex is usually referred to as “complex I” and can elicit 3 
different responses: One signalling pathway involves the activation of the MAP 
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kinase pathway via recruitment and activation of c-Jun N-terminal kinase 
(JNK)(Papa, Zazzeroni et al. 2004). Activated JNK translocates to the nucleus to 
activate diverse transcription factors such as c-Jun or ATF2 (Activating transcription 
factor 2) through phosphorylation. These transcription factors control the expression 
of diverse genes, including c-IAP (Inhibitor of Apoptosis) and c-FLIP (cellular FLICE-
like inhibitory protein), thus counteracting the induction of apoptosis(Karin and Lin 
2002). The canonical pathway of complex I signalling is the activation of the 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells). NF-κB is usually maintained in the cytosol by binding of its inhibitor IκBα 
(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha), 
but can be activated by TNF signalling via complex I. This is mediatied by Traf2 and 
RIP1 recruiting IκBα kinases (usually a heterodimer of IKKalpha and IKKbeta), TAK1 
(Transforming growth factor beta-activated kinase 1) (Blonska, Shambharkar et al. 
2005) and the regulatory protein NEMO (NF-kappa-B essential modulator) to the 
TNFR1 signalling complex. IκBα kinases phosphorylate certain serine residues of 
IκBα. This leads to its ubiquitination and rapid proteasomal degradation of IκBα, 
thus releasing the heterodimer of NF-κB (p55 and p65), allowing for its 
translocation to the nucleus and the transcriptional activation of prosurvival genes 
such as Bcl-2, cFLIP and cIAPs (Inhibitors or Apoptosis)(Liu 2005). 
The third signalling pathway activated through complex I involves the recruitment of 
RIP1-associated ICH-1/CED-3 homologous protein with death domain (RAIDD) via 
RIP. RAIDD contains a caspase activation and recruitment domain (CARD), which 
activates initiator pro-caspase 2 to form mature caspase 2(Ahmad, Srinivasula et al. 
1997; Duan and Dixit 1997) and initiates the induction of apoptotic cell death.  
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Pro-apoptotic Signalling Through TNFR1 Complex II 
As mentioned before, TNFR1 trimerizes upon TNFα binding, which brings the 
intracellular DD domains in close proximity and facilitates the recruitment the 
adapter protein (TRADD) and subsequent complex I formation. Complex I is 
detached from the TNFR1 in a RIP dependent manner, which allows for the 
recruitment of another adapter protein via the DD of RIP, namely the Fas-associated 
death domain (FADD)(Micheau and Tschopp 2003). Binding of TRADD and FADD to 
the TNFR1 initiates the recruitment of procaspase-8 by protein-protein interaction 
via the homologous death effector domain (DED) and formation of the death 
inducing signal complex (DISC). The resulting complex of TNFR1, TRADD, FADD and 
procaspases-8 is known as “complex II”. During DISC assembly, pro-caspase 8 
oligomerizes and is auto-proteolytically cleaved to produce active caspase 8. Active 
caspase 8 leaves the DISC complex to enzymatically activate downstream effector 
caspases in the cytoplasm. In certain cell types, caspase 8, once activated by the 
extrinsic pathway, cleaves Bid (BH3 interacting domain death agonist). Truncated 
Bid signals to the mitochondria and leads to the disruption of the outer 
mitochondrial membrane and release of pro-apoptotic factors, thereby linking the 
extrinsic to the intrinsic apoptosis pathway and amplifying the apoptosis signal (see 
chapter A.2.3 for more details)(Luo, Budihardjo et al. 1998). In the absence of 
TNFα, the pro-apoptotic signalling of TNFR1 is regulated by binding of Silencer of 
DD (SODD), which inhibits adaptor protein recruitment and caspase activation. 
However, upon TNFα binding, SODD is rapidly dissociated, thus exposing the DD 
domain and allowing for the formation of the DISC. Another important negative 
regulator of this pro-apoptotic signalling pathway is FLIP (Flice-inhibitory protein, 
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Casper, CASH, and MRIT), which exerts its function via binding to the DED domain 
of FADD and inhibition of initiator caspases(Irmler, Thome et al. 1997). FLIP also 
activates the pro-survival signalling of TNF receptors via recruitment of adapter 
proteins involved in cell survival signalling, thus leading NF-κB activation and Map 
kinase signalling(Kataoka, Budd et al. 2000). 
Conversion of complex I into complex II or the lack thereof determines the cellular 
response to TNFα stimulation. Amongst other proteins, this conversion is largely 
determined by proteins called cIAPS (cellular inhibitor of apoptosis); these 
determine the ubiquitination status of RIP1 by acting as E3 ubiquitin 
ligases(Bertrand, Milutinovic et al. 2008). Especially linear ubiquitination of RIP1 at 
residue K63 has been shown to favour activation of the canonical NF-κB survival 
pathway by recruitment of proteins including HOIL1/HOIP, kinase complexes 
TAK1/TAB2/TAB3 and IKKα/IKKβ/NEMO(Bianchi and Meier 2009). In support of this 
regulation model, loss of cIAPs impairs the conversion of complex I into complex II 
and thus impairs NF-κB activation and sensitizes cells for apoptosis by enhancing 
formation of caspase 8 activating complex I upon TNFα treatment(Mahoney, Cheung 
et al. 2008). 
Interestingly, research contributions to another project conducted during my PhD 
studies revealed that ubiquitin-specific protease USP2a is a component of the TNFR1 
complex and deubiquitinates RIP1 and TRAF2. Therefore, also USP2a has a pivotal 
role in the conversion of complex I into complex II and hence the decision for cell 
death over survival (Mahul-Mellier, Pazarentzos et al. 2011). 
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TNFα has also been shown to induce caspase-independent programmed necrosis 
(Necroptosis). This is based on the discovery that cells lacking FADD or caspase 8 
still undergo cell death upon treatment with death cytokines (TNFα, FasL and 
TRAIL); similarly, wild type cells also undergo necrosis when caspases are blocked 
using the pan-caspase inhibitor zVAD-fmk (benzyloxycarbonyl-Val-Ala-Asp 
fluoromethyl ketone)(Holler, Zaru et al. 2000). The kinase activity of RIP1 seems to 
be crucial in this context as demonstrated by reconstitution experiments with kinase 
inactive RIP1(Chan, Shisler et al. 2003); and necrostatin, a selective inhibitor of 
RIP1, can abrogate TNFα induced programmed necrosis(Degterev, Hitomi et al. 
2008). Another TNFR1-interacting protein recently identified to be crucial for 
necroptosis is RIP3 (receptor-interacting protein 3)(He, Wang et al. 2009). These 
results indicate that TNFα causes apoptosis in a caspase-dependent manner while 
under experimental settings that abrogate caspase activation, cells undergo 
programmed necrosis. 
 
Signalling Through TNFR2 
TNFR2 (also known as p75 and TNFRSF1B) is the receptor for TNFβ, but can also 
ligate to TNFα(Baud and Karin 2001). As mentioned before, the expression pattern 
of TNFR1 and TNFR2 differ significantly, with TNFR2 being found on certain 
subpopulations of immune cells such as activated T lymphocytes (CD4 and CD8 
cells)(Ware, Crowe et al. 1991), thymocytes(Grell, Becke et al. 1998) and B 
cells(Gehr, Gentz et al. 1992), as well as endothelial cells, osteoblasts, microglia 
and some neuronal subtypes, oligodendrocytes and cardiac myoctes(Faustman and 
Davis 2010). Both, TNFα and TNFβ, which is produced by activated lymphocytes, 
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result in TNFR2 trimerization and signalling induction. Generally speaking, TNFR2 
stimulation results in direct recruitment of TRAF2 and TRAF1 and activation and 
subsequent mobilization and nuclear translocation of NF-κB to promote transcription 
of diverse genes including pro-survival genes, adhesion molecules and cell 
activation genes(Rothe, Sarma et al. 1995; Beltinger, White et al. 1996). 
Accordingly, its activation triggers the proliferation of cytotoxic T cells, thymocytes 
and B cells, or is responsible of protection and survival of neuronal cells(Faustman 
and Davis 2010). Although TNFR2 signalling for long has been described as merely 
pro-survival as it does not have a cytosolic death domain, newer research indicates 
that there is some degree of TNFR1/TNFR2 crosstalk and overlapping function: TNF 
binding to TNFR2 has been shown to result in apoptosis via recruitment of FADD to 
RIP(Meylan and Tschopp 2005), or via production of endogenous intracellular TNFα, 
which in turn activates cell death via complex II formation in the TNFR1 pathway. 
Therefore – under certain circumstances - not only TNFR1, but also TNFR2 is 
involved in an array of cellular functions including cell death, proliferation, survival, 
differentiation and cytokine production(Shen and Pervaiz 2006). 
 
Distorted TNF signalling has been shown to play a role in many diseases including 
multiple sclerosis, Alzheimer’s disease, autoimmunity, rheumatoid arthritis and 
Crohn's disease(McDermott 2001) and diverse small molecules are currently under 
development to inhibit or modulate TNF-induced signalling pathways(Li, Thomas et 
al. 2004; He, Smith et al. 2005; Chan, Lee et al. 2010). 
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A.2.1.2 Fas Receptor (CD95)-Mediated Extrinsic Apoptosis 
The Fas receptor/Fas system (also known as CD95 receptor/CD95 ligand system) is 
a key regulator of apoptosis in several different cell types including the immune 
system. The Fas receptor is widely expressed in human tissues of lymphoid and 
non-lymphoid tissues and its expression on tumour cells has also been implicated in 
the escape of tumour cells from immune surveillance(Krammer 2000). Its ligand, 
Fas, is produced by activated T-cells and is capable of inducing apoptosis in cells by 
triggering autocrine suicide or paracrine cell death in target cells. The signalling 
through the Fas receptor is highly comparable to the pro-apoptotic TNFR1 signalling 
pathway described in chapter A.2.1.1: Binding of Fas to the Fas receptor, induces 
receptor trimerization, clustering of the cytoplasmic death domain and subsequent 
recruitment of adaptor molecules through homophilic interation of their DD 
domains(Walczak and Krammer 2000). The principal adaptor molecule in the Fas 
system is FADD, which recruits pro-caspase 8 to the activated Fas receptor complex 
through its DED domain. This gives rise to the Fas DISC(Kischkel, Hellbardt et al. 
1995), which, analogous to the TNFα-induced TNFR1 DISC, provides the platform 
for caspase 8 oligomerization and autoactivation through proteolytic cleavage. In 
so-called “type I” cells this gives rise to a signalling cascade that results in the 
proteolytic cleavage and activation of effector caspases including caspases 3, 6 and 
7, which ultimately execute cell death by substrate cleavage. In other cell types 
(“type II” cells), however, the DISC generates insufficient amounts of mature 
caspase 8 to activate downstream caspases. Thus, these cells depend on a 
mitochondrial amplification loop for the execution of cell death(Scaffidi, Fulda et al. 
1998) (see chapter A.2.3 for more details). This distinction between type I and type 
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II has also been described for other death receptors including TRAIL(Fulda, Meyer et 
al. 2002). 
 
 
A.2.1.3 TNF-Related Apoptosis-Inducing Ligand and its Receptors 
The TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) was discovered in 1995 
as a novel pro-apoptotic member of the TNF superfamily(Wiley, Schooley et al. 
1995; Pitti, Marsters et al. 1996). Its cognate receptors death receptor4 and death 
receptor 5 can activate apoptosis upon ligand association. However, TRAIL also 
interacts with a number of “decoy” receptors that are unable to transmit an 
apoptotic signal, namely DcR1, DcR2 and osteoprotegerin(Degli-Esposti, Smolak et 
al. 1997; Marsters, Sheridan et al. 1997; Pan, Ni et al. 1997; Emery, McDonnell et 
al. 1998). These decoy receptors are characterized by the lack or presence of a non-
functional intracellular death domain. Functional TRAIL receptors can induce 
apoptosis upon TRAIL ligation via formation of the TRAIL DISC complex. The 
physiological role of this conserved ligand-receptor pathway is not well 
defined(Fulda and Debatin 2006) and knock-out models confirmed that it is not 
necessary for normal embryonic development(Cretney, Takeda et al. 2002; Eimon, 
Kratz et al. 2006). However, its specific expression on the surface of natural killer 
cells, cytotoxic T cells, macrophages and dendritic cells points to its function in 
determining the immune repertoire, autoimmunity, and regulating the immune 
response, possibly also immune surveillance of tumours(Gonzalvez and Ashkenazi 
2010). Interestingly, TRAIL has been the focus of extensive studies as it emerged 
as a potentially promising candidate for cancer therapy – the recombinant soluble 
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protein has been shown to trigger apoptosis in numerous transformed cell lines 
without displaying significant toxicity towards normal cells(Ashkenazi, Pai et al. 
1999; Lawrence, Shahrokh et al. 2001; Pollack, Erff et al. 2001). 
 
 
A.2.1.4 Disruption of the Extrinsic Pathway in Cancers and Therapeutic 
Activation Thereof 
As described in chapter A.1.2, cancer cells can inhibit cell death induction principally 
by a surplus of anti-apoptotic molecules or by decreasing or defective function of 
pro-apoptotic molecules. Accordingly, cancer cells have been shown to have evolved 
various strategies to resist induction of apoptosis via the extrinisic pathway: 
Downregulation of surface death receptors, either by decrease expression or 
insufficient transport to the accessible cell surface, has been described for drug-
resistant leukemic, neuroblastoma and colon cancer cells(Friesen, Fulda et al. 1997; 
Jin, McDonald et al. 2004) suggesting that the accessible death receptor expression 
level might impact on drug sensitivity of the tumour. Signalling by the death 
receptors has also been shown to be negatively regulated by the expression of high 
amounts of proteins associating with their cytoplasmic domains and blocking 
caspase recruitment, e.g. high levels of FLIP or PED/PEA-15(phosphoprotein 
enriched in diabetes/phosphoprotein enriched in astrocytes-15 kDa). FLIP can be 
recruited to the DISC complex instead of caspases due to its sequence homology 
with caspase 8 and caspase 10, and its expression level has been correlated with 
chemotherapy resistance in cancer cells(Fulda, Meyer et al. 2000; Longley, Wilson 
et al. 2006). Despite these findings, other reports challenge the model that death 
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receptor signalling plays a role in drug-induced cell death: Overexpression of FLIP 
did not inhibit drug-induced apoptosis(Kataoka, Schroter et al. 1998) and genetic 
ablation of crucial death receptor signalling components such as FADD and caspase 
8 did not confer resistance against cytotoxic anti-cancer agents, whereas they 
rendered cells unresponsive to cell death receptor stimulation(Varfolomeev, 
Schuchmann et al. 1998; Yeh, Pompa et al. 1998). 
It has been suggested that the activation of the extrinsic apoptosis pathways in 
cancer cells could be harnessed for therapeutic intervention in the treatment of 
cancer(Ashkenazi 2002). This seems particularly attractive, since cell death 
induction by the extrinsic pathway is independent of p53 tumour suppressor gene, 
which has been described to be deleted or inactivated in the majority of tumours(El-
Deiry 2001). However, the clinical use of Fas and TNFα have been reported to result 
in severe side effects(Walczak and Krammer 2000). The application of TRAIL in a 
clinical setting to modify tumour response is still under investigation, since initial 
studies have shown that the recombinant soluble protein can trigger apoptosis in 
numerous transformed cell lines without displaying significant toxicity towards 
normal cells(Ashkenazi, Pai et al. 1999; Lawrence, Shahrokh et al. 2001; Pollack, 
Erff et al. 2001). Furthermore repeated intravenous injection into nonhuman 
primates did not cause significant toxicity, and TRAIL treatment of mice bearing 
solid tumours caused substantial tumour regression and improved 
survival(Ashkenazi, Pai et al. 1999). However, these results have been partly 
relativized by findings suggesting potential toxic side effects on human 
hepatocytes(Jo, Kim et al. 2000) and brain tissue(Nitsch, Bechmann et al. 2000). 
Currently, the assessment of therapeutic recombinant human TRAIL and its 
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agonistic monoclonal antibody against DR4 and DR5 as single agent or in 
combination with established cancer therapeutics is still ongoing. So far, several 
trials have reported monotherapy activity with isolated responses; however 
combination treatments have as of March 2012(Dimberg, Anderson et al. 2012) 
failed to improve clinical trial end points like response rate or progression-free 
survival. 
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A.2.2 The Intrinsic Apoptosis Pathway 
As opposed to the extrinsic apoptosis pathway, the intrinsic apoptosis pathway is 
initiated by a diverse array of non-receptor mediated stimuli, which generate 
intracellular signals acting directly within the cell. The intrinsic pathway is triggered 
by various cellular stress signals such as DNA damage, ischemia, oxidative stress 
and increased intracellular Ca2x concentrations. All these signals converge at 
mitochondria and impact on mitochondrial function and integrity. Upon cellular 
stress, the functional balance of proapoptotic Bcl-2 (B-cell lymphoma 2) family 
members, such as Bax (Bcl-2-associated X protein), Bad (Bcl-2-associated death 
promoter) or Bak (Bcl-2 homologous antagonist/killer) and anti-apoptotic Bcl-2 
family members such as Bcl-2 or Bcl-xL (B-cell lymphoma-extra-large) is shifted in 
favour of the pro-apoptotic proteins. These Bcl-2 family members will be discussed 
in more detail in chapter A.2.2.1. The resulting perturbation of mitochondria can 
induce the mitochondrial membrane permeabilisation, e.g. via the so-called 
‘mitochondrial permeability transition’ (MPT) – a sudden change in the inner 
mitochondrial membrane permeability(Kim, He et al. 2003). However, the exact 
mechanism of mitochondrial outer membrane permeabilisation, which has been 
described as a ‘point of no return’ in the mitochondria mediated apoptosis 
pathway(Vieira and Kroemer 1999; Green and Kroemer 2004), remains 
controversially discussed (see chapter A.3.1). MPT and the associated increase in 
inner mitochondrial membrane permeability eventually results in the rupture of the 
outer mitochondrial membrane causing the release of apoptogenic factors(Mayer 
and Oberbauer 2003). These pro-apoptotic proteins include cytochrome c(Yang and 
Cortopassi 1998), AIF (Apoptosis inducing factor)(Lorenzo, Susin et al. 1999; Susin, 
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Lorenzo et al. 1999), Endonuclease G(Li, Luo et al. 2001), Smac/Diablo (second 
mitochondria-derived activator of caspases/direct IAP-associated binding protein 
with low pI)(Du, Fang et al. 2000; Adrain, Creagh et al. 2001) and Omi/HtrA2 (high 
temperature requirement A2)(Suzuki, Imai et al. 2001). Cytochrome c and APAF1 
(Apoptosis protease activating factor 1) in conjunction with Pro-caspase9 constitute 
the so-called ‘apoptosome’(Zou, Li et al. 1999). The apoptosome provides the 
platform for the subsequent activation of initiator caspase 9, triggering the 
proteolytic activation of downstream effector caspases, which collectively 
orchestrate the execution of apoptosis. Smac/Diablo and Omi/HtrA2 antagonize 
cytosolic inhibitors of apoptosis (IAP family, e.g. c-IAP1, c-IAP2, Survivin, X-linked 
IAP) and thus promote apoptosis. AIF and Endonuclease G translocate to the 
nucleus and provoke nuclear condensation and chromatin fragmentation. 
 
 
A.2.2.1 The Bcl-2 Family Members 
As pointed out above, the structural disruption of the outer mitochondrial 
membrane represents the point of no return in the intrinsic apoptosis pathway. In 
this context, the balance of pro- and anti-apoptotoic Bcl-2 family members dictates 
the integrity of this mitochondrial membrane via complex interactions(Green and 
Evan 2002). Although the Bcl-2 family is highly conserved among different 
multicellular organisms, its crucial role for regulating the sudden permeability 
transition of the outer mitochondrial membrane (OMM) upon cellular stress has only 
been described for vertebrates. In invertebrates, Bcl-2 family members do not seem 
to control OMM integrity: The Bcl-2 protein cell death abnormality-9 (CED9) of 
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C.elegans does not impact on OMM permeabilization but still has been implicated in 
inhibiting apoptosis by sequestering the APAF-1 homolog CED4(Lettre and 
Hengartner 2006). However, in Drosophila Bcl-2 homologs do not seem to regulate 
cell death at all, with their actual physiologic function still to be elucidated(Mollereau 
2009). For this reason, the discussion in this thesis focuses on the function of Bcl-2 
family members in vertebrates; a list of the major human Bcl-2 family members is 
provided in Table A.2. 
 
Bcl-2 Family Members with Opposing Activities 
Most Bcl-2 family members are expressed simultaneously in the cell, and the 
balance of pro- and anti-apoptotic members dictates cell survival or commitment to 
cell death. Generally, Bcl-2 and its relatives have been grouped into three classes 
according to their structure and function, which is also displayed in Fig.A.8(Youle 
and Strasser 2008; Chipuk, Moldoveanu et al. 2010):  
The first class is referred to as anti-apoptotic Bcl-2 proteins and inhibits apoptosis. 
Its major members include Bcl-2-related gene A1 (A1), Bcl-2, Bcl-2-related gene, 
long isoform (BclXL), Bcl-2-like-2 (BclW), and myeloid cell leukemia 1 (Mcl1). These 
antiapoptotic Bcl-2 proteins contain four Bcl-2 homology domains (BH1-4) and 
directly inhibit proapoptotic Bcl-2 family proteins. They are generally integrated into 
the OMM but also reside in the cytosol and the ER membrane. 
The second class promotes apoptosis directly and important members include Bcl-2 
antagonist killer 1 (Bak), Bcl-2 associated x protein (Bax) and Bcl-2-related ovarian 
killer (BOK). Originally these were described to contain only BH1-3(Youle and 
Strasser 2008), however structure-based alignment revealed a conserved BH4 
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motif(Kvansakul, Yang et al. 2008) to be present in this class as well. Bak and Bax 
are referred to as effector proteins of the Bcl-2 family since they can homo-
oligomerize and form proteolipid pores within the OMM upon activation in order to 
contribute to mitochondrial outer membrane permeabilization (MOMP). 
A third divergent class of Bcl-2 proteins contains only the BH3 domain and includes 
Bcl-2 antagonist of cell death (BAD), Bcl-2 interacting domain death antagonist 
(BID), Bcl-2 interacting mediator of cell death (BIM), Bcl-2-interacting killer (BIK), 
Bcl-2 modifying factor (BMF), Noxa and Puma. These only affect apoptosis induction 
indirectly, either by binding to only the anti-apoptotic repertoire of Bcl-2 family 
members (so-called “sensitizers” and “derepressors”, e.g. BAD and Noxa) or by 
interacting with the anti-apoptotic repertoire as well as with pro-apoptotic effectors, 
i.e. induce direct activation of Bak or Bax (so-called “direct activators”, e.g. BID or 
BIM)(Chipuk, Moldoveanu et al. 2010). BH3-only proteins on their own are 
insufficient to induce apoptosis in the absence of Bak and Bax(Zong, Lindsten et al. 
2001) 
 
Bcl-2 
The founding member of the Bcl-2 family is Bcl-2, which was first identified as a 
proto-oncogene when expressed as a translocated fusion gene in B-cell 
lymphoma(Bakhshi, Jensen et al. 1985; Cleary, Smith et al. 1986); later  this fusion 
gene was described to be inducing extended B-cell survival as well as hyperplasia 
progression when overexpressed(Mcdonnell, Deane et al. 1989; Mcdonnell and 
Korsmeyer 1991). As opposed to typical proto-oncogenes promoting cell 
proliferation to form cancer, Bcl-2 expression was found to inhibit a diverse range of 
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physiological and pathological cell death stimuli establishing it as a negative 
regulator of cell death(Hockenbery, Nunez et al. 1990).  
Analysis of the subcellular localization of Bcl-2 revealed that it is prominent in 
mitochondria, the endoplasmic reticulum and also other perinuclear 
membranes(Akao, Otsuki et al. 1994). Bcl-2 has a pivotal role in the maintenance of 
mitochondrial membrane integrity by interacting with various other Bcl-2 family 
members (e.g. inhibition of Bax activation), but also plays a role in calcium 
homeostasis in the ER(Thomenius and Distelhorst 2003). It acts as an apoptosis 
inhibitor by preventing MOMP and the subsequent release of apoptogenic factors. 
 
Table A.2: List of Major Bcl-2 Family Members. 
 
 
Bax/Bak Activation 
A central step in the intrinsic apoptosis induction through pro-apototic Bcl-2 family 
members is the activation of Bax and Bak. Accordingly, Bax/Bak double knock-out 
cells haven been shown to be resistant to nearly all intrinsic apoptosis stimuli and 
Anti-apoptotic members 
Bcl-2 Bcl-XL Bcl-W Bfl-1 Boo/Diva Mcl-1 Bcl-B 
Pro-apoptotic members 
Bax Bak Bok Bfk Bcl-Xs 
BH3-only pro-apoptotic 
Bim Bik Bad Bmf PUMA NOXA Nip3 Bid 
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Bax and Bak were termed a requisite gateway to mitochondrial dysfunction(Wei, 
Zong et al. 2001). 
Inactive Bax is normally localized to the cytosol in a monomeric state, although low 
levels of inactive Bax have been described to be attached to the OMM. However, 
activation of the intrinsic apoptosis pathway results in activation of Bax by an 
allosteric conformational change, oligomerization (either homo-oligomerization or 
hetero-oligomerization, e.g. with Bak)(Chipuk and Green 2008) and insertion into 
the OMM(Hockenbery, Nunez et al. 1990). This activation induces MOMP and the 
release of apoptogenic factors including cytochrome c from the mitochondrial 
intermembrane space into the cytosol, and the downstream formation of a caspase 
activation platform. At the same time, Bax and Bak activation triggers mitochondrial 
fragmentation into smaller units suggesting a potential connection between 
mitochondrial fission and the role of Bcl-2 proteins(Martinou and Youle 2006). 
Activation of Bax and Bak has been explained by competing models, however, the 
contribution of pro-apoptotic BH3-only Bcl-2 family members is undisputed(Chipuk 
and Green 2008): BID and BIM are classified as “direct activators” and have been 
shown to directly induce effector function of Bak and Bax(Kuwana, Mackey et al. 
2002). In vitro synthesized peptides corresponding to the BH3 domains of BID and 
BIM can induce Bak/Bax oligomerization and pore-forming activity in isolated 
mitochondria(Kuwana, Bouchier-Hayes et al. 2005). 
 
Other BH3-only proteins, the so-called “sensitizers” and “derepressors” including 
BAD, BIK, Noxa and PUMA do not activate Bax or Bak directly, but exert their effect 
primarily by binding and inhibiting the anti-apoptotic Bcl-2 family members(Chipuk 
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and Green 2008). Sensitization refers to the binding of a BH3-only member to an 
anti-apoptotic Bcl-2 family member thus lowering the threshold for Bak/Bax 
activaton. Derepression, in contrast, refers to the situation when a direct activator 
(such as BID or BIM) is bound by an anti-apoptotic Bcl-2 member, and a 
subsequent binding of a BH3-only protein releases the direct activator promoting 
the induction of MOMP(Chipuk, Moldoveanu et al. 2010).  
Activation of Bax has classically been described to follow discrete steps: First, the 
direct activators BID or BIM associate with a membrane. This results in the 
recruitment of Bax, insertion into the membrane, conformational change and 
subsequent oligomerization(Leber, Lin et al. 2007). However, Bak/Bax-dependent 
apoptosis can still be observed in the absence of BID and BIM and points to the fact, 
that direct activation by these proteins is not necessary, or alternative mechanisms 
for achieving activation exist(Willis, Fletcher et al. 2007). Interestingly non-protein 
factors leading to Bax/Bak activation, such as mild heat(Pagliari, Kuwana et al. 
2005), detergents(Hsu and Youle 1997) and high pH(Khaled, Reynolds et al. 2001) 
have been proposed by in vitro studies. However, it remains uncertain how much 
these mechanisms contribute to apoptosis induction in a physiological setting. 
 
Although Bax activation has been described to be crucial for the release of 
apoptogenic factors, MOMP can also be achieved independently of Bax activation, 
e.g. through a multiprotein channel – the so-called “permeability transition pore”, 
which will be discussed extensively in chapter A.4. 
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Fig.A.8: Bcl2 Family Member Classification Based on Structural Alignment and 
Functon. A) A representation of an anti-apoptotic (Bcl2), effector (Bax), and BH3-only (BID) 
family protein is shown with the characteristic BH domains (1-4) labelled; tubes correspond 
to alpha helices in the secondary protein structure. The BH1, BH2 and BH3 domains fold to 
line a hydrophobic pocket that can bind BH3-only peptides. The BH3 domain of BH3-only 
proteins mediates their interaction with anti-apoptotic Bcl2 family members and thereby 
promotes apoptosis. B) Model of mechanism for Bax activation: A direct activator (BID) 
interacts with soluble Bax and the outer mitochondrial membrane, resulting in N-terminus 
exposure, membrane insertion and oligomerizaton. Activation of Bax promotes mitochondrial 
outer membrane permeabilisation. Pictures were adapted from (Chipuk, Moldoveanu et al. 
2010) 
A) 
B) 
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A.2.2.2 Events Downstream of MOMP – Release of Apoptogenic IMS 
Proteins and the Apoptosome Caspase Activation Platform 
The point of no return in commitment to apoptosis in the mitochondria-mediated 
pathway is the release of soluble apoptogenic factors from the mitochondrial 
intermembrane space (IMS) into the cytosol, see Fig.A.9. This induces the formation 
of a caspase activation platform – the apoptosome – for initiator caspase activation 
and the subsequent activation of effector caspases and execution of cell death(Youle 
and Strasser 2008). The pro-apoptotic IMS proteins can be divided into two main 
groups(Saelens, Festjens et al. 2004): The first group activates the caspase-
dependent mitochondrial apoptosis pathway and includes cytochrome c, 
Smac/Diabolo and the serine protease HtrA2/Omi. The second group of apoptogenic 
factors is released in later stages of apoptosis when the cell has committed to die, 
and includes AIF (Apoptosis Inducing Factor), endonuclease G and CAD (Caspase-
activated DNase). AIF and endonuclease G function independently of caspases. 
 
 
A.2.2.2.1 Mitochondrial Mediators of Caspase-Dependent Apoptosis 
 
Cytochrome c 
The most exhaustively studied protein of the apoptogenic IMS proteins is 
cytochrome c. Although primarily described as a key player of the electron transport 
chain during oxidative phosphorylation, it is crucial for the activation of caspases 
upon MOMP. Accordingly, deficiency of cytochrome c abrogates caspase activation 
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upon mitochondrial apoptosis induction(Li, Li et al. 2000). Upon release to the 
cytosol, cytochrome c binds Apaf1 (apoptotic proteinase activating factor 1). Apaf1 
is a CARD containing adaptor protein, that upon cytochrome c binding, recruits 
procaspase 9 in an ATP(Adenosine triphosphate)-dependent manner in order to 
form a heptamer of cytochrome c, Apaf1 and procascapse 9 known as 
apoptosome(Li, Nijhawan et al. 1997; Acehan, Jiang et al. 2002). The apoptosome, 
analogous to the DISC in the extrinsic pathway, provides the platform for the 
clustering and activation of the initiator caspase 9. Consecutive recruitment of the 
executioner procaspase 3 to the apoptosome, leads to its maturation into active 
caspase 3 by the resident caspase 9. 
 
Smac/Diablo and HtrA2/Omi 
Release of Smac/Diablo and HtrA2/Omi also promotes apoptosis by neutralizing a 
protein family of endogenous inhibitors of caspases (IAPs), thus facilitating caspase 
activation(Du, Fang et al. 2000; Suzuki, Imai et al. 2001). IAPs have the capacity to 
directly bind active caspases (caspase 3, 7 and 9) and thus block apoptosis. This 
imposes an anti-apoptotic hurdle on the cell, which accommodates for limited 
mitochondrial damage and neutralizes activated caspases after small amounts of 
cytochrome c are released. However, after more severe damage to the 
mitochondria, this block is overcome by the simultaneous release of Smac and 
HtrA2, which antagonize IAPs by direct binding. 
 
Smac is a nuclear encoded protein, which is imported into the IMS via its 
mitochondrial localization signal. Upon mitochondrial import, this pre-peptide is 
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cleaved off exposing a IAP-binding motif at the N-terminus(Du, Fang et al. 2000). 
Upon release from the IMS, Smac can bind to members of the IAP family including 
XIAP (X-linked inhibitor of apoptosis), cIAP1, cIAP2 and survivin; additionally it can 
also displace activated caspase 9 from its inhibitory interaction with 
XIAP(Srinivasula, Hegde et al. 2001; Saelens, Festjens et al. 2004). 
Similarly, Omi/HtrA2 is also a nuclear encoded protein that, upon import into the 
IMS and proteolytic maturation, exposes an N-terminal IAP-binding motive. Once 
released from the IMS, it functions in a pro-apoptotic way by antagonizing IAPs, and 
also exerts a caspase-independent function for cell death induction as a 
protease(Saelens, Festjens et al. 2004). 
 
CAD 
Caspase-activated DNase is activated in later stages of apoptosis via caspase-
dependent cleavage of its inhibitor (ICAD). It translocates to the nucleus, which 
results in pronounced chromatin condensation and DNA fragmentation(Enari, 
Sakahira et al. 1998).  
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Fig.A.9: The Caspase-dependent Intrinsic Apoptosis Pathway Downstream of 
Mitochondrial Outer Membrane Permeabilization (MOMP). Intrinsic apoptotic stimuli 
converge at the point of no return, the permeabilization of the outer mitochondrial 
membrane. MOMP results in the release of various apoptogenic proteins from the 
mitochondrial intermembrane space (IMS). Cytosolic cytochrome c recruits apoptotic 
protease-activating factor 1 (Apaf 1) and forms a caspase activation platform – the 
apoptosome. Formation of the apoptosome results in recruitment and activation of the 
initiator caspase 9. Caspase 9 cleaves and activates executioner caspases 3 and 7 which 
execute cell death. Release of second mitochondria-derived activator of caspase (Smac) and 
Omi antagonize the caspase inhibitory function of a protein family called Inhibitors of 
Apoptosis (IAPs), e.g. X-linked inhibitor of apoptosis protein (XIAP). Picture was modified 
from (Tait and Green 2010). 
 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |67 
 
A.2.2.2.2 Regulation of the Apoptosome Assembly 
The formation of the apoptosome caspase activation platform is regulated by many 
mechanisms: Apoptosome formation requires Apaf-1 mediated dATP binding(Kim, 
Du et al. 2005). However, physiological levels of dATP as well as transfer RNA 
(tRNA) have been shown to inhibit apoptosis by directly binding to cytochrome c 
and thus blocking the Apaf 1-cytochrome c interaction, which is needed for 
apoptosome formation(Chandra, Bratton et al. 2006; Mei, Yong et al. 2010). The 
apoptogenic activity of cytochrome c is also regulated by the its redox state with 
oxidation promoting its apoptosis inducing activity and reduction inhibiting 
it(Borutaite and Brown 2007). Another regulative mechanism is the nitrosylation of 
the heme moiety of cytochrome c, which attenuates the pro-apoptotic functions of 
cytochrome c and triggers a protective stress response(Schonhoff, Gaston et al. 
2003; Godoy, Munoz-Pinedo et al. 2009). Although apoptosis is generally associated 
with an increase in free cytosolic calcium, intracellular calcium has been found to 
prevent apoptosome formation by inhibiting nucleotide exchange on Apaf1(Bao, Lu 
et al. 2007). Contrarily, proteins such as cellular apoptosis susceptibility protein 
(CAS), heat shock protein 70 (Hsp70) or putative HLADR-associated protein 1 
(PHAP1) promote apoptosome activity and caspase activation by preventing 
monomeric Apaf 1 aggregate formation and stimulating nucleotide exchange on 
Apaf 1(Kim, Jiang et al. 2008). These mechanisms are summarized in Fig.A.10. 
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A.2.2.2.3 Mitochondrial Mediators of Caspase-independent Apoptosis 
 
AIF 
Compared to cytochrome c and Smac, AIF is released relatively late and slow during 
mitochondria-mediated apoptotic cell death, although the timing has been 
controversially discussed(Arnoult, Parone et al. 2002). AIF translocates to the 
nucleus and induces condensation of peripheral nuclear chromatin and DNA 
fragmentation although it lacks intrinsic DNase activity(Cande, Vahsen et al. 2004).  
Fig.A.10: Regulation of the Apoptosome Formation. Binding of cytochrome c to 
apoptotic protease-activating factor 1 (Apaf1) leads to its oligomerization and subsequent 
recruitment and activation of caspase 9. ATP, transfer RNA as well as physiologic calcium and 
potassium can inhibit apoptosome formation. Putative HLADR-associated protein 1 (PHAP1) 
enhances cytochrome c/Apaf1 oligomerization. Downstream, phosphorylation of caspase 9 by 
kinases such as cyclin-dependent kinase 1 (CDK1)–cyclin B1, extracellular signal-regulated 
kinase 1 (ERK1; also known as MAPK3) and ERK2 (also known as MAPK1), inhibit caspase 9 
activity post-MOMP. Figure modified from (Tait and Green 2010). 
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Endonuclease G 
Upon release from the mitochondrial IMS, endonuclease G also migrates to the 
nucleus and cleaves nuclear chromatin in order to form oligonucleosomal DNA 
fragments. However, knock-out models of endonuclease G proved that deficiency of 
endonuclease G does not abrogate apoptotic DNA fragmentation(Irvine, Adachi et 
al. 2005). 
 
 
A.2.2.3 Disruption of the Intrinsic Pathway in Cancer and its Significance in 
Therapeutic Interference 
Most cancer cells show mutations or some sort of dysregulation of genes involved in 
the mitochondria-mediated apoptosis pathway(Fulda and Debatin 2006), e.g 85% of 
human follicular lymphoma show a translocation and subsequent overexpression of 
the Bcl-2 oncogene(Tsujimoto, Finger et al. 1984), and Bcl-2 overexpression has 
been demonstrated to induce neoplastic transformation in several cell 
lines(Mcdonnell and Korsmeyer 1991; Traver, Akashi et al. 1998). 
There is also mounting evidence that the pro-apoptotic BH3-only Bcl-2 family 
members have a role as bona fide tumour suppressors and counteract malignant 
transformation: Deletions of the Bim gene are frequent in patients with Mantel cell 
lymphoma(Tagawa, Karnan et al. 2005). Murine knock-out models of Bid develop 
spontaneous myeloproliferative disorders and malignancies(Zinkel, Ong et al. 
2003). 
Furthermore, the tumour suppressor p53, which is most commonly mutated in 
human cancers, impacts on the intrinsic apoptosis pathway: It transcriptionally 
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regulates a number of genes sensitising cells for the activation of mitochondrial 
apoptosis induction, e.g. the pro-apoptotic BH3-only proteins Puma, Noxa and Bid 
have p53 responsive elements in their promoters(Oda, Ohki et al. 2000; Yu, Zhang 
et al. 2001; Sax, Fei et al. 2002). Additionally, direct destabilizing effects of p53 on 
mitochondria via interaction with Bcl-2 and BclXL (Mihara, Erster et al. 2003) as well 
as opening of the mitochondrial permeability transition pore via binding to 
cyclophilinD have been proposed(Vaseva, Marchenko et al. 2012). 
Interestingly, most tumours have also been found to express high basal levels of 
active caspase 3 and caspase 8 without showing increased apoptosis. This intrinsic 
drive to apoptosis is blocked by concomitant upregulation of IAPs which balance the 
high basal caspase activity in tumours(Yang, Cao et al. 2003). Therefore, targeting 
IAPs in cancer cells might enhance the therapeutic effects of conventional anti-
cancer therapies by shifting the dynamic balance of pro- and anti-apoptotic effector 
proteins in favour of proapoptotic molecules. 
 
Most chemotherapeutic anti-tumour agents trigger the mitochondrial apoptosis 
pathway, e.g. etoposide, doxorubicin, cisplatin and paclitaxel ultimately elicit 
mitochondrial permeabilization in an indirect way. This is achieved by perturbing the 
metabolism or elevating the levels of second messengers favouring apoptosis. 
Examples would be the induction of p53 expression (especially after DNA damage), 
the induction of the ceramide/GD3 pathway, the induction of the Fas/FasL system 
(tBid formation), the shifting of the balance of Bcl-2 family members in favour of 
the pro-apoptotic proteins or compromising the redox state and energy balance of 
the cell(Fulda and Debatin 2006). Recently, also caspase 2 has been implicated in 
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mediating the response to DNA damage after treatment via a combination of 
mechanisms: It can promote the mitochondrial apoptosis pathway by directly 
permeabilizing the OMM via interaction with putative proteins and phospholipids in 
order to release apoptogenic factors independently of several Bcl-2 family 
members(Robertson, Gogvadze et al. 2004). Furthermore it has diverse cellular 
substrates including the proapoptotic protein Bid. Caspase 2 generates tBid which 
signals to mitochondria to induce the release of proapoptotic proteins from the IMS 
into the cytosol(Guo, Srinivasula et al. 2002). Interestingly, caspase 2 can also 
disrupt the interaction of cytochrome c and cardiolipin in the inner mitochondrial 
membrane, thus freeing up a surplus of cytochrome c for apoptosis 
induction(Enoksson, Robertson et al. 2004). 
Chemotherapeutic agents also promote permeabilization of the OMM through the 
opening of the permeability transition pore. This mitochondrial megachannel is 
sensitive to changes in the cellular redox potential due to generation of reactive 
oxygen species or depletion of reduced glutathione or NADPH (Nicotinamide adenine 
dinucleotide phosphate). Additionally, inhibition of the respiratory chain, depletion 
of ATP and ADP or alkalization of the mitochondrial matrix can favour mitochondrial 
permeability transition induced by certain chemotherapeutics(Fulda and Debatin 
2006). Other experimental anticancer drugs such as arsenite, ionidamide, betulinic 
acid or retinoid CD437 act directly on mitochondria, as they have been 
demonstrated to induce mitochondrial membrane potential loss and permeability 
transition in isolated mitochondria(Debatin, Poncet et al. 2002). 
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A.2.3 Crosstalk between Intrinsic and Extrinsic Apoptosis Pathways 
Although intrinsic and extrinsic apoptosis pathways converge at the level of effector 
caspases for apoptosis induction, the initiation steps differ fundamentally in the 
molecular key players. Thus these pathways were thought to be separable. 
Accordingly, the knock-out of caspase 8(Varfolomeev, Schuchmann et al. 1998) or 
FADD(Yeh, Pompa et al. 1998) renders cells resistant against death ligand induced 
apoptosis while execution of apoptosis via the mitochondrial apoptosis pathway 
remains functional. Equally, knock-out of caspase 9(Hakem, Hakem et al. 1998) or 
Apaf 1(Cecconi, Alvarez-Bolado et al. 1998) abolishes apoptosis induction via 
mitochondria while leaving the apoptosis induction program via death ligands 
unaltered. However, it was speculated that the extrinsic and intrinsic apoptosis 
pathways are not completely independent, when Bcl-2 overexpression inhibited FasL 
induced apoptosis(Scaffidi, Fulda et al. 1998). Caspase 8, once activated by the 
extrinsic pathway, cleaves the BH3-only protein Bid. Truncated Bid signals to the 
mitochondria to induce the release of apoptogenic factors by activation of 
Bax(Eskes, Desagher et al. 2000), thereby promoting the formation of the 
apoptosome and subsequent maturation/activation of caspase 9. tBid is thus linking 
the extrinsic to the intrinsic apoptosis pathway and amplifying the apoptosis 
signal(Luo, Budihardjo et al. 1998). In contrast to the so called ‘type I’ cells, which 
do not depend on the described amplification loop to induce apoptosis upon death 
receptor activation, this crosstalk is mandatory for apoptosis induction in so called 
‘type II’ cells(Hao and Mak 2009): As mentioned before (refer to chapter A.2.1), 
ligation of a death ligand to its cognate receptor results in the assembly of the 
caspase 8 activation platform (the DISC). In “type I” cells, the DISC provides 
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sufficient amounts of activated caspase 8 to trigger the proteolytic signalling 
cascade that results in the activation of effector caspases – this induces activation 
of caspases 3, 6 and 7 which ultimately execute cell death by substrate cleavage. In 
contrast, the DISC of “type II” cells generates insufficient amounts of mature 
caspase 8 to activate downstream caspases. Thus, induction of apoptosis requires 
the presence of Bid, its proteolytic cleavage by caspase 8 to form tBid, and the 
activation of the mitochondrial amplification loop for cell death execution. 
 
 
A.2.4 Caspases as Crucial Enzymes for Apoptotic Cell Death 
Both, extrinsic and intrinsic apoptosis pathways depend on a system of caspases 
(cysteine-dependent aspartate-specific proteases) as the main initiators and 
executioners of apoptosis(Martin and Green 1995). Their name points to their 
mechanism of action as these proteases, when activated, bind to a cysteine residue 
of their substrate and cleave the peptide pond C-terminal to an aspartate residue 
(Stennicke and Salvesen 1998), although different caspases have distinct substrate 
specificity by recognizing neighbouring amino acids. Caspases are ubiquitously 
expressed in most cells as an inactive pro-enzyme and are regulated at the post-
translational level. Synthesized first as inactive pro-enzymes that consist of a 
prodomain, a small catalytic subunit and a large catalytic subunit, they rest dormant 
until activated by an apoptotic stimulus. 
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A2.4.1 Classification of Caspases 
To date, approximately 10 major caspases have been identified, which can be 
broadly classified depending on their function, structure, substrate preference and 
sequence homology. In the mammalian system, caspases can be grouped into 
initiator caspases (caspase 2, 8, 9, 10), effector or executioner caspases (caspase 
3, 6, 7) and inflammatory caspases (caspase 1, 4, 5)(Cohen 1997). The role of 
initiatior caspases and effector caspases will be discussed in detail in this thesis as 
they are crucial for the execution of cell death by both, the intrinsic and extrinsic 
apoptosis pathway. Inflammatory caspases have been shown to be involved in the 
procession of inflammatory cytokines and in eliciting the inflammatory response. 
Other caspases that have been discovered include caspase 11, which regulates 
apoptosis and cytokine maturation during septic shock(Kang, Wang et al. 2002), 
caspase 12, which is involved in the regulation of apoptosis triggered through 
endoplasmic reticulum stress in mice(Nakagawa, Zhu et al. 2000), but is only 
expressed in a minority of humans(Yeretssian, Doiron et al. 2009), and caspase 14 
which is involved in developmental processes as it is highly expressed in embryonic 
tissue but absent in adult tissue(Hu, Snipas et al. 1998).  
It also has to be mentioned that classic apoptotic caspases can have non-apoptotic 
roles under certain circumstances, e.g. activation of caspase 3 is involved in 
receptor internalisation in neurons(Li, Jo et al. 2010) or caspase 9 activity is 
required for the differentiation of skeletal myoblasts into myotubes(Murray, 
McMahon et al. 2008) – in both scenarios, caspase activity is not related to 
apoptosis induction.  
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All caspases share a highly homologous protease domain consisting of a large 
subunit (17-20 kDa) and a small subunit (10-12 kDa). The group of initiator 
caspases comprises caspase 2, 8, 9 and 10, which are the initial caspases involved 
in reacting to an apoptotic stimulus and triggering the apoptotic response. They 
contain long prodomains which mediate the recruitment of the procaspase 
molecules to specific death signaling complexes, leading to their autocatalytic 
activation(Fuentes-Prior and Salvesen 2004) (see Fig.A.11). The prodomain 
characteristically either contains two “death effector domains” (DED; present in 
caspase 8 and 10) or one “caspase recruiting domain” (CARD; present in caspase 2 
and 9) at the N-terminus. These domains mediate the homophilic interaction of 
procaspases with upstream adaptor molecules also containing a DED domain (e.g. 
the DED domain caspase 8 and the DED domain of FADD in the extrinsic apoptosis 
pathway) or the CARD domain (e.g. the CARD domain of caspase 2 and the CARD 
domain of RAIDD in the extrinsic apoptosis pathway)(Fuentes-Prior and Salvesen 
2004). Once self-activated, initiator caspases specifically cleave effector caspases 
due to their inherent substrate specificity(Thornberry, Rano et al. 1997). 
Effector caspases, including caspase 3, 6 and 7 are downstream of initiator caspases 
and their activation results in the execution of cell death. They lack long prodomains 
and the ability to get self-activated and thus require proteolytic processing by 
activated initiator caspases(Thornberry 1999; Degterev, Boyce et al. 2003) (see 
Fig.A.12). Activation of caspases requires cleaving off the small subunit in a first 
stage, followed by a second proteolytic cleavage separating the remaining 
prodomain and large subunit(Thornberry and Lazebnik 1998). The separated small 
and large subunits then interact and give rise to a heterodimerized enzyme which in 
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turn homodimerizes to form the fully mature caspase - a heterotetramer containing 
two active sites(Wolf and Green 1999). The final execution of cell death by both, the 
intrinsic and extrinsic apoptosis pathway, relies on the proteolytic activation of 
effector caspases. This proteolytic activity is responsible for most of the proteolytic 
events which create the morphological features of apoptosis. 
 
 
  
 
 
 
 
 
 
 
 
 
  
Fig.A.11: Domain Organization of Human Caspases. Alignment of human caspases 
allows grouping into three subfamilies. This is also in accordance with the physiologic 
function as inflammatory, initiator and effector caspases. The role of caspase 14 in not yet 
clearly defined as it is not expressed in adult tissue but highly expressed during 
development. Aspartate residues highlighted in red correspond to the position of maturation 
cleavage sites. L large subunit, S small subunit, CARD Caspase activation and recruitment 
domain, DED Death Effector Domain. The schematic representation of caspases was taken 
from (Fuentes-Prior and Salvesen 2004). 
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Fig.A.12: Caspase Classification, Structure and Activation. A) Apoptotic caspases 
comprise initiator and executioner caspases. Initiator caspases (caspase 2, 8, 9) are at the 
beginning of the apoptosis signalling cascade and activation thereof is required for the 
activation of executioner caspases (caspase 3, 6, 7). The substrate repertoire of initiator 
caspases is limited and includes self-cleavage, Bid and executioner caspases. In contrast, 
executioner caspases cleave a plethora of cellular substrates and are responsible for the 
phenotypic changes observed during apoptosis. B) Activation of initiator caspases involves 
the dimerization of inactive caspase monomers; e.g. capase 8, upon death receptor 
ligation, forms dimers by recruitment of monomers to the adaptor molecule Fas-associated 
death domain protein (FADD). This dimerization and the auto-cleavage of the interdomain 
are required for the activation of mature caspase 8. Executioner caspases are activated 
differently as they are present as dimers in the normal cell. They are active by cleavage 
and intramolecular rearrangement to form an active dimer. The pictures were adapted 
from(Tait and Green 2010). 
A) 
B) 
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A.2.4.2 Cellular Targets of Caspases and Execution of Cell Death 
Activation of effector caspases 3, 6 and 7 results in the cleavage of vital cellular 
proteins including nuclear lamins(Lazebnik, Takahashi et al. 1995), DNA repair 
enzymes such as PARP (poly-ADP-ribose-polymerase)(Lazebnik, Kaufmann et al. 
1994) and cytoskeletal proteins(Mashima, Naito et al. 1995) and also activates 
further downstream cytoplasmic endonucleases and proteases. Caspase 3 has been 
considered the central effector caspase and can be activated by any of the initiator 
caspases(Slee, Adrain et al. 2001). Caspase 3 specifically activates CAD (caspase 
activated DNase) via cleaving and releasing its complexed inhibitor ICAD(Sakahira, 
Enari et al. 1998). Subsequently CAD degrades and condenses chromosomal DNA 
within the nucleus. Active caspase 3 is also responsible for the disintegration of the 
cell into apoptotic bodies via cytoskeletal reorganization. The caspase substrate 
responsible for the cytoskeletal disintegration is gelsolin, an actin binding protein 
which physiologically induces actin polymerization and is also involved in 
phosphatidylinositol biphosphate regulated singal transduction. Proteolytical 
procession of gelsolin gives rise to cleaved fragments of gelsolin, which themselves 
act as actin filament specific proteases in a calcium dependent manner. This is the 
primary force driving the disruption of the cytoskeleton, intracellular transport, cell 
division and signal transduction(Kothakota, Azuma et al. 1997). Although caspase 3 
has been described as the primary driving force in the execution of cell death, the 
range of substrates of effector caspases is partly redundant, i.e. caspase 6 and 7 
share substrates with caspase 3 and therefore can compensate for caspase 3 loss in 
a knock-out model(Kothakota, Azuma et al. 1997). Other cytoskeletal targets of 
effector caspases include adherence junction proteins (beta catenin or plakoglobin 
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gamma-catenin). Their cleavage results in the disruption of cell-cell communication 
and cell detachment from the anchoring surface or surrounding tissue(Schmeiser, 
Hammond et al. 1998). Another important substrate of executioner caspases is 
NADH dehydrogenase ubiquione Fe-S protein 1 (NDUS1), the proteolytic cleavage of 
which relates to rendering mitochondria dysfunctional by disruption of the electron 
transport chain for ATP production and the generation of reactive oxygen 
species(Ricci, Munoz-Pinedo et al. 2004). Other studied substrates of executioner 
caspases include pro-apoptotic kinases which get active upon cleavage: Rho-
associated coiled-coil containing protein kinase 1 (ROCK1) has been reported to be 
both necessary and sufficient for induction of cell membrane blebbing(Coleman, 
Sahai et al. 2001); or caspase-mediated activation of p21-actived kinase 2 (PAK2) 
has been shown to contribute to the generation of apoptotic bodies(Rudel and 
Bokoch 1997). 
In summary, the progressive protolytic destruction of functionally and structurally 
vital cellular proteins by effector caspases and other downstream effectors in 
conjunction with nuclear DNA fragmentation and collapse ultimately result in cell 
death. 
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A.2.5 Caspase-independent Execution of Cell Death 
As described above, classic apoptosis requires the activation of initiator and 
executioner caspases. However there are also physiologic and artificial scenarios of 
apoptosis-like cell death that do not require the activation of caspases. Artificially, 
the cell-permeable irreversible inhibitor of caspases zVAD-fmk can be used to 
examine whether certain stimuli depend on caspase activation for the execution of 
cell death. zVAD-fmk binds the catalytic site of all caspases by mimicking the 
cleavage site and fluoromethyl ketone forms a covalent bond, thus resulting in an 
inactive inhibitor-enzyme complex(Slee, Zhu et al. 1996). While for some cell death 
stimuli, apoptosis induction can be potently blocked by zVAD-fmk, other stimuli still 
induce cell death with apoptotic characteristics. The first reported example is the 
overexpression of Bax, which triggers cell death via the breakdown of mitochondrial 
function even in the presence of zVAD-fmk(Xiang, Chao et al. 1996). Similarly, 
other proteases such as granzymeA/B, cathepsins and calpains can trigger caspase-
independent apoptosis(Leist and Jaattela 2001). Hence, although some caspases 
are substrates of these proteases and caspase activation can still be observed, it is 
not necessarily required for cell death execution. 
Mitochondrial mediators of caspase-independent apoptosis have already been 
described in chapter A.2.2.2.3 and include AIF and Endonuclease G – both 
translocate to the nucleus upon release from the mitochondrial IMS to contribute to 
nuclear DNA condensation and fragmentation. 
Granzymes (granule enzymes) belong to a family of highly homologous serine 
proteases contained in the granules of innate and adaptive immune killer cells 
(cytotoxic T lymphocytes and natural killer cells). These cytotoxic granules are 
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released via exocytosis and are used to eliminate virally infected cells or 
transformed target cells(Chowdhury and Lieberman 2008). There are five human 
granzymes, including Granzyme A and Granzyme B, the most abundant and 
extensively studied granzymes. Granzyme B has been shown to cleave substrates 
after aspartic acid residues and shares many substrates with effector caspases. The 
cytotoxic granules also contain perforin, a pore-forming protein that is needed to 
deliver the granzymes into the target cell. 
Cathepsins are proteases, which normally reside within the lysosomal 
compartments. Different mechanisms and certain stimuli induce the release of these 
lysosomal enzymes into the cytoplasm where they can induce apoptosis by 
releasing apoptogenic factors from mitochondria (or by direct activation of 
caspases)(Chwieralski, Welte et al. 2006). 
Calpains are Ca2+ activated cysteine proteases localized to the cytoplasm and the 
mitochondria. Calpains generally promote apoptosis (as well as necrosis) by 
cleavage of cytoskeletal proteins, induction of mitochondrial dysfunction (e.g. 
cleavage of electron transport chain proteins) and cleavage and activation of 
caspases(Smith and Schnellmann 2012). However, it remains vastly unclear, how 
calpain activity is regulated physiologically in a cell. 
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A.3 The Role of Mitochondrial Outer Membrane Permeabilization 
(MOMP) in Apoptosis 
As described earlier, the hallmark and key regulatory event in the mitochondria-
mediated apoptosis pathways is the permeabilization of the outer mitochondrial 
membrane and subsequent release of apoptogenic proteins from the IMS(Tait and 
Green 2010). MOMP is the point of no return committing the cell to cell death by 
inducing a spontaneous and progressive distortion of mitochondrial function – a 
feature of intrinsic apoptosis that can be observed physiologically and pathologically 
both, in vitro(Zamzami, Marchetti et al. 1995) and in vivo(Zamzami, Marchetti et al. 
1995). This induces cell death, either in a caspase-dependent way or in other cases 
even irrespectively of caspase activity. Consequently the integrity of the outer 
mitochondrial membrane is tightly controlled, e.g. through the interaction of pro-
and anti-apoptotic Bcl-2 protein family members as described in chapter A.2.2.1 or 
other mechanisms discussed in the following chapters. Although MOMP is a 
universal feature of cell death, the exact mechanisms governing this event are still 
unclear and remain controversially discussed. However, given the importance of 
MOMP, addressing how the integrity of the outer mitochondrial membrane can be 
selectively disturbed to cause cell death, is an area of intense basic and translational 
research. This chapter will present models explaining the molecular mechanism of 
MOMP. 
An interesting tool for studying the mechanisms and kinetics of MOMP is the use of 
green fluorescent protein tagged cytochrome c (GFP-cytochrome c) and its 
monitoring by live cell imaging. Using this technique, it has been demonstrated that 
the onset of MOMP is highly variable in the mitochondria within a cell, although 
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most undergo MOMP within several minutes of initiation. Recent studies focussing 
on the spatial and temporal dynamics of outer mitochondrial membrane 
disintegration revealed that MOMP can initiate from a defined spatial point within 
the cell and expand in a wave-like manner to affect all mitochondria within a 
cell(Lartigue, Medina et al. 2008; Bhola, Mattheyses et al. 2009; Rehm, Huber et al. 
2009). Inhibitor studies confirmed that this “wave of cell death” is dependent on 
signalling through protein phosphorylation and endoplasmic reticulum Ca2+ pumps; 
also the activation of caspases could be involved in wave propagation by the 
secondary cleavage of Bid (also see chapter A.2.3). Contradictory and somewhat at 
odds with these studies, is the finding that temporal kinetics are (i.e. the length of 
time spanning the first mitochondrion releasing cytochrome c and the last 
mitochondrion) not affected by lowering the temperature – this observation clearly 
argues against the involvement of an enzymatic process in the execution of 
MOMP(Goldstein, Waterhouse et al. 2000). Enzymatic processes therefore might 
indirectly affect MOMP only by lowering the cellular threshold for its induction rather 
than its execution. This apparent discordance in findings might also be due to the 
comparatively higher temporal and spatial resolution achieved in more recent 
studies(Tait and Green 2010). 
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A.3.1 Molecular Mechanisms of MOMP 
As described earlier, the molecular mechanisms of MOMP are poorly understood, 
and proposed models thereof include (1) the formation of a proteinacious channel 
by Bcl-2 family members, (2) the modification of existing mitochondrial multiprotein 
channels (i.e. the mitochondrial permeability transition pore MPTP) or (3) the 
formation of lipidic pores under assistance of activated Bax/Bak. 
 
 
A.3.1.1 Proteinacous Channels 
 
Bak/Bax Activation 
As described in chapter A.2.2.1, the activation of Bak or Bax can be seen as crucial 
in the induction of MOMP, as demonstrated by the fact that double knock-out cells 
for both proteins do not undergo MOMP and are resistant to diverse intrinsic 
apoptosis stimuli(Wei, Zong et al. 2001). Interestingly, Bax as well as Bak show 
pronounced structural similarity with bacterial pore-forming toxins, which fuelled the 
hypothesis that these proteins themselves could directly form pores in the 
mitochondrial outer membrane(Muchmore, Sattler et al. 1996; Suzuki, Youle et al. 
2000). Supporting evidence for this model comes from studies demonstrating Bax 
induced ion channel formation and pores in artificial membranes. Nevertheless this 
phenomenon can also be observed with anti-apoptotic Bcl-2 proteins in 
vitro(Antonsson, Conti et al. 1997). More experimental support for a Bax/Bak pore 
inducing MOMP comes from patch-clamping analysis of mitochondria: Upon tBid 
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addition to isolated mitochondria, a pore-like channel is formed in the outer 
mitochondrial membrane. This channel increases stepwise in conductance and size 
over time and its formation is dependent on the presence of either Bak or Bax, 
which suggests the sequential recruitment of membrane-bound activated Bax/Bak 
dimers in order to give rise to a pore of increasing conductance. Growth of this 
channel continues to allow for the release of cytochrome c(Martinez-Caballero, 
Dejean et al. 2009). However, most studies suggesting the Bax/Bak pore model for 
MOMP can only explain the formation of pores large enough for the release of 
cytochrome c (12kDa), while MOMP within the cellular setting clearly depends on a 
pore that accommodates much larger proteins (e.g. AIF 67kDa)(Tait and Green 
2010). 
In contrast to the de novo formation of Bax/Bak pores, other models have been 
proposed that explain MOMP as a result of the modulation of existing mitochondrial 
multiprotein channels. Especially, the mitochondrial permeability transition pore 
(MPTP), a mitochondrial multiprotein complex found at the contact sites of inner and 
outer mitochondrial membranes, has been suggested to play a causal role in MOMP. 
Its physiological relevance and molecular composition will be reviewed in detail in 
chapter A.4. 
 
 
A.3.1.2 Lipidic Pores 
The phenomenon of MOMP has also been explained through the formation of lipidic 
pores. According to this model, these pores form upon the interaction of activated 
Bax/Bak or putative other proteins with outer mitochondrial membrane lipids. This 
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interaction allows for membrane bending and the formation of inverted micelles as 
transient lipidic pores(Basanez, Nechushtan et al. 1999; Basanez, Sharpe et al. 
2002). The formation of lipid pores could explain the release of IMS proteins 
including large IMS proteins (e.g. AIF 67kDa) and the experimental difficulty of 
visualizing proteinacous pores in the outer membrane of mitochondria undergoing 
MOMP. Supporting evidence for the lipid pore mediated MOMP comes from cryo-
electron microscopy of Bax permeabilized liposomes, which displayed openings of 
variable sizes (25-100nm) that were abrogated upon addition of BclXL(Schafer, 
Quispe et al. 2009). The edges of these Bax-induced pores are devoid of 
proteinaceous complexes. This distinguishes these pores from protein pores formed 
by bacterial toxins which display protein clad channels when analysed by cryo-
electron microscopy(Tilley, Orlova et al. 2005). Nevertheless, there is no evidence 
that these lipid pores exist in vivo in cells undergoing MOMP. 
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A.4 Mitochondrial Permeability Transition and the PT-pore Complex 
The modification of existing mitochondrial multiprotein channels is another model 
proposed to explain mitochondrial membrane permeabilization (MMP) generally 
preceding apoptotic cell death, both in vitro(Zamzami, Marchetti et al. 1995) and in 
vivo(Zamzami, Marchetti et al. 1995). This process is caused by functional and 
possibly structural changes within a putative multi-protein megachannel, the 
mitochondrial permeability transition pore (MPT-pore) complex(Green and Kroemer 
2004) (Fig.A.13). MPT is defined as the sudden change in permeability of the inner 
mitochondrial membrane (IMM) which is initiated by the opening of a voltage-
dependent, high conductance channel within the IMM known as the PT-
pore(Halestrap, McStay et al. 2002). 
The concept of MPT was first proposed in the 70s and 80s when it was found that 
Ca2+ addition to isolated mitochondria induced a pronounced increase in the 
permeability of the IMM(Hunter, Haworth et al. 1976). This permeability transition 
manifests in mitochondrial matrix swelling, collapse of the mitochondrial membrane 
potential (ΔΨm) and shutdown of ATP synthesis. Later on, patch clamp studies 
confirmed the existence of a Ca2+-sensitive proteinaceaous mitochondrial 
megachannel mediating high conductances. The Ca2+-induced high conductances as 
well as the structural and functional consequences observed in mitochondria could 
be inhibited by Mg2+, Cyclosporin A, and adenosine di-phosphate (ADP) leading to 
the hypothesis that the mitochondrial megachannel mediates MPT; thus it was 
termed mitochondrial PT-pore(Szabo and Zoratti 1992). 
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A.4.1 Physiological Role of the PT-Pore 
Mitochondria are the site of energy generation within a cell and their normal 
function depends on the finely tuned regulation of the mitochondrial membrane 
potential Δψm, on the biosynthesis of molecules and the movement of metabolites. 
The PT-pore plays a major role in maintaining the normal function of mitochondria: 
It connects the outer and the inner mitochondrial membrane and tightly controls the 
transport of metabolites between mitochondrial subcompartments and the cytosol. 
Under physiological conditions, the PT-pore serves as a sensor and regulator of 
adenosine diphosphate (ADP)/adenosine triphosphate (ATP) fluxes between the 
mitochondrial matrix, the intermembrane space and the cytosol - a process termed 
ATP channeling(Brenner and Grimm 2006). The PT-pore also controls the 
homeostasis of protons and soluble metabolites <1.5kDa according to the energetic 
demand of the subcompartments. In line with this, the physiological function of the 
PT-pore is controlled by the adenine nucleotide pools, the intra-matrix pH, the 
mitochondrial membrane potential Δψm, and the redox state(Halestrap, Woodfield et 
al. 1997). Other authors pointed to the possibility that the physiological function of 
the PT-pore might be the formation of mitochondrial networks within a cell by 
establishing intermitochondrial junctions between mitochondria. These would allow 
conjugated mitochondria to function as a bioenergetics continuum permitting 
efficient energy transfer within distant parts of the cell(Crompton 1999); this is 
consistent with immunogold stainings showing enrichment of putative PT-pore 
proteins at mitochondrial contact sites(Konstantinova, Mannella et al. 1995). 
Alterations of the PT-pore composition and structure therefore can affect the cell 
fate via disturbance of its physiological function. Modifications of constituent PT-
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pore proteins can be observed in a variety of chronic and acute pathologies 
including diabetes, aging, neurodegenerative diseases, vascular diseases, cell 
transformation and tumourigenesis(Le Bras, Clement et al. 2005). Opening of the 
PT-pore does not necessarily affect cell viability, as transient opening – so-called 
flickering – of the PT-pore is a physiological phenomenon most likely resulting from 
the pore fluctuating rapidly between open and closed states in intact cells(Petronilli, 
Miotto et al. 1999). These transitory openings allow intra- and extramitochondiral 
solutes to equilibrate and is especially important for cytosolic/mitochondrial Ca2+ 
homeostasis: Ca2+ can enter the mitochondrial intermembrane space relatively 
freely as a result of the permeability of the outer mitochondrial membrane (e.g. via 
Voltage-dependent anion channels, VDACs). Contrarily, transport across the inner 
mitochondrial membrane into the matrix is a tightly controlled process – entry in to 
the matrix is regulated by the mitochondrial Ca2+ uniporter and exit by exchange 
through the Na+/ Ca2+ antiporter(Wong, Steenbergen et al. 2012). Continuous 
cycling of Ca2+ ensures matrix Ca2+ levels that stimulate oxidative phosphorylation 
and subsequent ATP production by allosteric activation of matrix-associated TCA 
(tricarboxylic acid) cycle enzymes. Flickering of the PT-pore has been proposed to 
provide mitochondria with a release mechanism for matrix Ca2+, i.e. preventing 
unwanted Ca2+ overload and associated irreversible PT-pore opening, thus blocking 
induction of apoptosis. 
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A.4.2 The PT-Pore as the Mediator of MOMP Under Apoptotic/Necrotic 
Conditions 
While a transient and controlled permeability of the IMM to protons, water and 
metabolites contributes to mitochondrial homeostasis, extended alterations such as 
the prolonged opening or closure negatively impact on cell viability. Upon cellular 
stress, the pore complex is converted into an unspecific channel resulting in a 
sudden permeability transition, which manifests in the dissipation of the proton 
gradient created by electron transport (dissipation of Δψm), i.e. the uncoupling of 
oxidative phosphorylation. The opening of the PT-pore allows for the massive influx 
of water into the mitochondrial matrix due to osmotic pressure, which in turn leads 
to mitochondrial matrix swelling, cristae remodelling and subsequent rupture of the 
outer mitochondrial membrane(Kroemer and Reed 2000). The rupture of the outer 
mitochondrial membrane manifests itself in MOMP, i.e. loss of mitochondrial 
structure and functional integrity. The concomitant release of apoptogenic factors 
stored in the intermembrane space triggers the activation of downstream apoptotic 
signalling including the caspase-dependent cellular self-destruction, see chapter 
A.2.2. 
Calcium-dependent MPT has been observed as a response to a variety of treatments 
and stimuli, including TNFα, ischemia or pro-oxidants and has been shown to be 
abrogated upon inhibition of MPT with cyclosporin A, sangliferin A or bongkrekic acid 
(Halestrap, Connern et al. 1997; Bradham, Qian et al. 1998; Pritchard, Singh et al. 
2000; Clarke, McStay et al. 2002; Cesura, Pinard et al. 2003; Lee, Bork et al. 
2005). However, this does not prove that in each case the PT-pore is exclusively 
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responsible and necessary for cell death induction, as PT-pore activation could be a 
secondary event or concomitant to other mechanisms. 
Several authors proposed that PT can result in both, apoptotic and necrotic cell 
death with the intensity of the insult, the duration of PTP opening and the level of 
ATP determining the induction as well as the mode of cell death: prolonged opening 
of the PT-pore would be lethal, high intracellular ATP level would prime apoptosis 
and a low ATP level would favour necrosis(Leist, Single et al. 1997; Halestrap 
2005). An extensively studied example of PT-pore involvement in necrosis, is the 
induction of cell death in cardiomyocytes upon ischemia/reperfusion (for a recent 
review refer to (Baines 2011)). In the late 90s, Kroemer et al. postulated that “PT 
pore opening is sufficient and (mostly) necessary for triggering apoptosis”(Kroemer 
1999) based on three lines of evidence: First, apoptosis induction is linked to the 
dissipation of the mitochondrial membrane potential and inhibitors of the PT-pore 
prevent both, mitochondrial depolarization as well as downstream apoptosis signals 
(e.g. caspase activation). Secondly, isolated mitochondria have been shown to 
release apoptogenic factors for the activation of pro-caspases upon PT-pore opening 
in a cell free system. Additionally, the artificial reconstitution of the purified PT-pore 
complex in liposomes showed that opening of the reconstituted pore could be 
inhibited by anti-apoptotic Bcl-2 family members which have been demonstrated to 
inhibit MPT in cells as well as in isolated mitochondria(Kroemer 1999). 
However, the causal involvement of the PT-pore in MOMP and apoptosis induction 
has been controversially discussed ever since, with some schools of thought 
suggesting that apoptosis induction is independent of the PT-pore. This criticism 
with be extensively discussed in chapter A.4.7.  
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A.4.3 Putative Molecular Composition of the PT-pore 
Despite several independent studies addressing the protein composition of the PT-
pore, the identity of actual constituents is subject to scientific debate and has yet to 
be experimentally confirmed in a conclusive fashion. The core proteins forming the 
PT-pore are thought to comprise, among others, the channel proteins ANT1 
(Adenine Nucleotide translocator1) and the voltage-dependent anion channel 
(VDAC) in the inner and outer mitochondrial membrane, respectively(Zamzami, 
Larochette et al. 2005) (Fig.A.13). Directly associated with ANT1 is CypD 
(Cyclophilin D) in the mitochondrial matrix(Tanveer, Virji et al. 1996). 
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Cytosol 
Fig.A.13: The Mitochondrial Permeability Transition Pore Complex and its Function. The PT-pore connects the outer and 
inner mitochondrial membrane (OMM, IMM) thus bridging the mitochondrial matrix and the cytosol. Putative constituents comprise 
ANT1 (Adenine Nucleotide translocator1), voltage-dependent anion channel (VDAC), CypD (Cyclophilin D), HKII (Hexokinase II), 
PBR (Peripheral Benzodiazepine Receptor), CK1 (CKMT1, Mitochondrial Creatine Kinase 1). The PT-pore controls the homeostasis 
and flux of protons and soluble metabolites <1.5kDa according to the energetic demands of the subcompartments. Diverse cellular 
stress signals converge at the mitochondria and regulate mitochondrial permeability transition via affecting the permeability 
transition pore (PT-pore) function. Continuous and unspecific channelling leads to the release of apoptogenic proteins from the 
mitochondrial intermembrane space to induce apoptosis through caspase-dependent and independent mechanisms. Calcium (Ca2+), 
atractyloside, adenine nucleotide depletion, chemotherapeutics and pro-oxidant agents favour membrane permeabilization via 
opening of the PT-pore. In contrast, agents including cyclosporine A, bongkrekic acid, Mg2+, high ADP/ATP) or pH<7 inhibit PT-pore 
opening and prevent apoptosis. The figure was adapted from (Brenner and Grimm 2006). 
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In addition to these components, which were described to constitute the functional 
core of the PT-pore, a number of associated proteins have been detected such as 
HKII (Hexokinase II) on its cytosolic interface, Bax and other Bcl-2 family members 
as well as PBR (Peripheral Benzodiazepine receptor) in the outer mitochondrial 
membrane and finally CKMT1 (Creatine Kinase 1) in the intermembrane 
space(Brenner and Grimm 2006). ANT1 allows the matrix ATP to be exported to the 
intermembrane space and subsequently to the cytosol via VDAC. ATP can also be 
used by the associated CKMT1 or HKII to phosphorylate their respective substrates. 
There is also consensus on the approximate size of this megachannel. The PT-pore 
is supposed to be a multi-protein complex of around 600kDa(Beutner, Ruck et al. 
1998), which spans and connects the outer and inner mitochondrial membranes. 
Some of the PT-pore proteins have also been speculated to be involved in other 
models of MOMP, e.g. VDAC has been shown to interact with Bax in mitochondrial 
extracts as well as in liposomes. Interestingly, Bax was unable to induce the release 
of cytochrome c from mitochondria in VDAC deficient yeast mutants, and VDAC 
transfection restored its Bax mediated release(Narita, Shimizu et al. 1998). VDAC 
isoforms have also been implicated in forming hybrid channels with activated Bax to 
allow for MOMP(Shimizu, Ide et al. 2000). 
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A.4.4 Alternative PT-Pore Models 
Alternatives to the “classical” PT-pore have also been suggested and could involve 
the mitochondrial import machinery constituents(Zoratti, Szabo et al. 2005): 
Accordingly, the outer and inner membrane protein import system, including 
translocase of outer mitochondrial membrane 40 (Tom40), translocase of the inner 
membrane 22 (Tim22) and translocase of the inner membrane 23 (Tim23), has 
been shown to form twin pores, with current records resembling those assigned to 
the PT-pore(Lohret, Jensen et al. 1997; Kunkele, Juin et al. 1998; Truscott, 
Kovermann et al. 2001; Kovermann, Truscott et al. 2002; Rehling, Model et al. 
2003). Evidence supporting the role of the protein import machinery also comes 
from early studies showing that leader peptides (synthetic targeting peptides 
resembling the N-terminus of inner membrane proteins) can induce a fast block of 
the so-called mitochondrial multiple conductance channel (MCC)(Lohret and Kinnally 
1995) but can also induce mitochondrial swelling and activation(Kushnareva, Campo 
et al. 1999). However, the pharmacological response of this MCC is, although 
similar, different to that of the “classical” PT-pore: Cyclosporin A, ADP and 
bongkrekic acid only partially inhibit its activation, whereas positively charged 
compounds which are known to inhibit protein import and Ca2+ induced MPT, display 
strong inhibition. These experimental discrepancies point to the fact that the pores 
formed by the protein import machinery are distinct from the classical PT-pore. 
Nevertheless, it cannot be excluded that these channels share certain constituents 
or are actually formed by the same proteins, but in a different organisation and 
conformation(Zoratti, Szabo et al. 2005).  
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In fact, a variety of permeability transition pores might exist, and their composition 
could depend on the tissue type and circumstances, i.e. experimental setup and 
stimuli used to examine their function. Additionally, the lack of agreement within 
the scientific community on the actual composition of this megachannel indicates 
that PT-pore forming complexes could be transient and disassemble/reassemble 
with relatively high frequency, and with their compositions depending on the actual 
stimuli used to examine their functions. In the subsequent chapters, the focus will 
be on the function of “classical” PT-pore components and experimental evidence for 
their individual contribution or redundancy. 
 
 
A.4.5 The Loss of the Mitochondrial Membrane Potential as an Early 
Indicator for MPT 
Under physiologic conditions, the inner mitochondrial membrane provides a tightly 
controlled frontier between the intermembrane as well as intercristae space and the 
mitochondrial matrix. It is impermeable to almost all ions (including protons), which 
allows the respiratory chain (complexes I-IV) to build a proton gradient across the 
inner mitochondrial membrane that can be harnessed during oxidative 
phosphorylation by the ATPase of the respiratory chain to drive ATP synthesis 
(Mitchell and Moyle 1965). This electrochemical gradient across the inner 
mitochondrial membrane is the basis of the inner mitochondrial transmembrane 
potential ΔΨm and is of critical importance for cellular biogenesis. Loss of the 
mitochondrial membrane potential therefore is an early indicator for changes in the 
permeability of the inner mitochondrial membrane – the priming event in PT-pore 
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mediated mitochondrial permeability transition. Transient fluctuations in the ΔΨm 
occur in physiological circumstances through “flickering” (see chapter A.4.1) of one 
or several pores located in the inner mitochondrial membrane(Zoratti and Szabo 
1995). Prolonged dissipation of ΔΨm is an indicator of the irreversible opening of the 
PT-pore and associated with apoptotic cell death(Marchetti, Castedo et al. 1996). 
Under physiological circumstances, the ΔΨm ranges from 120 to 180mV. As a result, 
the intramitochondrial concentration of cations is 10 to 100 fold higher in the 
mitochondrial matrix compared to the surrounding cytosol. This accumulation of 
cations in the matrix of cells with intact ΔΨm can be harnessed for the measurement 
of the ΔΨm through lipophilic cationic fluorochromes(Castedo, Ferri et al. 2002). 
Polarized mitochondria attract fluorochromes including 3,3′-dihexyloxacarbocyanine 
iodide (DiOC6(3); emission around 552nm), tetramethylrhodamine ethyl ester 
(TMRE, emission around 580nm) and 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide (JC1). JC1 exists as monomers emitting 
in the green spectrum (approximately 527nm), but in higher dye concentrations 
(e.g. when accumulating in mitochondria due to ΔΨm) forms oligomeric aggregates 
emitting in the orange/red spectrum (approximately 590nm). Thus the ratio of 
green and red fluorescence intensities can be used as a measurement of ΔΨm that is 
independent of the total mitochondrial mass/quantity. These mitochondrial 
membrane potential markers have widely been used to assess the loss of ΔΨm as a 
marker for PT-pore opening and apoptosis initiation, and are also used for this 
purpose in this study. 
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A.4.6 The PT-pore and Cancer 
As described in chapter A.1.2, repression of the apoptotic machinery is a 
fundamental characteristic that cancer cells acquire during tumourigenesis(Green 
and Evan 2002) and poses a major challenge in the clinical management of cancer 
by chemotherapy. Therefore, a protein complex such as the PT-pore that is involved 
in the procession of diverse proapoptotic signals, could theoretically be a key target 
for inactivation in cancer cells, or equally a key target for reactivation in the 
therapeutic setting. In fact, there is growing evidence that the dysregulation of the 
PT-pore and its components contributes to tumourigenesis, tumour progression, and 
metastasis(Townson, Naumov et al. 2003; Brenner and Grimm 2006). 
One of the apoptosis inducing signals cancer cells have to overcome to form a 
tumour is the lack of oxygen in the primary tumour or during metastasis formation 
before the de novo growth of blood vessels allows for efficient oxygenation (and 
nutrient supply)(Harris 2002). Considering the sensitivity of the PT-pore for 
hypoxia(Vande Velde, Cizeau et al. 2000), cancer cells must have adapted their 
response to hypoxic conditions, which most likely also includes changes to the 
function, sensitivity or composition of the PT-pore. In most cells, hypoxia induces 
MPT by transcriptional upregulation of specific proapoptotic Bcl-2 family members 
such as BNIP (BCL-2/adenovirus E1B 19 kd-interacting protein) and NIX (BCL-
2/adenovirus E1B 19kDa interacting protein 3-like) via the transcription factor HIF 
(hypoxia-inducible factor)(Vande Velde, Cizeau et al. 2000; Sowter, Ratcliffe et al. 
2001; Kubasiak, Hernandez et al. 2002). 
Another scenario that - under normal conditions – activates the PT-pore is the loss 
of cell to cell contact during the formation of metastases as tumour cells detach 
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from the primary tumour and migrate to distant sites via the blood stream or the 
lymphatic system. Apoptosis induced by loss of cell contact (also known as anoikis) 
is normally regulated by the proapoptotic proteins Bid and Bax, which directly 
modulate PT-pore activation(Valentijn, Metcalfe et al. 2003; Valentijn and Gilmore 
2004). 
Tumour cells also show an increased level of reactive oxygen species (ROS) and are 
therefore under permanent oxidative stress(Pelicano, Carney et al. 2004). High 
concentrations of ROS induce cell death and ROS have been demonstrated to be 
among the most effective activators of the PT-pore(Petronilli, Costantini et al. 
1994). Therefore, tumour cells must have established mechanisms to by-pass cell 
death induced by increased ROS generation: Protection mechanisms include on the 
one hand the upregulation of powerful anti-oxidants such as glutathione or 
thioredoxin(Dvorakova, Payne et al. 2002; Biaglow and Miller 2005), the 
upregulation of enzymes catalysing the break-down of ROS, e.g. via overexpression 
of manganese superoxide dismutase(Pani, Colavitti et al. 2004), or, on the other 
hand, the inhibition of the PT-pore rendering it unresponsive to increased oxidative 
stress and allowing for survival under these conditions(Le Bras, Clement et al. 
2005). This increased acquired or intrinsic resistance of cancer cells against ROS-
induced apoptosis is also relevant in the therapeutic intervention against cancer, as 
most chemotherapeutics induce the formation of ROS(Conklin 2004). Increase 
levels of ROS have been demonstrated to result in Ca2+ release from intracellular 
stores (specifically the ER) or calcium influx into the cytosol from the extracellular 
environment(Ermak and Davies 2002). As described earlier, Ca2+ is a very potent 
stimulus for MPT and it seems plausible, that inhibition of the PT-pore is responsible 
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for the observed resistance against Ca2+ induced apoptosis(Brenner and Grimm 
2006). Alternative mechanisms for reducing the effective Ca2+ concentration have 
been shown to include the reduced release of Ca2+ or the efficient sequestration of 
Ca2+ from mitochondria(Chandra, Mansson et al. 2002). 
 
These examples of pro-apototic signals arising during tumour formation, 
progression and treatment, provide a rational conceptual indication for the 
involvement of PT-pore inhibition in cancer cell survival. And indeed, specific 
components or proteins associated with the PT-pore complex are differentially 
expressed in cancer cells(Brenner and Grimm 2006). Examples thereof will be given 
in the following paragraphs.  
The PBR of the outer mitochondrial membrane has been found to be overexpressed 
in many carcinomas, including breast, ovarian, hepatic and colon. Interestingly, 
increased PBR expression correlated with aggressiveness of breast 
tumours(Hardwick, Fertikh et al. 1999), a shortened life expectancy in a patient 
cohort with astrocytomas(Miettinen, Kononen et al. 1995) and higher metastasis 
rates in colorectal cancer(Maaser, Grabowski et al. 2005). 
Hexokinase II is found upregulated in various tumour cell lines(Shinohara, Ichihara 
et al. 1991; Rempel, Mathupala et al. 1996), which is consistent with its function of 
promoting VDAC closure and preventing mitochondria-mediated apoptotic cell 
death(Azoulay-Zohar, Israelson et al. 2004). 
Another PT-pore component, cyclophilin D is upregulated in cancer cells from 
estrogen-responsive tissues such as ovary and uterus and inhibits the PT-pore in 
vitro(Schubert and Grimm 2004). There is also some data on the differential 
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expression of CKMT1 in cancer cells, which will be discussed separately in chapter 
A.5.4. 
Considering the above-mentioned data on the differential expression of subunits of 
the PT-pore, it seems plausible that PT-pore function and sensitivity could be 
regulated by the relative abundance of its components – and this could be the 
reason for the differential expression in normal versus transformed cells. 
 
 
A.4.7 Reappraisal of the PT-pore Composition/Model 
Despite the large number of studies providing evidence for a role of the PT-pore 
complex in cell death, there is no consensus on the constituent proteins that are 
essential for its function, and the standard model of the PT-pore has been 
challenged by recent studies: 
 
ANT isoforms, especially ANT1, have been described as classical PT-pore 
components. This is supported by the fact that purified ANT can induces pore 
formation in artificial membranes(Brustovetsky, Tropschug et al. 2002) and ANT1 
overexpression(Bauer, Schubert et al. 1999) as well as ANT3 overexpression 
(Zamora, Granell et al. 2004) dominantly induce apoptosis in cultured cells. 
However, recent knock-out studies demonstrated that cells deficient in ANT1 and 
ANT2 (a homolog of ANT-1) are still able to induce PT in response to increased Ca2x 
concentrations and show only minor alterations in cell death induction(Halestrap 
2004; Kokoszka, Waymire et al. 2004). Interestingly, putative PT-pore inhibitors 
acting as ANT ligands (e.g. atractyloside and ADP) did not have any inhibitory 
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impact on PT-pore activation anymore. Although one could thus argue that ANT 
isoforms are dispensable for MPT, the experimental data has several caveats: ANT 
deficient hepatocytes did not show an altered apoptotic response to Fas- and TNFα-
receptor stimulation. These cell death stimuli act via the death receptor pathway, 
and other authors suggest that the activation of the PT-pore might not be necessary 
for apoptosis induction(Kim, Zhao et al. 2000; Soriano, Nicolosi et al. 2004). Thus, 
it is questionable whether the studies on ANT deficient cells used the appropriate 
stimulus to test ANT requirement for PT-pore activation. Additionally, a 
compensatory phenomenon in this conventional knock-out mouse model cannot be 
excluded, especially since other structurally similar ANT isoforms like the recently 
discovered ANT4(Dolce, Scarcia et al. 2005) could compensate for the deficiency in 
ANT1/ANT2. 
 
VDAC has also been described as a core component of the PT-pore. Supporting 
experimental evidence comes from VDAC reconstitution in artificial liposomes as 
well as from mitochondrial fractionation experiments that isolated endogenous PT-
pore complexes containing VDAC(Beutner, Ruck et al. 1998). Additionally, more 
recent studies on VDAC oligomerization propose that oligomeric VDAC channels are 
coupled to apoptosis induction and could be responsible for the release of 
apoptogenic IMS proteins(Keinan, Tyomkin et al. 2010). Nevertheless, using knock-
out mice, Baines et al.(Baines, Kaiser et al. 2007) claimed that VDAC is dispensable 
for mitochondrial-dependent cell death: Mitochondria from VDAC-deficient mice 
(deletion of the VDAC1 and VDAC3 genes, knock-down of VDAC2) exhibit a Ca2x and 
oxidative stress-induced MPT that is indistinguishable from wild-type mitochondria. 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |103 
 
 
Cyclophilin D has also been postulated as a key regulator/component of the PT-
pore. Interestingly, the effect of cyclophilin D has been described as both, pro- and 
anti-apoptotic depending on the cellular setting and stimulus used to induce MPT: In 
vitro, overexpression of cyclophilin D can repress mitochondrial apoptosis(Lin and 
Lechleiter 2002; Li, Johnson et al. 2004; Schubert and Grimm 2004; Machida, Ohta 
et al. 2006; Eliseev, Malecki et al. 2009). Contrarily, cyclophilin D overexpressing 
transgenic mice show mitochondrial swelling and spontaneous cell death(Baines, 
Kaiser et al. 2005). Inhibition of cyclophilin D by cyclosporine A has also been 
shown to either repress PT-pore activation and apoptosis(Halestrap and Davidson 
1990; McGuinness, Yafei et al. 1990) or to induce apoptosis itself in certain cell 
lines(Grub, Persohn et al. 2000; Serkova, Christians et al. 2004). Equally 
unexpected is the finding that downregulation of cyclophilin D by RNAi (RNA 
interference) could both, sensitize towards(Machida, Ohta et al. 2006) as well as 
protect against apoptotic stimuli(Zhang and Armstrong 2007; Kato, Akao et al. 
2009; Hu, Chen et al. 2010). The question of the involvement of cyclophilin D in PT-
pore regulation and apoptosis induction has also been addressed by several knock-
out studies: In all fours studies, isolated mitochondria from liver, heart and brain of 
Cyclophilin D knock-out mice are resistant to mitochondrial swelling caused by 
permeability transition(Baines, Kaiser et al. 2005; Basso, Fante et al. 2005; 
Nakagawa, Shimizu et al. 2005; Schinzel, Takeuchi et al. 2005) – although PT-pore 
opening can still be observed when applying a stronger stimulus, i.e. higher Ca2x 
concentrations. These studies corroborated the critical role of cyclophilin D in MPT, 
however they failed to consistently prove involvement of the PT-pore in apoptosis 
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regulation: Cyclophilin D deficient cells showed normal apoptotic sensitivity towards 
a range of apoptotic stimuli including tBid, Bax, etoposide, TNFα, staurosporine, and 
A23187 (a Ca2+ ionophore)(Baines, Kaiser et al. 2005; Nakagawa, Shimizu et al. 
2005). On the other hand, primary cyclophilin D knock-out cells were largely 
protected against Ca2+ overload induced by ionomycin or thapisgargin and oxidative 
stress-induced (via H2O2) apoptotic cell death(Baines, Kaiser et al. 2005). Nakagawa 
et al. claim that cyclophilin D is only involved in necrotic cell death, whereas Baines 
et al. showed that cyclophilin D deficient cells show an altered apoptotic response. 
Considering these controversial findings, the model of the opening of the PT-pore as 
the MOMP inducing mechanism can neither be rejected nor validated, but remains 
the topic of intense scientific discussions. Furthermore, it could be that the variation 
in the duration and strength of the stimulus used for cell death induction accounts 
for the discrepancy of the findings. Also, long-term adaptive responses of the 
knock-out cells might obscure the actual effect of loss of cyclophilin D(Grimm and 
Brdiczka 2007). 
Another protein that has been consistently mentioned to contribute to the PT-pore is 
mitochondrial creatine kinase 1 (CKMT1) - experimental data on its contribution to 
MPT and relevance for apoptosis induction will be discussed in the subsequent 
chapter A.5. 
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A.5 The Function of Mitochondrial Creatine Kinase CKMT1 
Mitochondrial creatine kinase (CKMT1) is ubiquitously expressed in human tissues. 
It is found in the mitochondrial cristae and intermembrane space near contact sites 
of the outer and inner mitochondrial membranes and has been implicated to play an 
inhibitory role in mitochondrial permeability transition(Schubert and Grimm 2004; 
Brenner and Grimm 2006). In humans, two genes located near each other on 
chromosome 15, CKMT1A and CKMT1B, have been identified, which encode identical 
mitochondrial creatine kinase proteins(Stallings, Olson et al. 1988) – their 
respective full length cDNAs however can be distinguished by 2 synonymous point 
mutations. 
 
 
A.5.1 CKMT1 as Part of the Cellular Creatine Kinase/Phosphocreatine 
Shuttle 
The existence of compartment specific isoenzymes of creatine kinase (CK) is key to 
the function of creatine kinases in cellular energy metabolism(Schlattner, Tokarska-
Schlattner et al. 2006). By their name, creatine kinases catalyse the reversible 
transphosphorylation of phosphocreatine and ADP to creatine and ATP. The pool of 
rapidly diffusible phosphocreatine can function as a temporal and spatial buffer for 
cellular ATP levels, which is especially critical in tissues with large and fluctuating 
energy demands (e.g. muscle or brain). Mitochondrial and cytosolic creatine kinases 
link the site of energy production (mitochondria) to sites of energy consumption 
(various cellular ATPases) via creatine/phosphocreatine shuttling(Dolder, Walzel et 
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al. 2003); see Fig.A.14. ATP generated by oxidative phosphorylation in mitochondria 
is supplied by ANT1 and used by CKMT1 to phosphorylate creatine. Phosphocreatine 
subsequently leaves the mitochondria via VDAC, diffuses in the cytosol and buffers 
the cytosolic ATP/ADP pool via transphosphorylation of phosphocreatine to ATP; 
creatine is then shuttled back to mitochondria for recharging. In less oxidative 
tissues (e.g. glycolytic muscle), the cytoplasmic pool of phosphocreatine is mainly 
supplied by cytosolic creatine kinases, which can associate with glycolytic 
enzymes(Vial 2006). Cytosolic CKs are also found associated and functionally 
coupled with ATP consuming processes and maintain locally high ATP concentrations 
and ATP/ADP ratios. Of note, this phosphocreatine shuttle system only works in the 
presence of its basic substrate – creatine. Originally, it was believed that creatine is 
only synthesiszed by a few types of cells including liver and kidney cells. Other cells 
would depend on creatine uptake from the extracellular environment via the blood 
stream, which depends on the expression of a specific creatine transporter CRT(Vial 
2006). The cell-specific expression of CRT has not been extensively studied on the 
protein level, however microarray data available supports the idea that it is 
expressed to some degree in various cell types. Furthermore, there is some 
evidence, that creatine can directly be synthesised by a variety of cell types, e.g. 
neuronal cells(Carducci, Santagata et al. 2012) and seminiferous epithelium(Moore, 
Gray et al. 1998). In line with this, considerable mRNA levels of enzymes involved 
in creatine biosynthesis have also been detected in heart, lung, spleen, muscle, 
brain, testis, ovary and thymus(Wyss and Kaddurah-Daouk 2000). 
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A.5.2 Structure/Function Relationship of CKMT1 
The CKMT1 precursor is 417 amino acids in length; however the mature protein is 
generated by cleaving off the mitochondria targeting transit peptide (amino acids 1-
39) upon import into the mitochondrial intermembrane space(Haas and Strauss 
1990). The mature CKMT1 then assembles into dimers, which rapidly associate to 
form octamers. Although octamer formation is a reversible process, the octameric 
Fig.A.14: The Creatine Kinase/Phosphocreatine Shuttle System. Compartment-
specific isoenzymes of creatine kinase (CK) are found in the mitochondria and the 
cytosol. They are either associated with ATP-generating processes (oxidative 
phosphorylation and glycolysis), or with ATP-consuming processes (cytosolic ATP-
consumption) or occur as cytoplasmic soluble CK to maintain cytosolic ATP/ADP 
ratios(Schlattner, Tokarska-Schlattner et al. 2006). 
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state is strongly favoured at the local pH and CKMT1 concentration in the 
intermembrane space. Octameric CKMT1 then binds to the mitochondrial 
membranes following a biphasic binding process(Maniti, Lecompte et al.) depending 
on polar interaction with cardiolipin and hydrophobic interactions within the lipid 
bilayer(Schlame and Augustin 1985; Schlattner and Wallimann 2000). This leads to 
the assembly of proteolipid complexes containing CKMT1, VDAC, ANT and 
phospholipids. The principal receptors of CKMT1 in the inner mitochondrial 
membrane is cardiolipin, whereas receptors in the outer mitochondrial membrane 
include VDAC and anionic phospholipids(Muller, Moser et al. 1985; Rojo, Hovius et 
al. 1991; Vial 2006). While the interaction between VDAC and CKMT1 is 
direct(Schlattner, Dolder et al. 2001), the interaction with ANT has been speculated 
to be indirect via mutual binding to cardiolipin(Beyer and Klingenberg 1985; Vial 
2006). A model of CKMT1 maturation, localisation and function is presented in 
Fig.A.15. 
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Fig.A.15: Model of CKMT1 Maturation, Dimerization, Octamerization, Membrane Binding and Substrate Shuttling. 
Nascent CKMT1 is imported into the mitochondrial intermembrane space followed by cleavage of the N-terminal mitochondrial 
targeting sequence (transit peptide). Mature CKMT1 forms dimers which assemble into octamers. Octameric CKMT1 binds to 
mitochondrial membranes via a biphasic binding process, which is thought to involve 2 interaction sites: Electrostatic interaction 
of C-terminal basic residues (bas) with acidic cardiolipin mediates fast membrane binding, whereas slower association is 
achieved via the insertion of a C-terminal hydrophobic stretch (hps) into the lipid bilayer(Maniti, Lecompte et al.). This process 
anchors CKMT1 firmly to the mitochondrial membranes. CKMT1 is mainly found in mitochondrial contact sites associated with 
VDAC and ANT, as well as in the mitochondrial cristae space associated with ANT only. This arrangement facilitates metabolite 
channelling and results in the directed transport of phosphocreatine into the cytosol. The figure has been adapted from(Vial 
2006) 
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A.5.3 The Role of CKMT1 Proteolipid Complexes in Apoptosis and 
Mitochondrial Ultrastructure 
Metabolite channelling between ANT1, CKMT1 and VDAC takes place in a 
microcompartment that might associate with or constitute the putative PT-pore and 
is hypothesized to be required for protection against PT-pore opening(Lenz, Schmidt 
et al. 2007). In vitro, reconstituted contact site complexes containing, among 
others,  CKMT1, ANT and VDAC have been shown to display many features of the 
PT-pore, such as Ca2+-dependent pore opening and release of intravesicular 
contents(Beutner, Ruck et al. 1996; Beutner, Ruck et al. 1998). In line with this 
hypothesis, isolated liver mitochondria from transgenic mice containing CKMT1 
(liver tissue does not normally express high levels of CKMT1) showed impaired PT-
pore opening under certain conditions. PT-pore inhibition could only be observed in 
the presence of creatine(O'Gorman, Beutner et al. 1997), which resulted in the 
conclusion that not CKMT1 presence per se, but rather its enzymatic activity and the 
production of metabolites is responsible for PT-pore inhibition(Dolder, Walzel et al. 
2003; Vial 2006). 
Efforts to identify the putative PT-pore complex by TritonX100 membrane extraction 
succeeded in isolating liposome vesicles containing VDAC1, a CKMT1 octamer 
(Fig.A.16), HKII, and ANT1. In vitro, these vesicles showed properties of Ca2x-
dependent PT-pore opening(Beutner, Ruck et al. 1998) suggesting that the CKMT1 
octamer plays a role in MPT. Furthermore, CKMT1 is believed to induce the 
formation of contact sites between the outer and inner mitochondrial membrane by 
binding the intermembrane sides of both, the inner as well as the outer 
mitochondrial membrane. This leads to membrane crosslinking and increased 
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stability of the mitochondrial architecture as demonstrated by resistance against 
detergent induced lysis(Speer, Back et al. 2005). 
 
 
 
  
Fig.A.16: Tertiary and Quaternary Structure of CKMT1 as Obtained by 
Crystallography. CKMT1 is organized as an octamer with the membrane binding residues 
illustrated in yellow; the active centre of the enzyme is depicted in red; left: horizontal 
perspective; right: vertical perspective relative to the mitochondrial membranes; Rasmol 
was used to visualize protein data bank entry pdb1qk1(Eder, Fritz-Wolf et al. 2000). 
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A.5.4 CKMT1 in Pathological Settings 
Early studies performed in the 1980ies suggested that CKMT1 is upregulated in 
several malignancies with poor prognoses, such as lung cancer, gastric cancer and 
prostate cancer(DeLuca, Hall et al. 1981; Tsung 1983; Kanemitsu, Kawanishi et al. 
1984; Pratt, Vallis et al. 1987). Additionally, more recent studies examining gene 
expression profiling using microarray analysis in breast cancer tissue from patient 
groups with distinct clinical outcomes identified that CKMT1 expression is 
significantly associated with both, disease free survival and overall patient 
survival(Cimino, Fuso et al. 2008). This data suggests that CKMT1 expression could 
serve as an independent prognostic marker, see Fig.A.17. 
It has also been speculated that impairment of CKMT1 function and structure could 
contribute to neurodegenerative disorders, as well as ischemia induced cell death 
and cardiomyopathies(Vial 2006). This is based on the assumption that these 
pathological phenotypes often display oxidative damage via reactive oxygen species 
(ROS) formation and a poor energetic state of the cell. And indeed, several in vitro 
and in vivo studies show that ROS interfere with the enzymatic activity, oligomeric 
state and membrane binding capacity of CKMT1(Stachowiak, Dolder et al. 1998; 
Soboll, Brdiczka et al. 1999; Tokarska-Schlattner, Wallimann et al. 2002; Wendt, 
Schlattner et al. 2003). In these instances, CKMT1 would no longer protect against 
mitochondrial permeability transition and maintain the ultrastructural architecture of 
mitochondria – however, evidence of the physiological relevance of this model is not 
available yet. 
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A.6 On the Search for Novel Candidates Involved in MPT 
Considering the experimental data available on the PT-pore up to date, it is critical 
to state that the actual molecular constituents and regulators of the PT-pore, as well 
as its dynamic changes upon apoptosis induction, are still elusive. Thus, so far 
poorly defined proteins located in the mitochondrial membranes and intermembrane 
space, could be functionally involved in MPT. One candidate protein examined in this 
study that might be functionally involved in PT-pore regulation, is IκBα (nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha). IκBα has 
recently been found to reside in mitochondria and interact with ANT1(Bottero, Rossi 
et al. 2001; Cogswell, Kashatus et al. 2003), a mediator of the mitochondrial PT. 
Fig.A.17: Association of CKMT1B Expression with Overall Survival and Time to 
Relapse in Breast Cancer Patients. Microarray studies suggest that CKMT1 expression 
could be used as an independent prognostic marker in breast cancer: Kaplan-Meier plots of 
overall survival (A) and time to relapse (B) for patient groups with low and high expression 
levels of CKMT1B are shown(Cimino, Fuso et al. 2008). 
A) B) 
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However, the actual functional role of mitochondrial IκBα has not been addressed in 
any experimental setting. Interestingly, IκBα is a direct target gene of NF-кB 
(nuclear factor kappa b), a transcription factor that has recently been shown to 
mediate malignant transformation, tumour progression and resistance to apoptotic 
stimuli by inducing the transcription of anti-apoptotic genes when rendered 
constitutively active(Ravi and Bedi 2004). Thus it is conceivable that mitochondrial 
IκBα could contribute to the apoptosis resistant phenotype in cells with constitutive 
NF-кB signaling via impacting on PT-pore function. A possible relevance of IκBα in 
regulating MPT is examined in this study (see B.2), and therefore the basics of 
canonical NF-κB signalling are outlined in the following chapter. 
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A.6.1 A Short Glimpse on NF-κB Signalling 
The “nuclear factor κ-light-chain-enhancer of activated B-cells” (NF-κB) family is a 
group of transcription factors that is expressed in various cell and tissue types and 
plays a crucial role in mediating the inflammatory response(Baeuerle and Henkel 
1994). Under normal conditions, NF-κB is inactive as it is sequestered in the cytosol 
by binding of a family of inhibitory proteins (“inhibitors of κB” – IκB), which will be 
further discussed below. However, upon activation, a sequence of molecular events 
results in the degradation of these inhibitory proteins, and allows NF-κB to form 
dimers – either a homodimer or a heterodimer of 5 subunits: NF-κB1 (p50/p105), 
NF-κB2 (p52/p100), RelA (p65), RelB, and c-Rel (Gilmore 2006). Dimeric NF-κB can 
enter the nucleus and functions as a transcriptional activator or repressor. NF-κB1 
and NF-κB2 can only repress transcription since they lack the crucial transactivation 
domain (TD), which is present in the other subunits and functionally necessary to 
promote the transcription of target genes(Li and Verma 2002). The various dimer 
combinations allow the cell to specifically activate the expression/repression of 
certain genes in a stimulus specific way as dimers exhibit differential binding 
affinities to promoter regions depending on their composition(Gilmore 2006). 
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A.6.1.1 Inhibitors of NF-κB 
As mentioned above, IκBs reside primarily in the cytosol and sequester the NF-κB 
subunits, thereby blocking their activity as a transcription factors. Binding of IκBs to 
NF-κB is via multiple contact sites and typically masks the nuclear localization signal 
and DNA binding domain(Chen and Ghosh 1999). The IκB protein family comprises 
IκBα, IκBβ, IκBε and Bcl-3, each of which displays several copies of a structural 
motif called “ankyrin repeat” (ANK) involved in protein-protein interactions and 
binds differentially to NF-κB subunits(Hayden and Ghosh 2012).  
 
IκBα 
The best characterised IκB and the one studied in this project is IκBα, the structure 
of which is shown in Fig.A.18. IκBα consists of three distinct domains – an N-
terminal regulatory domain for signal dependent degradation, an ankyrin repeat 
domain comprising ANK1-ANK5 thought to mediate protein-protein interaction, and 
a C-terminal regulatory sequence containing a PEST sequence(Haskill, Beg et al. 
1991). 
The N-terminal domain has 2 critical serine residues at position 32 and 36 which are 
phosphorylated upon cellular stress signals, diverse cytokines or bacterial infections. 
Phosphorylation triggers the polyubiquitination at lysines 21 and 22 via K48 
ubiquitin chains, which demarks the protein for proteasomal 
degradation(Palombella, Rando et al. 1994; Scherer, Brockman et al. 1995; 
DiDonato, Mercurio et al. 1996; Rodriguez, Wright et al. 1996; Roff, Thompson et 
al. 1996; DiDonato, Hayakawa et al. 1997; Lee, Hagler et al. 1997; Lee, Peters et 
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al. 1998). Degradation of IκBα exposes the nuclear localization signal of NF-κB, 
allowing for its translocation into the nucleus. 
The intermediate ANK repeat motives are the interaction domains for binding NF-κB 
subunits. Binding of IκBα to NF-κB dimers usually results in masking the nuclear 
localisation sequence of one NF-κB subunit, which is sufficient to prevent 
transcriptional activity(Li and Verma 2002). Although inactive IκBα/NF-κB 
complexes can still enter the nucleus, they can be rapidly exported by the nuclear 
export signal of IκBα(Baeuerle and Henkel 1994; Turpin, Hay et al. 1999; Li and 
Verma 2002). IκBα can inhibit activation of cytosolic NF-κB, but can also dissociate 
active DNA-bound NF-κB. This activity seems to be dependent on the C-terminal 
PEST sequence(Ernst, Dunn et al. 1995). 
IκBα knock-out mice display constitutive NF-κB activation, increased neonatal 
lethality and enhanced granulopoiesis(Beg, Sha et al. 1995; Hayden and Ghosh 
2012). 
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A.6.1.2 NF-κB Activation  
As mentioned beforehand, canonical NF-κB activation depends on stimuli degrading 
IκBα. This degradation is achieved via phosphorylation, subsequent ubiquitination 
and proteolytic degradation by the 26s proteasome. Phosphorylation of IκBα is 
mediated by the IkappaB kinase complex (IKK complex)(Karin and Ben-Neriah 
2000) which consists of IKKα and IKKβ and the NF-κB essential modulator (NEMO) 
or IKKγ. The canonical NF-κB pathway can be triggered by stimulation of TNFR1/2, 
T cell receptor (TCR), B cell receptors (BCR) and toll like receptors (TLR) and results 
in the upregulation of chemokines, cytokines, adhesion molecules, cell survival and 
Fig.A.18: Structural Representation of IκBα. The quaternary structure of IκBα 
binding NF-κB: The ribbon diagram on the left shows the X-ray crystal structure of the 
IκBα (blue)/p65(red)/p50(green) heterodimer; the nuclear localisation sequence of p65 is 
shown in violet(Bergqvist, Croy et al. 2006). This model shows 6 ankyrin repeats (AR), 
whereas the protein database Uniprot describes 5 AR and considers AR6 as part of the C-
terminal domain. On the right, important residues and domains of IκBα are depicted 
according to Uniprot. The figure was modified from the PhD thesis of E. Pazarentzos. 
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inflammatory responses. Non-canonical NF-κB signalling involves activation of TNF 
receptor family members including LTβR (lymphotoxin β receptor), BAFF-R (B cell 
activating factor), CD40 or CD30 and primarily controls lymphoid organ 
development and the adaptive immune system(Hayden and Ghosh 2004; Gilmore 
2006; Hayden and Ghosh 2008; Hayden and Ghosh 2012). Most cytokines of the 
TNF family, but also apoptosis inducing chemotherapeutics elicit an NF-κB response 
(Aggarwal 2000). The pro-survival NF-κB response is a major determinant of 
responsiveness to chemotherapy, and inhibition of NF-κB signalling has been shown 
to increase chemotherapy-induced apoptosis(Monks, Biswas et al. 2004). 
 
 
A.6.1.3 NF-κB Target Genes and Transcriptional Feedback Loops 
Active NF-κB regulates the transcription of genes involved in inflammation 
(cytokines and cytokine receptors, growth factors, adhesion molecules, etc.). These 
also include pro-inflammatory cytokines (e.g. interleukin1, TNFα) which enhance 
NF-κB activation via a positive feedback loop(Blackwell and Christman 1997). 
However, active NF-κB also triggers a negative feedback loop via the transcriptional 
upregulation of anti-inflammatory cytokines (e.g. interleukin10) as well as by 
promoting the transcription of its own inhibitor IκBα, which is normally sufficient to 
switch off NF-κB signalling(Blackwell and Christman 1997). 
Given the fact that the multi-component NF-κB signalling pathway crucially 
regulates the expression of a plethora of genes involved in various key cellular 
processes (such as cell proliferation, cell survival, the cellular stress response, 
innate immunity and inflammation; see Fig.A.19), it comes as no surprise, that 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |120 
 
dysregulation of NF-κB signalling is associated with diseases such as chronic 
inflammation, immunodeficiency or cancer(Courtois and Gilmore 2006). Due to NF-
κB targeting many genes promoting cell proliferation and survival, its activation is 
associated with a decreased susceptibility to apoptosis. Accordingly, its inhibition 
renders cancer cells more susceptible to apoptosis(Van Antwerp, Martin et al. 1996; 
Baichwal and Baeuerle 1997; Clifton, Goss et al. 1998; Van Antwerp, Martin et al. 
1998; Aggarwal 2000; Edderkaoui, Odinokova et al. 2008; Bauerle, Schweppe et al. 
2010). Similarly, IκBα in its exhaustively studied role as a cytoplasmic inhibitor of 
NF-κB, is thought to have a pro-apoptotic function as it blocks the anti-apoptotic 
NF-κB signalling pathway. 
 
 
A.6.2 Mitochondrial Localisation of NF-κB and IκBα 
In recent years, experimental evidence has accumulated indicating a role of NF-κB 
subunits and IκBα in mitochondria: Electron microscopy studies identified NF-κB and 
IκBα in all mitochondrial compartments – the matrix, the inner mitochondrial 
membrane, the intermembrane space, and the outer mitochondrial membrane 
(Bottero, Rossi et al. 2001; Cogswell, Kashatus et al. 2003; Zamora, Merono et al. 
2004; Lee, Sharma et al. 2008). Interestingly, IκBα was identified as an interaction 
partner of ANT1(Bottero, Rossi et al. 2001) and subsequent studies identified NF-κB 
subunits as negative regulators of ANT1 induced apoptosis(Zamora, Merono et al. 
2004): NF-κB gets recruited to mitochondria upon ANT1 overexpression. This 
recruitment prevents DNA binding and pro-survival gene activation and contributes 
to extensive apoptosis following ANT1 overexpression.  
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Fig.A.19: NF-κB Stimuli and Target Genes. NF-κB is a central mediator of key cellular 
processes such as the immune and inflammatory responses or stress responses via 
regulation of cell proliferation and apoptosis. Representative examples of NF-κB inducers 
and NF-κB-dependent target genes are given. LPS lipopolysaccharide, dsRNA double 
stranded RNA, TCR T cell receptor, BCR B cell receptor, TNFα tumour necrosis factor alpha, 
IL-1 interleukin1, UV ultra violet, VCAM vascular cell adhesion protein 1, ICAM intercellular 
adhesion molecule 1, MHC major histocompatibility complex, IκBα nuclear factor of kappa 
light polypeptide gene enhancer in B-cells inhibitor alpha, G-CSF Granulocyte colony-
stimulating factor, M-CSF macrophage colony-stimulating factor, Bcl-XL B-cell lymphoma-
extra large, IAPs inhibitor of apoptosis. The figure was modified from(Oeckinghaus and 
Ghosh 2009). 
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Additionally, mitochondrial NF-κB has been shown to regulate mitochondrial gene 
expression by repressing the transcription of certain mtRNAs(Cogswell, Kashatus et 
al. 2003; Johnson, Witzel et al. 2011). Both, IκBα and NF-κB are released from 
mitochondria during FasL induced apoptosis(Bottero, Rossi et al. 2001). Although 
these data provide initial evidence that the mitochondrial IκBα/NF-κB pool 
participates in apoptosis regulation, further studies are need to decipher its 
functional involvement in regulating the apoptotic cascade. 
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B.HYPOTHESES 
 
B.1 The Role of CKMT1 in Mitochondrial Apoptosis Regulation 
Considering the central role of mitochondrial permeability transition in apoptosis 
regulation, understanding the composition and function of the PT-pore may be the 
basis for a rational, therapeutic intervention for a variety of disease states involving 
deregulated cell death(Kroemer 2003). At one end of the spectrum, acquired 
insensitivity to apoptotic stimuli and a lack of cell death can be observed in cancer 
cells and contributes to tumourigenesis(Hanahan and Weinberg 2000) as well as 
chemotherapy resistance(Pommier, Sordet et al. 2004). At the other end of the 
spectrum, increased apoptosis sensitivity fuelling an excess of cell death can be 
observed in neurodegenerative pathologies(Mattson 2000). Another determinant of 
cell viability is the regulation of the energy metabolism, with recent evidence that 
the dysregulation of metabolic pathways on the cellular level is a major determinant 
of disease formation, e.g. metabolic reprogramming fuels tumourigenesis(Hanahan 
and Weinberg 2011) or the impairment of energy metabolism causes 
neurodegeneration(Schon and Manfredi 2003). 
The function of the mitochondrial creatine kinase CKMT1 could therefore be a prime 
determinant of cellular fate: CKMT1 has been described to be associated with and 
speculated to regulate the putative PT-pore forming complex and thus apoptosis; 
and at the same time CKMT1 influences, via its enzymatic function, the cellular 
energy homeostasis. However, the functional role of CKMT1 in mitochondrial 
apoptosis is poorly defined and its mechanistic and/or metabolic contribution has 
not been addressed yet. 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |124 
 
Interestingly, in vitro studies demonstrated that PT-pore activation could only be 
achieved after dissociation of multimeric CKMT1 from the PT-pore(Beutner, Ruck et 
al. 1998). Thus, we hypothesize that CKMT1 exerts its anti-apoptotic effect through 
direct protein-protein interactions with PT-pore members, possibly independently of 
its enzyme activity. We aim to establish CKMT1 as a functionally necessary 
multimeric gatekeeper of the PT-pore that - upon apoptosis induction - dissociates 
from the PT-pore. This dissociation could be a priming event for the opening of the 
PT-pore, resulting in mitochondrial permeability transition, subsequent caspase 
activation and execution of apoptotic cell death. 
We expected that an increase of CKMT1 levels would provide cells with and 
advantage (proliferation, apoptosis resistance, etc.) whereas a reduction of 
endogenous CKMT1 levels by RNAi would be disadvantageous for the cell (inhibit 
growth, sensitize cells to apoptosis, etc.). These effects could be due to PT-pore 
regulation as CKMT1 is hypothesized to keep the PT-pore complex inactive. A 
catalytically inactive CKMT1 mutant will be used to study the involvement of the 
kinase activity in any effects observed. 
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B.2 The Role of IκBα at Mitochondria 
The actual molecular composition of the PT-pore as well as its regulation and 
dynamic changes upon apoptosis induction are still elusive. Thus, the second part of 
the project aims to investigate the relevance of IκBα as a regulator of MPT as it has 
recently been found to reside in mitochondria and interact with ANT1(Bottero, Rossi 
et al. 2001; Cogswell, Kashatus et al. 2003), a PT-pore regulator. Unpublished data 
by Dr. Foy Osborne indicated that mitochondrial IκBα can act as a potent apoptosis 
inhibitor. Interestingly, IκBα is a direct target gene of NF-кB (nuclear factor kappa 
b), a transcription factor that is constitutively active in numerous cancers(Nakshatri, 
Bhat-Nakshatri et al. 1997; Sovak, Bellas et al. 1997; Karin, Cao et al. 2002) and 
that mediates malignant transformation, tumour progression and resistance to 
apoptotic stimuli by inducing the transcription of anti-apoptotic genes(Ravi and Bedi 
2004). The best-described function of IкBα is the inhibition of NF-кB signaling by 
sequestering NF-кB in the cytosol(Le Bail, Schmidt-Ullrich et al. 1993; Karin and Lin 
2002). However, recent studies have revealed a novel locale of IкBα – the 
mitochondrial intermembrane space(Bottero, Rossi et al. 2001; Cogswell, Kashatus 
et al. 2003). The function of mitochondrial IκBα has not been addressed yet. 
Therefore we proposed that elevated levels of mitochondrial IκBα might result in an 
apoptosis-resistant phenotype. This function of IκBα would be in contrast to its well-
described ability to inhibit the anti-apoptotic NF-кB signaling(Bradham, Qian et al. 
1998; Muenchen, Lin et al. 2000). 
Overexpression of an IκBα construct that is specifically targeted to mitochondria will 
be used to study the effects of increased mitochondrial IκBα levels on apoptosis. 
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B.3 Specific Aims of the Project 
The experimental work conducted during this PhD aimed to address the following 
questions: 
Project focusing on CKMT1: 
- What cellular effect does CKMT1 overexpression have in terms of 
proliferation, cell death sensitivity/resistance, and PT-pore activation? 
- Does the proposed function of CKMT1 in apoptosis regulation depend on its 
kinase activity? 
- What cellular effects does downregulation of endogenous CKMT1 expression 
have in terms of proliferation, cell death sensitivity/resistance, and PT-pore 
activation? 
- Does CKMT1 function as an apoptosis inhibitor via PT-pore regulation? 
- Is CKMT1 a functionally necessary gatekeeper for PT-pore opening? 
- Does the multimeric assembly of CKMT1 change to initiate apoptosis? 
- Is CKMT1 released from the IMS during apoptosis? 
 
Project focusing on mitochondrial IκBα: 
- Does mitochondrial IκBα play a role in apoptosis regulation? 
- Does mitochondrial IκBα interact with and regulate the PT-pore? 
- If mitochondrial IκBα regulates apoptosis, what are the functional domains 
and/or interaction partners necessary for this effect?  
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C. Methods and Materials 
 
C.1 List of Non-standard Commercial Reagents and Materials 
The following reagents were purchased from Sigma-Aldrich (UK): 2-
mercaptoethanol (M7522), acrylamide (40% solution, A7168), agarose (A9539), 
ammonium persulfate (A3678), ampicillin sodium salt (A9518), arsenic trioxide 
(A1010), bongkrekic acid solution (B6179), bovine serum albumin (BSA, A7906), 
calcium chloride (C7902), cycloheximide (C7698), cyclosporinA (C3662), dimethyl 
sulfoxide (D2650), DIDS (D3514), Dulbeco’s modified Eagles medium (DMEM, 
D6429), docetaxel (01885), doxorubicin (D1515), EGTA (E4378), etoposide 
(E1383), foetal calf serum (F7524), hexamethrine bromide (H9268), ionomycin 
(I3909), Luria-Bertani broth (LB, L3022), L-glutamine (G7513), NP-40 (I3021), 
phosphate buffered saline (D8537), phosphocreatine (P7936), Polybrene® (H9268), 
propidium iodide solution (P4864), puromycin dihydrochloride (P8833), RPMI-1640 
(R5886), sodium azide (S8032), sodium butyrate (30,341-0), sodium citrate 
(S1804), sodium deoxycholate (30970), sodium pyruvate (S8636), staurosporin 
(S4400), TEMED (T9281), Triton X-100 (T8532), Trypsin-EDTA (T4174), TWEEN® 
(P5927), yeast extract (Y1625) and Z-VAD-FMK (V116). 
The following agents were bought from Life Technologies (UK): DAPI (D3571), 
DiOC6 (D273), blotting filter papers (25mm thickness, LC2010) library efficiency® 
DH5a™ chemocompetent bacteria (18263-012), MAX efficiency DH5α (18258-012), 
non-essential amino acids (11140035), OPTI-MEM (22600134), 
penicillin/streptomycin (100U/ml and 100μg/ml respectively, 15070-063), 
pLenti7.3/V5-TOPO® TA cloning kit (K5310-00), PureLink™ HiPure plasmid filter 
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purification kit (K2100-07). DNA oligos (primers) and RNA oligos (siRNA) were also 
purchased from Invitrogen. 
The reagents below were purchased from Thermofisher (UK): 5x protein loading 
buffer (R0891), 6x DNA loading dye (R0611), 50x TAE buffer (#B49), Bradford 
(500-0006), GeneRuler™ 1kb DNA ladder (SM0314), GeneRuler™ 1kb plus DNA 
ladder (SM1334), T4 DNA ligase HC (EL0013), PageRuler™ prestained protein 
ladder (SM1811 or SM0671), ProteoBlock™ protease inhibitor cocktail (R1321) and 
Phusion® polymerase (F530-L). All the restriction endonucleases used in this study 
were bought from the FastDigest™ series of Thermofisher (UK); formerly Fermentas 
(UK). The Fermentas* Genomic DNA Purification Kit was also obtained from 
Thermofisher (UK). 
0.5M Tris-HCl pH 6.8 solution (161-0799), 1.5M Tris-HCl pH 8.8 solution (161-
0798), 10x TGS buffer (161-0772) and SDS solution (10% w/v, 161-0416) were 
from Bio-Rad Laboratories (UK); Hyper film™ high performance chemoluminescent 
film (28906837) was from GE Healthcare; PureProteome™ Protein G Magnetic 
Beads (LSKMAGG10) and PVDF membrane (IPVH00010) were from Millipore (UK). 
Polyvinyl alcohol mounting medium with DABCO (10981) and saponine (47036) 
were purchased from Fluka (UK); pAdVantage™ vector (E1711), Wizard SV gel PCR 
clean-up system (A9282) were from Promega (UK); Effectene (301427) and 
Superfect (301307) from QIAGEN (UK), Xfect  and the In-Fusion HD cloning Kit 
were purchased from Clontech(UK). AnnexinV-FITC was from Biovision(UK). 
GelRed™ nucleic acid gel stain (41002) was purchased from Biotium (UK); TNFα 
(520-002-C050) from Enzo Lifesciences (UK).; enhanced chemoluminescent reagent 
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(#32106), mitochondria isolation kit for cultured cells (89874) and 
paraformaldehyde (28908) from PIERCE Thermo Scientific (UK). 
 
C.2 Cell Culture 
HeLa (human cervical carcinoma), MCF7 (Metkar, Wang et al. 2003), 293T (human 
embryonic kidney), 293FT (for viral production), MDA-MB-231 cells (human breast 
adenocarcinoma), HCT-116 (human colon carcinoma, kind gift from Dr Nabil Hajji), 
N2A cells (a kind gift from Dr Magdalena Sastre), HFF1 (human foreskin fibroblasts; 
kind gift from Dr. Odu Okoturo), MLE12 cells (a kind gift of Dr. Klaus Schulze-
Osthoff), MEF WT (mouse embryonic fibroblasts) and MEF CypD-/-  (a kind gift of 
Dr. Andrea Rasola) cells were cultivated in high glucose (4.5 g/L) DMEM (Sigma-
Aldrich). LNCap cells were grown in RPMI-1640 (Sigma Aldrich). Both culture media 
were supplemented with 10% v/v heat-inactivated foetal calf serum (FCS, Sigma-
Aldrich), 2 mM L-glutamine (Sigma-Aldrich), 2mM sodium pyruvate (Sigma-Aldrich), 
penicillin (100 U/ml, Invitrogen) and streptomycin (100 μg/ml, Invitrogen). Cells 
were cultured in tissue culture flasks or dishes and maintained in 5% atmospheric 
CO2 at 37°C in a humidified incubator. Prior to reaching confluence, cells were split 
by trypsinization, spun down at 1200 rpm for 5 min and plated into respective cell 
culture flasks with fresh media. For siRNA experiments, cells were transfected in 
antibiotic and serum free media. Cell lines were routinely tested to be free of 
mycoplasma. A modified Neubauer haemocytometer was used for measuring cell 
densities. The cell lines with stably down-regulated proteins by Lentiviral shRNA 
constructs or stable overexpression of pIRES constructs were cultured as above in 
the presence of 1μg/ml puromycin (Sigma-Aldrich).  
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C.3 Plasmid Vectors 
All genes were cloned into mammalian expression vectors with Cytomegalovirus 
(CMV) promoters and U6 promoter for the expression of shRNA.  The commercial 
expression vectors pcDNA3 (Invitrogen), pEGFP-N1 (Clontech), pIRESpuro2 
(Clontech) and pIRES2-EGFP (Clontech) containing the gene of interest were used 
for the transient and stable expression of genes by plasmid transfection. pLenti7.3 
(Invitrogen) was used for the production of lentiviruses. pLKO.1 (Sigma-Aldrich) 
was used for the production of lentiviruses or for the expression of shRNA 
constructs. Apoptosis-inducing genes (ANT1, RIP1, Bax, Casp2, Casp8) were 
isolated from a genetic screen for apoptosis inducers(Albayrak and Grimm 2003) 
and subsequently tagged C-terminally with hemagglutinin (HA-tag). Mammalian 
expression vectors encoding DsRed-ER, CFP-mito, YFP-mito or GFP-mito were a kind 
gift of Dr. Remy Sadoul (INSERM U836, Grenoble, France). A list of all shRNA 
plasmids and siRNAs used to target human and/or murine CKMT1 can be found in 
Table E.1. 
 
C.4 Cloning 
Standard molecular biology techniques were used for cloning. Genes of interest 
were cloned either by recombinant PCR, restriction digest cloning, whole vector PCR 
or In-Fusion cloning (Clontech). For the primer sets used please refer to Table C.1. 
All vectors used during this PhD studies were sequenced by the MRC sequencing 
facility of Imperial College London (Hammersmith Campus) to confirm successful 
cloning. 
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The ΙκΒα gene was purchased from Origene (USA) and sub-cloned into pcDNA3 
(Invitrogen, UK) vector by restriction digestion.  
pcDNA3 Mcr1-IκBα and was created by recombinant PCR using primers for the first 
47 amino acids of the yeast Mcr1 (NADH-cytochrome reductase b5)(Haucke, Ocana 
et al. 1997). Recombinant PCR was used to amplify and fuse the Mcr1 localization 
sequence with the IκBα gene. Primer set 1a was used to amplify 141 bp with the 
BamHI enzyme and a Kozak sequence and the set 1b to amplify the IκBα gene with 
XbaI restriction enzyme sequence. PCR products were mixed and the forward primer 
from set 1a and the reverse primer for set 1b were used to amplify and fuse the 
sequences. Functionality of the construct was tested and will be analysed further in 
the results section. A C-terminal FLAG-tagged version of MCR1-IκBα was generated 
by inserting a C-terminal FLAG-sequence (GACTACAAAGACGATGACGACAAGTAG) 
into the pcDNA3 Mcr1-IκBα vector using the QuickChangeII Mutagenesis Kit 
(Stratagene, UK) according to the manufacturer’s instructions. Briefly, 
complimentary primers containing the FLAG sequence and 21bp complementary to 
the flanking sequence of the original vector on either side were used to generate 
recombinant plasmids by PCR. The template was digested by DpnI digestion and 
bacteria transformed according to standard molecular biology methods.  
MEET-IκBα was created by amplifying the N-terminal 32aa of MitoNEET that are 
sufficient to target any protein at the outer mitochondrial membrane (Wiley, Murphy 
et al. 2007). pEGFP-N1 vector was digested at HindIII/PstI sites and the N-terminal 
32aa of MitoNEET were inserted in frame with the following eGFP gene of the vector 
creating MEET-eGFP vector. Primer set 3 was used to amplify IκBα (aa 2-317) –full 
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length human IκBα – with restriction sites KpnI and BamHI at the 5’ and 3’ end, 
respectively. The PCR product was inserted into the MEET-GFP vector in frame with 
the MitoNEET mitochondrial targeting sequence and HindIII and BamHI was used to 
excise MEET-IκBα gene fusion (N-terminal 32aa of MitoNEET fused to full length 
human IκBα), which was subseqeuently inserted into the pcDNA3 vector. A C-
terminal FLAG-tagged version of MEET-IκBα was generated by inserting a C-
terminal FLAG-sequence (GACTACAAAGACGATGACGACAAGTAG; Table C.1). 
pcDNA3 SD-IκBα was created by fusing the mitochondrial targeting sequence 
(intermembrane space) of Smac/DIABLO to IκBα. Following the same procedure as 
for MEET-IκBα, the N-terminal 57 aa of Smac/DIABLO were amplified with primer 
set 4 and inserted into pEGFP-N1 (Ozawa, Natori et al. 2007). This created the SD-
eGFP vector were IκBα was inserted by restriction enzyme cloning. 
pcDNA3 Actin-IκBα was created using primer sets 5 and 6 to amplify IκBα and β-
actin genes respectively. The PCR products were mixed, and the forward primer 
from set 6 and reverse from set 7 used to generate IκBα/β-actin fusion protein.  
pcDNA3 MEET-IκBα deletion mutants were created to identify the necessary domain 
of IκBα that is responsible to inhibit apoptosis. The vector MEET-IκBα-Flag was used 
as the backbone and the respective mutagenesis primers used to create the 
respective deletion (Table C.1). 
pcDNA3 mCKMT1-HA and pcDNA3 hCKMT1-HA were created by Dr. Foy Osborne 
and contain the murine/human coding sequence of CKMT1 (except the TAAs stop-
codon) within the HindIII and NotI cloning sites. The C-terminal HA-tag was 
inserted between the NotI and XbaI sites. 
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The pcDNA3 mCKMT1mut-HA was created Dr. Foy Osborne by a GAGTTG 
mutation corresponding to an EL mutation at aa position 266 of the mCKMT1 cds 
(this corresponds to the EL mutation at aa position 265 of the hCKMT1 cds). 
IRES-PURO-mCKMT1-HA and IRES-PURO-mCKMT1mut-HA were created using the 
In-Fusion HD cloning Kit (Clontech) according to the manufacturer’s instructions. 
PCR primers universal for mCKMT1-HA/mCKMT1mut-HA with 15 bp extensions that 
are complementary to the ends of the pIRESpuro2 linearized vector (NheI and NotI) 
were used to amplify the respective constructs. The PCR product was purified using 
the Wizard SV gel and PCR clean-up system (Promega) and fused into the linearized 
vector. The IRES-PURO-hCKMT1-HA was created using the same strategy. 
IRES-EGFP-mCKMT1-HA, IRES-EGFP-mCKMT1mut-HA and IRES-EGFP-hCKMT1-HA 
were also created using the In-Fusion HD cloning Kit (Clontech). PCR primers 
spanning the mCKMT1-HA/mCKMT1mut-HA and hCKMT1-HA sequences with 15 bp 
extensions that are complementary to the ends of the pIRES2-EGFP linearized 
vector (NheI and BamHI) were used to amplify the respective constructs. The PCR 
product was purified using the Wizard SV gel and PCR clean-up system (Promega) 
and fused into the linearized vector. 
IRES-PURO-hCKMT1(COD)-HA and IRES-PURO-hCKMT1(COD)mut-HA were created 
using site directed mutagenesis and whole vector PCR with the codon usage 
mutagenesis primer as outlined in Table C.1. 
IRES-PURO-hCKMT1, IRES-PURO-hCKMT1(COD), IRES-PURO-hCKMT1(COD)mut 
were created by whole vector PCR inserting a TAA stop codon before the HA-tag of 
the respective HA-tagged plasmids. 
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IRES-PURO-CKMT1(iso) was created by whole vector PCR inserting 93 base pairs 
within the hCKMT1 coding sequence 
pcDNA3 CKMT1(GEN) was created by amplifying the genetic human CKMT1 locus 
from genomic DNA from HeLa cells using the primers as outlined in Table C.1. 
Isolation of genomic DNA was performed using the Fermentas Genomic DNA 
Purification Kit (Thermofisher). The genomic CKMT1 locus was cloned into pcDNA3 
vector via EcoRI and NotI sticky ends. 
The ASB9 expression plasmid was a kind gift from Dr. Kwon, and contains the full 
length human ASB9 coding sequence in the pcDNA3.1/Myc-His (Invitrogen) 
expression vector. 
The CKMT1∆BS construct was also a kind gift from Dr. Kwon, and contains the 
human CKMT1 with aa 112-192 deleted and a C-terminal HA-tag in the pcDNA3 
expression vector. 
The shCypD pLKO.1-puro plasmid was obtained from Sigma-Aldrich and 
corresponds to the official identifier TRCN0000232681. The shRNA-loop sequence is 
5’CCGGGCTTGGTCTAGGACTGGAATTCTCGAGAATTCCAGTCCTAGACCAAGCTTTTT3’ 
The shVDAC1 pLKO.1-puro plasmid was obtained from Sigma-Aldrich and 
corresponds to the official identifier TRCN0000029126. The shRNA-loop sequence is 
5’CCGGGCTTGGTCTAGGACTGGAATTCTCGAGAATTCCAGTCCTAGACCAAGCTTTTT3’ 
The human CypD pCMV6 was obtained from Origene (UK) and contains the full 
length human peptidylprolyl isomerase F. 
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BclXl and Bcl-2 expression plasmids were obtained from Prof. Stefan Grimm and 
correspond to the respective human cds in the pcDNA3delta vector (pcDNA3 with 
neomycin resistance cassette deleted) 
 
 
Table C.1: Primer Sets Used for Cloning. Primer sequences used for the amplification of 
genes or sequences. Unless otherwise stated, Phusion high fidelity DNA polymerase was 
used according to the manufacturer’s instructions for all PCR reaction and mutagenesis 
reactions. ∆ indicates the site of deletion. Bold sequences indicate insertions. Multiple 
Point Mutations, insertions and deletions were created using complementary primers for 
whole vector PCR (one of these is given in the table), DpnI degradation of the parental 
plasmid and standard bacterial transformation techniques. 
Primer Sequence (5’-3’) 
Set 1a    
(Mcr1) 
(FOR)-ACTGTGGATCCCCGCCATGTTTTCCAGATT  
(REV)-ACTGTGAACACTTTATTAGA 
Set 1b   
(IκBα) 
(FOR)-ATGTTCCAGGCGGCCGAGCGC 
(REV)-TCTAGATCATAACGTCAGACGCTG 
Set 2 
(MitoNEET) 
(FOR)-GTAAGCTTCCACCATGAGTCTGACTTC 
(REV)-GCTGTCTGCAGTTTGTAAGCTAGATAACC 
Set 3   
(IκBα) 
(FOR)-ACTGTGGTACC ATTCCAGGCGGCCGAG 
(REV)-ACTGTGGATCCTCATAACGTCAGACG 
Set 4    
(Smac) 
(FOR)-ACTGTAAGCTTCCGCCATGGCGGCTCTGAGA 
(REV)-ACTGTCTGCAGAATAGGAACCGCACACAG 
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Set 5    
(IκBα) 
(FOR)-AAGCTTCCACCATGTTCCAGGCGGCCGAG 
(REV)-TAACGTCAGACGCTGGCCTCCAAA 
Set 6       
(β-actin) 
(FOR)-ATGGATGATGATATCGCCGCG 
(REV)-TCTAGACTAGAAGCATTTGCGGTG 
hCKMT1(GEN) (FOR)-GAATTCACCTTCTCCTCCAGCACAGGAACTAGGAAC 
 (REV)-CATCCTAGTAAAGACTCCTTGCTATGCTGCGCGGCCGC 
 Whole Vector PCR Primers (100% complementary primers 
used) 
MEET-IκBα1-31 TTCAATGAATCCAATAAAGTATTC-∆-
ACCGAGGACGGGGACTCGTTCCTGC 
MEET-IκBα1-70 CTCGGAGCCCTGGAAGCAGCAGCTC-∆-
ACCAACTACAATGGCCACACGTGTC 
MEET-IκBα1-
109 
GCACCTCCACTCCATCCTGAAGGCT-∆-
GGCCGCCCAAGCACCCGGATACAGC 
MEET-IκBα1-
142 
TATTCTCCCTACCAGCTCACCTGG-∆-
GACTACAAAGACGATGACGACAAG 
IκBα 
Flag-insertion 
GGAGGCCAGCGTCTAACGTTAGACTACAAAGACGATGACGACAAGT
AGTCTAGAGGGCCCTATTCTATAG 
hCKMT1 
(COD)mut 
E265L 
CCTGATCTGGGTGAATGAGTTGGATCATACACGGGTGATC 
 
hCKMT1  
HA-deletion 
TCATCCACACCAAGCATTAACGCGGCCGC 
hCKMT1(COD) 
codon usage 
GGTATTTGCTGACCTGTTTGACCCTGTCATTCAGGAAAGGCATAATGGAT
ATGACCCCCGGACAATGAAG 
hCKMT1(iso) 
31aa 
insertion 
GGAGGCTGTATCCCCCGAGCCAGACATGGCCAACTGGACAGCTCCC
AGGTAACTGCACTAGGTCTAGGCGTCTGTGCCCTCCCTCCATGGTT
ACTGGGTACCCCCTCCCCAGCGCTGAGTACCCAGACCTCCG  
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C.5 Bacteria Transformation 
Chemically competent Library Efficient DH5α and Max Efficiency DH5α E.coli bacteria 
(Life Technologies) were used to transform DNA plasmids. A 50 ul bacterial aliquot 
was thawed on ice and the DNA plasmid was added to the cells. After 30 minutes 
incubation on ice, bacteria were heat-shocked for 45 seconds at 42°C (25 seconds 
for Max Efficiency bacteria) and immediately placed on ice for 2 minutes. 1ml of 
SOC medium (2% trypton, 0.5% yeast extract, 10mM NaCl, 10mM MgSO4, 2.5mM 
KCl, 20mM glucose) was then added and bacteria were incubated for 1 hour at 37°C 
whilst (35°C for Max Efficiency bacteria). Transformed bacteria were then plated 
onto LB agar supplemented with the appropriate antibiotics and cultured at 37°C 
(35°C for Max Efficiency bacteria) overnight. 
 
C.6 Plasmid DNA Extraction and Purification From Bacteria 
Plasmid DNA was extracted from transformed bacteria grown in LB media plus 10g/l 
yeast extract and the appropriate antibiotic overnight in a shaking incubator at 
37°C. 
Maxipreps were carried out using the recommended protocol of the Plasmid Maxi 
Prep Kit (Qiagen) or the PureLinkTMHiPure plasmid Filter Purifictation kit (Life 
Technologies) using 250ml of bacterial growth. The concentration and purity of the 
resulting DNA were measured using NanoDrop (Thermo Fisher Scientific) or 
PicoGreeen (Molecular Probes). For PicoGreen measurements, DNA was sequentially 
diluted to achieve concentrations of approximately 0.1μg/μl. Then 50μl of TE buffer 
were added to each well followed by 50μl of diluted PicoGreen reagent (1:200 in TE 
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buffer). The plate was incubated for 5 minutes and the fluorescence was measured 
with FLUOstar OPTIMA (BMG Labtech) with excitation at 480nm and emission at 
520nm. The DNA concentrations were calculated using internal DNA standards. 
 
C.7 Plasmid/siRNA Transfections 
Following the manufacturer’s instructions, Effectene (Qiagen, UK) was used for 
transfection of HeLa cells: For the 24 well plate format, 200-400ng of the respective 
plasmid were mixed with 1.6ul Enhancer in a total volume of 60ul in EC buffer. 
Following 5 min incubation, 2.5ul Effectene was added, the mixture vortexed for 10s 
and incubated for 15min for complex formation before adding 250ul of medium. 
After replacing the medium of the cells with 250ul fresh medium, the complexes 
were added. In order to reduce cytotoxicity of the transfection procedure, the 
medium was changed after 5 hours. 293T, N2A and MLE12 cells were transfected 
using Xfect (Clontech) according to the manufacturer's instructions. For a 24-well 
plate, 1g of the DNA plasmid and 0.3ul of the transfection polymer were used. For a 
6-well plate, 7.5g of DNA and 2.25ul of transfection polymer were used. Cells were 
washed 4-5 hours post transfection. 
β-Galactosidase or a scrambled shRNA construct were used as control plasmids and 
a co-transfected GFP plasmid was used to determine the transfection efficiency. 
 
siRNA transfections were performed using Effectene. Per 24 well plate, 3.33ul 20mM 
siRNA (Invitrogen, UK, sequence see Tab.2) mixed with 2ul Enhancer in a total 
volume of 50ul EC buffer. Following 5 min incubation, 3ul Effectene were added, the 
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mixture vortexed for 10s and incubated for 15min to allow for complex formation 
before adding 50ul of serum- and antibiotic-free medium. After replacing the media 
of the cells with 225ul serum- and antibiotic-free media, the complex mixture was 
added. 166ul 3x medium (30% FCS) was added after 4h and the medium was 
changed completely 8 hours after transfection. 
 
C.8 Production of Stable Cell Lines by Viral Infection 
The cell line of interest was seeded on a well of 6-well plate 15 hours prior to the 
transduction. On the following day, cells were transduced with the viral supernatant 
supplemented with 1μg/ml of Polybrene® (Sigma-Aldrich) for 6 hours or overnight. 
The viral supernatant was then removed; fresh medium added followed by 
incubation for a further two to three days. The medium was then replaced with 
medium containing puromycin (varying concentration, 5μg/ml for HeLa cells)  
Upon completion of the selection, cells were maintained in DMEM containing 1μg/ml 
of puromycin. In the case of shRNA constructs, the downregulation of the target 
protein in the stable clones was confirmed by Western blotting. 
 
C.9 Production of Stable Cell Lines After Plasmid Transfection 
Cells were seeded in 6-well plates 24 hours prior to transfection. 24 hours after the 
transfection with the IRES-PURO constructs, cells were selected with 2μg/ml 
puromycin. Clone pools were established or single clones picked after 100% of the 
control cells (no puromycin resistance transfected) were dead. 
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For IRES-EGFP constructs, cells were selected in medium containing G418 at a 
concentration of 800μg/ml. Colonies were analysed for GFP expression by 
microscopy and positive colonies picked with cloning rings. 
The ectopic expression of the gene of interest was verified using immunofluorescent 
and/or autofluorescent FACS analysis and Western blot analysis. Stable cell clones 
were maintained in 200μg/ml G418. 
 
C.10 Mitochondria Isolation 
Mitochondria were isolated with an established protocol (Gogvadze, Orrenius et al. 
2003), re-suspended in the protocol’s mitochondria buffer and kept at -80°C. 
Briefly, after trypsinisation, cell were harvested, washed with PBS and centrifuged 
for 5 minutes at 2100 rpm. 400μl to 600μl of mitochondria lysis buffer [Buffer A: 20 
mM HEPES pH 7.5, 1.5 mM MgCl2 (6H2O), 10 mM KCl, 1mM EDTA, pH 7.4; lysis 
Buffer was prepared using 12 ml Buffer A with 3 ml sucrose 1.25M] was added to 
the pellet and left for 2 minutes on ice. Meanwhile a dounce homogenizer (Wheaton 
357542) was washed with cold lysis buffer and cells homogenized by 60-80 strokes. 
200 μl of lysis buffer were added and lysed cells were left on ice for 20 minutes. A 
subsequent centrifugation step (3000rpm, 10 min) was used to pellet nuclei and 
debris. The supernatant containing the mitochondria was re-centrifuged at 13000 
rpm for 20 minutes. The pellet contained the isolated mitochondria. 
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C.11 Cell Cycle Analysis 
The supernatant and trypsinized cells were transferred into FACS tube and 
centrifuged for 5min at 1500rpm. The supernatant was discarded and cells fixed by 
resuspending them in ice-cold methanol. After centrifugation (5min at 1500rpm), 
the pellet was resuspended in 150ul of PBS containing 40ug/ml propidum iodide. 
After incubation for at least 10min at room temperature, cells were analysed on a 
FACS Calibur (Beckton-Dickinson, UK). PI fluorescence was recorded in Fl3. The cell 
cycle wizard of FlowJo 7.25 (Stanford University, USA) was used for subsequent cell 
cycle analysis. 
 
C.12 Crystal Violet Cell Viability Assay 
Cells were fixed for 5 min in 4% paraformaldehyde and stained with 0.05% crystal 
violet in distilled water for 1 hour. After washing 3 times with distilled water, dishes 
were dried at 37C and photographed. The crystal violet stain was then solubilised by 
adding methanol in a volume corresponding to half the total well volume. The OD at 
540nm was read with the FLUOstar OPTIMA (BMG Labtech). 
 
C.13 PI SubGo/G1 Analysis  
Supernatant and trypsinized cells were transferred to FACS tube and centrifuged for 
5min at 1500rpm. The supernatant was discarded and cells resuspended in 150ul of 
PBS. After addition of lysis buffer (0.1% sodium citrate and 0.1% Triton X-100 in 
PBS, 40ug/ml propidum iodide and incubation for at least 10min at room 
temperature, cells were analysed on a FACS Calibur (Beckton-Dickinson, UK). 
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Forward and side scatter were used to characterize the cell population and PI 
fluorescence was recorded in Fl2 and Fl3. FlowJo 7.25 (Stanford University, USA) 
was used for subsequent analysis. 
 
C.14 PI Exclusion Staining 
Supernatant and trypsinized cells were transferred to FACS tube and centrifuged for 
5min at 1500 rpm. The supernatant was discarded and cells resuspended in 150ul 
of PBS containing 40 ug/ml propidum iodide. After incubation for 10 min at room 
temperature, cells were analysed on a FACS Calibur (Beckton-Dickinson, UK). 
Forward and side scatter were used to characterize the cell population and PI 
fluorescence was recorded in Fl3. FlowJo 7.25 (Stanford University, USA) was used 
for subsequent analysis. 
 
C.15 DiOC6/PI Co-staining 
Supernatant and trypsinized cells were transferred to a FACS tube and centrifuged 
for 5min at 1500rpm. The supernatant was discarded and cells resuspended in PBS. 
Mitochondria were loaded with DiOC6 at a final concentration of 50nM for 30 min in 
a humidified incubator (5% CO2, 37°C) and another 30 min at RT. PI was used as a 
cell viability dye at a final concentration of 5mg/ml. Forward and side scatter were 
used to characterize the cell population, DiOC6 fluorescence was acquired in Fl1, PI 
fluorescence in Fl2. FlowJo 7.25 (Stanford University, USA) was used for subsequent 
analysis. 
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C.16 JC1 Staining 
Mitochondria of living cells were loaded with JC1 diluted in media at a final 
concentration of 10 μg/ml. Fluorescence of JC1 aggregates was acquired in Fl2, 
emission of monomeric JC1 was recorded in Fl1 and the ratio between Fl1/Fl2 
staining used as an indicator of mitochondrial membrane potential. The same 
staining protocol was used for live cell confocal imaging. 
 
C.17 AnnexinV Staining 
AnnexinV stainings were performed according to the protocol of the Annexin V-FITC 
Apoptosis Detection Kit (Biovision) with slight modifications: The supernatant and 
trypsinized cells were transferred to a FACS tube and centrifuged for 5min at 
1500rpm. The supernatant was discarded and cells resuspended in 100ul AnnexinV 
binding buffer and 1ul of AnnexinV-FITC solution was added. After 10min of 
incubation at room temperature, cell were analysed by FACS. Forward and side 
scatter were used to characterize the cell population and Fl1 fluorescence was for 
AnnexinV staining. FlowJo 7.25 (Stanford University, USA) was used for subsequent 
analysis. 
 
C.18 Fluorescein Diacetate Staining of Viable Cells 
Cell death was indirectly quantified by assessing cell viability through quantifying 
the presence of cytoplasmic esterases. In this assay cellular esterases cleave 
moieties from the lipid soluble non-fuorescent fuorescein diacetate (FDA) probe to 
give a fluorescent product that is charged and retained within the cell membrane if 
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its function is still intact, leaving viable cells bright and nonviable cells dim(Robinson 
and International Society for Analytical Cytology. 1997). Harvested cells were 
resuspended in 200 ul of 2 ug/ml FDA (Sigma-Aldrich) in PBS. 2 ug/ml FDA was 
prepared in PBS from a stock of 1 mg/ml FDA in acetone. Cells were mixed, 
incubated for 15 min at 37C, and analysed using the FACS Calibur (Beckton-
Dickinson, UK). Forward and side scatter were used to characterize the cell 
population and fluorescence was recorded in Fl1. FlowJo 7.25 (Stanford University, 
USA) was used for subsequent analysis. 
 
C.19 Immunostaining for FACS Analysis 
The supernatant and the adherent cells were harvested, centrifuged (1500rpm, 5 
minutes) and fixed in 2% paraformaldehyde (Thermo Scientific) in PBS for 20 
minutes at 4ºC, then blocked in 10% FCS in PBS for 30 minutes and permeabilized 
with 0.02% TritonX100 for 30 minutes at 37C. Cells were then centrifuged (1500 
rpm, 5 minutes) and the primary antibody, diluted in 3% FCS in PBS, added and 
incubated for 1 hour at 37C. Cells were then washed two times with 2ml of 3% FCS 
in PBS. For Alexa-labelled primary antibodies, cells were subsequently analysed in 
the respective channel for fluorescence intensity (Fl1 for Alexa488, Fl4 for 
Alexa643). For staining using un-labelled primary antibodies, cells were centrifuged 
and the isotype-matched secondary antibody conjugated with Alexa488 or 
Alexa633, diluted in PBS at a dilution of 1/500, was added to the tube and 
incubated for 1 hour at 37C. Two washing steps with 2ml of PBS were used to wash 
off unbound secondary antibody. The cells were analysed by FACS using the Fl1 
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channel or Fl4 channel. FlowJo 7.25 (Stanford University, USA) was used for 
subsequent analysis. 
 
Primary antibodies used (dilution 1:200 from stock): 
Anti-activated caspase 3 (polyclonal rabbit anti-cleaved Caspase-3 Asp175, Cell 
Signaling, #9661), Anti-activated Bax (monoclonal mouse anti-Bax, BD 
Pharmingen, 556467, clone 6A7), Anti-HA (HA.11 Clone 16B12 monoclonal 
antibody, Alexa488 labelled; Catalogue number: A488-101L, Covance); Anti-CKMT1 
(rabbit polyclonal CKMT1A Antibody 15346-1-A, Proteintech). 
 
Secondary antibodies used (dilution 1:500 from stock): 
Anti-mouse IgG (H+L)from goat, Alexa488 labelled; Anti-rabbit IgG (H+L)from 
goat, Alexa488 labelled; Anti-mouse IgG (H+L)from goat, Alexa643 labelled; Anti-
rabbit IgG (H+L)from goat, Alexa643 labelled (all from Invitrogen). 
 
C.20 Protein Extraction and Quantification 
Cell pellets were resuspended in 100ul RIPA buffer supplemented with complete 
protease inhibitor cocktail (Thermo Fisher Scientific) and incubated on ice for 30min. 
The whole cell lysate was then centrifuged at 13300 rpm for 30 minutes at 4°C. The 
supernatant containing the protein lysate was collected. Protein concentrations were 
measured using either the Bradford protein assay reagent (Bio-Rad) or BCA protein 
assay kit (Sigma-Aldrich) according to the respective guidelines of the 
manufacturer. 
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Required volumes of protein lysates were diluted in 5X loading buffer (Thermo 
Fisher Scientific) containing: 0.005% bromophenol blue as loading dye, 5% β-
mercaptoethanol (Sigma-Aldrich) as a reducing agent, 10% SDS as denaturing 
agent, 45% glycerol for loading, and 0.5M Tris buffer. Samples were then kept to 
boil at 100°C for 10 min to ensure complete denaturation of the proteins. 
 
C.21 SDS Page and Western Blotting 
Cells were harvested at appropriate time points after transfection and lysed in RIPA 
buffer (150 mM NaCl, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris, pH 8.0) containing Complete Protease Inhibitor Cocktail (Roche, UK). 
Protein concentrations were measured by the Bradford assay (Bio-Rad, UK). The 
samples were supplemented with loading dye containing DTT and β-mercapto-
ethanol and incubated at 95ºC for 5min before applying on sodium dodecyl sulphate 
polyarcylamide gel electrophoresis (SDS-PAGE). 20-200 μg of the total cell lysate 
were separated by SDS-PAGE (stacking gel: 4.8% polyacrylamide, 125mM Tris-HCl 
pH 6.8, 0.1% SDS, 0.1% APS, 0.1% TEMED; resolving gel: 10-15% polyacrylamide, 
375 mM Tris-HCl pH8.8, 0.1% SDS, 0.1% APS, 0.05% TEMED) in TGS-running 
buffer (25 mM Tris-HCl, 192mM Glycin, 0.1% w/v SDS). PageRulerTM pre-stained 
protein ladder (Fermentas) was used for the protein size estimation. Separated 
proteins were then transferred onto a 0.2 um pore size PVDF membrane (Millipore, 
UK) by semidry Electroblotting (Biorad, UK). Membranes were blocked with 5% BSA 
or milk in PBS containing 0.1% Tween (PBS-T), incubated with primary antibody, 
washed three times with PBS-T, and incubated with horseradish peroxidase-
conjugated secondary antibody. For a list of all the antibodies used refer to Table 
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C.2. After washing, membranes were developed by enhanced chemiluminescence 
with Immobilon ECL reagent (Millipore, UK) onto photographic films (Amersham, 
UK). For multiple probing, membranes were incubated in Restore Western Blot 
Stripping Buffer (Pierce, UK) for 15 min at 37°C and washed in PBS-T to completely 
remove primary and secondary antibodies. Subsequently, membranes were blocked 
and probed with respective primary and secondary antibodies as previously 
described. 
 
Table C2: Primary and Secondary Antibodies Used for Western blotting (WB) and 
Immunofluorescence Microscopy (IF). 
Antibody Source Company Dilutions 
αCKMT1 mouse Proteintech 1:500 (WB) 
αANT1  rabbit Proteintech 1:1000 (WB)  
αANT1 mouse  Mitosciences 1:100 (WB) 
αPARP rabbit Cell Signalling Technology 1:500 (WB) 
αCleaved CASP3 rabbit Cell Signalling Technology 1:500 (WB); 1:100 (IF) 
α-ATubulin rabbit Santa Cruz 1:2000 (WB) 
αGAPDH mouse Santa Cruz 1:500 (WB) 
αFLAG mouse Sigma 1:100 (IF) 
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αFLAG rabbit Sigma 1:2000 (WB) 
αCytochrome c mouse BD-Pharmingen 1:200 (IF) 
αHexokinase II mouse Sigma-Aldrich 1:500 (WB) 
αCyclophilin D mouse Calbiochem, AP1035 1:500 (WB) 
αVDAC1 rabbit Abcam, 15895 1:1000 (WB) 
αVDAC1 mouse Santa-Cruz, sc-58649 1:500 (WB) 
αVDAC1 goat Santa-Cruz, sc-32063 1:1000 (WB) 
αVDAC1/2/3 rabbit Santa-Cruz, sc-98708 1:500 (WB) 
αHA rabbit Sigma-Aldrich 1:2000 (WB), 1:200 (IF) 
αMouse HRP goat Molecular Probes 1:5000 (WB) 
αRabbit HRP goat Sigma-Aldrich 1:20 000 (WB) 
αGoad HRP rabbit Sigma-Aldrich 1:20 000 (WB) 
αMouse Alexa488 goat Molecular Probes 1:500 (IF) 
αMouse Alexa594 goat Molecular Probes 1:500 (IF) 
αMouse Alexa555 goat Molecular Probes 1:500 (IF) 
αMouse Alexa633 goat Molecular Probes 1:500 (IF) 
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αRabbit Alexa488 goat Molecular Probes 1:500 (IF) 
αRabbit Alexa594 goat Molecular Probes 1:500 (IF) 
αRabbit Alexa555 goat Molecular Probes 1:500 (IF) 
αRabbit Alexa633 goat Molecular Probes 1:500 (IF) 
 
 
C.22 Co-Immunoprecipitation 
Cells were washed once with PBS and lysed in 500 μl of RIPA buffer containing 
protease inhibitors (Fermentas). For immunoprecipitations of endogenous proteins, 
approximately 7mg of total cell lysate was used per condition. For 
immunoprecipitations of overexpressed proteins, 500 ug of total cell lysate was 
used per condition. The cell lysates were placed on ice for 30 min, centrifuged (1300 
rpm) for 30 minutes at 4°C. The supernatant was pre-cleared twice with 50μl of 
protein G sepharoseTM 4 fast flow (GE Healthcare) or with PureProteome magnetic 
protein G beads (Millipore) for 30 minutes each with gentle rotation at 4°C. After 
the pre-clearing, appropriate amounts of antibody (according to the antibodies’ data 
sheets) was added to the supernatant and incubated overnight with rotation at 4°C. 
No antibody was added to the control immunoprecipitations. The antibody-protein 
complexes were then precipitated with 50 ul of beads and incubated rotating for at 
least 2 hours at 4°C. Beads were washed five times with RIPA lysis buffer and re-
suspended in SDS loading dye (Fermentas) supplemented with reducing agent (β-
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mercaptoethanol). Each tube was immediately boiled for 10 min and solubilized 
proteins were subjected to Western blotting. 
For co-immunoprecipitations in isolated mitochondria, mitochondria were lysed in 
RIPA buffer supplement with 1% n-dodecyl maltoside. 
 
C.23 Immunofluorescence and Autofluorescence Microscopy 
Cells grown on borosilicate coverslips were fixed in 4% paraformaldehyde for 30 
min at 4°C. After blocking in 5% goat serum, the respective primary antibody 
diluted in tris buffered saline (TBS) supplemented with 0.02% saponin were applied 
for 1 hour at RT. After washing, the coverslips were incubated with AlexaFluor 
405/488/555/594/633 conjugated antibodies or phalloidin-Alexa-fluor633 for 1h in 
the dark. A comprehensive list of antibodies can be found in Table C.2. DAPI 
(Invitrogen, UK) was used as a nuclear stain at 1μg/ml. After washing, coverslips 
were mounted onto slides with polyvinyl alcohol mounting medium with DABCO 
(Sigma-Fluka, UK). A confocal microscope (Leica, UK) was used to acquire images 
and Leika Application Suite software used for analysis. Where applicable, 
mitochondria and endoplasmic reticulum were visualised by transfecting plasmids 
encoding mitochondria or endoplasmic reticulum-targeted GFP/dsRED (Clonetech, 
UK). Confocal immunofluorescence microscopy was also used to visualise Alexa647 
labelled siRNA upon siRNA transfections.  
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C.24 Semi-quantitative Reverse Transcription PCR 
RNA was isolated using 1ml Trizol (Invitrogen, UK) per well of a 6 well plate and 
resuspended in 20 μl ultrapure H20. The Titan One Tube RT-PCR kit (Roche, UK) 
was used to carry out RT-PCR using 2 μg total RNA. Specific primers for CKMT1 and 
βActin were used for PCR reactions (see Table C.3). 29 PCR cycles were used (10‘’ 
at 94°C, 30” at 54°C and 50” at 68°C; followed by 7′ at 68°C). PCR products were 
separated by gel electrophoresis on a 1% agarose gel. 
 
Table C.3: PCR primer sequences for semi-quantitative reverse transcription PCR. 
CKMT1 (FOR) 5’ATGGCTGGTCCCTTCTCCCGTCTGCTG3’ 
(REF) 5’GTGGCCAGGGTTGTCCACGCCAGTCTG3’ 
βActin (FOR) 5’ATATCGCTGCGCTGTTGT3’ 
(REV) 5’GGTCATCTTTTCACGGTTGG3’ 
 
 
C.25 DNA Electrophoresis and DNA Recovery 
DNA electrophoresis was performed using agarose (Sigma-Aldrich) gels. Briefly, 
agarose (usually 0.8-2% w/v) was dissolved in TAE buffer (Fermentas). The Gel 
Red™ nucleic acid stain (Biotium) was then added (1/20000) dilution), the mixture 
cooled and poured into custom-made DNA gel electrophoresis cassettes to solidify. 
The DNA was mixed with 6x DNA loading dye (Fermentas) and separated by gel 
electrophoresis in TAE buffer or TBE buffer (Fermentas). The GeneRuler™ 1kb plus 
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DNA ladder or GeneRuler™ 1kb DNA ladder (Fermentas) was used for size 
estimation. 
When needed, DNA bands of interest were excised under the UV lamp and 
subsequently purified using the Wizard SV gel and PCR clean-up system (Promega). 
Briefly, a gel piece was mixed with binding buffer to dissolve agarose. The dissolved 
gel and the buffer were transferred to a DNA binding spinning column, centrifuged, 
washed twice and eluted with DNAase/RNAase-free H2O. 
 
C.26 Sequencing of CKMT1 cds 
RNA was isolated from cell pellets using the recommended protocol of the RNeasy 
Mini Kit (Qiagen). RNA was then treated with DNase I (Sigma-Aldrich) for 15 
minutes at room temperature to remove contaminating DNA. The DNase I was then 
inactivated by heating with the stop solution. Reverse transcription of the RNA was 
performed using SuperScript III Reverse Transcriptase (Life Technologies) and 
Oligo(dT)20 Primer (Life Technologies) according to the manufacturer's 
recommended protocol. cDNA concentrations were then measured using NanoDrop 
and used in subsequent PCR. Equal amounts of synthesized cDNA were amplified 
with polymerase chain reaction using the recommended protocol of Phusion High-
Fidelity DNA Polymerase (Finnzymes) and the corresponding primer sets for each 
target (Table C.4). Annealing temperature for each reaction was calculated 
according to the melting temperatures of each primer set. Purified PCR products 
(see C.25 DNA Electrophoresis and DNA Recovery) were sent for sequencing to the 
MRC sequencing facility of Imperial College London (Hammersmith Campus).  
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Table C.4: Primers Used for PCR and Sequencing CKMT1 Transcripts From cDNA. 
CKMT1, FOR cds position 1 5’ATGGCTGGTCCCTTCTCCCGTCTGCTG3’ 
CKMT1, REV cds position 297 5’GTGGCCAGGGTTGTCCACGCCAGTCTG3’ 
CKMT1, REV siCK1(1) 
cds position 431 
5’AGATCCGTGGTGTGCTTCA3’ 
CKMT1, REV cds position 1249 5’GCTTGGTGTGGATGACAGGTGTGGGGATG3’ 
 
 
C.27 Production of Lentiviral Particles and Viral Transduction 
Virulent media was produced in HEK293FT cells (Invitrogen, UK) using the following 
optimised protocol for lentiviral production: Plasmids encoding Vesicular Stomatitis 
Virus Glycoprotein (pVSV-G), group antigen and reverse transcriptase (pGag.Pol) 
and mRNA export helper protein (pRev) were isolated from ViraPower™ lentiviral 
packaging mix (Invitrogen). The expression vector for the pAdVantage was from 
Promega. The cell line used was 293FT cells from Invitrogen.  
The day before the transfection, 293FT cells were plated onto 10cm2 dishes so that 
the plate would be approximately 50-60% confluent on the day of transfection. Two 
hours prior to transfection, the medium was replaced with fresh DMEM. 5.4μg of the 
pVSV-G, 3.8 μg of the pRev, 7.8 μg of the pGag.Pol, 9 μg of the pAdVantage and 
20μg of the lentiviral transgene plasmid were mixed in a 2 ml Eppendorf tube and 
H2O was added to achieve a final volume of 437.5μl. Then, 62.5 μl of 2M CaCl2 
were added, mixed thoroughly and incubated for 5 minutes. Meanwhile, 500μl of 
2xHBS (50 mM HEPES, 281 mM NaCl, 1.5 mM Na2HPO4 pH 7.08-7.1, filter 
sterilized) were prepared in a 15 ml conical tube. The DNA/CaCl2 mixture was 
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added drop by drop into 15 ml conical tube while vigorously shaking the tube on a 
vortex machine. The mix was immediately added to the dish in a dropwise fashion. 
The culture medium was replaced with fresh warm medium containing sodium 
butyrate (1 mM, Sigma-Aldrich) on the following morning (16 hours post 
transfection). Note that a fresh sodium butyrate stock solution was prepared in PBS 
for each experiment. After 2 to 3 days post transfection, the supernatant was 
harvested and centrifuged (500 g, 10 min, RT) to remove cells and large debris, 
then passed through a 0.45μm sterile filter. The viral titer of the virulent media was 
determined prior to aliquoting and storing at -80°C. 
In order to measure the viral titre, HeLa cells were seeded on 12-well plates to 
make a plate ~30% confluent on the day of transduction. On the day of the 
transduction the viral stock was serially diluted in 400 μl of DMEM containing 
polybrene® (hexadimethrine bromide, 6μg/ml, Sigma-Aldrich). The diluted viruses 
were added onto the cells, incubated overnight, media changed and incubated for 
another 24 hours to allow expression of the puromycin resistance. The number of 
cells present in a well was counted. The cells were then selected with puromycin (2-
6μg/ml) for 24 hours and the number of surviving cells was recorded. The viral titre 
was calculated using the following equation:  
  
  
  ⁄  
     
 
  
Where TU is the transforming unit (=number of virions), F is the percentage of 
surviving cells, N is the number of cells at the time of transduction, D is the dilution 
factor, and V is the volume of diluted viral sample added into each well in ml. TU 
can also be referred as CFU which is the Colony Forming Unit (number of virions). 
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In order to avoid under-estimation of the virus titre, only dilutions that were 
showing less 10-20% transduced cells were used. 
For viral infections, the cell line of interest was seeded 6-well plates 15 hours prior 
to the transduction. On the following day, cells were transduced with the viral 
supernatant supplemented with 1μg/ml of Polybrene® (Sigma-Aldrich) overnight. 
The viral supernatant was then removed and fresh medium added. If selection was 
required, medium was supplement with puromycin (varying concentration, 2-5μg/ml 
for most cell used). A concentration of 1μg/ml of puromycin was used for long-term 
culture of infected cells. 
 
C.28 Densitometric Analysis of Western Blots Using ImageJ 
High resolution grayscale scanned images were uploaded onto ImageJ programme 
and converted to 8-bit image (image→type→8-bit). The image was then inverted 
(Edit→invert) and appropriate fields selected using “rectangular selection” tool. The 
plot profile (analyse→plot profile) was created and the background intensities were 
subtracted by drawing a straight line using “straight line selection.” Then distinctive 
peaks were separated with “straight line selection” and the intensities of bands were 
analysed upon selection of the appropriate area with “wand tool” followed by the 
measurement (analyse → measure). 
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C.29 Native Blue Gel Electrophoresis 
Native blue gel electrophoresis was performed using the NativePAGE™ Novex® Bis-
Tris Gel System (Invitrogen). The NativePAGE™ Gel system is based on the Blue 
Native Polyacrylamide Gel Electrophoresis (BN PAGE) technique for isolating 
mitochondrial protein complexes(Schagger and von Jagow 1991; Schagger 2001) 
that uses Coomassie G-250 as a charge-shift. The near neutral pH 7.5 environment 
during electrophoresis results in maximum stability of both proteins and gel matrix, 
providing better band resolution than other gel systems including the traditional 
Tris-glycine native electrophoresis (Laemmli) system. The NativePAGE™ Novex® 3–
12% Bis-Tris gels and the NativePAGE™ Novex® 4–16% Bis-Tris gels resolve 
proteins in the molecular weight range of 30-10,000 kDa and 15-1,000 kDa, 
respectively. Sample preparation and electrophoresis was performed according to 
the manufacturer’s instructions. Briefly, the supernatant and trypsinized cells were 
harvested by centrifugation. 1 confluent T175 flask was lysed in 1ml of 
NativePAGE™ sample buffer supplemented with 2% n-Dodecyl β-D-maltosid 
(Sigma-Aldrich), 0.4% Coomassie G-250 (Invitrogen) and protease inhibitor cocktail 
(Fermentas). Lysates were incubated for 1 hour on ice and centrifuged at 13000 
rpm for 1 hour to clear cell debris. Precast gels were washed with distilled water and 
placed in the XCell™ SureLock™ Mini-Cell (Life Technologies). The anode buffer 
consists of 1x NativePAGE™ Running Buffer, the cathode buffer of “Dark Blue 
Cathode Buffer” (Running Buffer containing 0.02% G-250 Coomassie); both chilled 
to 8C with the XCell™ SureLock™ Mini-Cell placed on ice during the whole run. 20 ul 
of native lysates were loaded. NativeMark™ Unstained Protein Standard (Invitrogen) 
and BSA (Sigma-Aldrich) were used as markers for size estimations. Electrophoresis 
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performed at a constant voltage of 150 V corresponding to 12-16 mA at the start of 
the run, until the blue running front reached one third of the gel. At this point the 
cathode buffer was substituted to Light Blue Cathode Buffer (Running Buffer 
containing 0.002% G-250 Coomassie) and the run resumed at 150V until the dye 
front reached the end of the gel. 
The gel was then removed and soaked in transfer buffer (5 mM Tris, 192 mM 
Glycine and 0.1% w/v SDS). Proteins were transferred onto 0.2 um pore size PVDF 
membrane (Millipore, UK) by semidry Electroblotting (Biorad, UK). Proteins were 
subsequently fixed and denatured by shaking in 8% acetic acid solution in PBS for 
10min. Membranes were then processed as described in C.21 for staining with 
primary and secondary antibodies. 
The markers were visualised either in the gel before electroblotting or on the PVDF 
membrane using Coomassie staining:  
Staining in 0.25% Coomassie Blue R-250 for 2-4 hours until uniform blue colour is 
achieved. Destaining was achieved by shaking and changing of the destaining 
solution for 4 - 24 hours in 5% MeOH, 7.5% acetic acid in H2O until bands began to 
appear. 
 
C.30 Statistical Analysis  
Statistical analysis was performed using unpaired student’s t-test (one- or two-
tailed depending on the hypothesis tested). Samples were regarded to have an 
equal variance unless the f-test returned p<0.05. Data were regarded as 
statistically significant if p<0.05 based on the t-test.  
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D. RESULTS PART I 
D.1 CKMT1 is a Potent Apoptosis Inhibitor Independent of its 
Enzymatic Kinase Activity 
Although numerous studies imply a role of CKMT1 in mitochondrial permeability 
transition and mitochondrial integrity (see chapter A.5), the involvement of CKMT1 
in regulating the mitochondrial apoptosis pathway is not fully understood. In this 
study, evidence for the role of CKMT1 as an apoptosis inhibitor independent of its 
enzymatic kinase activity is provided. 
 
D.1.1 CKMT1 is Upregulated at the mRNA Level in Diverse Tumours 
Early studies performed in the 1980ies suggested that CKMT1 is upregulated in 
several malignancies with poor prognoses, such as lung cancer, gastric cancer and 
prostate cancer(DeLuca, Hall et al. 1981; Tsung 1983; Kanemitsu, Kawanishi et al. 
1984; Pratt, Vallis et al. 1987). Using microarray data available at the Oncomine 
database (accessible at www.oncomine.org), CKMT1 could be shown to be 
overexpressed at the mRNA level in diverse tumours compared to the respective 
normal tissues (Fig.D.1), including tumours of the bladder(Sanchez-Carbayo, Socci 
et al. 2006), ovaries(Hendrix, Wu et al. 2006), endometrium(Wong, Selvanayagam 
et al. 2003), lung(Garber, Troyanskaya et al. 2001), pancreas(Iacobuzio-Donahue, 
Maitra et al. 2003), prostate(Dhanasekaran, Dash et al. 2005), kidney(Yusenko, 
Kuiper et al. 2009) and breast(Sorlie, Perou et al. 2001)  
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Fig.D.1: Microarray Data on the Overexpression of CKMT1 in Various Tumours 
Compared to Normal Tissue. The mRNA level of CKMT1 is significantly higher in 
tumours of the bladder(Sanchez-Carbayo, Socci et al. 2006), ovaries(Hendrix, Wu et al. 
2006), endometrium(Wong, Selvanayagam et al. 2003), lung(Garber, Troyanskaya et al. 
2001), pancreas(Iacobuzio-Donahue, Maitra et al. 2003), prostate(Dhanasekaran, Dash 
et al. 2005), kidney(Yusenko, Kuiper et al. 2009),breast(Sorlie, Perou et al. 2001) 
compared to normal tissue samples. The Oncomine cancer microarray database 
(www.oncomine.org) was used to retrieve the referenced individual microarray studies. 
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However this data is only indicative of a correlation rather than implying a role for 
CKMT1 in tumourigenesis or tumour progression; therefore we investigated if and 
how CKMT1 could have an impact on and contribute to hallmarks of tumour 
formation. 
As reviewed by Hanahan and Weinberg(Hanahan and Weinberg 2000), cancer cells 
have acquired characteristics that provide them with a survival and growth 
advantage during tumourigenesis. Given the overexpression of CKMT1 in tumours, 
we therefore investigated whether elevated amounts of CKMT1 could be one of 
these characteristics causally linked to tumour formation. 
 
D.1.2 Overexpression of CKMT1 Does not Result in Increased Proliferation 
and Does not Affect Cell Cycle Regulation 
Deregulated proliferation by changes in the cell cycle is among the main driving 
force of tumourigenesis(Evan and Vousden 2001). This proliferation can be fuelled 
by dysregulation of the energy systems of the cell to meet the unusually high 
amounts of energy needed by the tumour cell to survive and grow(Garber 2006). 
Thus we hypothesized that increased CKMT1 expression could boost the cellular 
energy metabolism by increasing the availability of diffusible phosphocreatine 
needed to buffer cellular ATP levels. As phosphocreatine conversion depends on the 
kinase activity of CKMT1, we constructed an enzymatically inactive mutant 
(Fig.D.2A) to use as a control in this experiment. Introducing this E266L266 
mutation in the CKMT1 protein results in almost total loss of the enzymatic activity 
(0.002% of the wild type kinase activity) without affecting its structural 
integrity(Eder, Stolz et al. 2000). 
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Confocal microscopy revealed that both, overexpressed CKMT1 as well as 
CKMT1mut localized specifically to mitochondria (Fig.D.2). However, neither 
overexpression of CKMT1mut nor the enzymatically intact CKMT1 had any impact on 
the proliferation or cell-cycle distribution (G0/1, S, G2 and SubG0) of HeLa cells 
within the recorded 4 day time course post transfection (Fig.D.3). 
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Fig.D.2: Overexpression of CKMT1 and CKMT1mut in HeLa cells. A) Domain 
structure of CKMT1 – the mitochondrial transit peptide (aa 1-39) is responsible for 
correct mitochondrial localization of mature CKMT1 and is cleaved off upon import 
into the intermembrane space. The depicted E266 to L266 mutation results in the loss 
of enzymatic activity; numbers correspond to the amino acid. B) Western blot 
showing equal expression of CKMT1 and the enzymatically inactive mutant CKMT1mut 
24h after transfection of respective plasmids using an anti-HA antibody. C) Confocal 
immunofluorescence microscopy 24h after transfection of Bgal (upper panel), CKMT1 
(middle panel) or CKMT1mut (lower panel): CKMT1 and CKMT1mut were stained with 
anti-HA antibody and an AlexaFluor555 labelled secondary antibody, mitochondria 
were visualized via autofluorescence of mitochondria-targeted CFP, cell shape was 
indicated by phalloidin633 F-actin staining, DAPI was used as a nuclear stain. The 
scale bar indicates 10um. 
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Fig.D.3: Cell Cycle Analysis and Growth Curve After Overexpression of CKMT1 and CKMT1mut. A) Relative 
distribution of cells in the cell cycle within 4 days of transfection of the respective plasmids. Data was acquired using PI 
staining of fixed and permeabilized cells and subsequent FACS analysis. B) Proliferation Curve of HeLa cells – The relative 
cell number of cells transiently transfected with Bgal, CKMT1 and CKMT1mut was determined using the cell count parameter 
of a FACS Calibur over a 2 min acquisition period; un untreated. 
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D.1.3 Overexpression of CKMT1 Inhibits ANT1 Induced Apoptosis 
Independently of its Enzymatic Activity 
As overexpression of CKMT1 did not have any effect on the cell cycle and 
proliferation, we hypothesized that CKMT1 could still contribute to tumourigenesis 
via inhibition of apoptosis under cellular stress. Previous studies had suggested 
CKMT1 to be an anti-apoptotic gene(O'Gorman, Beutner et al. 1997; Schubert and 
Grimm 2004). Therefore we addressed the question, whether overexpression of 
CKMT1 could counteract apoptosis induced by the overexpression of well-
characterized pro-apoptotic genes (Fig.D.4A, data acquired in collaboration with Dr. 
Foy Osborne). Overexpression of CKMT1 in 293T cells significantly reduced the pro-
apoptotic effect of ANT1. Strikingly, also the enzymatically inactive CKMT1mut 
inhibited ANT1 induced apoptosis to the same extent: While approximately 50% of 
cells underwent apoptosis upon ANT1 transfection, CKMT1 and CKMT1mut 
coexpression abrogated apoptosis induction by ANT1 reducing the apoptotic cell 
population to approximately 20% over background. Neither CKMT1 nor CKMT1mut 
expression had a significant effect on apoptosis induced by RIP1, Bax, caspase2 or 
caspase8. 
These results suggest that CKMT1 specifically inhibits apoptosis regulated by the 
mitochondrial permeability transition pore, whereas signals acting via the extrinsic 
apoptotic pathway, such as Rip1 and caspase8 overexpression, cannot be blocked. 
CKMT1 and ANT1 have been described to be associated with the PT-pore 
complex(Brenner and Grimm 2006). Indeed, endogenous CKMT1 
coimmunoprecipitates with ANT1 (Fig.D.4B) in mitochondrial extracts suggesting 
that CKMT1 might inhibit apoptosis via indirect or direct interaction with ANT1. 
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Based on the observed coimmunoprecipitation with ANT1, we hypothesized that 
CKMT1 exerts its anti-apoptotic effect via protein-protein interactions with 
components of the PT-pore, thus functioning as a structurally necessary gatekeeper 
of PT-pore opening. Accordingly, this inhibition is independent of the kinase activity 
of CKMT1 as demonstrated by introducing the enzymatically inactive CKMT1mut 
(Fig.D.4A). 
In order to test whether creatine kinase isoenzymes counteract apoptosis in 
general, we used sarcomeric mitochondrial creatine kinase CKMT2 as a control: 
ANT1-induced apoptosis was specifically inhibited by CKMT1 coexpression only, 
whereas CKMT2 did not alter ANT1 induced apoptosis significantly (Fig.D.4B). 
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Fig.D.4: CKMT1 and CKMT1mut Specifically Inhibit Apoptosis Induced by 
Overexpression of Pro-apoptotic ANT1. A) Plasmids coding for luciferase (Luc), 
wild type CKMT1 or the enzymatically inactive CKMT1mut were cotransfected in a 3-
fold excess with the apoptosis inducers Ant1, Rip1, Bax, Caspase2 and Caspase8 into 
293T cells. CKMT1 and CKMT1mut overexpression significantly inhibit Ant1 induced 
apoptosis. B) CKMT1 co-expression but not CKMT2 co-expression inhibits Ant1 
induced apoptosis. Propidium iodide staining and subsequent FACS analysis were used 
to assess nuclear fragmentation 24h post transfection. Standard deviations of a 
representative experiment done in triplicate are shown; **p<0.01 (student’s t-test, 
two-tailed); ns non-significant; data provided by Dr. Foy Osborne. C) Co-
immunoprecipitation of endogenous CKMT1 with endogenous Ant1 in isolated 
mitochondria lysates from 293T cells. IP immunoprecipitation; c control; WB Western 
blotting. 
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A) 
** 
ns 
ns 
ns ns 
B) 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |168 
 
D.1.4 CKMT1 Protects Against External Cellular Stress Stimuli Independent 
of its Enzymatic Activity 
CKMT1 and CKMT1mut were transiently overexpressed by plasmid transfection and 
cells challenged with an external stimuli for apoptosis induction. Wild type CKMT1 as 
well as the CKMT1 mutant significantly reduced apoptosis induced by treating cells 
with H2O2 and As2O3, reagents, which have been shown to induce cell death via the 
PT-pore(Cai, Shen et al. 2000; Zheng, Shi et al. 2004; Nakagawa, Shimizu et al. 
2005). Of note, no difference in the anti-apoptotic activity could be observed when 
comparing wild type CKMT1 and CKMT1mut, which is devoid of its enzymatic 
activity (Fig.D.5A, Dr. Foy Osborne). 
 
D.1.5 CKMT1 Protects Against Mitochondrial Depolarization Independent of 
its Enzymatic Activity 
To further investigate whether CKMT1 overexpression has an effect on 
mitochondrial function and the PT-pore in particular, we induced the loss of the 
mitochondrial membrane potential by ionomycin after overexpression of CKMT1 and 
the enzymatically inactive CKMT1mut. Ionomycin increases the intra-mitochondrial 
Ca2x concentration, which is a potent trigger for mitochondrial permeability 
transition via the PT-pore. PT-pore opening can be measured by the dissipation of 
the mitochondrial membrane potential Δψm. Both, CKMT1 and CKMT1mut 
overexpression significantly and equally protected cells against mitochondrial 
depolarization induced by ionomycin (Fig.D.5B, Dr. Foy Osborne). 
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Fig.D.5: CKMT1 and the Enzymatically Inactive CKMT1mut Protect Against 
Apoptosis and Mitochondrial Membrane Depolarization. Plasmids coding for 
luciferase (Luc), CKMT1 and CKMT1mut were transfected into HeLa cells. A) 24h post 
transfection apoptosis was induced by 500uM hydrogen peroxide or 10uM arsenic 
trioxide for 24h and apoptosis assessed by propidium iodide staining and subsequent 
FACS analysis. B) Mitochondrial membrane depolarization was induced after 24h by 
incubation of cells with 20ug/ml ionomycin for 2h. DiOC6 staining was used to assess 
the mitochondrial membrane potential Δψm by FACS; standard deviations of a 
representative experiment performed in triplicate are shown. ** p<0.01 compared to 
Luc overexpression (student’s t-test); data provided by Dr. Foy Osborne. 
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D.2 Investigation of the Cell Death Effect of CKMT1 Downregulation 
 
D.2.1 Knock-down of Endogenous CKMT1 Expression Results in Apoptosis 
The previous experiments established CKMT1 as an apoptosis inhibitor upon 
overexpression, an effect that was independent of its kinase activity. In order to 
address the function of endogenous CKMT1, we employed siRNA-mediated knock-
down of CKMT1 expression in HeLa cells and assayed for effects on apoptosis using 
subG1/G0 analysis and AnnexinV staining as indicators for apoptotic cell death.  
Interestingly, induction of apoptosis could be observed upon CKMT1 knock-down: 
The proportion of apoptotic cells continuously increased from 48h post siRNA 
transfection. At 96h approximately 60-65% of siRNA-transfected cells showed DNA 
fragmentation and externalization of phosphatidyl-serine compared to 
approximately 10% and 15% in the control population, respectively (Fig.D.6C and 
6D). Representative phase contrast microscopy pictures of CKMT1 knock-down and 
control cells are shown in Fig.D.6E. Cells with apoptotic morphology can be 
observed from 48 hours post-transfection onwards. 
The transfection efficiency, as assayed by incorporation of AlexaFluor647 labelled 
siRNA, proved to be comparable in the siCK1 transfected and control transfected 
cells, in both cases reaching approximately 85% (Fig.D.6A). In order to validate 
that the observed effect was due to depletion of endogenous CKMT1, we used semi-
quantitative reverse transcription PCR to quantify CKMT1 mRNA levels. In HeLa 
cells, the siRNA approach specifically downregulated CKMT1 on the mRNA level for 
at least as long as 72h post transfection (Fig.D.6B). As the siRNA-mediated knock-
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down efficiency depends on protein stability and turnover kinetics, the CKMT1 
expression on the protein level was visualized by Western blotting in 24h intervals 
throughout the 96h time course. CKMT1 protein expression started to be reduced 
48h post transfection correlating to the onset of apoptosis at this time point. CKMT1 
protein levels further decreased after 72h and 96h (Fig.D.6F), again kinetically 
correlated to the increase in apoptosis observed by subG1/Go analysis and 
AnnexinV staining (compare Fig.D.6C and Fig.D.6D). Further corroborating our 
hypothesis that the cell death observed after knock-down of CKMT1 expression is 
apoptotic (in contrast to necrotic cell death that is also regulated by the PT-
pore(Nakagawa, Shimizu et al. 2005)), we detected proteolytic cleavage of PARP 
and activation of caspase3, two generally accepted hallmarks of apoptosis. 
Increasing cleavage of PARP and activation of caspase3 could be observed from 48h 
post-transfection onwards (Fig.D.6F). Confocal immunofluorescence microscopy also 
showed the presence of cleaved caspase3 and activated Bax in HeLa cells containing 
siRNA against CKMT1 (siRNA was coupled to Alexa647 fluorochrome in order to 
visualise cellular uptake). Immunofluorescent staining of activated caspase3 and 
Bax were further quantified using FACS analysis, which confirmed significantly 
higher activation of both proteins upon knock-down of CKMT1 compared to the 
control (Fig.D.7A and 7B). As expected, the apoptotic cell death upon CKMT1 
downregulation depends on caspase activity as demonstrated by the inhibition of 
cell death with the pan-caspase inhibitor zVAD (Fig.D.7C). 
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Fig.D.6: Knock-down of Endogenous CKMT1 Expression Results in Apoptosis. HeLa cells 
were transfected with siRNA targeted against CKMT1 (siCK1) or a scrambled control sequence. A) 
Transfection efficiency of siRNAs labelled with Alexa647 as determined by FACS analysis in HeLa 
cells. Error bars represent the standard deviation of a representative experiment done in triplicate; 
representative overlay histograms for the FL4 channel are shown on the right, unlabelled control 
(grey), Alexa647 labelled si control (blue) and siCK1 (red). B) Semi-quantitative reverse 
transcription PCR 48h and 72h post siRNA transfection using specific primers for human CKMT1 
and βActin in HeLa cells; data provided by Dr. Anne-Laure Mahul-Mellier. Apoptosis was assessed 
in 24h intervals over the next 4 days. C) Propidium iodide staining and subsequent Sub G1/G0 
analysis by FACS. Representative FACS profiles and Sub G1/G0 gating are shown on the right D) 
Assessment of apoptosis by AnnexinV staining and FACS analysis; representative FACS profiles 
and gating for AnnexinV positive cells are shown on the right. Error bars in histograms represent 
the standard deviation of the means of at least 3 independent experiments each done in triplicate; 
*p<0.05, **p<0.01, ***p<0.001 (student’s t-test). E) Representative phase contrast light 
microscopy pictures of HeLa cells after siCK1 transfection F) Western blot analysis for CKMT1 
expression, PARP cleavage and activation of Caspase3 after siRNA transfection in HeLa cells; si 
siRNA against CKMT1, c siRNA against scrambled sequence. 
E) 
F) 
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Fig.D.7: Cell Death Induction in Cells Transfected with Alexa647 labeled 
siRNA against CKMT1 Coincides with Caspase3 Activation and Bax Activation 
and can be Inhibited by the Pan-caspase Inhibitor zVAD. A) Confocal 
immunofluorescence microscopy: siRNA fluorescence was acquired using the 
autofluorescence of Alexa647 labeled siRNA (cyan); activated Caspase3 was detected 
via a specific primary and an Alexa488 labelled secondary antibody (green). 
Activation of Bax was assessed using a conformation specific primary and Alexa 555 
labeled secondary antibody (red) 72 hours post transfection in HeLa cells; DAPI was 
used as a nuclear counterstain. Representative fields are shown for siCK1 and control 
transfections; note that the reduced number of cells after siCK1 transfection 
compared to the control transfection is due to washing off apoptotic cells loosely 
attached to the coverslip and unaltered proliferation in the control population. B) 
Quantification of Caspase3 and Bax activation by immunostaining and subsequent 
FACS analysis using Alexa488 and Alexa633 secondary antibodies 72 hours post 
transfection. Error bars in histograms represent the standard deviation of the means 
of 3 independent experiments, **p<0.01 (student’s t-test). C) Inhibition of cell death 
induction mediated by siCK1 by treatment of cells with the pan caspase inhibitor. 
HeLa cells were transfected with siCK1 or si control, treated with the indicated 
concentration of zVAD 24 and 48 hours post transfection. Cell death was assessed by 
propidium iodide (PI) dye exclusion staining and subsequent FACS analysis; *p<0.05, 
**p<0.01, ns non-significant (student’s t-test). 
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D.2.2 Depletion of CKMT1 Results in MPT 
The depolarization of mitochondria is a priming event in the intrinsic apoptosis 
pathway. In order to assess whether CKMT1 knock-down results in dissipation of 
Δψm, live cell confocal microscopy and FACS analysis using JC1 (5,5’,6,6’-
tetrachloro-1,1’,3,3’ tetraethylbenzimidazolylcarbocyanine iodide) as a 
mitochondrial membrane potential indicating dye was performed. JC1 accumulates 
in mitochondria with intact membrane potential, forms aggregates and emits 
fluorescence in the red spectrum when excited at 488nm, whereas JC1 monomers 
distributed throughout the cell fluorescence in the green spectrum. 96h post 
transfection, knock-down of CKMT1 clearly results in mitochondrial depolarization 
(Fig.D.8A and 8B), whereas control transfected cells maintain their Δψm. In order to 
rule out that dissipation of Δψm was a secondary event after induction of apoptosis 
via a mitochondria-independent pathway, we monitored Δψm using DiOC6 and FACS 
analysis at earlier points in time (24-96 hours post-transfection, Fig.D.8C). Knock-
down of endogenous CKMT1 resulted in the depolarization of mitochondria, again 
with its onset kinetically correlated with the knock-down of CKMT1 protein (compare 
Fig.D.6F). 48h post transfection, approximately 20% of the siCK1-transfected cells 
showed dissipation of Δψm compared to 10% in the control. The percentage of cells 
with depolarized mitochondria increased to approximately 70% on day 4 in the 
siCK1-transfected cells compared to approximately 20% in the control. Considering 
the transfection efficiency of approximately 80% at this time point and the residual 
CKMT1 expression as observed by Western blotting, it can be assumed that 
mitochondrial depolarization coincides exactly with the depletion of CKMT1 protein. 
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Fig.D.8: Downregulation of CKMT1 Results in Mitochondrial Membrane Potential 
Dissipation. A) Confocal live cell imaging using JC1 as an indicator for mitochondrial 
membrane polarization 96h post siRNA transfection in HeLa cells. Note that DAPI is not cell 
permeable in viable cells, whereas it permeates apoptotic cells. B) FACS analysis of 
mitochondrial membrane polarization using JC1 96h post transfection. Error bars indicate 
the standard deviation of three independent experiments, **p<0.01 (student’s t-test); 
representative ratiometric contour plots are shown; mon monomer, agg aggregate. C) 
Kinetics of mitochondrial depolarization after down-regulation of CK1 by siRNA as monitored 
by DiOC6/propidium iodide costaining and subsequent FACS analysis. Error bars indicate the 
standard deviation of three independent experiments; representative multiparametric 
contour plots are shown on the right; *p<0.05, **p<0.01 (student’s t-test). 
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D.2.3 MPT Observed After Knock-down of CKMT1 Can be Abrogated by 
Specific Inhibition of the PT-pore Complex with Bongkrekic Acid 
Dissipation of the mitochondrial membrane potential Δψm is an early event in 
apoptosis and is caused by mitochondrial permeability transition(Zamzami, 
Marchetti et al. 1995; Zamzami, Marchetti et al. 1995; Zamzami, Larochette et al. 
2005; Brenner and Grimm 2006). This sudden change in outer mitochondrial 
membrane permeability is thought to be mediated by the opening of the PT-pore. 
Thus we hypothesized that the dissipation of Δψm observable after siRNA mediated 
knock-down of CKMT1 expression is due to the activation of the PT-pore complex 
and that consequently, pharmacological inhibition of the PT-pore would counteract 
mitochondrial depolarization and apoptosis induction. In order to address this 
question, we used bongkrekic acid, which is often used as a specific PT-pore 
inhibitor (Klingenberg, Grebe et al. 1970). Strikingly, the mitochondrial permeability 
transition observed after knock-down of CKMT1 expression could be abrogated by 
this compound (Fig.D.9). Bongkrekic acid prevented cells from mitochondrial 
permeability transition as well as cell death induced by siRNA mediated knock-down 
of endogenous CKMT1 expression. 
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Fig.D.9: Bongkrekic Acid Inhibits MPT Induced by Downregulation of 
Endogenous CKMT1. HeLa cells were transfected with siRNA against CKMT1 (siCK1) or 
a scrambled sequence (si control) and treated with the indicated amount of bongkrekic 
acid (BA) after 24h. A) Mitochondrial permeability transition was assessed using DiOC6/PI 
costaining and FACS analysis 72h post transfection. B) Representative FACS dot plots 
and gating are shown: I corresponds to normal living cells (DiOC6 positive, PI negative), 
II corresponds to early apoptotic cells with depolarized mitochondria (decreased DiOC6 
staining) but intact outer cell membrane (PI negative); II also contains very late stage 
apoptotic cells with extensive DNA degradation and thus decreased PI staining. III 
corresponds to late apoptotic cells with collapsed mitochondrial membrane potential 
(DiOC6 negative) and lost integrity of the outer cell membrane (PI positive). C) Cell death 
was assessed using PI exclusion staining and subsequent FACS analysis; nt non-treated, 
*p<0.05, **p<0.01 (student’s t-test). 
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D.2.4.1 MPT Observed After Knock-down of CKMT1 Cannot be Abrogated by 
Supplementation with Phosphocreatine 
CKMT1 works as an enzyme to transphosphorylate creatine and ATP to provide 
phosphocreatine to the cell. Knock-down of endogenous CKMT1 therefore might 
induce a shortage of available phosphocreatine. Therefore, we investigated whether 
supplementation of cells with phosphocreatine could counteract the effects observed 
after knock-down of endogenous CKMT1. As can be observed in Fig.D.10A, diverse 
supplementation schedules did not impact on cell death induction as well as the loss 
of mitochondrial membrane potential upon knock-down of endogenous CKMT1. 
These results provide supporting evidence that CKMT1 regulates MPT independently 
of its enzymatic activity as supplementation with the enzymatic end product 
(phosphocreatine) could not compensate for the depletion of the CKMT1 protein. 
Therefore, irrespective of its kinase activity, CKMT1 is structurally and/or 
functionally necessary for mitochondrial integrity per se. 
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Fig.D.10A: Phosphocreatine Supplementation Does not Rescue from 
Mitochondrial Depolarization Upon Depletion of Endogenous CKMT1. HeLa cells 
were transfected with siRNA constructs targeting the coding sequence of CKMT1 (siCK1) 
or a scrambled sequence (sc). Cells were supplemented twice daily with the indicated 
doses of phosphocreatine right after transfection for the next 92 hours. A) Cell Death was 
assessed by PI exclusion staining and subsequent FACS analysis. B) The mitochondrial 
membrane potential was assessed by DiOC6 staining and subsequent FACS analysis every 
24 hours. Representative data acquired 96 hours post transfection is shown; ns non-
significant (student’s t-test). 
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D.2.4.2 Of Diverse Anti-apoptotic Genes, only BclXL Partially Inhibits Cells 
form Mitochondrial Depolarization Upon Depletion of Endogenous CKMT1 
As CKMT1 depletion results in mitochondrial apoptosis, we examined whether the 
overexpression of established anti-apoptotic genes could overcome the induction of 
MPT after CKMT1 knock-down. All anti-apoptotic genes tested (cyclophilin D, BclXL, 
Bcl-2 and Mito-IKBα - refer to chapter F. for details on the apoptosis inhibition by 
mitochondrial IKBα) showed a strong inhibition of mitochondrial depolarisation 
induced by overexpression of ANT1 (Fig.D.10B). However, cyclophilin D, Mito-IKBα 
and Bcl-2 completely failed to protect cells from mitochondrial depolarisation upon 
knock-down of endogenous CKMT1. Only the co-transfection of BclXL marginally – 
but statistically significantly - inhibited the loss of the mitochondrial membrane 
potential upon knock-down of CKMT1. 
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Fig.D.10B: MPT Induction by Knock-down of CKMT1 Cannot be Inhibited by 
Concomitant Overexpression of CypD, Mito-IKBα and Bcl2 While BclXL 
Overexpression Partially Inhibits MPT. A) HeLa cells were transfected with shRNA 
plasmids targeting the coding sequence for CKMT1 (shCK1) or a scrambled sequence. 24 
hours and 48 hours later, cells were transfected with anti-apoptotic genes and their effect 
on the mitochondrial membrane potential assessed by DiOC6 staining and subsequent 
FACS analysis. Cyclophilin D (CypD), mitochondrially targeted IKBα (Mito- IKBα) and Bcl2 
fail to show any inhibitory effect on mitochondrial depolarization. Only overexpression of 
BclXL partially inhibited shCK1-induced mitochondrial membrane potential loss. B) The 
protective effect of the anti-apoptotic genes tested in this experiment is demonstrated by 
their ability to counteract ANT1 overexpression-induced loss of the mitochondrial 
potential.* p<0.05; **p<0.01; ***p<0.001 (student’s t-test). 
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D.2.5 CKMT1 Expression is Necessary for the Survival of All Transformed 
Human Cell Lines Tested 
In order to investigate whether the depletion of endogenous CKMT1 would be a 
universal signal inducing mitochondrial depolarization and subsequent apoptosis 
induction, we examined the shRNA-mediated knock-down of CKMT1 in various 
transformed human cell lines, including HeLa cells (human cervical carcinoma cell 
line), 293T cells (established by transformation of human embryonic kidney cells, 
but potentially of neuronal lineage(Shaw, Morse et al. 2002)), MCF7 and MDA231 
cells (human breast adenocarcinoma cell lines), HCT116 (human colorectal 
carcinoma cell line), and LNCaP cells (human prostate carcinoma cell line). Viral 
particles encoding shRNA targeting CKMT1 were used to knock-down CKMT1 
expression and resulted in massive mitochondrial depolarization and apoptosis 
induction (Fig.D.11). 
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Fig.D.11: Knock-Down of CKMT1 Results in the Dissipation of the Mitochondrial 
Membrane Potential and Apoptosis in All Transformed Human Cell Lines Tested. 
Cells were infected with viral particles encoding for shRNA constructs specifically 
targeting the CKMT1 coding sequence (shCK1) or a scrambled sequence (sc). 4-7 days 
post transfection the CKMT1 expression level was assessed by Western blotting and the 
mitochondrial membrane potential was measured using DiOC6 staining and subsequent 
FACS analysis; phase contrast microscopy of representative fields in shCK1 and sc 
infected cells are shown. Knock-down of CKMT1 results in highly significant mitochondrial 
depolarization in A) HeLa cells, B) 293T cells, C) MCF7 cells, D) HCT116 cells, E) LNCaP 
cells and F) MDA231 cells; *** p<0.001 (student’s t-test). 
 
 
 
 
 
 
 
 
 
D.2.6 Apoptosis Regulation via CKMT1 is Independent of Cyclophilin D 
Cyclophilin D has also been postulated as a key regulator/component of the PT-pore 
(although its effect has been described as both, pro- and anti-apoptotic depending 
on the cellular setting and stimulus used to induce MPT – see chapter A.4.7 for 
further details). 
Overexpression as well as downregulation of cyclophilin D can repress mitochondrial 
apoptosis(Lin and Lechleiter 2002; Li, Johnson et al. 2004; Schubert and Grimm 
2004; Machida, Ohta et al. 2006; Zhang and Armstrong 2007; Eliseev, Malecki et 
al. 2009; Kato, Akao et al. 2009; Hu, Chen et al. 2010). Thus, we investigated 
whether apoptosis induced by depletion of endogenous CKMT1 could be regulated 
by overexpression or siRNA mediated downregulation of cyclophilin D. As can be 
seen in Fig.D.12A, overexpression of cyclophilin D significantly abrogated ANT1 
induced apoptosis, whereas apoptosis by depletion of endogenous CKMT1 could not 
be inhibited by overexpression of cyclophilin D. Equally, downregulation of 
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cyclophilin D (both, transient as well as stable downregulation of cyclophilin D) did 
not impact on siCK1 induced apoptosis (Fig.D.12A). As the level of cyclophilin D 
downregulation was not complete (see Western blots in Fig.D.12B), we 
hypothesized that the remaining cyclophilin D might obscure any changes in 
apoptosis regulation. Thus we investigated apoptosis induction by siCK1 under 
pharmacological inhibition of cyclophilin D by concomitant treatment with either 
cyclosporinA, SanglifehrinA or compound BC544(Moss 2011). However, none of 
these cyclophilin D inhibitors had any effect on siCK1 induced mitochondrial 
membrane depolarization (Fig.D.12C). Also other treatment schedules including 
pretreatment and daily treatment were investigated but failed to show any effect on 
siCK1-induced mitochondrial membrane potential – (data not shown). 
Considering the potential unspecific effects of the inhibitors used that might obscure 
an effect of cyclophilin D inhibition, we examined cyclophilin D knock-out cells 
(SV40 immortalized adult fibroblasts; kindly provided by Dr. Andrea Rasola) as the 
ultimate tool for investigating the involvement of cyclophilinD siCK1 mediated 
apoptosis. Various shRNA constructs targeting the murine CKMT1 (mCKMT1) coding 
sequence were tested for their ability to downregulate mCKMT1 protein expression 
(Fig.D.12D). Two constructs, shmCK1 TRC25 and TRC27 showed profound 
downregulation of mCKMT1 and were thus used in WT and cyclophilin D-/- cells. WT 
and cyclophilin D-/- cells were infected with viral particles produced for shmCK1 
TRC25 and TRC27, and mitochondrial depolarization and cellular morphology 
assessed over a time course of 6 days. Viral particles for GFP expression were used 
to monitor equal infection rates in WT and cyclophilin D-/- cells (Fig.D.12.F). The 
cyclophilin D expression status did not have any effect on apoptosis induction 
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(Fig.D.12E) nor on the loss of the mitochondrial membrane potential after 
downregulation of mCKMT1 (Fig.D.12G). Although no difference in sensitivity 
towards apoptosis induced by downregulation of mCKMT1 was observed, cyclophilin 
D-/- cells were more resistant against other apoptotic stimuli including ANT1, 
Ionomycin, H2O2 and Menadione (data only shown for ANT1 in Fig.D.12G).  
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Fig.D.12: Apoptosis Induction by Downregulation of CKMT1 is Independent of 
CypD. A) Overexpression of cyclophilin D significantly inhibits ANT1 induced apoptosis 
whereas siCK1 induced apoptosis remains unchanged. Equally, neither transient nor stable 
downregulation of cyclophilin D has any effect on apoptosis induced by depletion of 
endogenous CKMT1. The histograms on the right show the assessment of the 
mitochondrial membrane potential after transfection with siRNA against CKMT1 combined 
with overexpression or downregulation of cyclophilin D. The endogenous expression level 
of cyclophilin D was assessed by Western blotting (right panel). B) Pharmacological 
inhibition of CypD activity by cyclosporinA (CysA), SanglifeherinA and the compound 
BC544 do not affect siCK1 induced apoptosis. Cells were transfected with the indicated 
siRNA constructs and treated with the listed inhibitors 20 hours post transfection. The 
mitochondrial membrane potential was assessed via DiOC6 and subsequent FACS analysis 
72 hours post transfection. C) Validation of shRNA constructs against murine CKMT1 
(mCKMT1) – shCK1 TRC25 and TRC27 show strong downregulation of mCKMT1 and were 
selected for further experiments (red arrows); overexpression of mCKMT1 24 hours after 
shRNA plasmid transfection in HeLa cells was used for validation of the shRNA constructs; 
protein lysates were collected another 24 hours later. D) Phase contrast microscopy of WT 
and CypD-/- immortalized adult fibroblast cells after infection with viral particles leading 
to expression of GFP, sh scramble, shmCK1 TRC25 and shmCK1 TRC27 – the apoptotic 
morphology of cells is clearly visible in the shmCK1 TRC25 and TRC27 infected cells. F) 
GFP expression as assessed by FACS Fl1 analysis in WT and CypD-/- cells 48hours after 
infection with viral particles encoding GFP. F) Analysis of the mitochondrial membrane 
potential via DiOC6 staining and subsequent FACS analysis: CypD-/- cells are resistant to 
ANT1 induced apoptosis (data kindly provided by Evangelos Pazarentzos, 24hours post 
transfection), whereas the CypD expression status does not have any impact on apoptosis 
induction by viral particles encoding for shmCK1 TRC25 and TRC27. The data shown was 
acquired 6 days post infection; ** p<0.01 (student’s t-test) ns non-significant. 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |195 
 
D.2.7 ASB9 Overexpression Results in Ubiquitination of Endogenous CKMT1 
Complexes, Subsequent Degradation and Apoptosis Induction via 
Mitochondrial Membrane Depolarization 
The ankyrin repeat and suppressor of cytokine signalling box protein 9 (ASB9) has 
recently been identified to interact with and induce the ubiquitination of CKMT1 as 
well as to induce abnormal mitochondrial structure(Kwon, Kim et al.). Thus we 
hypothesized that ASB9 overexpression-mediated ubiquitination of CKMT1 would 
result in proteasomal degradation of CKMT1 – this ASB9-mediated depletion of 
CKMT1 should then, in line with our RNAi experiments (see D.2.1 and D.2.2), lead 
to mitochondrial depolarization and apoptosis induction. Indeed, ASB9 has access to 
high molecular weight CKMT1 complexes (including the CKMT1 octamer, refer to 
chapter D.3.3 for the identification of the CKMT1 octamer) as observed by blue 
native gel electrophoresis (Fig.D.13): ASB9 transfection resulted in an upshift smear 
of CKMT1 complexes 24hrs post transfection indicative of CKMT1 polyubiquitination 
(Fig.D.13A). Overexpression of ASB9 also resulted in the downregulation of CKMT1 
protein levels after 48hrs and 72hrs (Fig.D.13B), which was concomitant with the 
dissipation of the mitochondrial membrane potential and induction of apoptotic cell 
death (Fig.D.13C-13E). Thus it appears that ASB9 overexpression leads to the 
polyubiquitination and subsequent degradation of CKMT1, which in turn results in 
the dissipation of the mitochondrial membrane potential and subsequent induction 
of apoptotic cell death comparable to the apoptosis observed after RNAi-mediated 
CKMT1 protein depletion (compare chapter D.2.1 and D.2.2). 
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Fig.D.13: ASB9-Mediated Ubiquitination and Degradation of CKMT1 Complexes Coincides 
with Loss of Mitochondrial Membrane Potential and Apoptosis Induction. A) Analysis of 
endogenous CKMT1 complexes using native blue gel electrophoresis and immunoblotting: BSA 
and NativeMark (Invitrogen) markers were visualized using Comassie staining and were used as 
molecular weight markers ranging from 20kDa to 1236kDa. High molecular weight CKMT1 
complexes were detected using a CKMT1 antibody for immunoblotting. 24 hours post transfection, 
ASB9 transfection results in an upshift smear of the CKMT1 complexes suggesting 
polyubiquitination. B) ASB9 overexpression results in CKMT1 protein degradation as shown by 
Western blot analysis for CKMT1 expression 48hrs and 72hours post-transfection with ASB9. C) 
Phase contrast microscopy pictures of HeLa cells after overexpression of ASB9; arrows indicate 
cells with apoptotic morphology. D) ASB9 overexpression results in the collapse of the 
mitochondrial membrane potential as analysed by DiOC6 staining and subsequent FACS. E) ASB9 
overexpression results in cell death as assayed by the fluorescein diacetate (FDA) assay for 
enzymatic hydrolysis of FDA. Significance **p<0.01, ***p<0.001 (student’s t-test). 
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D.2.7.1 Overexpression of CKMT1∆BS Induces Mitochondrial Membrane 
Potential Dissipation and Apoptosis 
As ASB9 seemed to induce apoptosis via ubiquitination and subsequent degradation 
of CKMT1, we hypothesized that a CKMT1 deletion mutant that cannot interact with 
ASB9 would rescue cells from ASB9 induced degradation of endogenous CKMT1. A 
deletion mutant of CKMT1, CKMT1∆BS (CKMT1 with amino acids 112 to 192 
corresponding to the so-called substrate binding site deleted), has previously been 
shown not to interact with ASB9(Kwon, Kim et al.). However, overexpression of this 
deletion mutant itself induced a high degree of mitochondrial membrane potential 
dissipation and cell death after 48 hrs (Fig.D.14). Due to this clear pro-apoptotic 
effect of CKMT1∆BS on its own, this construct was unsuitable for investigating the 
potential rescue effect upon co-expression with ASB9. Indeed co-transfections of 
CKMT1∆BS and ASB9 resulted in massive apoptosis in all setups tested (data not 
shown). 
As CKMT1∆BS was toxic to cells, we investigated the possibility of constructing 
another CKMT1 mutant with mutations in relevant lysine residues. However, there 
are no discrete published ubiquitination sites in CKMT1 sequence and the 
ubiquitination site prediction software UbPred(Radivojac, Vacic et al. 2010) 
predicted numerous candidate lysine residues (data not shown). 
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Fig.D.14: Overexpression of CKMT1∆BS Induces Mitochondrial Membrane Potential 
Dissipation and Apoptosis. A) Phase contrast microscopy of 293T cells transfected with beta-
galactosidase (Bgal), CKMT1 or the deletion mutant CKMT1∆BS (CKMT1 with amino acids 135 to 
145 deleted). Numerous cells with apoptotic morphologies are visible 48 hrs post CKMT1∆BS 
transfection. B) CKMT1∆BS overexpression results in significant mitochondrial membrane 
potential dissipation 48hrs and 72hrs post transfection. C) CKMT1∆BS overexpression results in 
cell death as assayed by the fluorescein diacetate (FDA) assay for enzymatic hydrolysis of FDA; 
**p<0.01, ***p<0.001 student’s t-test. 
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D.3 Investigation of the Mechanism of Apoptosis Regulation by 
CKMT1 
 
D.3.1 CKMT1 Depletion/Degradation is not a Physiological Mechanism for 
Initiating Mitochondrial Depolarization in Response to Diverse Cytotoxic 
Reagents 
As our previous experiments (chapters D.2.1 and D.2.2) indicated that depletion of 
CKMT1 potently induces apoptosis via perturbation of the mitochondrial membrane 
potential, we hypothesized that degradation of endogenous CKMT1 could be a 
universal mechanism of apoptosis induction for stimuli that directly or indirectly 
impact on mitochondrial function. Therefore we investigated whether mitochondrial 
depolarization and subsequent apoptosis induction by cytotoxic agents such as 
ionomycin, hydrogen peroxide (H2O2), arsenic trioxide (As2O3), doxorubicin, 
docetaxel and etoposide would be preceded by degradation of endogenous CKMT1. 
As can be observed in Fig.D.15A, the collapse of the mitochondrial membrane 
potential did not depend on the degradation of CKMT1. A titration of As2O3 was used 
to further investigate the kinetic relation of mitochondrial depolarization, PARP 
cleavage as an indicator of caspase dependent apoptosis, and the CKMT1 expression 
level (Fig.D.15B). Mitochondrial depolarization and PARP cleavage preceded the 
degradation of CKMT1. Thus CKMT1 depletion is unlikely to be mechanistically 
involved in initiating the apoptosis induction. Nevertheless, although not a priming 
event for mitochondrial depolarization, the downregulation of CKMT1 might act as a 
signal to amplify the apoptotic response: CKMT1 degradation could be observed 
Imperial College London 2013 
Christoph DATLER – PhD Thesis  |201 
 
before the cleavage of cellular substrates by caspases in late apoptosis, as GAPDH 
expression was not affected at these time points. 
 
 
 
  
A) 
A) 
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Fig.D.15: Assessment of the Degradation of Endogenous CKMT1 During Apoptosis.        
A) Cells were treated with ionomycin (10uM, 2hrs 293T cells), hydrogen peroxide (H2O2 
500uM, 24hrs HeLa cells), arsenic trioxide (As2O3 10uM, 24hrs MCF7 cells), docetaxel (100nM, 
72hrs MCF7 cells), doxorubicin (2.5uM, 24hrs 293T cells) and etoposide (150uM, 24hrs 293T 
cells). Mitochondrial Depolarization was assessed by DiOC6 staining and subsequent FACS 
analysis. Protein lysates were collected and analysed for CKMT1 expression levels. B) HeLa 
cells were subjected to a range of concentrations of As2O3 for 18hrs. The mitochondrial 
membrane potential was assessed by DiOC6 staining and subsequent FACS analysis. Protein 
lysates were assayed for CKMT1 expression and PARP cleavage, both of which were quantified 
using densitometric analysis of immunoblots and blotted against the loss of mitochondrial 
polarization. 
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D.3.2 CKMT1 is not Released From Mitochondria Upon Apoptosis Induction 
As the previous results (Fig.D.15) suggested that degradation of endogenous 
CKMT1 contributes to but is not the initiation point for apoptosis induction by 
cytotoxic stimuli, we hypothesized that CKMT1 might be released from mitochondria 
(without changing the overall expression level) in order to initiate mitochondrial 
apoptosis. As a reference for the release of proteins from the IMS upon apoptosis, 
we monitored the cellular distribution of cytochrome c using confocal 
immunofluorescence microscopy. As expected, the IMS proteins CKMT1 and 
cytochrome c co-localized to a high extent in non-treated HeLa cells (Fig.D.16, 
upper panel – co-localization shown by yellow staining). Upon induction of 
mitochondrial permeability transition and depolarization with the ionophore 
ionomycin (compare Fig.D.5B for data on mitochondrial depolarization), cytochrome 
c redistributed and showed diffuse cytoplasmic staining whereas CKMT1 staining 
remained punctuate (Fig.D.16, lower panel). Apoptosis induction upon treatment 
with ionomycin was also demonstrated by the shrinkage of the nucleus as visualised 
by staining with DAPI. This data indicates that apoptosis induction is not functionally 
coupled to the release of CKMT1 from mitochondria. 
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Fig.D.16: CKMT1 is not Released from Mitochondria During Initiation of Apoptosis. 
Confocal immunofluorescence microscopy of HeLa cells upon treatment with ionomycin (3hrs 
10uM): Primary antibodies specific for CKMT1 and cytochrome c and fluorescently labelled 
secondary antibodies were used to visualise the localisation of the respective proteins; DAPI was 
used as a nuclear counterstain. Untreated cells show a clear colocalisation of CKMT1 and 
cytochrome c. Upon treatment with ionomycin cytochrome c is released from mitochondria and 
shows diffuse cytoplasmic staining, whereas punctuate CKMT1 staining indicates retention in 
mitochondria. Nuclear shrinkage can also be observed in ionomycin treated cells, which is 
indicative of apoptosis. The white bar inserted in each pictures is equal to 10um. 
DAPI 
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D.3.3 The Multimeric Assembly of CKMT1 in Mitochondria 
Artificial downregulation of endogenous CKMT1 clearly resulted in apoptosis 
induction (compare Fig.D.11). However, physiologically, CKMT1 degradation is not 
the initiation step of mitochondrial depolarization. CKMT1 was not released from its 
mitochondrial locale in early apoptosis, and total CKMT1 levels only changed later 
during apoptosis induction. Thus we suspected that CKMT1 might initially control 
cellular apoptosis through two other mechanisms: First - instead of being degraded 
or changing its locale - the oligomeric configuration of CKMT1 might change to 
signal for apoptosis induction. And second, its association with other mitochondrial 
proteins (especially PT-pore family members which have been shown to interact 
with CKMT1 previously – see chapter A.4 for details) might determine whether 
apoptosis is induced or inhibited. As can be demonstrated employing native blue gel 
electrophoresis coupled with immunoblotting (see Fig.D.17) endogenous CKMT1 
forms high molecular weight complexes, which could be due to assembly as 
multimeric CKMT1 molecules (octamers) or interactions with diverse other cellular 
proteins, e.g. members of the PT-pore. Blue native gel electrophoresis revealed that 
CKMT1 exists mainly as an octamer (Fig.D.17): Although native CKMT1 runs at an 
apparent size comparable to that of native apoferritin (24 subunits corresponding to 
approximately 480 kDa), comparison with purified CKMT1, which readily forms 
octamers in solution(Schlegel, Zurbriggen et al. 1988), indicated that the main 
native complex observed corresponds to octameric CKMT1 (336 kDa). Two distinct 
bands can be seen when analysing purified CKMT1 on a native gel – octameric 
CKMT1 and dimeric CKMT1. Urea treatment of purified CKMT1 was used as it has 
been reported to dissociate CKMT1 octamers into dimers(Schlegel, Zurbriggen et al. 
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1988); however no striking effect of urea addition on octamer/dimer distribution 
was observed in our experimental setting. There was no dimeric CKMT1 in native 
lysates from untreated 293T cells, even after prolonged exposure (Fig.D.17 right 
blots). However, a clear additional band to the CKMT1 octamer could be noticed in 
native cell lysates (CKMT1*complex), which corresponds either to CKMT1 molecules 
complexed with another protein, CKMT1 octamers formed of unprocessed CKMT1 
(mitochondrial import sequence not cleaved off), yet unidentified multimeric 
isoforms of CKMT1 or corresponding to (post-translationally) modified CKMT1 
octamers (e.g. phosphorylation). As we succeeded in identifying discrete CKMT1 
complexes, we went on to examine whether these complexes change during and 
therefore could be functionally connected to apoptosis induction. 
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Fig.D.17: CKMT1 is Present as an Octamer and an Unidentified High Molecular Weight Complex in Native Cell Lysates. 
Blue native gel electrophoreses was used to analyse the migration behaviour (size and quaternary structure) of purified CKMT1 
and CKMT1 complexes present in native 293T cell lysates. Purified CKMT1 readily forms dimers and octamers. Urea treatment was 
used as it has been reported to dissociate CKMT1 octamers into dimers(Schlegel, Zurbriggen et al. 1988) – however, no striking 
dissociation effect was observed in our experiments. In native cell lysates, the majority of CKMT1 forms complexes displaying 
identical migration behaviour to the CKMT1 octamer. Also, an additional CKMT1 band is visible running at an apparently higher 
molecular weight (CKMT1*complex). 
CKMT1*complex 
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D.3.3.1 The CKMT1 Octamer, as Analysed by Blue Native Gel 
Electrophoresis Does not Dissociate Upon Apoptosis Induction 
As several other authors suggested that the dissociation of the CKTMT1 octamer 
could induce mitochondrial permeability transition and apoptosis(Beutner, Ruck et 
al. 1998; Soboll, Brdiczka et al. 1999), we examined whether the CKMT1 octamer, 
as detected by blue native gel electrophoresis, would dissociate upon apoptosis 
induction (Fig.D.18). 
 
 
 
A) 
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D) 
CKMT1*complex  
CKMT1  octamer 
Fig.D.18: The CKMT1 Octamer Does not Dissociate Upon Apoptosis Induction 
Whereas the CKMT1*complex Does. A) Blue native gel electrophoresis and 
immunoblotting of native 293T cell lysates upon induction of apoptosis with 20uM As3O3 
for 16 hrs. Dissociation of the octamer into dimeric complexes is not detectable. 
However, the higher molecular weight CKMT1 complex disappears in apoptotic cells; 
mitochondrial depolarization (DiOC6 staining) and cell death (propidium iodide exclusion 
staining) are quantified in the right panel. B) Analysis of CKMT1 complexes upon 
apoptosis induction with various concentrations of As3O3 (1-20uM) and H2O2 (200 and 
1000uM) for 16 hrs. Dissociation of the octamer is not detectable, however the higher 
molecular weight complex of CKMT1 disappears in a concentration-dependent manner C) 
The same blot as is B is shown after extended exposure. Even under these conditions no 
octamer dissociation can be detected. D) Correlation of mitochondrial depolarization (as 
assessed by DiOC6 staining and subsequent FACS analysis) and disappearance of the 
CKMT1*complex in the CKMT1 blot upon treatment with As3O3 and H2O2 as described in 
B: The histogram shows the percentage of cells with depolarized mitochondria (mito 
depolarization) and the CKMT1 complex ratio (ratio of higher molecular weight complex 
and the octamer complex as determined by densitometric quantification of immunoblots 
using ImageJ). The CKMT1 complex ratio observed in healthy cells was set to 100 %. 
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As CKMT1 overexpression had an inhibitory effect on As2O3 treatment (Fig.D5) and 
As2O3-induced apoptosis has been demonstrated to be mediated via mitochondrial 
depolarization(Cai, Shen et al. 2000), we used cell lysates from As2O3 treated 293T 
cells to assay for changes in CKMT1 quaternary organization upon apoptosis. In line 
with data presented on the stability of CKMT1 upon apoptosis induction (Fig.D.15), 
no striking changes in the overall CKMT1 level could be detected. As can be 
observed in Fig.D.18A, the octamer of CKMT1 was also unaffected by As2O3 
treatment, although clear effects on the mitochondrial membrane potential as well 
as cell death induction (cell membrane integrity staining) were recorded. Dimeric 
CKMT1 is virtually undetectable in native 293T cell lysates under all conditions 
examined (untreated, As2O3, and H2O2 treatment – Fig.D.18B and 18C; data for 
ionomycin treatment not shown). However, the higher molecular weight complex of 
CKMT1 (as described in Fig.D.17) disappeared in a concentration dependent 
manner. Fig.D.18D shows the correlation between mitochondrial depolarization and 
the change in the CKMT1 complex ratio (ratio of higher molecular weight complex 
and the octamer complex as determined by denstiometric quantification of 
immunoblots). As the nature of the higher molecular weight CKMT1 complex is not 
known, further experiments are ongoing to reveal the underlying molecular 
mechanism. 
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D.3.4 Apoptosis Regulation by CKMT1 is not Mediated by VDAC1 
As CKMT1 and VDAC1 have been suggested as constituents of the functional 
mitochondrial PT-pore(Beutner, Ruck et al. 1998) and show a direct interaction that 
is modulated by calcium(Schlattner, Dolder et al. 2001), we speculated that it is this 
interaction that mediates apoptosis regulation by CKMT1. In order to test this 
hypothesis, we first knocked down endogenous VDAC1 using a specific shRNA 
construct and assessed mitochondrial depolarization upon knock-down of 
endogenous CKMT1. However, reduced VDAC1 levels did not significantly impact on 
the perturbation of the mitochondrial membrane potential upon CKMT1 depletion 
(Fig.D.19A and Fig.D.19B). Additionally, pharmacological inhibition of VDACs by 
4,4'-Diisothiocyanatostilbene-2,2'-disulfonate (DIDS)(Keinan, Tyomkin et al.) also 
did not inhibit siCK1-induced dissipation of the mitochondrial membrane potential, 
although it could significantly reduce VDAC1 overexpression-induced mitochondrial 
membrane potential loss (Fig.D.19C and Fig.D.19D). 
Next we assessed whether the interaction of CKMT1 and VDAC1 might act as a 
gatekeeper for mitochondrial permeability transition, i.e. the loss of interaction of 
CKMT1 and VDAC1 would be a signal for mitochondrial disintegration. We 
investigated the association of CKMT1 and VDAC1 under normal and apoptotic 
conditions using co-immunoprecipitation: As can be observed in Fig.D.19E and 
Fig.D.19F, endogenous CKMT1 and VDAC1 interacted in untreated cells. However, 
this interaction remained stable upon apoptosis induction by various concentrations 
of doxorubicin and As2O3 (data only shown for doxorubicin). 
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This data indicates that VDAC1 function is not required for apoptosis induction by 
siCK1 and that the endogenous interaction of VDAC1 and CK1 is not relevant for 
apoptosis regulation under the treatment conditions tested. 
 
D.3.5 CKMT1 Depletion Does not Change the Interaction of Constituents of 
the “Traditional” PT-pore Model 
As numerous authors (see chapter A.5 for a review) and our data suggested that 
CKMT1 regulates mitochondrial permeability transition via interacting (e.g. as a 
molecular gatekeeper for opening) with the so-called PT-pore, we hypothesized that 
depletion of endogenous CKMT1 would open the PT-pore by changing the interaction 
of its molecular constituents. Previously, our experiments identified ANT1 as an 
interactor of CKMT1 (Fig.D.4C) and apoptosis induced by ANT1 overexpression could 
be significantly abrogated by CKMT1 overexpression (Fig.D.4A and Fig.D.4B). 
Additionally, ANT1 has been described as a central member of the PT-pore in the 
literature, although its requirement for mitochondrial permeability transition has 
been controversially discussed (see chapter A.4.3 for a summary of studies on ANT1 
and permeability transition). Therefore, we immunoprecipitated ANT1 in protein 
lysates of CKMT1 knock-down and control cells and assayed for changes in its 
protein interaction partners. As can be observed in Fig.D.20, endogenous ANT1 
interacted with endogenous CKMT1, VDAC1, cyclophilin D and hexokinase II. 
However, the almost complete knock-down of CKMT1 did not change the level of 
these co-immunoprecipitated PT-pore members: The protein-protein interaction 
with hexokinase II, VDAC1 and cyclophilin D remained stable and quantitatively 
unchanged even in the shRNA-induced absence of co-immunoprecipitated CKMT1.  
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Fig.D.19: VDAC1 Does not Mediate Apoptosis Regulation by CKMT1. A) Knock-
down of VDAC1 by shRNA constructs specific for VDAC1 does not affect apoptosis 
induction by knock-down of endogenous CKMT1 72hrs and 96hrs post transfection. B) 
Validation of VDAC1 knock-down by Western blot analysis. C) Co-immunoprecipitation of 
CKMT1 with VDAC1 in untreated and doxorubicin treated MCF7 cells (cells were treated 
with the indicated doxorubicin concentration and lysates obtained after 12 hours. The 
asterix (*) indicates the 50kDa heavy chain antibody fragment of the antibody used for 
the IP. D) Phase contrast microscopy pictures of MCF7 cells treated with the indicated 
concentrations of doxorubicin for 12hrs and 20hrs. Early apoptotic morphology features 
are clearly visible in treated cells after 12hrs, and dose dependent apoptosis can be 
observed after 20hrs. E) VDAC inhibition by 4,4'-Diisothiocyanatostilbene-2,2'-disulfonate 
(DIDS) does not impact on apoptosis induced by knock-down of CKMT1 (72hrs post 
siCK1 transfection), whereas VDAC1 overexpression induced apoptosis (F) can be 
significantly inhibited by DIDS; ** p<0.01 (student’s t-test). 
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Fig.D.20: CKMT1 Depletion Does not Change the Interaction of Major 
Constituents of the “Classical” PT-pore Model. 293T cells were infected with viral 
particles encoding for short hairpin RNA against the CKMT1 coding or a scrambled 
sequence and protein lysates obtained 6 days post transfection. Immunoprecipitation of 
ANT1 resulted in co-immunoprecipitation of hexokinase II, CKMT1, VDAC1 and cyclophilin 
D. These interactions remained stable in the shRNA-induced absence of CKMT1. 
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D.4 CKMT1 Expression is Necessary for Cell Viability in a Transient 
Setting 
 
D.4.1 Despite Reports on the Absence of a Mouse Knock-out Phenotype, 
CKMT1 is Essential for Cell Viability in All Mouse Tumour Cell Lines Tested 
In an attempt to elucidate the functional role of creatine isoenzymes in vivo, knock-
out mice lacking cytosolic and/or mitochondrial creatine kinase were generated and 
studied extensively(Steeghs, Oerlemans et al. 1995; Steeghs, Peters et al. 1995; 
Steeghs, Oerlemans et al. 1998; de Groof, Oerlemans et al. 2001). Mice lacking 
CKMT1 are fertile, viable, and phenotypically normal in many aspects. Thus it was 
hypothesized that CKMT1 is not absolutely mandatory for mouse viability. In order 
to assess whether murine CKMT1 (mCKMT1) is essential for mouse cell survival, we 
investigated the effects of transient knock-down of mCKMT1 in diverse mouse 
tumour cell lines. Knock-down of mCKMT1 in murine MLE12 cells resulted in greatly 
reduced cell viability and apoptotic cell death induction (Fig.D.21). In line with this 
and previous experiments, targeting of mCKMT1 in murine N2A cells resulted in 
mitochondrial depolarization (Fig.D.22) and apoptotic cell death induction (data not 
shown). Thus, CKMT1 expression is necessary for the survival of murine cells, at 
least for the survival of transformed murine cell lines. 
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Fig.D.21: Knock-Down of murine CKMT1 Results in Apoptotic Cell Death in MLE12 
Cells. A) Upper panel: photographs of MLE12 cells infected with viral particles encoding 3 
different shRNA constructs targeting mCKMT1 (sh TRC25, sh TRC27, sh TRC703) or a 
scrambled sequence (sc) sequence. 6 days post infection, cell colonies were stained with 
crystal violet. Lower panel: Phase contrast light microscopy pictures of the respective 
infections. B) Quantification of cell viability by photometric measurement of crystal violet 
absorbance at 590nm C) Western blot analysis of MLE12 control and CKMT1 knock-down 
cells: CKMT1 depletion is achieved by all knock-down constructs used and results in clear 
PARP cleavage and degradation indicative of apoptotic cell death. 
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Fig.D.22: Knock-Down of Murine CKMT1 Results in the Dissipation of the 
Mitochondrial Membrane Potential in N2A Cells. A) Assessment of the mitochondrial 
membrane potential in murine N2A cells after transient knock-down of CKMT1 by shRNA 
plasmid transfection (sh HUSH14 and sh HUSH15 constructs) or the use of viral particles 
encoding shRNA constructs against murine CKMT1 (sh TRC25, shTRC27, sh TRC703). All 
constructs resulted in efficient knock-down of mCKMT1 expression 5 days post 
application as analysed by Western blotting for mCKMT1 expression (B) and induced 
significant mitochondrial depolarization when compared to the non-targeting scrambled 
construct (sc); *** p<0.001 (student’s t-test). 
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D.4.2 CKMT1 Expression is Vital not Only for Transformed Cell Lines but 
Also for Human Primary Cells 
Our results so far established that CKMT1 expression is necessary for the survival of 
human and murine transformed cell lines (see Fig.D.11, Fig.D.21 and Fig.D.22). 
Combining this data and the phenotypically normal appearance of CKMT1 knock-out 
mice(Steeghs, Oerlemans et al. 1995), one could speculate that CKMT1 expression 
is only necessary for the survival of transformed cells, whereas “normal” cells would 
not require CKMT1 expression under physiological conditions. To address this 
hypothesis, we obtained human primary cells (human foreskin fibroblasts) and 
examined the effect of transient CKMT1 knock down. As can be observed in 
Fig.D.23, knock-down of CKMT1 in these primary cells resulted in both, 
mitochondrial membrane potential dissipation and induction of apoptosis. Depletion 
of CKMT1 resulted in the loss of the mitochondrial membrane potential indicated by 
the shift to the left in the cell populations shown in Fig.D.23B as well as in the 
permeabilisation of the outer cell membrane as indicated by the upshift of the cell 
population in Fig.D.23B. This coincided with the appearance of rounded up apoptotic 
cells in the phase contrast microscopy pictures presented in Fig.D.23.A. 
These results indicate that CKMT1 expression is universally required, i.e. in 
transformed as well as untransformed human cells. 
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Fig.D.23: Knock-Down of CKMT1 in Human Primary Cells Induces Mitochondrial 
Membrane Potential Dissipation and Apoptosis. Primary human foreskin fibroblasts 
(HFF1) were infected with viral particles encoding shRNA constructs targeting specifically 
the coding sequence of CKMT1 (shCK1) or a scrambled sequence (sc). A) Phase contrast 
microscopy of HFF1 cells 6 days post infection; rounded up apoptotic cells are clearly 
visible in the shCK1-infected cells. B) Assessment of the mitochondrial membrane 
potential and cell membrane permeability by simultaneous staining with DiOC6 and 
propidium iodide (PI). Representative FACS dot blots are shown for shCK1 and sc 
infections. C) Quantification of mitochondrial membrane potential loss upon shCK1 
infection. D) Western Blot validation of CKMT1 knock-down by the respective viral 
constructs; *** p<0.001 (student’s t-test). 
 
 
 
 
 
 
 
 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |224 
 
E. RESULTS PART II 
E.1 CKMT1 RNAi Validation Experiments and the Analysis of CKMT1 
Gene Products 
The previous experiments indicated that the anti-apoptotic effect of CKMT1 upon 
overexpression is independent of its enzymatic activity (Fig.D.4 and Fig.D.5), and 
downregulation of endogenous CKMT1 induces apoptosis (Fig.D.6 and Fig.D.10A), 
even in the presence of exogenously supplemented phosphocreatine - the 
enzymatic product of CKMT1. Thus it is highly likely that the enzymatic activity of 
CKMT1 (phosphocreatine production) is not crucial for cellular vitality and apoptosis 
induction by depletion of endogenous CKMT1 is not due to loss of CKMT1 enzyme 
activity, but rather a consequence of other functions of CKMT1 (e.g. a gatekeeper 
function of the CKMT1 as an octamer coordinating mitochondrial permeability 
transition). However, our experiments so far do not provide a detailed molecular 
mechanism of how mitochondrial permeability transition and subsequent apoptosis 
induction is regulated by CKMT1, although they demonstrate that CKMT1 keeps a 
mitochondrial permeability transition complex inactive that is sensitive to 
bongkrekic acid (Fig.D.9). 
Thus, we aimed at creating a human cellular system in which endogenous CKMT1 
would be downregulated by siRNA or shRNA, while at the same time expressing a 
“siRNA-resistant” CKMT1 construct in order to rescue cells from apoptosis (in the 
following chapters this cellular system is referred to as “RNAi CKMT1 phenotype 
rescue experiment”).  
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This cellular system could be used to determine which domains or functions of the 
CKMT1 protein are vital to the cell. Establishing this system is crucial to answer 
important questions as to whether an enzymatically inactive CKMT1 protein would 
rescue cells from apoptosis induced by depletion of endogenous CKMT1 or whether 
a CKMT1 mutant incapable of octamerisation could replace endogenous CKMT1. 
Other questions regarding the necessity of certain residues or protein interaction 
domains could also be addressed using this experimental setup. 
 
E.1.1 Establishing the Cellular Model for CKMT1 Rescue Experiments 
In order to design the rescue experiment as outlined above, we investigated the 
possibility to use highly homologous CKMT1 genes that deviate from the human 
CKMT1A/B sequence in areas predicted to be suitable for siRNA targeting. The 
murine CKMT1 protein shows greater than 98% identity on the amino acid sequence 
level and approximately 92% base pair identity in the coding sequences 
(percentages calculated using the BLAST online tool of the National Library of 
Medicine). Exploiting base pair dissimilarities between human and murine CKMT1, 
we designed siRNA duplexes that target the human CKMT1 but do not recognize 
murine CKMT1. 
  
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |226 
 
E.1.1.1 Expression of Murine CKMT1 Induced by Plasmid Overexpression is 
not Affected by the Knock-Down of Endogenous Human CKMT1 
HeLa cells were used to assess whether the ectopic expression of murine CKMT1 
was affected by the simultaneous downregulation of endogenous human CKMT1 
using the siCK1 sequence described in Fig.E.1A. Additionally, we also tested the 
enzymatically inactive murine CKMT1mut construct in the same experimental 
setting. As can be seen in Fig.E.1B, the expression of the murine HA-tagged 
constructs (murine CKMT1 and murine CKMT1mut) was not affected by transfection 
of siRNA targeting bp 413-431 of the human coding sequence of CKMT1A/B. Thus, 
these murine CKMT1 expression constructs are unrecognizable to the siRNA duplex 
targeting the human CKMT1 mRNA and were expected to rescue the phenotype of 
endogenous CKMT1 depletion (mitochondrial depolarization and subsequent 
apoptosis induction). 
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Fig.E.1: Overexpression of Murine CKMT1 by Plasmid Transfection is not Affected 
by siRNA Against Human CKMT1. A) Alignment of human and murine CKMT1 at the 
chosen siCK1(I) binding site. Mismatches are indicated by a star and mismatching 
basepairs are highlighted in red. B) HeLa cells were transfected with an siRNA targeted 
against the coding sequence of human CKMT1 (siCK1) or a scrambled control sequence 
(sc). 24 hours post siRNA transfection, cells were transfected with plasmids encoding HA-
tagged murine CKMT1 (mCKMT1-HA) or the enzymatically inactive mutant mCKMT1mut-HA 
containing the E266 to L266 mutation as described in Fig.C.2. Protein lysates were 
obtained 72 hours after siRNA transfection and assayed for expression of the respective 
constructs using a monoclonal HA antibody. 
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E.1.2 Transient Overexpression of Murine CKMT1 Does not Rescue HeLa 
Cells from Mitochondrial Depolarization Induced by Knock-Down of 
Endogenous Human CKMT1 
As the ectopic expression of murine CKMT1 constructs was not affected by the 
siRNA against human CKMT1, we set up a transient rescue experiment: First, HeLa 
cells were transfected with the siRNA specifically targeting the coding sequence of 
human CKMT1 or a scrambled sequence. Previous experiments on the kinetics of 
protein downregulation after siCK1 transfections showed that there is no detectable 
CKMT1 depletion nor apoptosis induction within at least the first 24 hours after 
siRNA transfection (compare Fig.D.7). Thus, a second round of plasmid 
transfections, 16 hours after the siRNA transfection, was used to overexpress 
constructs encoding for the murine wild type CKMT1 or the enzymatically inactive 
murine CKMT1 mutant. However, neither overexpression of the murine CKMT1 wild 
type nor the enzymatically inactive mutant, rescued cells from mitochondrial 
depolarisation (Fig.E.2A). This was unexpected since Western blot analysis for total 
CKMT1 expression revealed that while endogenous CKMT1 was depleted by siCK1 
transfection, the murine CKMT1 constructs were expressed at even higher levels 
than endogenous human CKMT1 (Fig.E.2B). The same experiment was also 
performed using different transfection schedules: However, neither concomitant co-
transfection of siCK1 and murine CKMT1 nor reversing the transfection order 
(plasmid transfection first) had any impact on the outcome (data not shown). 
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Fig.E.2: Overexpression of murine CKMT1 Does not Rescue HeLa Cells from 
Mitochondrial Depolarization Induced by Knock-Down of Endogenous CKMT1. A) 
HeLa cells were transfected with siRNA targeted against the coding sequence of human 
CKMT1 (siCK1) or a scrambled sequence (sc). 16 hours post transfection, cells were 
transfected with constructs encoding murine CKMT1 (mCKMT1-HA or mCKMT1mut-HA), 
Bgal was used as a control. Staining with DiOC6 and subsequent FACS analysis were used 
to assess the mitochondrial membrane potential 72 hours post siRNA transfections; ns non-
significant (student’s t-test). B) Western blot analysis of protein lysates obtained from cells 
manipulated as described in (A) without DiOC6 staining. CKMT1 expression was detected 
with a polyclonal CKMT1 primary antibody recognizing human CKMT1 as well as murine 
CKMT1.  
B) 
A) 
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E.1.3 Establishment of HeLa Cell Clones Stably Expressing Murine CKMT1 
Constructs 
The reconstitution of CKMT1 expression by transient overexpression of murine 
CKMT1 did not rescue the phenotype of the depletion of endogenous human CKMT1 
(compare Fig.E.2). We hypothesized that the failure of the phenotype rescue could 
be due to the transient nature of the experiment (possible complication of 
transfection schedules, abrupt changes of expression levels, etc.). Therefore, HeLa 
cells stably expressing the murine CKMT1 constructs were obtained. Stable clones 
for murine CKMT1 and murine CKMT1mut were established using two different 
approaches: One set of experiments used a plasmid encoding a bicistronic mRNA for 
murine CKMT1 followed by an internal ribosome entry site (IRES) coupled to a 
puromycin resistance for antibiotic selection. The other approach used a plasmid 
encoding a bicistronic mRNA for murine CKMT1 followed by an IRES coupled to an 
EGFP marker for fluorescent selection. Several individual clones as well as a clone 
pool were obtained for each set of experiments and the expression of the respective 
murine construct in >99% of cells was verified by Western blot analysis indicating 
that the murine constructs were expressed at a higher level than endogenous 
CKMT1 in cell lysates (Fig.E.3A and 3B). Additionally, FACS analysis was employed 
to demonstrate the presence of the HA-tagged constructs in greater than 99% of all 
cells of the IRES-PURO clones as well as the presence of EGFP in the IRES-EGFP 
clones. As EGFP expression alone is not a totally conclusive evidence for the 
expression of the murine CKMT1 construct (even though an IRES system was used), 
confocal microscopy was employed to verify the co-expression of EGFP and the HA-
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tagged murine construct in all cells. This also confirmed the mitochondrial staining 
pattern of the ectopically expressed murine CKMT1 constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.E.3 : Verification of Stable HeLa Cell Clones for Murine CKMT1 Constructs. 
A) Stable HeLa clones expressing murine, HA-tagged CKMT1 constructs (mCKMT1-HA, 
mCKMT1mut-HA) were established using the IRES-EGFP and IRES-PURO systems. 
Protein lysates of the clones were assayed for the expression of total CKMT1 using a 
polyclonal CKMT1 antibody recognising human and murine CKMT1. For Fig.E.3B) and 
E.3C) see following page 
A) 
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B) C) 
Fig.E.3 B-C: Verification of Stable HeLa Cell Clones for Murine CKMT1 Constructs. For Fig.E.3A) refer to the previous page.   
B) Stable IRES-PURO clones for the CKMT1 constructs were analysed by FACS analysis for the presence of the ectopically 
expressed CKMT1 via fluorescent HA-tag staining. C) Stable IRES-EGFP clones for the CKMT1 constructs were analysed by FACS 
analysis for the expression of EGFP as well as by confocal microscopy for the ectopic expression of the respective CKMT1 
constructs. 
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E.1.4 HeLa Cell Clones Stably Expressing Murine CKMT1 Undergo 
Mitochondrial Depolarization Upon Specific Depletion of Endogenous 
Human CKMT1 
The HeLa cell clones stably expressing the ectopic CKMT1 constructs (see Fig.E.3) 
were used for RNAi CKMT1 phenotype rescue experiments (as described in chapter 
E.1). According to the results presented in Fig.E.1, siRNA against human CKMT1 did 
not affect the expression of murine CKMT1 constructs. Therefore, we expected that 
HeLa cells stably expressing wild-type murine CKMT1 would not be affected by 
siRNA transfection specifically targeting the endogenous human CKMT1 (phenotype 
rescue). We further hypothesized that the enzymatically inactive murine CKMT1mut 
would also rescue the siCKMT1 phenotype. Stable clones for Bgal and ectopic 
human CKMT1 expression were used as a control. As a further control, we used two 
different siRNA sequences both specifically targeting human CKMT1 and not 
affecting murine CKMT1 due to base pair mismatches (Fig.E.4). 
As expected, Western blot analysis revealed that siRNA transfection targeting 
human CKMT1 could deplete cells efficiently of endogenous human CKMT1 
(Fig.E.5A, Bgal clone) as well as ectopic human CKMT1 (Fig.E.5B, hCKMT1-HA 
clone). In contrast, the expression of murine CKMT1 constructs was not affected by 
the siRNA transfection targeting human CKMT1 (Fig.E.5C, mCKMT1-HA clone; and 
Fig.E.5D, mCKMT1mut-HA clone). Despite the presence of unaltered murine CKMT1 
levels, downregulation of endogenous human CKMT1 by two different siRNA 
constructs resulted in mitochondrial membrane potential dissipation in the IRES-
EGFP and IRES-PURO clones stably expressing the murine CKMT1 constructs 
(Fig.E.5E and Fig.E.5F).  
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A) 
B) 
Fig.E.4: Alignment of the siRNA Target Sequences of Human and Murine CKMT1. 
A) The siRNA targeting coding sequence base pairs 413-431 (siCK1(1)) has two 
mismatches with the respective murine CKMT1 sequence. B) The siRNA targeting coding 
sequence base pairs 426-444 (siCK1(2)) has three mismatches with the respective murine 
CKMT1 sequence. Mismatches are indicated by a star and the mismatching base pair of the 
murine CKMT1 sequence is highlighted in red. 
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Fig.E.5: The Expression of the Murine CKMT1 Homologue Does not Rescue the Phenotype of Endogenous CKMT1 
Depletion in HeLa Cells. Stable HeLa cell clones for hCKMT1-HA, mCKMT1-HA and mCKMT1mut-HA (IRES-EGFP and 
IRES-PURO clones) were transfected with siRNAs targeting specifically the coding sequence of human CKMT1 (siCK1(1) 
and siCK1(2)), or a scrambled sequence (sc). A)-D) 72 hours post transfection, protein lysates of the cells (IRES-EGFP 
clones) were assayed for the expression of total CKMT1 content using a polyclonal antibody recognizing human and 
murine CKMT1. E) 72 hours post transfection the IRES-EGFP clones were analysed for mitochondrial depolarization via 
DiOC6 staining and subsequent FACS analysis. F) 72 hours post transfection the IRES-PURO clones were analysed for 
mitochondrial depolarization via DiOC6 staining and subsequent FACS analysis. 
 
F) 
IRES-PURO clone 
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In order to rule out that the two siRNA constructs targeting human CKMT1 - 
siCK1(1) and siCK1(2) – were both inducing mitochondrial depolarization 
independently of CKMT1 downregulation (i.e. as a so-called off-target effect that 
both siRNAs have in common), we tested another 3 target sequences for specific 
downregulation of human CKMT1. A list of all RNAi sequences used to specifically 
downregulate human CKMT1 (for Western blot validation please refer to Fig.E.11) 
and their alignments with murine CKMT1 are shown in Fig.E.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig.E.6: Alignment of the RNAi Target Sequences of Constructs Targeting 
Specifically Human but Not Murine CKMT1. Mismatches are indicated by a star and the 
mismatching base pairs of the murine CKMT1 sequence are highlighted in red; numbers 
refer to the base pair number of the human CKMT1 coding sequence (cds). 
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Transfection of these RNAi constructs in the IRES-PURO as well as IRES-EGFP clones 
stably expressing CKMT1 constructs resulted in mitochondrial depolarization 
irrespective of the unaffected expression of murine CKMT1 (Fig.E.7). Therefore the 
presence of murine CKMT1 does not rescue from the RNAi phenotype when 
endogenous human CKMT1 is depleted. 
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Fig.E.7: The Expression of the Murine CKMT1 Homologue Does not Rescue the Phenotype of Endogenous CKMT1 
Depletion in HeLa Cells. Stable HeLa cell clones for hCKMT1-HA, mCKMT1-HA and mCKMT1mut-HA were transfected with RNAi 
constructs targeting specifically the coding sequence of human CKMT1 or a scrambled sequence (sc). A) 72 hours (siRNA 
constructs) and 96 hours (shRNA constructs) post transfection the IRES-EGFP clones (A) and IRES-PURO clones (B) were analysed 
for mitochondrial depolarization via DiOC6 staining and subsequent FACS analysis; ns non-significant (student’s t-test). 
 
 
 
A) 
B) 
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E.1.5 Developing a CKMT1 RNAi Phenotype Rescue Experiment Using 
hCKMT1(COD)-HA, an HA-tagged Codon Usage Modified Human CKMT1 
Construct 
Although the murine CKMT1 protein shows greater than 98% identity with human 
CKMT1, the presence of murine CKMT1 did not rescue the CKMT1 RNAi phenotype 
(compare Fig.E.5). We speculated that subtle differences between human and 
murine CKMT1 might be responsible for this observation. Therefore we aimed to 
design an RNAi rescue experiment using a 100% identical human CKMT1 protein. 
This can be achieved by two different approaches – targeting the endogenous 
human CKMT1 mRNA at the 5’UTR or 3’UTR (untranslated region) and rescuing with 
the expression of a human CKMT1 construct lacking UTRs or by exploiting the 
degeneration of the genetic code (as sixty-four codons are available to code for the 
20 amino acids and the three stop codons). As the 5’UTR and 3’UTR proved to be 
inaccessible for the RNAi constructs tested (data not shown), we constructed a 
human CKMT1 codon usage construct: The base pair triplets of the target sequence 
of shCK1 TRC058 were analysed, and synonymous mutations introduced taking into 
account the homo sapiens codon usage frequencies for nuclear encoded proteins 
accessible at the EBI server (European Bioinformatics Institute, Cambridge, UK). A 
comparison of the human CKMT1 and the synonymous codon usage human CKMT1 
construct- hCKMT1(COD) – is shown in Fig.E.8A. Additionally, we also generated the 
enzymatically inactive human CKMT1 harbouring these codon usage mutations - 
hCKMT1(COD)mut (refer to Fig.D.2) for the enzymatic inactivation mutation). 
Western Blot analysis confirmed that the overexpressed codon usage CKMT1 
construct was expressed at the same level as overexpressed wild-type CKMT1 
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(Fig.E.8B left panel). Furthermore it is resistant to shRNA-mediated depletion by 
transfection of the shCK1 TRC058 construct, whereas wild-type CKMT1 expression is 
readily abrogated (Fig.E.8B right panel). 
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A) 
B) 
Fig.E.8: Construction and Validation of the Synonymous Human Codon Usage 
CKMT1 Mutant. A) Introduction of 7 silent mutations into the human CKMT1 coding 
sequence results in a human codon usage CKMT1 mutant - hCKMT1(COD). Translation of 
its base pair sequence results in an amino acid sequence identical to wild type human 
CKMT1. Numbers written above and below the base triplet refer to the relative codon usage 
frequencies in human proteins according to data available online at the European 
Bioinformatics Institute server. B) HeLa cells were transfected with an shRNA construct 
targeting human CKMT1 (shCK1 TRC058) or a scrambled sequence (sc). 24 hours post 
transfection, constructs encoding hCKMT1-HA, hCKMT1(COD)-HA and hCKMT1(COD)mut-
HA were overexpressed. Another 24 hours later, protein lysates were obtained and 
analysed by Western blotting for total CKMT1 levels. 
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E.1.6 RNAi-Mediated Depletion of Endogenous hCKMT1 in HeLa Clones 
Stably Expressing the RNAi-resistant Synonymous hCKMT1 Mutant Does not 
Rescue the RNAi CKMT1 Phenotype 
We created stable HeLa cell clones expressing the HA-tagged hCKMT1(COD) and 
HA-tagged hCKMT1(COD)mut constructs that are resistant against the shRNA 
construct shCK1 TRC058 (Fig.E.8 and Fig.E.9). Stable clones expressing either Bgal 
or wild-type HA-tagged hCKMT1 were used as a control. For the CKMT1 RNAi 
phenotype rescue experiment, we transfected these clones with shCK1 TRC076 
(targeting all hCKMT1 constructs), shCK1 TRC058 (targeting endogenous and 
ectopically expressed wild-type hCKMT1, but not hybridizing to the mRNA of the 
hCKMT1(COD) codon usage construct), and a scrambled shRNA sequence. 
Unexpectedly, transfection of both shCK1 constructs resulted in mitochondrial 
depolarization in all clones (Fig.E.9B). The shCK1 RNAi phenotype was observable 
despite the expression of hCKMT1(COD)-HA, which shares an identical amino acid 
sequence with endogenous human CKMT1 over the whole coding sequence but can’t 
be accessed by the shCK1 TRC058 construct. Western blot analysis confirmed that 
the hCKMT1-HA construct could efficiently be downregulated by both shCK1 
constructs. In contrast, the hCKMT1(COD)-HA construct was only downregulated by 
shCK1 TRC076, but shCK1 TRC078 transfection did not alter its expression level 
(Fig.E.9C). Nevertheless, mitochondrial depolarization was observed after 
transfection of either RNAi construct targeting the endogenous CKMT1 mRNA. 
Therefore the expression of the HA-tagged synonymous CKMT1 protein could not 
rescue the CKMT1 RNAi phenotype. 
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Fig.E.9: Expression of the HA-tagged Synonymous CKMT1 Mutant Does not Rescue 
the Phenotype of RNAi Specifically Targeting Endogenous CKMT1. A) Validation of 
the expression of the HA-tagged hCKMT1 constructs in stable HeLa cell clones (IRES-PURO) 
by immunofluorescence staining for HA and subsequent FACS analysis. B) Stable HeLa cell 
clones were transfected with shRNA constructs targeting endogenous hCKMT1. Both shCK1 
TRC076 and shCK1 TRC758 target endogenous human CKMT1 as well as ectopically 
expressed hCKMT1-HA. In addition, shCK1 TRC076 also targets ectopically expressed 
hCKMT1(COD)-HA, while shCK1 TRC758 does not target the ectopically expressed 
synonymous hCKMT1(COD)-HA mutant of human CKMT1. 96 hours post transfection, cells 
were analysed for mitochondrial depolarization using DiOC6 staining and subsequent FACS 
analysis. C) Protein lysates from cells processed as in (B) were obtained and probed for the 
presence of CKMT1 using a polyclonal CKMT1 antibody. 
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E.1.7 Developing a CKMT1 RNAi Phenotype Rescue Experiment Using 
Untagged Codon Usage Modified Human CKMT1 – hCKMT1(COD)  
The above CKMT1 RNAi rescue experiments established that a HA-tagged CKMT1 
protein, which is identical to endogenous human CKMT1 on the amino acid level 
could not compensate for the loss of endogenous CKMT1. The difference of the 
ectopically expressed hCKMT1(COD)-HA protein and the published endogenous 
CKMT1 protein sequence of 417 amino acids (the only published CKMT1 gene 
product) is the C-terminal HA-tag. Thus, we speculated that this HA-tag interfered 
with the physiological function of CKMT1. This seemed plausible since a very specific 
C-terminal domain has been described for CKMT1 to mediate membrane association 
and integration (via electrostatic interaction of C-terminal basic residues with acidic 
cardiolipin and binding of a C-terminal hydrophobic stretch to the lipid 
bilayer(Maniti, Lecompte et al.) – refer to chapter A.5.2 for further information). 
Additionally, we hypothesized that the HA-tag might interfere with the octamer 
assembly of CKMT1. However, this was ruled out using blue native gel 
electrophoresis, which confirmed that the C-terminal HA-tag did not interfere with 
the octamer assembly as a band almost identical in size to the octamer could be 
detected upon overexpression of HA-tagged constructs (data not shown). 
Nevertheless, this octamer could in theory comprise a mixture of endogenous 
CKMT1 and HA-tagged ectopic CKMT1. Therefore, we designed a hCKMT1(COD) 
construct lacking the HA-tag, thus being identical to the published human CKMT1 
protein, but still harbouring the codon usage mutation making it resistant to the 
RNAi-mediated depletion by shCK1 TRC058. Stable IRES-PURO clones were 
established for the following constructs: hCKMT1, hCKMT1(COD) and 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |247 
 
hCKMT1(COD)mut; a Bgal clone served as an additional control (Fig.E.10). Both, 
HeLa cells as well as 293T cells were used to cover the possibility of cell-specific 
problems with the CKMT1 RNAi rescue experiment. The expression of the respective 
CKMT1 constructs was verified using immunofluorescent staining for CKMT1 
expression followed by FACS analysis (Fig.E.10A) and Western blotting (Fig.E.10B). 
The stable clones were infected with viral particles encoding shCK1 TRC076 
(targeting all hCKMT1 constructs), shCK1 TRC058 (targeting endogenous and 
ectopically expressed wild-type hCKMT1, but not the mRNA of the hCKMT1(COD) 
codon usage construct), and a scrambled shRNA sequence. Both shCK1 constructs 
resulted in mitochondrial depolarization (Fig.E.10C and E.10D) in all clones. The 
shCK1 RNAi phenotype was observable despite the expression of hCKMT1(COD), 
which shares an identical amino acid sequence with endogenous human CKMT1 over 
the whole coding sequence but can’t be accessed by the shCK1 TRC058 construct 
due to the synonymous mutations. Western blot analysis confirmed that the 
hCKMT1 construct could efficiently be downregulated by both shCK1 constructs. In 
contrast, the hCKMT1(COD) construct was only downregulated by shCK1 TRC076, 
while shCK1 TRC078 did not alter its expression level (Fig.E.10E). Nevertheless, 
mitochondrial depolarization was observed after infection with either RNAi construct 
targeting the endogenous CKMT1 mRNA. Surprisingly, the expression of the 
synonymous CKMT1 protein could not rescue the CKMT1 RNAi phenotype. 
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Fig.E.10: Expression of the Synonymous CKMT1 Mutant Does not Rescue the 
Phenotype of RNAi Specifically Targeting the Endogenous CKMT1. A) Validation 
of the expression of the hCKMT1 constructs in stable HeLa and 293T cell clones (IRES-
PURO) by immunofluorescent staining for CKMT1 and subsequent FACS analysis. B) 
Western blot analysis of these stable clones. C) Stable HeLa clones were infected with 
shRNA constructs targeting endogenous hCKMT1. Both shCK1 TRC076 and shCK1 
TRC758 target endogenous human CKMT1 as well as ectopically expressed hCKMT1. In 
addition, shCK1 TRC076 also targets ectopically expressed hCKMT1(COD), while shCK1 
TRC758 does not target the ectopically expressed synonymous hCKMT1(COD) mutant of 
human CKMT1. 6 days post infection, cells were analysed for mitochondrial 
depolarization using DiOC6 staining and subsequent FACS analysis; ns non-significant 
(student’s t-test). D) same as in (C) for 293T cell clones. E) Protein lysates from cells 
processed as in (C) and (D) were obtained and probed for the presence of CKMT1 using 
a polyclonal CKMT1 antibody. 
 
 
 
 
 
 
 
 
 
 
 
  
E) 
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E.1.8 Addressing the Likelihood of Off-target Effects of RNAi Against CKMT1 
– Experiments on the Specificity of the CKMT1 RNAi Effect 
Taking into consideration the lack of the RNAi CKMT1 phenotype rescue despite the 
presence of a protein identical to the wild-type gene product (Fig.E.10), it seemed 
conceivable, that the RNAi sequences used could have a non-specific off-target 
effect that is independent of CKMT1 downregulation on the protein level. 
Alternatively, the published CKMT1 protein might not be the vital gene product of 
the CKMT1 gene. In order to address the first point, a plethora of RNAi sequences 
designed to target the CKMT1 mRNA was used and analysed for its capacity (1) to 
downregulate CKMT1 and (2) to match the level of downregulation with the 
observed phenotype. Initial studies (Fig.D.7 and Fig.D.8) have already shown, that 
using the siCK1(1) construct in HeLa cells resulted in a clear kinetic correlation of 
downregulation of the CKMT1 protein and mitochondrial depolarisation. As can be 
observed in Fig.E.11, a total of 19 RNAi sequences were tested for their capacity to 
downregulate the CKMT1 protein and induce mitochondrial depolarisation. Table E.1 
lists the RNAi constructs used, their respective target specificity, and the mapping 
to the exons of the CKMT1 gene. 11 constructs were effective in downregulating 
CKMT1 expression on the protein level. Thereof 4 construct downregulated murine 
CKMT1, 5 constructs downregulated human CKMT1 and 2 constructs could be used 
to downregulate both human and murine CKMT1 (Fig.E.11A and E.11.E). The 
remaining 8 RNAi constructs (3 targeting specifically murine CKMT1, 4 targeting 
exclusively human CKMT1, and 1 construct targeting both murine and human 
CKMT1), failed to downregulate CKMT1 protein levels (Fig.E.11B and E.11F). 
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Table E.1: RNAi Constructs Targeting CKMT1 – Alignment, Specificity and Phenotype. All RNAi constructs used in this study 
were mapped to exons 1-9 of the coding sequence (cds) of human (h) or murine (m) CKMT1. RNAi constructs were evaluated for the 
efficiency in CKMT1 protein knock-down (KD) and phenotype of mitochondrial depolarization (mito depol). Y yes; N no; n.a. not 
applicable. 
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Fig.E.11:CKMT1 RNAi Constructs That Knock-down CKMT1 Expression Induce Mitochondrial Depolarization, While 
CKMT1 RNAi Constructs That do not Knock-down CKMT1 Expression do not Show any Effect on Mitochondrial 
Polarization . A)-B) HeLa cells were transfected with RNAi constructs targeting human CKMT1 (see Table E.1) or a scrambled 
sequence. 6 days post transfection, protein lysates were assayed for CKTM1 expression by Western blot analysis using a 
polyclonal CKMT1 antibody. C)-D) Cells manipulated as in (A) and (B), respectively, were analysed for mitochondrial 
depolarization using DiOC6 staining and subsequent FACS analysis. E)-F) Murine N2A cells were transfected with RNAi constructs 
targeting murine CKMT1 (see Table E.1) or a scrambled sequence. 6 days post transfection, protein lysates were assayed for 
CKTM1 expression by Western blot analysis using a polyclonal CKMT1 antibody. G)-H) Cells manipulated as in (E) and (F), 
respectively, were analysed for mitochondrial depolarization using DiOC6 staining and subsequent FACS analysis. ***p<0.001, ns 
non-significant (student’s t-test). 
 
 
 
 
 
 
 
 
 
 
All 11 constructs that efficiently knock-down CKMT1, resulted in highly significant mitochondrial depolarization 
(Fig.E.11G). In contrast, the 8 RNAi constructs that did not knock-down CKMT1 on the protein level, did not have any 
effect on mitochondrial polarization (Fig.E.11H). 
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E.1.9 The Search for Novel CKMT1 Isoforms or CKMT1 Gene Products 
As our previous attempts to rescue the CKMT1 RNAi phenotype by simultaneous 
expression of diverse CKMT1 constructs (HA-tagged murine CKMT1, HA-tagged 
human CKMT1 (codon usage modified) as well as untagged human CKMT1 (codon 
usage modified)) failed, we hypothesized that cells express an alternative CKMT1 
gene product. This gene product, together with the published CKMT1 protein, would 
be downregulated by the RNAi against CKMT1 – and simultaneous expression of the 
published CKMT1 gene product alone would not rescue the phenotype: The 
ectopically expressed CKMT1 substitute does not correspond to the endogenous 
CKMT1 gene product that is vital for the cell. Therefore we investigated the 
endogenous expression of the CKMT1 gene in more detail. 
 
 
E.1.9.1 The Human CKMT1 Gene is Expressed From Both CKMT1 Gene 
Copies – CKMT1A and CKMT1B Are Functional in HeLa and 293T Cells 
As described in chapter A.5, two copies of the CKMT1 gene are located in a 
duplicated genomic area, surrounded by functional copies of PPIP5KI 
(diphosphoinositol pentakisphosphate kinase 1), CATSPER2 (cation channel, sperm 
associated 2) and STRC (stereocilin) in the first, as well as dysfunctional 
pseudogenes thereof in the second part of the duplicated area (see Fig.E.12A). 
Therefore, we wanted to establish whether CKMT1 is expressed from both loci 
(CKMT1A and CKMT1B) in our cellular system, or whether one of the copies is a 
pseudogene. Indeed, CKMT1 was expressed from both genes in HeLa and 293T cells 
as demonstrated by sequencing of the CKMT1 cds as amplified by a primer pair 
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aligning with the 5’ and 3’ end of the cds from CKMT1A/B. Sequencing revealed a 
consistent double peak at cds position 1056 and position 1086, indicating the 
presence of a mixture of amplified mRNAs corresponding to the CKMT1A and 
CKMT1B locus (Fig.E.12B). There is some indication that CKMT1B mRNA is 
expressed at a higher level since the nucleotide peaks in Fig.E.12B are quantitative. 
However, the sequencing of the PCR products has only been performed once, and 
might not be generally representative of cellular CKMT1A/B expression levels. These 
two different mRNAs still encode identical proteins since they originate from 
synonymous mutations. 
 
E.1.9.2 Searching for Novel Functional CKMT1 Transcripts Using Alignment 
of CKMT1 RNAi Sequences Against the AceView cDNA Database 
Following the hypothesis that the ectopically expressed CKMT1 substitute does not 
correspond to the endogenous CKMT1 gene product that is vital for the cell, we 
analysed all publicly available mRNA sequences at the AceView database(Thierry-
Mieg and Thierry-Mieg 2006). AceView provides a curated, comprehensive and non-
redundant sequence representation of all public mRNA sequences (mRNAs from 
GenBank or RefSeq, and single pass cDNA sequences from dbEST and Trace) and is 
accessible at http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/. 615 cDNA 
clones aligning to genomic CKMT1A and 654 cDNA clones aligning to genomic 
CKMT1B were analysed for matching CKMT1 RNAi constructs – with the idea that if 
an mRNA originating from either CKMT1 gene is vital for cell survival, it must have a 
binding site for the RNAi constructs that have been shown to result in mitochondrial 
depolarization (Table.E.1).  
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Fig.E.12: CKMT1 is Expressed From Both Genomic Loci – CKMT1A and CKMT1B are Both Functional. A) Genomic 
Context of CKMT1A and CKMT1B: Both CKMT1 copies are located on chromosome 15, within a duplicated area. The other 
duplicated genes have one functional copy (PPIP5KI diphosphoinositol pentakisphosphate kinase 1, CATSPER2 cation channel, 
sperm associated 2, and STRC stereocilin) and a pseudogene (PPIP5KIP1, CATSPER2P1, and STRCP1). B) cDNA from HeLa cells 
was amplified with primers spanning the published start and stop codon for human CKMT1. The PCR product was sequenced and 
the sequencing profile is shown (Chromas software). Blue circles indicate the position where mRNAs from CKMT1A and CKMT1B, 
respectively, differ by synonymous mutations as outlined in the right panel. Cds coding sequence; Lys Lysine; Ala Alanine. 
 
 
 
 
 
 
 
For the CKMT1A gene, only 5 transcripts (Fig.E.13A, indicated by black arrowheads) display all functionally validated 
RNAi sites and thus were candidates for alternative vital gene products. For the CKMT1B gene, only 3 transcripts 
(Fig.E.13B, indicated by black arrowheads) display all functionally validated RNAi sites and were thus candidates for 
alternative vital gene products. Taken together, these transcripts either encode the published CKMT1 mRNA associated 
with different UTRs, or transcripts with a 5’ extended Exon2 associated with different UTRs (alternatively spliced, 
Fig.E.13A transcripts a, b and c as well as Fig.E.13B transcript a). Incorporation of the extended version of exon 2 
would be predicted to - compared to the published CKMT1 - encode for a 93 bp longer exon 2 on the mRNA level and 
contribute to a 31aa longer protein upon translation. 
Analysis of publicly available cDNAs associated with the CKMT1 genes therefore pointed to the possibility of as of yet 
undescribed CKMT1 gene products. In particular, the existence of other CKMT1 protein isoforms is conceivable, and 
should be addressed in more detail in a cellular system. 
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Fig.E.13: Alternative CKMT1 Gene Products - Alignment of Publicly Available cDNAs 
Mapped to the CKMT1 Genes Against CKMT1 RNAi Constructs. Alternative CKMT1 
mRNAs are shown aligned from 5' to 3' on a virtual genome (CKMT1A in (A), and CKMT1B in 
(B)) where introns have been shrunk to a minimal length. Exon size is proportional to 
length; intron height reflects the number of cDNAs supporting each intron. Introns of the 
same colour are identical, of different colours are different. 'Good proteins' are pink, partial 
or “not-good” proteins are yellow, uORFs are green. 5' cap or3' poly A flags show 
completeness of the transcript. Introns are depicted by broken lines; the height of the top of 
each intron reflects the relative number of clones supporting this intron. ]^[ A pink broken 
line denotes an intron with standard boundaries (gt-ag or gc-ag) that is exactly supported 
(i.e. a cDNA sequence exactly matches the genome over 16 bp, 8 on both sides of the 
intron). For exons, wide filled pink areas represent putative protein coding regions, narrow 
empty pink boxes represent the 5'UTR (on the left) and 3' UTR (on the right). Flags identify 
validated endings: cap site on the 5' side, polyadenylation site on the 3' side. Filled flags 
correspond to frequent events while empty flags have lesser supporting cDNAs (yet all are 
validated); at the 3' side, black flags are associated to the main AATAAA signal, blue flags to 
any single letter variant of the main.  
All functionally validated CMT1 RNAi constructs (compare Table E.1) were aligned to the 
exons of the different transcripts (top row) A) 615 cDNAs are associated with the CKMT1A 
gene. Thereof only 5 transcripts (indicated by arrowheads) display all functionally validated 
RNAi sites and are thus candidates for alternative vital gene products. B) 654 cDNAs are 
associated with the CKMT1B gene. Thereof only 3 transcripts (indicated by arrowheads) 
display all functionally validated RNAi sites and are thus candidates for alternative vital gene 
products. The asterisk indicates an alternative exon2 splice variant. The data was retrieved 
from AceView database(Thierry-Mieg and Thierry-Mieg 2006). For a more comprehensive 
explanation of the AceView generated gene diagrams (e.g. definition of a “good/not-good” 
translated protein sequence) please refer to the AceView manual available at: 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/HelpGene.html#HelpGeneDiagram 
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E.1.9.3 HeLa and 293T Cells Express at Least two Different mRNA-
Transcripts From the CKMT1 Loci 
As outlined in the previous chapter, at least one additional hypothetical CKMT1 
protein isoform (apart from the published CKMT1 protein) exists among all publicly 
available cDNAs aligning to the CKMT1 genes. 
In order to examine the existence of relevant alternatively spliced variants of 
CKMT1 in our cellular system (293T cells and HeLa cells), we set up experiments 
based on the following premises: The failed CKMT1 RNAi phenotype rescue 
experiments could be due to the lack of substitution of an alternatively spliced 
CKMT1 isoform as only the published CKMT1 protein was substituted. If such an 
alternatively spliced CKMT1 isoform is vital for cell survival, it should contain all 
functionally validated CKMT1 RNAi binding sites. The hypothetical isoform must be 
present in HeLa and 293T cells as these cells have been used extensively for RNAi 
phenotype rescue experiments; and PCR in cDNA pools of these cells might be 
useful to determine the presence of such splice isoforms. 
Initially we used a forward primer hybridizing to a sequence at the ATG start codon 
and 2 different reverse primers, one corresponding to the binding sequence of RNAi 
construct siCK1(1) in exon3, and a second reverse primer corresponding to the 
beginning of published exon2. The PCR products were visualised and assessed for 
their size by running them on an agarose gel (Fig.E.14A). Interestingly, both primer 
sets resulted in two clearly distinguishable bands – one corresponding to the 
expected published CKMT1 transcript (Fig.E.14A, white arrow) and an unknown, 
approximately 100bp longer second band (Fig.E.14A, red arrow). The PCR products 
were sent for sequencing, which confirmed the existence of 2 different products 
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having an identical 5’ but different 3’ sequences (Fig.E.14B). Sequencing of excised 
single bands confirmed the existence of 2 different transcripts, which aligned to the 
human CKMT1 genes. Indeed, the longer CKMT1 transcript corresponds to a 5’ 
extended alternatively spliced exon 2 which can be aligned to both CKMT1A and 
CKMT1B. Transcripts differing by exactly this alternatively spliced exon 2 were also 
present when amplifying CKMT1 mRNA transcripts with primer sets aligning to the 
start and published stop codon of the published CKMT1 mRNA (Fig.E.14C). A Clustal 
Omega sequence alignment of the sequenced PCR products is shown in Fig.E.14D. 
Theoretically, these 2 different CKMT1 mRNA transcripts could encode a 417aa and 
448aa CKMT1 isoform. A BLAST search of the extended CKMT1 transcript aligned 
with several human cDNA clones and other predicted mRNAs, with the extended 
exon 2 being present across predicted mRNAs and sequenced genomes of the 
mammalian kingdom (BLAST results not shown). Searching non-redundant human 
protein sequence database available at the NCBI, the translated undescribed CKMT1 
mRNA transcript aligns to 100% with the “unnamed protein product [Homo 
sapiens], accession BAH14495”. 
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Fig.E.14: Experimental Verification of an Alternatively Spliced Full Length mRNA 
for the CKMT1 Gene. A) cDNA from HeLa and 293T cells was used for amplifying CKMT1 
transcripts using primers aligning to the start codon area (ATG), the siCK1(1) hybridization 
site in exon 3 or the beginning of exon 2. The PCR product was separated on a 2% agarose 
gel. The white arrow indicates the predicted band for the published CKMT1 transcript 
whereas the red arrow indicates an approximately 100bp longer unknown PCR product (data 
only shown for HeLa cells). B) Chromas sequencing file for the PCR products shown in (A). 
C) cDNA from HeLa and 293T cells was used for amplifying CKMT1 transcripts using primers 
aligning to the start codon area and stop codon area. PCR products were separated on 2% 
agarose gel and individual bands excised, purified and sent for sequencing. The alignment of 
the sequenced PCR products with the published CKMT1 mRNA is shown in a dot matrix view. 
D) Clustal Omega alignment of the different 5’ region of sequenced PCR products from (C). 
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E.1.9.4 Construction of a Mammalian Expression Vector Containing the 
Complete CKMT1 Gene 
We isolated genomic DNA from HeLa cells and used primers spanning the whole 
CKMT1 gene (including a 1151bp upstream region of the published start ATG most 
likely to include the whole promoter and a 131 downstream region from the 
published TAA stop codon including the predicted polyadenylation site; primers were 
amplifying the CKMT1A or CKMT1B gene). The resulting 6.3kb fragment (Fig.E.15A) 
was subcloned into the pcDNA3.1 expression vector and clones were analysed for 
their capacity to express CKMT1 gene products by plasmid overexpression. The 
clone with the highest CKMT1 expression level as determined by Western blot 
analysis using a polyclonal CKMT1 antibody was selected for further studies 
(Fig.E.15B). For the full-length sequencing file of the genomic clone please refer to 
the chapter I. Appendix. 
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Fig.E.15: Cloning and Verification of Expression of the 6.3kb Genomic CKMT1 Locus 
Into a Mammalian Expression Vector. A) Genomic DNA was isolated from HeLa cells and 
the 6.3kb CKMT1 locus (including promoter and polyadenylation signal) was amplified by 
PCR – a 0.8% agarose gel electrophoresis of the PCR product is shown. B) The genomic 
CKMT1 locus was subcloned into pcDNA3.1; a Western blot analysis of HeLa cells 
transfected with the selected genomic clone is shown. A polyclonal CKMT1 antibody was 
used to visualise overexpressed and endogenous CKMT1. 
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E.1.9.5 Supporting Evidence for the Existence of a CKMT1 Isoform on the 
Protein Level – Analysis of Endogenous CKMT1 and Comparison to 
Overexpressed CKMT1 constructs. 
As the failed RNAi rescue experiments could theoretically be explained by the 
existence of the alternative CKMT1 isoform verified on the mRNA level (Fig.E.13), 
we set out to analyse whether different CKMT1 isoforms could exist on the protein 
level in our cellular system. Supporting evidence came from CKMT1 SDS-page and 
Western blots using a polyclonal CKMT1 antibody (Fig.E.16A). Assuming a sufficient 
specificity of the CKMT1 antibody used (following siRNA validation in previous 
experiments), endogenous CKMT1 could be detected as 2 distinct bands (Fig.E.16A, 
first lane). Taking into account the relative size difference, the second upshifted 
band (blue arrowhead) could be the 31aa extended CKMT1 isoform - CKMT1(iso). 
However, the upshifted CKMT1 could also be due to the unprocessed CKMT1 
precursor, which consists of the uncleaved CKMT1 precursor (mitochondrial 
localization signal + mature CKMT1). The CKMT1 precursor is 39aa longer in length 
compared to the mature CKMT1 and has recently been detected experimentally by 
another research group(Cui, Yu et al. 2011). In line with this, overexpression of 
hCKMT1-HA also resulted in a double band, that corresponds to the unprocessed 
and processed precursor of the hCKMT1-HA protein as shown by Western blot 
analysis for the HA tag (Fig.E.16A, second lane). Nevertheless, it should be noted 
that the higher band in the hCKMT1-HA lysates runs marginally higher than the 
endogenous higher band of CKMT1. Thus we subcloned the CKMT1(iso) as described 
in Fig.E.14 into a mammalian expression vector for further studies. Plasmid 
transfection of CKMT1(iso) yielded a protein confirming that this CKMT1 transcript 
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can be expressed. Surprisingly, overexpression of CKMT1(iso) resulted in 3 distinct 
bands (Fig.E.16A, red arrows), with the lowest one running at the same size as the 
upshifted endogenous CKMT1 band (Fig.E.16, blue arrows). Furthermore, 
overexpression of the genomic CKMT1 locus by plasmid transfection of CKMT1(GEN) 
resulted in 2 distinct bands (Fig.E.16A lane 5) identical in appearance to those 
observed when probing for endogenous CKMT1. 
Interestingly, native blue gel electrophoresis of endogenous CKMT1 also resulted in 
2 bands - one for the CKMT1 octamer as observable in purified CKMT1 and one with 
a slightly higher molecular weight (Fig.E.16B, second lane, green arrow). 
Additionally, this higher molecular weight band was depleted upon apoptosis. Thus 
we speculated that this higher molecular weight band could well be the octameric 
31aa extended CKMT1(iso). Therefore we analysed the CKMt1(iso) on a blue native 
gel. Surprisingly, the CKMT(iso) was not able to from octameric multimers, but 
showed a very strong band at a molecular weight comparable to dimeric purified 
CKMT1 (Fig.E.16B, blue arrow), as well as a distinct band running between 20 kDa 
and 60 kDa most likely corresponding to the CKMT1(iso) monomer (orange arrow). 
Overexpression of CKMT1(GEN) resulted in a comparable staining pattern to 
endogenous CKMT1 – a pronounced octamer band (Fig.E.16B, black arrow) as well 
as an upshifted band (Fig.E.16B, green arrow) were visible. Additionally a third 
band running at the size of the CKMT1 dimer (Fig.E.16B blue arrow) was also 
detectable. Overexpression of CKMT1(COD) showed a comparable staining pattern 
to endogenous CKMT1, i.e. a clear octamer band and an additional upshifted band. 
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Fig.E.16: Analysis of CKMT1 Gene Products by SDS and Native Page. A) SDS Page 
and Western blot of endogenous CKMT1, overexpressed (OE) HA-tagged CKMT1, 
overexpressed CKMT1(iso) and overexpressed CKMT1 from a genomic clone CKMT1(GEN). 
Bands were aligned according to the size marker loaded on the same gel (this technique 
was used due to hugely different expression levels and band intensities). Black arrows 
indicate the size of the main band of endogenous CKMT1, blue arrows indicate bands 
running at the same size as the upshifted endogenous CKMT1 band; red arrows indicate the 
3 distinct bands observed after overexpression of CKMT1(iso). B) Blue native gel 
electrophoresis of CKMT1 gene products detected by a polyclonal CKMT1 antibody. Blue 
arrows indicate the size of the CKMT1 dimer; black arrows indicate the CKMT1 octamer. The 
green arrow indicates and upshifted CKMT1 band observable in the cellular system (not in 
purified CKMT1); and the orange arrow most likely (based on the apparent approximate 
size) indicates the CKMT1(iso) monomer. 
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E.1.10 Setting up an RNAi CKMT1 Rescue Experiment With the CKMT1 
Isoforms Detected at the mRNA-level 
As the previous experiments indicated the existence of a CKMT1 isoform that could 
also be targeted by all the CKMT1 RNAi constructs used (Table E.1 and Fig.E.13), 
we speculated that the absence of this isoform in the CKMT1 RNAi phenotype rescue 
experiments had been responsible for the lack of phenotype rescue. Therefore we 
constructed a CKMT1(iso) construct which would be resistant to RNAi by shCK1 
TRC058 (as described in Fig.E.8A ). After validating that the CKMT1(iso)COD was 
indeed not affected by shCK1 TRC058 transfection (Fig.E.17A), we set up a 
transient rescue experiment. HeLa cells were transfected with plasmids encoding 
shCK1 TRC058 or a scrambled control sequence, and 24 hours later transfected with 
CKMT1(iso)COD, CKMT1(iso)COD plus CKMT1(COD) or hCKMT1 as a control. 
Analysis for mitochondrial depolarization 5 days after transfection revealed equal 
loss of the mitochondrial membrane potential in approximately 60% of cells 
(Fig.E.17B) regardless of the transfected CKMT1 construct. As can be observed in 
Fig.E.17C, mitochondrial depolarization was induced although CKMT1(iso)COD 
expression levels (Fig.E.17C and Fig.E.17D) as well as combined CKMT1(iso)COD 
and hCKMT1(COD) expression levels are above the endogenous CKMT1 expression 
level (in >76% or >80% of cells, respectively). 
Other transfection schedules (for RNAi constructs and CKMT1 expression constructs) 
including simultaneous co-transfections, multiple transfections for the CKMT1 
constructs, etc. were also examined, but yielded similar results. Therefore, neither 
the CKMT1(iso) isoform nor a combination of CKMT1 and CKMT1(iso) resulted in the 
rescue of the CKMT1 RNAi phenotype.  
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Fig.E.17: CKMT1(iso) Does Not Rescue the RNAi CKMT1 Phenotype in a Transient 
Experiment. A) HeLa cells were transfected with RNAi plasmids encoding shCK1 TRC058 or 
a scrambled sequence. 24 hours post transfection, cells were transfected with CKMT1(iso) 
or CKMT1(iso)COD. Another 24 hours later protein lysates were harvested and assayed for 
CKMT1 expression using Western blotting with a polyclonal CKMT1 antibody. B) HeLa cells 
were transfected as in (A) and assayed for mitochondrial depolarization 5 days post the 
initial transfection by DiOC6 staining and subsequent FACS analysis; ns non-significant 
(student’s t-test). C) FACS analysis for CKMT1 expression in cells manipulated as in (A) 5 
days post the initial transfection. D) Western Blot analysis for CKMT1 expression in cells 
manipulated as in (A) 4 days post the initial transfection. 
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E.1.11 Using RNAi Resistant Genomic CKMT1 Constructs, 
CKMT1(GEN)COD(058) and CKMT1(GEN)COD(076), in RNAi CKMT1 
Phenotype Rescue Experiments 
As we had previously established a mammalian expression vector containing the 6.3 
kb CKMT1 genomic locus, which yielded a protein expression pattern comparable to 
endogenous CKMT1, we wanted to use this vector as the ultimate approach for 
rescuing the CKMT1 RNAi phenotype. The whole 6.3 kb region was sequenced (for 
the exact sequence please refer to chapter J. Appendix) and codon usage mutations 
for shCK1 TRC058 as well as shCK1 TRC076 designed (Fig.E.18A and E.18B). As 
numerous attempts for PCR based multiple site directed mutagenesis failed due to 
the plasmid size (11.7 kb) and the lack of unique convenient enzyme restriction 
sites, mutations as outlined in Fig.E.18A/B were introduced commercially by 
Genscript (USA) and fully sequence-verified. 
The expression and RNAi resistance of the resulting constructs - 
CKMT1(GEN)COD(058) and CKMT1(GEN)COD(076) - were verified using Western 
blot analysis for CKMT1. As expected, the parent plasmid CKMT1(GEN) could be 
downregulated by the RNAi constructs shCK1 TRC058 and shCK1 TRC076, whereas 
the CKMT1(GEN)COD(058) construct was resistant to RNAi by the shCK1 TRC058 
construct but still was susceptible to downregulation by shCK1 TRC076 construct. 
The CKMT1(GEN)COD(076) construct was resistant to RNAi by the shCK1 TRC076 
construct but was downregulated by the shCK1 TRC058 construct(Fig.E.18C). 
Additionally, a time-course experiment using Western blotting revealed that the 
CKMT1(GEN) plasmid was expressed at higher levels than endogenous CKMT1 for at 
least 6 days post transfection (Fig.E.18D). However, this only reflected of the total 
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cell population and did not indicate the relative percentage of cells having an 
expression level of CKMT1 higher than the endogenous level. Therefore FACS 
analysis was used to determine CKMT1 expression levels in the following 
experiments. 
The RNAi resistant CKMT1(GEN) constructs were subsequently used in a transient 
rescue experiment. As the transfection efficiency of the 11.7kb genomic plasmids 
was comparatively low (50%-60%), viral particles were used for RNAi in order to 
assure efficient delivery of the RNAi construct to the cells. As can be observed in 
Fig.E.19A, transient overexpression of the RNAi resistant genomic constructs in their 
matching RNAi construct, resulted in a pronounced increase in total CKMT1 levels. 
CKMT1(GEN)COD(058) transfection in cells infected with shCK1 TRC058 resulted in 
an elevated CKMT1 expression level compared to endogenous CKMT1 in >61% of 
cells. CKMT1(GEN)COD(076) transfection in cells infected with shCK1 TRC076 
resulted in an elevated CKMT1 expression level compared to endogenous CKMT1 in 
>54% of cells. Endogenous CKMT1 levels refer to the level of CKMT1 in cells 
infected with an RNAi construct encoding a scrambled shRNA sequence. 
Theoretically, cells expressing CKMT1 at a higher level than endogenous CKMT1 
should not display the RNAi CKMT1 phenotype. However, mitochondrial 
depolarization was detectable in all cells infected with RNAi constructs targeting 
CKMT1 (Fig.E.19B) – irrespective of the positive staining for CKMT1. Therefore 
transient expression of synonymous RNAi resistant CKMT1 from a genomic 
expression construct containing the human 6.3 kb CKMT1 locus did not rescue cells 
from mitochondrial depolarization induced by RNAi against CKMT1.  
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Fig.E.18: Construction and Verification of RNAi Resistant Codon Usage Mutations in 
the CKMT1(GEN) Expression Vector. A)-B) Alignment of the genomic CKMT1 sequence 
with the synonymous codon usage mutations introduced to achieve RNAi resistant 
transcripts. CKMT1(GEN)COD(058) is resistant to shCK1 TRC058 due to 7 introduced 
mismatches (highlighted in red). CKMT1(GEN)COD(076) is resistant to shCK1 TRC076 du to 
5 introduced mismatches (highlighted in red). Numbers written above and below the base 
triplets refer to their relative codon usage frequencies in human proteins according to data 
available online at the European Bioinformatics Institute server. C) HeLa cells were 
transfected with shCK1 TRC058, shCK1 TRC076 or a scrambled RNAi construct. 24 hours 
post transfection, cells were transfected with CKMT1(GEN), CKMT1(GEN)COD(058) or 
CKMT1(GEN)COD(076). Another 24 hours later, protein lysates were obtained and assayed 
for the expression of CKMT1 by Western blotting using a polyclonal CKMT1 antibody. D) 
HeLa cells were transfected with CKMT1(GEN) or Bgal as a control. Expression of CKMT1 
was monitored over the following 6 days by Western blotting using a polyclonal CKMT1 
antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) 
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Fig.E.19: RNAi Resistant CKMT1(GEN) Does Not Rescue the RNAi CKMT1 Phenotype in a Transient Experiment. A) HeLa 
cells were infected with viral RNAi particles coding for shCK1 TRC058, shCK1 TRC076 or a scrambled sequence. 24 and 72 hours 
post infection, cells were transfected with CKMT1(GEN), CKMT1(GEN)COD(058), CKMT1(GEN)COD(076) or Bgal as a control. 6 days 
after the initial infection, CKMT1 expression was quantified by immunofluorescent CKMT1 staining and subsequent FACS analysis; 
OE transient overexpression. B) Cells manipulated as in (A) were assayed for mitochondrial depolarization by DiOC6 staining and 
subsequent FACS analysis; ns non-significant (student’s t-test). 
 
 
 
 
 
 
 
A) 
B) 
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F. RESULTS PART III 
 
F.1 The Role of Mitochondrial IκBα in Apoptosis Regulation 
 
F.1.1 Optimisation of a Fusion Protein to Target IκBα Specifically to 
Mitochondria 
 
F.1.1.1 Localisation of the Mcr1- IκBα Fusion Construct 
In order to examine the function of mitochondrial IκBα, we aimed to create IκBα 
fusion proteins that are specifically targeted to mitochondria. One of these 
constructs previously constructed in our lab is IκBα fused to a 47 aa putative N-
terminal mitochondrial targeting sequence from yeast Mcr1 (mitochondrial NADH-
cytochrome b5 reductase) to create the Mcr1-IκBα construct (Dr. Foy Osborne). 
According to the model published by Haucke et al.(Haucke, Ocana et al. 1997), the 
first 12 amino acids of MCR1 are inserted into the inner mitochondrial membrane 
and amino acids 13 to 47 reside in the intermembrane space where they are 
cleaved in order to release the fused protein. 
As these studies have been performed in isolated yeast mitochondria and have not 
been verified in a human cellular system, we employed high resolution confocal 
immunofluorescence microscopy in order to verify the exact subcellular localisation 
of the Mcr1-IκBα fusion protein. As can be observed in Fig.F.1, Mcr1-IκBα localised 
in a distinct structure, however it did not colocalise substantially with mitochondria 
as visualised via the autofluorescence of mito-CFP. The merged picture (Fig.F.1, 
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right panel) did not show a high extent of yellow staining which would indicate 
colocalisation of the mito-CFP and Mcr1-IκBα construct. 
  
Fig.F.1: Localisation of the Mcr1-IκBα Fusion Construct by Confocal 
Immunofluorescence Microscopy. HeLa cells were transfected either with plasmids encoding 
β-galactosidase (Bgal) or the Mcr1-IκBα fusion protein (C-terminal Flag tag). 24 hours post 
transfection Mcr1-IκBα was detected by staining with a primary Flag antibody and a secondary 
Alexa595 labelled antibody, while mitochondria were visualised using the autofluorescence of a 
cotransfected mito-CFP protein. DAPI was used as a nuclear counterstain. A high resolution 
magnification of the acquired picture is shown in the lower panels. 
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The reticular staining pattern of Mcr1-IκBα rather suggests a predominant 
localization of the Mcr1 fusion proteins in a different organelle that tightly interacts 
with mitochondria, the endoplasmic reticulum (ER). Therefore we went on to test 
this hypothesis using an autofluorescent construct (DsRed-ER) to visualise the 
endoplasmic reticulum. Indeed, co-transfection of a DsRed-ER construct and Mcr1-
IκBα revealed a very high degree of colocalisation. The predominant localisation in 
the ER was demonstrated by the intense violet staining in the merged picture 
(Fig.F.2A, right panel). Furthermore, we compared the localisation of Mcr1-IκBα, 
mito-CFP and DsRed-ER (concomitantly visualised in one cell), which confirmed the 
ER as the major locale of Mcr1-IκBα (Fig.F.2B). 
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A) 
B) 
A) 
Fig.F.2: Mcr1-IκBα Colocalises Predominantly with the Endoplasmic Reticulum. 
A) HeLa cells were transfected with plasmids encoding DsRed-ER and the Mcr1-IκBα 
fusion protein (C-terminal Flag tag). 24 hours post transfection Mcr1-IκBα was detected 
by staining with a primary Flag antibody and a secondary Alexa488 labelled antibody 
while the endoplasmic reticulum was visualised using the autofluorescence of DsRed-ER. 
B) The same procedure as described in (A) was applied with the addition of mito-CFP to 
visualize mitochondria; an Alexa633 labelled secondary antibody was used to visualize 
Mcr1-IκBα. Purple staining in the merged picture (right panel) is indicative of 
colocalisation. 
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F.1.1.2 Validation of the SD-IκBα and MEET-IκBα Constructs 
Considering the data on the localisation of Mcr1- IκBα, a more robust mitochondrial 
localization signal was needed for studying the effect of IκBα in mitochondria and its 
hypothesized involvement in MPT. 
Aiming to target IκBα to mitochondria, we constructed another set of fusion 
proteins: An N-terminal fusion of IκBα with the mitochondrial localisation sequence 
of Smac/Diablo (SD-IκBα), and an N-terminal fusion with the first 32 amino acids of 
MitoNEET (MEET-IκBα). The Smac/Diablo (SD) sequence should target IκBα into the 
mitochondrial intermembrane space, and the first 32 amino acids of MitoNEET have 
been shown to target diverse proteins to the outer mitochondrial membrane(Wiley, 
Murphy et al. 2007). Additionally, a purely cytosolic IκBα construct was created by 
N-terminal fusion of IκBα to βActin (Fig.F.3A for a schematic representation of all 
constructs). Using high-resolution confocal immunofluorescence microscopy, we 
confirmed that both, MEET-IκBα as well as SD-IκBα colocalised extensively with 
mitochondria as indicated by the yellow staining in the merged picture (Fig.F.3B). In 
contrast Actin-IκBα did not colocalise at all with mitochondria and, as expected, 
showed staining resembling cytoskeletal fibres. As previously observed (compare 
Fig.F.2B), Mcr1-IκBα was closely associated to mitochondria but did not colocalise 
extensively. Further studies validating that MEET-IκBα is indeed targeted to the 
outer mitochondrial membrane and SD-IκBα is targeted into the mitochondrial 
intermembrane space, can be found in the PhD thesis of Evangelos Pazarentzos 
(publicly available at the Imperial College library; submitted for publication). Using 
subcellular fractionation techniques and proteinase K digestion protocols (proteinase 
K does not have access to mitochondria when used in the appropriate 
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concentration), Evangelos Pazarentzos demonstrated that the MEET-IκBα construct 
is localized predominantly at the outer mitochondrial membrane while SD-IκBα 
resides in the mitochondrial intermembrane space. 
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Fig.F.3: Localisation of Diverse IκBα Fusion Constructs by Confocal Immunofluorescence Microscopy. A) 
Schematic representation of the N-terminal IκBα fusion constructs: IκBα was fused to the first 47 amino acids of yeast 
Mcr1, the first 32 amino acids of MitoNEET, the first 57 amino acids of Smac/Diablo or βActin. Numbers refer to base pair 
numbers of the respective coding sequence. B) HeLa cells were transfected with mito-CFP and either Mcr1-IκBα, MEET-
IκBα, SD-IκBα or Actin-IκBα. 24 hours post transfection, the IκBα constructs were visualised using a primary Flag antibody 
and an Alexa595 labelled secondary antibody. Mitochondria were detected via the autofluorescence of the mito-CFP 
construct. Yellow staining in the merged picture (right panel) is indicative of colocalisation. 
A) 
B) 
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F.1.2 IκBα Localised to the Outer Mitochondrial Membrane Inhibits 
Mitochondrial Depolarisation 
Having constructed the necessary tools for investigating the effect of overexpression 
of IκBα fusion proteins and validated their expression in different subcellular 
locations, we investigated their effects on apoptosis regulation. Overexpression of 
ANT1 was used to induce apoptosis in 293T cells and the effect of co-overexpressing 
the different IκBα constructs assessed by evaluating the mitochondrial membrane 
potential. As can be seen in Fig.F.4, ANT1 induced mitochondrial depolarization in 
approximately 60 percent of cells 24 hours post transfection. Co-transfection of 
IκBα significantly protected against mitochondrial depolarization reducing the 
amount of depolarized cells to approximately 40 percent. Mcr1-IκBα overexpression 
equally inhibited the loss of the mitochondrial membrane potential reducing the 
relative depolarized cell population to approximately 30 percent. However, this 
reduction was not significantly different from the effect of wild-type IκBα 
coexpression. Strikingly, targeting IκBα to the outer mitochondrial membrane using 
MEET-IκBα completely abrogated ANT1-induced depolarization reducing it to the 
same background level as displayed by the control transfection. In contrast, IκBα 
located in the mitochondrial intermembrane space (SD-IκBα) did not have any 
effect on ANT1 induced mitochondrial depolarization. Similarly, the Actin-IκBα fusion 
protein did not counteract mitochondrial apoptosis (Fig.F.4). 
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Fig.F.4: IκBα Targeted to the Outer Mitochondrial Membrane Completely Inhibits 
Mitochondrial Depolarization Induced by ANT1 Overexpression. 293T cells were 
co-transfected with ANT1 and different IκBα constructs including Mcr1-IκBα, MEET-IκBα, 
SD-IκBα and Actin-IκBα (ratio ANT1:construct = 1:2); Bgal transfection was used as a 
control. 24 hours post transfection the mitochondrial membrane potential was assessed 
using DiOC6 staining and subsequent FACS analysis. **p<0.01 ***p<0.001 (student’s t-
test), ns non-significant. 
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F.1.3 Mitochondrial IκBα Interacts with Members of the PT-pore 
IκBα at the outer mitochondrial membrane acts as a strong inhibitor of 
mitochondrial depolarisation which can be mediated by mitochondrial permeability 
transition (refer to chapter A.4.5 for a description of the connection between 
mitochondrial permeability transition and the loss of the mitochondrial membrane 
potential). Thus we speculated that IκBα might interact directly with members of 
the PT-pore to modulate its opening. Therefore, we performed immunoprecipitation 
of endogenous IκBα in protein lysates from isolated mitochondria. Interestingly, 
immunoprecipitation of IκBα co-immunoprecipitated members of the PT-pore: An 
interaction with VDAC1, ANT1 and CKMT1 is clearly demonstrated in Fig.F.5 (data 
by Evangelos Pazarentzos). 
Fig.F.5: Endogenous Mitochondrial IκBα Interacts with Members of the 
“Classical” PT-pore. Endogenous IκBα was immunoprecipitated (IP) from mitochondrial 
protein lysates (input) obtained from HeLa cells. Co-immunoprecipitated proteins were 
subjected to SDS page and Western blotting (WB) and probed for the presence of PT-pore 
members including VDAC1, ANT1 and CKMT1. The IMS protein cytochrome c was used as 
a negative control; C no-antibody control for IP. Data kindly provided by Evangelos 
Pazarentzos. 
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F.1.4 Inhibition of Mitochondrial Depolarisation by IκBα Depends on VDAC1 
As IκBα showed the strongest effect on the inhibition of mitochondrial depolarization 
when targeted to the outer mitochondrial membrane (Fig.F.4) and interacted with 
VDAC1 of the outer mitochondrial membrane (Fig.F.5), we hypothesized that this 
interaction of IκBα with VDAC1 might mediate the inhibitory effect of IκBα. In order 
to test whether the inhibition of mitochondrial depolarization depends on the 
presence of VDAC1, we used VDAC1 knock-down cells in our experimental setup: 
ANT1 was transfected into VDAC1 knock-down and control cells to induce 
mitochondrial depolarization. Co-transfection of Meet-IκBα completely inhibited 
ANT1-induced mitochondrial depolarization in the control cells, whereas VDAC1 
knock-down abolished the ability of IκBα to counteract mitochondrial depolarization 
(Fig.F.6A and 6B). 
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A) 
B) 
Fig.F.6: Inhibition of Mitochondrial Depolarization by IκBα at the Outer 
Mitochondrial Membrane Depends on VDAC1. A) VDAC1 was stably knocked-down in 
293T cells using lentiviral particles encoding shRNA specifically targeted against the 
coding sequence of VDAC1. A scrambled shRNA sequence was used as the control. ANT1 
overexpression was used to induce mitochondrial depolarization and the effect of co-
transfecting MEET-IκBα analysed by staining with DiOC6 and subsequent FACS analysis. 
B) The expression of VDAC1 in the cells used in (A) was checked by SDS page and 
Western blotting for VDAC1; ***p<0.001 (student’s t-test). Data was kindly provided by 
Evangelos Pazarentzos. 
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F.1.5 The N-terminal domain of IκBα is Necessary for the Inhibition of 
Mitochondrial Depolarization 
In order to identify the domain of IκBα necessary for the inhibition of mitochondrial 
depolarization, we generated deletion mutants of IκBα. We used the MEET-IκBα 
fusion construct since MEET-IκBα expression completely abrogated mitochondrial 
depolarization mediated by ANT1 (compare Fig.F.4). Using the MEET localisation 
sequence targeting IκBα to the outer mitochondrial membrane further allowed for 
the separation of the domains responsible for inhibiting mitochondrial depolarization 
from those responsible for IκBα mitochondrial targeting. The deletion mutants 
correspond to an N-terminal (∆1-70), two internal (ankyrin repeat deletions: ∆71-
178 and ∆179-258) and a C-terminal deletion mutant (∆259-317) and all constructs 
contained a C-terminal Flag-tag for ease of detection. A schematic representation of 
these deletion mutants can be found in Fig.F.7. The expression and correct 
mitochondrial localisation of these constructs were validated using confocal 
immunofluorescence microscopy (Fig.F.8). All constructs were expressed in 
mitochondria as demonstrated by the extensive colocalisation with a mitochondrial 
fluorescent protein (mito-CFP): Colocalisation of the MEET-IκBα deletion constructs 
and mito-CFP is indicated by the yellow staining in the merged microscopy pictures 
(Fig.F.8 right panel). 
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Fig.F.7: Schematic Representation of MEET-IκBα Deletion Mutants. A) Domain 
Structure and important residues of IκBα according to the Uniprot database. Numbers refer 
to the position of the amino acid. B) Deletion mutants were constructed according to the 
domain structure of IκB: ∆1-70 is lacking the N-terminal 70 amino acids, ∆71-178 is 
lacking ankyrin repeats 1-3, ∆179-258 is lacking ankyrin repeats 3-5 and ∆259-317 is 
lacking the C-terminal domain. 
A) 
B) 
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Fig.F.8: Localisation of MEET-IκBα Deletion Mutants by Confocal Immunofluorescence 
Microscopy. HeLa cells were transfected with mito-CFP and MEET-IκB deletion mutants (∆1-
70, ∆71-178, ∆179-258, ∆259-317; compare Fig.D.7 for a schematic representation).24 hours 
post transfection, the IκBα constructs were visualised using a primary Flag antibody and an 
Alexa595 labelled secondary antibody. Mitochondria were detected via the autofluorescence of 
the mito-CFP construct. Yellow staining in the merged picture (right panel) is indicative of 
colocalisation. 
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Having established the mitochondrial localisation of all MEET-IκBα constructs, we 
overexpressed ANT1 to induce mitochondrial depolarization and tested the MEET-
IκBα deletion constructs for their ability to counteract depolarization. As can be 
observed in Fig.F.9, three of the four deletion constructs (∆71-178, ∆179-258 and 
∆259-317) completely inhibited ANT1-induced loss of the mitochondrial membrane 
potential and showed an inhibition as strong as full length MEET-IκBα. In contrast, 
the ∆1-70 deletion lacking the first 70 N-terminal amino acids of IκBα did not show 
any inhibitory effect on mitochondrial depolarization. Thus the first 70 amino acids 
of mitochondrial IκBα are necessary for counteracting the loss of the mitochondrial 
membrane potential. 
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Fig.F.9: The N-terminal Domain of IκB is Necessary for its Ability to Counteract 
Mitochondrial Depolarisation. 293T cells were transfected with ANT1 and co-transfected 
with either MEET-IκB, or MEET-IκB deletion mutants (∆1-70, ∆71-178, ∆179-258, ∆259-
317; compare Fig.D.7 for a schematic representation). Bgal transfection served as a 
control transfection. 24 hours post transfection, the mitochondrial membrane potential was 
assayed using DiOC6 staining and subsequent FACS analysis. ***p<0.001 (student’s t-test) 
compared to Bgal/ANT1 co-transfection. 
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F.1.6 The N-terminal domain of IκBα is Necessary for the Interaction of 
IκBα With VDAC1 
As previous experiments indicated that mitochondrial IκBα interacts with VDAC1 of 
the outer mitochondrial membrane (compare Fig.F.5), and depends on VDAC1 to 
exert its protective effect on the mitochondrial membrane potential (compare 
Fig.F.6), we assayed for the ability of the IκBα deletion mutants to interact with 
VDAC1. The ∆71-178, ∆179-258 and ∆259-317 constructs showed an interaction 
with VDAC1 that was comparable to that of full length MEET-IκBα (Fig.F.10, lanes 1 
and 3-5). Strikingly, the N-terminal ∆1-70 deletion mutant, which has previously 
been demonstrated to lack the ability to inhibit mitochondrial depolarization, also 
lost the ability to interact with VDAC1 to a great extent (Fig.F.10, second lane). 
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Fig.F.10: The N-terminal Domain of IκB is Necessary for the Interaction With 
VDAC1. 293T cells were transfected with MEET-IκB or MEET-IκB deletion mutants (∆1-
70, ∆71-178, ∆179-258, ∆259-317). 24 hours post transfection the MEET-IκB were 
immunoprecipitated with a FLAG antibody, and the co-immunoprecipitated proteins 
assayed for VDAC1 using Western blotting with a specific VDAC1 antibody. Individual blue 
arrows indicate the band corresponding to the full-length MEET-IκB deletion construct. 
Data produced in collaboration with Evangelos Pazarentzos. 
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G. DISCUSSION 
 
G.1 Apoptosis Regulation by CKMT1 
The crucial step in the mitochondrial pathway of apoptosis involves the rupture of 
the outer mitochondrial membrane and the subsequent leak of apoptogenic 
proteins. It has been demonstrated that mitochondrial inner membrane 
permeabilization generally precedes apoptotic cell death, both in vitro(Zamzami, 
Marchetti et al. 1995) and in vivo(Zamzami, Marchetti et al. 1995). This process 
was thought to be caused by functional and possibly structural changes within the 
mitochondrial permeability transition pore complex(Green and Kroemer 2004). 
Numerous apoptosis signals would convert this protein aggregate into an unspecific 
pore, thus activating mitochondria for the cellular self-destruction process. In this 
study we present evidence that the mitochondrial creatine kinase CKMT1 plays an 
important role in regulating apoptosis by acting as a crucial gatekeeper for 
mitochondrial permeability transition independently of its kinase activity. 
Interestingly – and contrary to previous scientific speculations - this regulation of 
mitochondrial permeability and subsequent apoptosis is also independent of the 
“traditional” PT-pore model. 
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G.1.1 Overexpression of CKMT1 as a Mechanism for Apotptosis Inhibition 
Early studies from the 1980ies indicated that CKMT1 is upregulated in several 
malignancies with poor prognoses, such as lung cancer, gastric cancer and prostate 
cancer(DeLuca, Hall et al. 1981; Tsung 1983; Kanemitsu, Kawanishi et al. 1984; 
Pratt, Vallis et al. 1987). Additionally, more recent studies describing gene 
expression profiling in cancer patients using microarray analysis identified that 
CKMT1 expression is significantly associated with both, decreased disease free 
survival and overall patient survival(Cimino, Fuso et al. 2008). In line with these 
findings, a micro array data mining approach using cancer transcriptome profiles 
available at Oncomine (Vers 4.4.3) confirmed that CKMT1B is, compared to their 
respective normal tissues, expressed significantly higher on the mRNA level in 
tumours samples from bladder, breast, lung and pancreatic tissue (Fig.D.1). This 
data is only indicative of high CKMT1B mRNA levels in tumours of certain origin 
rather than implying a general functional role for CKMT1 in their formation and/or 
tumour progression as higher CKMT1 expression could also be due to a “passenger” 
effect, i.e. high CKMT1 levels can be observed, but do not functionally contribute to 
tumourigenesis. Using the Oncomine database, other malignancies, including 
colorectal cancer, brain and central nervous system cancer showed a significant 
downregulation of CKMT1B on the mRNA level, pointing to the fact that CKMT1 
expression might only be involved in certain types of malignancies and not in 
others. Another recent study even identified CKMT1 protein downregulation in oral 
squamous cell carcinoma(Onda, Uzawa et al. 2006). In addition to the varying 
correlation of mRNA level changes and their reflection in protein changes(Gry, 
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Rimini et al. 2009), the Oncomine microarray data has to be interpreted with 
caution, as sequencing analysis of cDNA from transformed cells performed during 
this PhD studies revealed that both genes, CKMT1A and CKMT1B, are expressed in 
the cell, with their respective full length sequence only differing by 2 base pairs out 
of a total of 1254 basepairs (Fig.E.12). Although the microarray identifier of the 
Oncomine profiles lists either CKMT1B or CKMT1A, it remains uncertain whether the 
hybridization sequences used on the actual chip were indeed specific for either gene 
copy. Even assuming specificity, the assays did not test for CKMT1A and CKMT1B 
quantities simultaneously. Therefore, the total amount of CKMT1 mRNA expression 
comprising the sum of CKMT1A and CKMT1B mRNA remains unclear, e.g. it is 
conceivable that the upregulation of the transcription of one gene locus might mask 
the transcriptionally less active other gene or vice versa (thereby increasing the 
possibility of false positive and false negative results). 
As the microarray data presented is merely correlative, we overexpressed CKMT1 
and examined the cells for features (“hallmarks”) that would imply a role for CKMT1 
in tumour formation. Models of tumour formation and progression point to the 
obvious role of excess proliferation in neoplastic diseases as tumour growth partly 
relies on an aberrant proliferation of cells(Hetts 1998). Considering the function of 
CKMT1 in energy metabolism (refer to chapter A.5.1), increased CKMT1 levels in 
tumour cells were speculated to be part of a metabolic adaptation allowing and 
fostering high growth rates even during hypoxia and nutritional supply 
restrictions(Vial 2006). However, a proliferation assay and detailed cell cycle 
analysis over 4 days following CKMT1 overexpression (Fig.D.3) did not show any 
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significant changes in cell growth as well as in the G2, G0 and S phase distribution. 
Therefore, CKMT1 overexpression does not drive cellular proliferation in vitro. 
Tumour development only partly relies on an aberrant proliferation of cells, and 
insufficiency in apoptosis (as discussed in conjunction with other hallmarks of 
cancer, compare chapter A.1.2) can be equally detrimental(Hetts 1998; Hanahan 
and Weinberg 2000; Hanahan and Weinberg 2011). In this study, we provide 
evidence that overexpression of CKMT1 results in increased resistance against 
external apoptotic stimuli acting via the mitochondrial apoptosis pathway (Fig.D.5). 
More specifically, CKMT1 overexpression dramatically increases resistance against 
induction of apoptosis and mitochondrial depolarization by stimuli that have 
previously been linked to PT-pore activation (overexpression of ANT1(Bauer, 
Schubert et al. 1999), treatment with the ionophore ionomycin(Schubert and Grimm 
2004); Fig.D.4 and Fig.D.5). Expression of CKMT1 has already been described to 
impair PT-pore activation in isolated liver mitochondria from transgenic mice 
ectopically expressing CKMT1 in liver tissue(O'Gorman, Beutner et al. 1997). 
However this effect could only be observed in an in vitro system in the presence of 
the CKMT1 substrates creatine and cyclocreatine. Therefore, O’Gorman et 
al.(O'Gorman, Beutner et al. 1997) assumed that binding of creatine or 
cyclocreatine by CKMT1 induces a subtle structural change required for the 
proposed interaction of CKMT1 and ANT1. In our cellular system, simple 
overexpression CKMT1 resulted in significant apoptosis inhibition, even without the 
supplementation of creatine or cyclocreatine. Our results are not contradictory to 
these previous findings, since creatine as a substrate for CKMT1 is readily available 
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within the cell. Additionally, we provide evidence that endogenous ANT1 and CKMT1 
interact in mitochondrial protein extracts (Fig.D.4). Previously, this interaction has 
been speculated to be indirect via mutual binding to cardiolipin(Beyer and 
Klingenberg 1985; Vial 2006). However, our results suggest that ANT1 interaction 
with CKMT1 can also happen by direct or indirect protein-protein interaction since 
non-denaturing immunoprecipitations have been performed in the presence of 
detergent (RIPA buffer:1% IGEPAL® CA-630; compare chapter C.22), which is 
sufficient to solubilize proteins and remove them from lipid complexes. However, it 
is likely that the ANT1-CKMT1 interaction is indirect (involving yet unidentified 
proteins): Schlattner et al. provided evidence that isolated and reconstituted ANT1 
and CKMT1 do not interact, while VDAC1 and CKMT1 interact in reconstituted 
liposomes(Schlattner, Dolder et al. 2001). As their experimental setup used isolated 
proteins, other proteins that mediate their indirect interaction would not be present, 
while our approach using immunoprecipitation of endogenous proteins performed in 
mitochondrial lysates does not exclude the presence of other proteins in the CKMT1-
ANT1 complex. 
 
The creatine kinase system is essential for cellular energetics in tissues or cells with 
high and fluctuating energy requirements(Wallimann, Wyss et al. 1992). This is due 
to the reversible creatine kinase reaction, which can provide high concentrations of 
phosphocreatine (transphosphorylation of ATP and creatine) as a highly diffusible 
energy buffer. This buffering function is important, since conventional ATP 
generating pathways such as glycolysis or oxidative phosphorylation in mitochondria 
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are not able to cater for short-term peak energy requirements of the cell. Along 
those lines, other researchers speculated that increased CKMT1 levels in tumour 
cells could be part of a metabolic adaptation allowing high growth rates despite 
cellular stress, e.g. even during hypoxia and nutritional supply restrictions(Vial 
2006). Strikingly, our experiments demonstrate that the kinase activity of CKMT1, 
i.e. the buffering of cellular energetic demands through higher availability of 
phosphocreatine, is not responsible for the apoptosis inhibition observable after 
CKMT1 overexpression: A single point mutation (E266L266; Fig.D.2) results in an 
enzymatically inactive but structurally intact CKMT1 mutant (Eder, Stolz et al. 
2000). This mutant shows exactly the same anti-apoptotic activity when 
mitochondrial apoptosis is induced by cytotoxic compounds or ANT1 overexpression 
(Fig.D.4). It also protects cells from mitochondrial permeability transition as 
measured by DiOC6 staining for mitochondrial depolarization (Fig.D.5). The 
introduced mutation was designed to affect the ATP binding site only. Therefore, it 
can be speculated that the creatine binding site, which enables the PT-pore 
gatekeeping function after the induced conformational change upon substrate 
binding as proposed by O’Gorman et al.(O'Gorman, Beutner et al. 1997), is still 
intact. Another piece of evidence supporting the conclusion that the enzymatic 
activity (potentially equalling the generation of higher amounts of phosphocreatine) 
is not necessary for apoptosis inhibition, comes from studies examining the effects 
of creatine and phosphocreatine supplementation in cancer cells – all studies show a 
slight but significant inhibition of cancer cell growth with creatine/phosphocreatine 
supplementation in vitro as well as in vivo(Bergnes, Yuan et al. 1996; Vial 2006). 
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Interestingly, the question as to whether CKMT1 overexpression could contribute to 
tumourigenesis was also addressed by another research group that published their 
results after the experimental work for this thesis had been completed. Qian et 
al.(Qian, Li et al. 2012) found evidence that high levels of CKMT1 protein expression 
as determined by immunohistochemical staining of breast cancer samples were 
significantly correlated with reduced progression-free survival and overall survival. 
In line with our findings, Qian et al. did not observe changes in proliferation upon 
CKMT1 overexpression under normal cell culture conditions (compare Fig.D.3). 
However, they observed a significant rescue from growth inhibition by overcrowding 
in cell clones expressing exogenous CKMT1, along with a decreased early apoptotic 
population in CKMT1 overexpressing cells (overcrowding resulted in growth 
inhibition in the control cell clones after 5 days). Thus, it comes as no surprise that 
we did not find any differences in cell growth within 5 days of overexpressing 
CKMT1 as cells did not reach over-confluency and nutrient deprivation. However, we 
clearly showed that overexpression of CKMT1 results in inhibition of mitochondrial 
depolarization and apoptosis inhibition. We assume that protection against 
apoptosis is also the main driving force for the apparent continued growth of CKMT1 
overexpressing clones as presented by Qian et al.(Qian, Li et al. 2012)– CKMT1 
overexpression results in the protection of cells against apoptotic elimination via 
mitochondrial permeability transition under cellular stress conditions (induced by 
over-confluency and nutrient deprivation in the case of the data presented by Qian 
et al.; or PT-pore activation by treatment with cytotoxic agents, ionophores or 
overexpression of ANT1 as presented in this study). Furthermore, CKMT1 is present 
at higher levels in protein lysates from crowded cells compared to non-confluent 
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cells cultures(Qian, Li et al. 2012), which could be a physiologic reaction to endure 
stress conditions. 
Qian et al. also present convincing evidence for the contribution of the 
overexpression of CKMT1 to tumour progression, as cell clones overexpressing 
CKMT1 gave rise to tumours showing an approximately 9-fold difference in tumour 
volume compared to control clones when inoculated in nude mice for 8 weeks(Qian, 
Li et al. 2012).  
Taken together, these results demonstrate that CKMT1 protects tumour cells from 
apoptotic elimination, therefore potentially contributing to more invasive and 
aggressive tumours resulting in poor prognosis. As CKMT1 expression protects 
against cell death induced by cytotoxic agents (Fig.D.5), it is also conceivable, that 
CKMT1 expression protects tumours from the cytotoxic effects of anti-neoplastic 
therapies (chemotherapy, hormonal and biologic therapies, and radiotherapy). 
Therefore, the downregulation of CKMT1 might be an effective adjuvant intervention 
in cancer therapy – however, the effects of downregulating CKMT1 have been poorly 
addressed so far. 
 
G.1.2 Apoptosis Induction Induced by CKMT1 Downregulation 
Considering the potential benefits of decreasing CKMT1 expression in terms of 
tumour growth and therapy responsiveness, we went on to examine the effects of 
CKMT1 downregulation on the cellular level. In an attempt to elucidate the 
functional role of creatine kinase isoenzymes in vivo, other research groups 
generated knock-out mice lacking cytosolic and/or mitochondrial creatine kinase 
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(Steeghs, Oerlemans et al. 1995; Steeghs, Peters et al. 1995; Steeghs, Oerlemans 
et al. 1998; de Groof, Oerlemans et al. 2001). Mice lacking CKMT1 were fertile, 
viable, and phenotypically normal in many aspects(Steeghs, Oerlemans et al. 1995) 
as were mice lacking both, mitochondrial CKMT1 as well as the cytosolic creatine 
kinase MCK(Steeghs, Oerlemans et al. 1998). Thus it was hypothesized that CKMT1 
is not mandatory for mouse viability. Additionally, CKMT1 was described to be “not 
expressed in liver cells”(Miller, Halow et al. 1993; Hatano, Tanaka et al. 2004) and 
thus could not be mandatory for cell survival in theses specialized cells. However, 
consulting with the “Human BodyMap 2.0” data from Illumina” (accessible online at 
the EBI) there is evidence that liver tissue expresses endogenous CKMT1 at least on 
the mRNA level, although the level might be considerably lower than in other 
tissues.  
Despite the lack of a clear CKMT1 knock-out phenotype, constitutive knock-out mice 
for CKMT1 might develop a metabolic and morphological remodelling of their cells 
and tissues to compensate for the lack of CKMT1, thus possibly obscuring the 
primary phenotype linked to the gene knock-out. This phenomenon has been 
described to limit the conclusions drawn from knock-out mice studies(Rudmann and 
Durham 1999; Gingrich and Hen 2000). Indeed, later studies proved that the 
CKMT1 knock-out resulted in cyto-architectural and metabolic adaptations involving 
mutations and coordinated regulation of divergent but functionally coupled groups 
of proteins in muscle cells (Steeghs, Oerlemans et al. 1998; de Groof, Oerlemans et 
al. 2001). 
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Surprisingly, there is also no published research data available that examined the 
phenotype of specific downregulation of CKMT1 in a transient setting. Only one 
publication described that inhibition of cytosolic and mitochondrial creatine kinase 
by siRNA affected cell viability and mitochondrial morphology(Lenz, Schmidt et al. 
2007); however no evidence for the specific knock-down of CKMT1 on the protein 
level is presented in this piece of research. 
Thus, we used RNAi-mediated transient depletion of CKMT1 in order to assay for 
effects of transient knock-down of endogenous CKMT1. The cell phenotype was 
examined 24h to 96h post-transfection eliminating longterm metabolic and/or 
cytoarchitectural adaptations, which complicate analysis of the classical constitutive 
mouse knock-out models. Downregulation of CKMT1 resulted in highly significant 
induction of cell death (Fig.D.6 and Fig.D.11). The modality of cell death was 
confirmed to be apoptotic, as major hallmarks of apoptotic cell death such as 
phosphatidyl serine externalisation (AnnexinV staining), nuclear fragmentation 
(SubG1/G0 DNA content), PARP cleavage, caspase 3 and Bax activation could be 
detected in cells depleted of CKMT1 (Fig.D6 and Fig.D7). The appearance of these 
features was kinetically correlated with the extent of CKMT1 downregulation on the 
protein level. Additionally, cell death induced by depletion of endogenous CKMT1 is 
executed in a caspase-dependent way, as application of the pan-caspase inhibitor 
zVAD abrogated cell death (Fig.D7). The apoptotic phenotype of CKMT1 
downregulation was universally observable in the panel of human transformed cell 
lines tested - HeLa cells (cervical cancer), 293T cells (embryonic kidney), MCF7 cells 
(breast cancer), HCT116 cells (colon cancer), LNCaP cells (pancreatic cancer) and 
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MDA231 cells (breast cancer)(Fig.D.11). The pronounced phenotype of CKMT1 
downregulation is in stark contrast to the CKMT1 knock-out phenotype. As 
discussed above, this could be due to metabolic and morphological compensations. 
However, it could also be that the physiology of the human system we studied and 
the murine system used in the knock-out experiments differ in their requirements 
for CKMT1 expression: CKMT1 could be necessary for the survival of human cells 
but not murine cells. Alternatively, all cell lines tested in Fig.D.11 are transformed 
cells (and tumorigenic; with the potential exception of 293T cells which can also 
induce tumour formation at high passage number(Shen, Gu et al. 2008)), which 
could also be a pre-requisite for the CKMT1 knock-down phenotype. Bearing in mind 
the recently developed model of “metabolic dependency” of cancer cells(Burgess 
2012), i.e. the acquired dependency of cancer cells to a specific metabolic pathway 
for energy supply and proliferation, it could well be that the transformed cells used 
in our study are metabolically dependent on CKMT1 expression whereas CKMT1 
expression could be dispensable in untransformed (as in CKMT1 knock-out mice). In 
order to address these two questions, we went on to examine the CKMT1 RNAi 
phenotype in cultured murine cells as well as in primary human cells. In contrast to 
the murine CKMT1 knock-out, depletion of endogenous CKMT1 in murine cells 
(MLE12 lung cancer cells, and N2A neuroblastoma cells) in vitro resulted in the 
induction of apoptosis (Fig.D.21 and Fig.D.22). Human primary cells (HFF1 human 
foreskin fibroblasts) also underwent apoptosis upon downregulation of endogenous 
CKMT1. Thus, we conclude that depletion of endogenous CKMT1 is causally linked to 
apoptosis induction and expression of CKMT1 generally necessary for cell viability – 
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and this feature is neither cell type- nor tumour-specific, but is more likely to be a 
universal phenomenon. 
Unfortunately, neither CKMT1 knock-out cells nor CKMT1 knock-out mice are readily 
available to investigate their properties, and the only potential source identified 
were frozen embryos. The closer investigation of these knock-out cells would be 
interesting, since the knock-out of CKMT1 in the original publication of Steeghs et 
al.(Steeghs, Oerlemans et al. 1995) was only verified using zymogram analysis for 
enzymatic creatine kinase activity – and the data presented in this thesis 
demonstrates that the enzymatic activity of CKMT1 is not necessary for its function 
as an apoptosis inhibitor (Fig.D.4 and Fig.D.5). In more detail, the knock-out was 
established by substituting exons 7 and 8 with a selection marker, making it 
possible that a shortened, but enzymatically inactive CKMT1 transcript (compare 
Fig.E.13) could still be expressed (and functional, despite the shortened sequence 
and lacking kinase activity). However, the hypothesis that a 3’-shortened CKMT1 
transcript might be functionally necessary can almost be excluded as RNAi 
constructs targeting exons7/8 as well as exon9 (final exon) result in apoptosis 
induction. Similarly, transcripts excessively shortened at the 5’ are unlikely to be 
functionally necessary as RNAi constructs targeting exon2 and exon3 result in 
apoptosis induction (compare Table E.1 and Fig.E.11). The existence of alternative 
CKMT1 transcripts will be discussed separately in more detail (please refer to 
chapter G.2.2.1). 
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As the depletion of endogenous CKMT1 through RNAi induces apoptosis, the 
downregulation of CKMT1 could constitute a physiologic mechanism of apoptosis 
induction under excessive stress conditions. Supporting evidence comes from 
transcriptional profiling of neuronal tissue after injury – studies in rat detected 
significant downregulation of CKMT1 mRNA in neurons after spinal cord 
contusion(Aimone, Leasure et al. 2004) and neurodegeneration following spinal cord 
root avulsion(Swanberg, Duvefelt et al. 2006). In line with this, downregulation of 
CKMT1 expression by RNAi in N2A neuronal cells also resulted in apoptosis 
(Fig.D.22). Since there is no evidence (yet) of the regulation of CKMT1 expression 
through the endogenous RNAi system (microRNAs), we examined other ways for 
downregulating CKMT1 expression that might be of more physiologic relevance. 
Recently, Kwon et al.(Kwon, Kim et al. 2010) demonstrated, that the ankyrin repeat 
and suppressor of cytokine signalling (SOCS) box protein 9 (ASB9) interacts with 
CKMT1 and mediates its polyubiquitination. The biological function of ASB9 is poorly 
defined but as part of the SOCS box protein family, it regulates biological processes 
including proliferation and differentiation and is involved in the negative regulation 
of cytokine signalling(Debrincat, Zhang et al. 2007). Overexpression of ASB9 also 
induced reduced growth rates and decreased total creatine kinase activity(Kwon, 
Kim et al.). Taking into consideration that CKMT1 downregulation results in 
apoptosis induction, ASB9 could mediate CKMT1 ubiquitination and its subsequent 
proteasomal degradation would result in CKMT1 depletion an apoptosis induction. In 
this study we provide evidence, that ASB9 can access mitochondria and directly 
ubiquitinates the CKMT1 octamer complex (Fig.D.13). This ubiquitination is followed 
by the degradation of CKMT1, most likely through the “cytosolic” ubiquitin-
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proteasome system, which has recently been shown to be involved in the 
degradation of mitochondrial proteins(Azzu and Brand 2010). Degradation of CKMT1 
following ASB9 overexpression is concomitant with mitochondrial depolarization and 
apoptosis induction (Fig.D.13). Kwon et al. also observed abnormal mitochondrial 
structure and a decrease of mitochondrial membrane potential after ASB9 
overexpression, and our studies link these observations with the degradation of 
endogenous CKMT1, which induces mitochondrial depolarization and apoptosis. 
Unfortunately, a deletion mutant of CKMT1 lacking the ASB9 binding site 
(CKMT1∆BS) induced mitochondrial apoptosis on its own (Fig.D.14). Therefore the 
“gold standard” proof for the assumption that ASB9-induced apoptosis depends on 
CKMT1 depletion (rescuing ASB9-induced apoptosis by supplying a degradation 
resistant CKMT1) could not be achieved. On another note, it is quite interesting that 
the CKMT1∆BS mutant lacking the so-called substrate binding site (aa 125-190) 
induces mitochondrial depolarisation on its own considering that full length CKMT1 
protects against the loss of the mitochondrial membrane potential and apoptosis 
induction (Fig.D.4 and Fig.D.5). This fits in with the assumption that substrate 
binding is necessary for CKMT1 to induce a subtle structural change important for 
its PT-pore inhibiting function(O'Gorman, Beutner et al. 1997). The substrate 
binding site of CKMT1 for creatine is located between N- and C-terminal domains 
(aa 1-100 and aa 113-417) which are connected via a long linker region without 
secondary structure (residues 101-112), while the ATP binding site is located in a 
cleft within the large subunit. However, considering all the literature available, it 
seems to be a misconception that substrate binding of CKMT1 is mediated by the 
residues 125-190 as described by Kwon et al., as a large number of residues 
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stretching the large subunit as well as the linker region of CKMT1 is involved in 
binding and correct positioning of its substrates – please refer to Vial 2006 for the 
most recent review of CKMT1 structure-function relationship(Vial 2006). Of note, 
the publication by Kwon et al. actually described the substrate binding site deletion 
mutant of CKMT1, CKMT1∆BS, as a deletion of amino acids 135-145 of the cds. 
However, using the primer sequences provided in the methods section of their 
publication, the deletion stretches amino acids 112-192, which is consistent with the 
size difference of full length CKMT1 and CKMT1∆BS observed in the Western blots 
shown(Kwon, Kim et al.), as well as with our sequencing result of the CKMT1∆BS 
plasmid sent to our lab (a kind gift of Dr. Kwon) and used in this study. Considering 
the relatively large deletion present in the CKMT1∆BS mutant, it is not surprising 
that it also lacks several residues described to be crucial for the dimer as well as 
octamer formation. Thus it is highly speculative to give the exact reason for 
CKMT1∆BS acting as an apoptosis inducer. The possibility of constructing other 
CKMT1 mutants with mutations in relevant lysine residues (targets of ubiquitination 
mediated by ASB9) was investigated. However, there are no discrete published 
ubiquitination sites in CKMT1 sequence and numerous candidate lysine residues as 
predicted by the ubiquitination site prediction software UbPred(Radivojac, Vacic et 
al. 2010). 
As proposed earlier, it is conceivable that the degradation of CKMT1 (as 
experimentally induced by RNAi and ASB9 overexpression) plays a general 
functional role in the initiation of the mitochondrial apoptotic signalling pathway. 
Examining this hypothesis, we observed that CKMT1 is not degraded in early stages 
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of apoptosis induced by various drugs (Fig.D.15) and thus CKMT1 downregulation is 
not the initiation point of mitochondrial apoptosis under these conditions. However, 
we show clear evidence that CKMT1 is downregulated subsequent to the beginning 
of PARP cleavage, later on during the apoptotic process (Fig.D.15). This is not an 
artefact of proteolytic cleavage of cellular substrates by caspases in late apoptosis, 
as GAPDH expression is not affected at these time points. Therefore we propose 
that CKMT1 downregulation upon apoptosis induction – though not the priming 
event – acts as a positive feedback loop to reinforce the commitment of cells to 
apoptotic execution. Additionally lower CKMT1 levels would render cells more 
susceptible to apoptosis. This is concordant with in vivo studies showing CKMT1 
downregulation on the mRNA level in neuronal cells upon spinal cord 
contusion(Aimone, Leasure et al. 2004) and axonal damage(Swanberg, Duvefelt et 
al. 2006), both inducers of neuodegeneration. 
The release of apoptogenic factor from the mitochondrial intermembrane space is a 
crucial event in the mitochondrial apoptosis pathway (compare chapter A.2.2.2). 
These factors execute their pro-apoptotic function upon leaving mitochondria. 
Similarly we examined the possibility that CKMT1 leaves mitochondria to instigate 
apoptosis induction. Loss of mitochondrial CKMT1 would result in the loss of its 
apoptosis inhibition function, thus enabling apoptosis to proceed. However, CKMT1 
remains mitochondrial during apoptosis, even after the release of apoptogenic 
factors (Fig.D.16). This is not surprising, since CKMT1 interacts with and is strongly 
incorporated into mitochondrial membranes (Ortega Ferrusola, Gonzalez Fernandez 
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et al. 2010)(compare Fig.A.15) – thus remaining tethered to mitochondrial 
remnants even after loss of mitochondrial outer membrane integrity. 
 
G.1.3 CKMT1 Mediated Mitochondrial Permeability Transition and the PT-
pore 
As numerous previous studies suggest an involvement of CKMT1 in the regulation of 
mitochondrial apoptosis via PT-pore regulation (please refer to chapter A.5.3 for a 
summary thereof), we addressed whether CKMT1 downregulation would result in 
PT-pore opening, consequent mitochondrial permeability transition (MPT) and 
commitment to apoptosis through outer mitochondrial membrane permeabilisation. 
As introduced in chapter A.4.5, the loss of the mitochondrial membrane potential is 
an indicator for MPT. Therefore we assayed for the dissipation of Δψm upon CKMT1 
downregulation as a priming event in mitochondrial apoptosis using DiOC6 and JC1 
staining (please refer to chapter A.4.5 for the rationale behind using these dyes). 
Downregulation of CKMT1 resulted in significant mitochondrial depolarization 
(Fig.D.8), with its onset kinetically very closely correlated with the knock-down of 
CKMT1 on the protein level. Previously, we have shown that apoptosis inhibition by 
CKMT1 overexpression does not require its enzymatic activity. Similarly, we 
speculated that that the loss of the mitochondrial membrane potential and 
subsequent apoptosis induction are not due to the lack of mitochondrial creatine 
kinase activity, i.e. decreased phosphocreatine levels. In line with this, 
supplementation of cells with the enzymatic end product – phosphocreatine – did 
not rescue the CKMT1 RNAi phenotype (Fig.D.10). Supporting evidence that 
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phosphocreatine system is not absolutely required for cell viability comes from data 
relating to MCK knock-out mice, which lack the cytosolic creatine kinase isoenzyme 
and thus cannot utilize phosphocreatine in the cytosol (although it is still present), 
but are phenotypically relatively normal(Steeghs, Oerlemans et al. 1998). Evidence 
that phosphocreatine is dispensable for cell viability in human cells comes from data 
relating to creatine deficiency syndromes (creatine deficiency is linked to 
subsequent phosphocreatine deficiency). These deficiencies arise from genetic 
errors in creatine metabolism as genes involved in the biosynthesis or transport of 
creatine are affected (guanidinoacetate methyltransferase (GMAT) deficiency, L-
arginine:glycine amidinotransferase (AGAT or GATM) deficiency, and the creatine 
transporter (SLC6A8) deficiency). These genetic disorders are not lethal. However, 
patients affected suffer from neurodevelopmental delay, seizures, weak muscle tone 
and delayed development of motor skills (Schulze 2003; Sykut-Cegielska, 
Gradowska et al. 2004; Braissant, Henry et al. 2011). These symptoms are due to 
the lack of creatine/phosphocreatine for ATP regeneration and energy buffering, but 
also due to the lack of creatine/phosphocreatine as a neurotransmitter or 
osmolyte(Braissant, Henry et al. 2011). Additionally, knock-down of CKMT1 does 
not automatically result in decreased phosphocreatine levels: As can be observed in 
Fig.A.14, cytosolic creatine kinases can use ATP and creatine to generate 
phosphocreatine and thus, in theory, replenish the phosphocreatine levels until the 
enzymatic equilibrium of the ATP/phosphocreatine is achieved. This argument is 
corroborated by research showing that in less oxidative tissues (e.g. glycolytic 
muscle), the cytoplasmic pool of phosphocreatine is mainly supplied by cytosolic 
creatine kinases, which can associate with glycolytic enzymes(Vial 2006). 
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Therefore we conclude that depletion of CKMT1 is lethal by inducing mitochondrial 
depolarization, which is not related to the lack of mitochondrial creatine kinase 
enzyme activity and, as a consequence, the lack of phosphocreatine as the 
enzymatic product, but rather due to an – as of yet – undefined function of the 
CKMT1 protein. An experimental approach for proving this conclusion would be 
CKMT1 RNAi phenotype rescue experiments with an enzymatically inactive mutant 
or the knock-down of endogenous CKMT1 expression in cells obtained from a GMAT 
or AGAT deficient background cultured in creatine-free medium. The lack of creatine 
in the culture medium is important, as GMAT or AGAT deficient cells still take up 
creatine through culture medium (this caveat also applies to the interpretation of 
data on genetic GMAT/AGAT deficiency syndromes as patients sill take up creatine 
through their food). Thus, in a cellular system, one would have to analyse 
GMAT/AGAT deficient cells in a creatine-free environment or have a double knock-
out/down of GMAT or AGAT together with the creatine transporter SLC6A8. 
 
Since the opening of the PT-pore manifests itself in the loss of the mitochondrial 
membrane potential, pharmacological inhibition the PT-pore opening should prevent 
mitochondrial depolarization as well as subsequent apoptosis/cell death induced by 
depletion of CKMT1. A pharmacologic agent extensively studied in this context is 
bongkrekic acid(Henderson and Lardy 1970). Bongkrekic acid has consistently been 
described as a specific inhibitor of the PT-pore and mitochondrial permeability 
transition(Marchetti, Castedo et al. 1996; Hirsch, Marzo et al. 1997; Schubert and 
Grimm 2004; Ortega Ferrusola, Gonzalez Fernandez et al. 2010; Yamada, 
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Nakamura et al. 2013). For long, bongkrekic acid has been used as a specific 
inhibitory ligand of the mitochondrial adenine nucleotide translocase (ANT), fixing 
its conformation in the “m-state” and thus inhibiting PT-pore opening(Henderson 
and Lardy 1970; Chua and Shrago 1977; Klingenberg 1989; Halestrap and Brenner 
2003; Bernardi, Krauskopf et al. 2006). However, the involvement of ANT in 
mitochondrial permeability transition, in particular the requirement of ANT for PT-
pore opening, has been controversially discussed (please refer to chapter A.4.7 for 
an extended discussion). Therefore it seems to be a misconception that bongkrekic 
acid selectively inhibits the PT-pore via specific inhibition of ANT, which is supported 
by more recent findings on the mechanism of action of bongkrekic acid(Malekova, 
Kominkova et al. 2007) and which will be discussed in more detail in chapter G.1.6. 
However, despite the discussion on the mechanism of action and on the actual PT-
pore composition, bongkrekic acid is widely accepted as an PT-pore 
inhibitor(Marchetti, Castedo et al. 1996; Hirsch, Marzo et al. 1997; Schubert and 
Grimm 2004; Ortega Ferrusola, Gonzalez Fernandez et al. 2010; Yamada, 
Nakamura et al. 2013). Treatment of cells with the “PT-pore inhibitor” bongkrekic 
acid abrogated mitochondrial depolarization as well as cell death induced by 
downregulation of endogenous CKMT1(Fig.D.9). These findings provide specific 
evidence that the activation of the PT-pore (or another structure targeted by 
bongkrekic acid) is causally linked to the depletion of CKMT1 and suggest that 
CKMT1 acts a crucial and mandatory gatekeeper of the PT-pore (or an alternative 
complex), permeability transition and mitochondrial apoptotic cell death. 
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G.1.4 Verdict of Innocence – Regulation of Mitochondrial Permeability 
Transition by CKMT1 Does not Involve the “Usual Suspects” 
 
G.1.4.1 Cyclophilin D 
Our experiments established that CKMT1 acts as a mandatory gatekeeper of 
mitochondrial permeability transition involving a mechanism that is sensitive to 
bongkrekic acid, a compound that is often used as an inhibitor of the PT-pore. 
Cyclophilin D has also been postulated as a key regulator/component of the PT-pore 
(refer to chapter A.4.7 for a full summary of data relating to the involvement of 
cyclophilin D in PT), especially since Baines et al. recently showed that cyclophilin D 
knock-out cells are resistant to mitochondrial permeability transition(Baines, Kaiser 
et al. 2005) and pharmacologic targeting of cyclophilin D with cyclosporin A(Nicolli, 
Basso et al. 1996) and sanglifehrin A (Clarke, McStay et al. 2002) inhibits 
mitochondrial permeability transition via the PT-pore. Schinzel et al. and Nakagawa 
et al. also showed that cyclophilin D deficient isolated mitochondria are resistant 
against mitochondrial permeability transition in vitro(Nakagawa, Shimizu et al. 
2005; Schinzel, Takeuchi et al. 2005). Additionally, overexpression as well as 
downregulation of cyclophilin D can repress MPT and mitochondrial apoptosis(Lin 
and Lechleiter 2002; Li, Johnson et al. 2004; Schubert and Grimm 2004; Machida, 
Ohta et al. 2006; Zhang and Armstrong 2007; Eliseev, Malecki et al. 2009; Kato, 
Akao et al. 2009; Hu, Chen et al. 2010). Therefore, we examined the involvement 
of cyclophilin D in mitochondrial permeability transition induced by downregulation 
of CKMT1. Strikingly, neither overexpression, nor downregulation, nor knock-out, 
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nor pharmacological targeting of cyclophilin D had any effect whatsoever on the loss 
of mitochondrial membrane potential induced by CKMT1 depletion (Fig.D.12). This is 
remarkable considering that all these interventions - overexpression, 
downregulation, knock-out and pharmacological targeting of cyclophilin D(Schubert 
and Grimm 2004) - significantly reduced ANT1 induced mitochondrial depolarization 
in the same settings. This proves that the mitochondrial permeability transition 
induced by CKMT1 depletion does not depend on the same mechanism as cyclophilin 
D-dependent permeability transition. This data fits well with the finding that 
cyclophilin D deficient cells can still undergo normal apoptosis in response to most 
apoptotic stimuli(Nakagawa, Shimizu et al. 2005; Schinzel, Takeuchi et al. 2005). 
Nakagawa et al. even suggested that cyclophilin D-dependent mitochondrial 
permeability transition only regulates necrosis and not apoptosis. However, we 
provide evidence that cyclophilin D does regulate apoptosis induction – at least by 
certain stimuli, i.e. ANT1 overexpression in our study(Fig.D.12). Our data showing 
that cyclophilin D does not play a role in CKMT1 RNAi-mediated apoptosis induction, 
is in line with the conclusion of cyclophilin D knock-out studies presented by Basso 
et al.: The mitochondrial permeability transition pore can form and open in the 
absence of cyclophilin D, although cyclophilin D modulates PT-pore sensitivity in 
response to certain stimuli(Basso, Fante et al. 2005). 
 
G.1.4.2 VDAC1 
Another protein, previously implicated as a key player in mitochondrial permeability 
transition via the PT-pore, is VDAC. This is based on the reconstitution of VDAC in 
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artificial liposomes as well as from mitochondrial fractionation experiments that 
isolated endogenous PT-pore complexes containing VDAC(Beutner, Ruck et al. 
1998). Additionally, VDAC oligomerization is coupled to apoptosis induction and the 
release of apoptogenic IMS proteins(Keinan, Tyomkin et al. 2010). Interestingly, the 
principal protein receptor of CKMT1 in the outer mitochondrial membrane is VDAC 
(CKMT1 also binds to anionic phospholipids) (Muller, Moser et al. 1985; Rojo, Hovius 
et al. 1991; Vial 2006). The interaction between VDAC1 and CKMT1 is direct and - 
comparable to the PT-pore - modulated by calcium(Schlattner, Dolder et al. 2001). 
Therefore we assessed whether the interaction of CKMT1 and VDAC1 might act as a 
gatekeeper for mitochondrial permeability transition. Our endogenous 
immunoprecipitations show that that CKMT1 and VDAC1 interact under physiological 
conditions. However, no changes in their interaction are observable during apoptosis 
induction, ruling out that the CKMT1/VDAC1 interaction regulates mitochondrial 
disintegration (Fig.D.19). Additionally, our studies show that VDAC1 downregulation 
as well as pharmacological inhibition does not affect mitochondrial depolarization 
induced by CKMT1 knock-down. Therefore VDAC1 is dispensable for CKMT1 
depletion-induced mitochondrial depolarization and subsequent apoptosis induction. 
This data is in agreement with research conducted by Baines et al., which claimed 
that VDAC is not required for mitochondrial-dependent cell death by studying VDAC-
null mice (deletion of the VDAC1 and VDAC3 genes, knock-down of VDAC2)(Baines, 
Kaiser et al. 2007). 
Supporting evidence that CKMT1-regulated permeability transition is independent of 
a VDAC1 containing PT-pore, comes from data presented on a novel mitochondrial 
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permeability transition inhibitor – IKBα. Mitochondrial IKBα strongly inhibits 
mitochondrial permeability transition specifically through its interaction with VDAC1 
(please refer to chapter D for details; unpublished data in collaboration with Dr. 
Evangelos Pazarentzos). However, it does not affect mitochondrial permeability 
transition induced by CKMT1 knock-down (Fig.D.10B). 
 
G.1.4.3 The PT-pore Interactome (via ANT1) 
Our data suggested that CKMT1 acts as a molecular gatekeeper for mitochondrial 
permeability transition: Depletion of endogenous CKMT1 would thus open the PT-
pore by changing the interaction of its molecular constituents. As discussed earlier, 
our immunoprecipitations identified ANT1 as a protein-interactor of CKMT1. This is 
surprising since previous literature had suggested that ANT1 and CKMT1 do not 
interact via protein-protein interactions(Beyer and Klingenberg 1985; Schlattner, 
Dolder et al. 2001; Vial 2006). Additionally, apoptosis induced by ANT1 
overexpression could be significantly abrogated by CKMT1 overexpression (Fig.D.4) 
and the ANT1 inhibitor bongkrekic acid abrogated mitochondrial permeability 
transition, apoptosis induction and cell death upon depletion of CKMT1 (Fig.D9). 
These experiments indicated that apoptosis regulation by CKMT1 might involve its 
interaction with ANT1. Furthermore, other authors provided evidence suggesting 
that ANT might be a central member of the PT-pore, especially as purified ANT 
induced pore formation in artificial membranes(Brustovetsky, Tropschug et al. 
2002) and ANT1 overexpression(Bauer, Schubert et al. 1999) as well as ANT3 
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overexpression (Zamora, Granell et al. 2004) dominantly induced apoptosis in 
cultured cells.  
As depletion of CKMT1 results in mitochondrial permeability transition (supposedly 
via the PT-pore), we used the pull down of endogenous ANT1 by 
immunoprecipitation to examine the composition of the potential PT-pore in the 
presence or absence of CKMT1. In the absence of CKMT1, no changes in the PT-
pore interactome could be noticed – ANT1, hexokinaseII, VDAC1 and cyclophilin D 
interactions were all stable and did not depend on the presence of CKMT1 
(Fig.D.20). This also demonstrates that ANT1 and VDAC1 interact irrespective of the 
presence or absence of CKMT1. According to a model proposed by Vyssokikh et al., 
the opening of the PT-pore is induced by the interaction of VDAC1 and ANT1, which 
is normally restrained by the presence of the CKMT1 as an octamer. Dissociation of 
CKMT1 from VDAC1/ANT1 would enable the interaction of VDAC1 and ANT1 to form 
an unspecific permeability transition pore(Vyssokikh and Brdiczka 2003). Our 
experiments demonstrate a stable interaction of ANT1 and VDAC1 in healthy and 
early apoptotic cells, which is irrespective of CKMT1 presence, and thus invalidate 
this model. 
This data indicates, that the interactome of the “proposed” PT-pore with ANT1 at its 
core, does not change upon CKMT1 depletion. Therefore, these proposed PT-pore 
members (ANT1, VDAC1, cyclophilin D, hexokinaseII) are not likely to be involved in 
apoptosis regulation by CKMT1, i.e. the induction of mitochondrial permeability 
transition in the absence of CKMT1. The involvement of a PT-pore with ANT isoforms 
at its core has also been addressed by knock-out studies: Cells deficient in ANT1 
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and ANT2 (a homolog of ANT1) are still able to induce permeability transition and 
show only minor alterations in cell death induction(Halestrap 2004; Kokoszka, 
Waymire et al. 2004). Although the experimental setup of these studies can be 
questioned as to whether the correct stimulus has been used to test for ANT 
requirement in the PT-pore activation or as to whether recently discovered 
additional ANT isoforms could compensate for ANT1/ANT2 deficiency (please refer to 
chapter A.4.7 for more details), these results suggest that ANT might not be 
involved in all scenarios of PT-pore mediated permeability transition. 
The antiapoptotic Bcl-2 family proteins, especially Bcl-2 and BclXl, have previously 
been shown to act as inhibitors of the PT-pore(Marzo, Brenner et al. 1998). 
Therefore we also addressed whether these proteins could inhibit permeability 
transition by depletion of CKMT1. Bcl-2 overexpression significantly inhibited ANT1-
induced mitochondrial depolarization, while it had no effect on CKMT1 knock-down 
induced depolarization. BclXL overexpression abrogated ANT1 induced loss of the 
mitochondrial membrane potential, while CKMT1 depletion induced mitochondrial 
depolarization was only inhibited marginally – albeit statistically significant 
(Fig.D.10B). Therefore we conclude that the anti-apoptotic Bcl-2 family members 
are not major regulators/inhibitors of CKMT1 downregulation-induced apoptosis. 
 
G.1.5 The Multimeric Assembly of Native CKMT1 Complexes 
The multimeric assembly of CKMT1 and the importance thereof for regulation of the 
PT-pore has been addressed by several studies: CKMT1 has been shown to form 
octameric structures(Schlegel, Zurbriggen et al. 1988) and octameric mitochondrial 
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creatine kinase induced and stabilized contact sites between the inner and outer 
membrane(Speer, Back et al. 2005). Of note, contact sites were proposed to be the 
location of the PT-pore proteins(Kroemer 1999; Armstrong 2006). Interestingly, PT-
pore activation in vitro (in reconstituted liposomes displaying PT-pore properties 
containing VDAC1, CKMT1 and ANT1) could only be achieved after dissociation of 
multimeric CKMT1 from the “PT-pore”(Beutner, Ruck et al. 1998). After dissociation 
of the CKMT1 octamer, the reconstituted “PT-pore” mediated the release of vesicle-
internal metabolites upon addition of Ca2+. This model gained further support, as 
mouse models demonstrated that impairment of heart function and mitochondrial 
energy metabolism in response to ischemia was associated with a significant 
decrease of CKMT1 octamer/dimer ratios(Soboll, Brdiczka et al. 1999), i.e. octamer 
dissociation. Our studies presented in this thesis established that CKMT1 depletion 
results in mitochondrial permeability transition, apoptosis induction and cell death. 
However – physiologically - neither total CKMT1 levels were changed to initiate 
apoptosis, nor was CKMT1 released from its mitochondrial locale, nor did its 
association with PT-pore candidate proteins change to signal for apoptosis induction. 
Combining these experiments with the data presented on CKMT1 octamer stability 
and functional implications thereof, we speculated that the oligomeric configuration 
of CKMT1 might be the key change to allow for mitochondrial permeability transition 
and instigate apoptosis induction. Using blue native gel electrophoresis we clearly 
demonstrate that native CKMT1 is present predominantly as an octamer in the cell, 
while dimeric CKMT1 is not detectable (Fig.D.17). A band in addition to the CKMT1 
octamer can be noticed in native cell lysates (CKMT1*complex), which runs at an 
apparent higher molecular weight (Fig.D.17). The nature of this band is undefined 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |326 
 
 
as of yet, but could be of crucial importance: The CKMT1*complex disappeared 
upon treatment with cytotoxic drugs in a dose dependent manner, and 
disappearance is correlated to mitochondrial depolarization (Fig.D.18). In contrast, 
the octamer of CKMT1 was stable under all conditions and the dissociation of the 
octamer was dispensable for mitochondrial permeability transition to proceed in our 
experimental setup. Potential caveats include that buffers used in our blue native 
gel electrophoresis could lead to re-association of CKMT1 octamers upon lysis of the 
cell or that the CKMT1 octamer might change its conformation. And this 
conformational change might enable mitochondrial permeability transition without 
changing its octameric assembly. 
Given the extensive data on the involvement of CKMT1 in apoptosis regulation via 
overexpression as well as downregulation presented in this study, the 
identity/composition of the apoptosis-sensitive CKMT1*complex is of great interest:  
One could speculate that the CKMT1*complex corresponds to CKMT1 molecules 
(including, but not restricted to octameric CKMT1) complexed with another protein – 
this protein-protein interaction could in theory be an additional guardian of 
mitochondrial permeability transition and contribute to the physiological PT-pore.  
Alternatively, CKMT1 octamers formed of unprocessed CKMT1 (39 aa mitochondrial 
import sequence not cleaved off) could also run at a comparable size. Another 
research group already detected unprocessed CKMT1 monomers using denaturing 
gel electrophoresis(Cui, Yu et al. 2011). However, it remains highly speculative 
whether unprocessed CKMT1 can actually interact to form dimers and subsequent 
octamers as the prolonged N-terminus might interfere with correct folding. 
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Additionally, import of such an octamer into mitochondria would hardly be possible, 
and it is questionable whether the CKMT1 precursor could be imported into 
mitochondria without cleavage of the import sequence. 
Another alternative giving explanation for the CKMT1*complex observed under blue 
native conditions would be the existence of yet unidentified multimeric isoforms of 
CKMT1, as our data provides evidence that the CKMT1 gene encodes alternatively 
spliced transcripts, at least on the mRNA level (Fig.E.14). These potential CKMT1 
isoforms could play a role in mitochondrial permeability transition. 
Post-translational modifications of CKMT1 or the CKMT1 octamers (e.g. 
phosphorylation), could also contribute to a changed electrophoretic migration 
behaviour accounting for the CKMT1*complex band. Although posttranslational 
modification of CKMT1 such as oxidation(Schuck, Rosa et al. 2004), tyrosine 
phosphorylation(Ballif, Carey et al. 2008), tyrosine nitrosylation(Sacksteder, Qian et 
al. 2006)) have been detected, the exact sites of modification and cellular effect 
thereof have not been addressed in more detail. Our studies also present data on 
another post-translational modification, namely ASB9 mediated polyubiquitination of 
CKMT1 octamer, which results in degradation of CKMT1 (most likely proteasomal 
degradation), mitochondrial depolarization and apoptosis induction (Fig.D.13). 
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G.1.6 Who’s to Blame? The Elusiveness of the PT-pore, yet Again…… 
The PT-pore occupies a central role in cell death induction and there is increasing 
evidence indicating a role of its specific subunits for apoptosis inhibition during 
tumorigenesis(Brenner and Grimm 2006). Thus, understanding the molecular 
composition and function of its components might prove crucial for developing novel 
therapeutic interventions for disease states that involve the dysregulation of 
apoptosis, not exclusively in cancers (apoptosis resistance) but also in other 
pathological conditions such as neurodegenerative and cardiac diseases (apoptosis 
sensitivity of neuronal and myocardial cells). 
Despite extensive efforts aimed at identifying the exact molecular constituents of 
the PT-pore, its actual composition is still elusive. In this study, we present evidence 
that CKMT1 is a central regulator of mitochondrial permeability transition and 
subsequent apoptosis induction. However, its functional involvement in regulating 
mitochondrial integrity seems to be independent of proteins and interactions with 
proteins previously implicated in PT-pore formation and regulation (please refer to 
chapter G.1.5). Efficient inhibition of mitochondrial permeability transition could 
only be achieved by bongkrekic acid (Fig.D.9), which is commonly accepted to act 
as a specific PT-pore inhibitor in numerous publications(Marchetti, Castedo et al. 
1996; Hirsch, Marzo et al. 1997; Schubert and Grimm 2004; Ortega Ferrusola, 
Gonzalez Fernandez et al. 2010; Yamada, Nakamura et al. 2013). The specificity of 
the inhibitory effects of bongkrekic acid on mitochondrial membrane channels has 
been re-addressed recently(Malekova, Kominkova et al. 2007). Indeed, in addition 
to acting as an inhibitory ligand of ANT by fixing its conformation in the “m-state” 
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and thus inhibiting PT-pore opening(Henderson and Lardy 1970; Chua and Shrago 
1977; Klingenberg 1989; Halestrap and Brenner 2003; Bernardi, Krauskopf et al. 
2006), Malekova et al. discovered that bongkrekic acid also inhibits unidentified 
anion/chloride channels present in the mitochondrial membranes of isolated 
mitochondria in a dose dependent manner(Malekova, Kominkova et al. 2007). 
Based on the conductance profiles of the isolated single channels, it could be 
excluded that these channels are made up of the previously well-described anion 
channel VDAC. Furthermore concentrations of around 50uM already completely 
inhibited mitochondrial chloride channels. This is a concentration that has been 
described to have a pronounced effect on a number of phenomena linked to 
apoptosis – such as inhibition the externalization of phosphatidylserine residues, 
chromatin condensation and oligonucleosomal DNA fragmentation, generation of 
reactive oxygen species and depletion of reduced glutathione(Marchetti, Castedo et 
al. 1996); it has also been shown to reduce the uncoupling of mitochondrial 
oxidative phosphorylation(Kopustinskiene, Toleikis et al. 2003), protect tumour cells 
against apoptosis(Wang, Perchellet et al. 2005), inhibit the PT-pore opening in 
response to pro-oxidants and protonophores(Zamzami, Susin et al. 1996), suppress 
calcium-dependent morphological changes in mitochondria(Akao, O'Rourke et al. 
2003) and to prevent cytochrome c release and loss of mitochondrial membrane 
potential(Adams, Pagel et al. 2000; Teshima, Akao et al. 2003; Armstrong, 
Whiteman et al. 2004). However, the concentration stated in experiments involved 
the addition of bongkrekic acid externally to the cells, and the actual concentration 
reached at mitochondria might have differed significantly (and Malekova et al. 
applied the stated concentration of bongkrekic acid directly to mitochondrial 
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membranes). Nevertheless, the inhibitory effect of bongkrekic acid on other 
mitochondrial channel proteins might help to explain some of the cellular effects 
observed in previous studies and in the experiments presented in this thesis. This is 
especially relevant since there is increasing evidence that ion channels located in 
the inner and outer mitochondrial membranes are key regulators of cellular 
signalling for life and death(Ryu, Peixoto et al. 2010): Mitochondrial ion channels 
regulate respiration, mitochondrial morphology, cell proliferation and cell 
death(Peixoto, Ryu et al. 2010). Chloride channels in particular have been described 
to be involved in numerous pathological as well as physiological cellular events. 
These include cancer cell proliferation/tumour growth and cancer cell 
migration/invasion(Kunzelmann 2005; Suh, Mutoh et al. 2005; Li and Xiong 2011), 
neurodegeneration(Jentsch, Poet et al. 2005), cardioprotection(Batthish, Diaz et al. 
2002; Chen, Liu et al. 2004; Wang, Takahashi et al. 2005). Studies describing the 
apoptosis regulation(Azoulay-Zohar, Israelson et al. 2004) and free radical release 
by VDAC(Han, Antunes et al. 2003) and apoptosis regulation by the organellular 
chloride channel protein CLIC4(Fernandez-Salas, Suh et al. 2002; Suh, Mutoh et al. 
2004; Suh, Mutoh et al. 2005) further point to the function of mitochondrial ion 
channels in cell death signalling. Although numerous mitochondrial ion channels 
have been identified early on using patch-clamp techniques or reconstitution into 
bilayer lipid membranes(Sorgato, Keller et al. 1987; Klitsch and Siemen 1991; 
Hayman, Spurway et al. 1993; Antonenko, Smith et al. 1994; Ballarin and Sorgato 
1995; Brustovetsky and Klingenberg 1996; Borecky, Jezek et al. 1997), data on 
their exact identities and function is still far from being complete. 
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The loss of mitochondrial membrane potential through CKMT1 depletion could only 
be prevented by bongkrekic acid (Fig.D.9), proving that the mechanism involved in 
apoptosis regulation by CKMT1 is sensitive to inhibition by bongkrekic acid. 
However, given the emerging data on the specificity of bongkrekic acid as presented 
above, this inhibition profile – albeit very specific – cannot reveal the identity of the 
proteins involved. However, this data points to the fact, that mitochondrial channel 
proteins other than VDAC1 and ANT1 could be at the core of CKMT1 mediated 
apoptosis regulation. It would be tempting to postulate that, given that CKMT1 
universally acts as a gatekeeper of mitochondrial membrane permeability transition 
(as assessed by the loss of the mitochondrial membrane potential upon 
downregulation) in our experiments (Figures D.6, D.7, D.8, D.10, D.11, D.12, D.15, 
D.19, D.21, D.22 and D.23), CKMT1 is the common key constituent of a 
mitochondrial pore complex which is formed by as yet unidentified mitochondrial 
channel proteins. However, although our experiments provide evidence that CKMT1 
depletion obligatorily results in mitochondrial permeability transition, apoptosis 
regulation by CKMT1 overexpression is restricted to very specific apoptotic stimuli 
(Fig.D.4 and Fig.D.5). Actually, apoptosis inhibition by upregulation of CKMT1 and 
mitochondrial permeability transition induced by downregulation, could potentially 
act through independent mechanisms. Given the lack of agreement within the 
scientific community on the actual composition of the PT-pore, and the increasing 
evidence that some mitochondrial proteins regulate mitochondrial permeability 
transition only under certain stimuli (refer to chaper A.4.2), the following non-
simplistic model might be a more accurate representation of the physiologic PT-
pore: A variety of permeability transition complexes might exist or even coexist in 
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cells and their prolonged opening results in the commonly described phenomenon of 
permeability transition and apoptosis induction. But their composition and activation 
could depend on the actual stimuli and cell type used to examine their functions. 
PT-pore forming complexes could thus be flexible in their molecular make-up, 
transient in nature and disassemble/reassemble with relatively high frequency in 
response to cellular requirements. This model does not debase the importance of 
PT-pore opening as a key regulator of cell death signalling, it rather calls for a more 
detailed description of “individual” PT-pore complexes identified, in order to discern 
when/how they form, which physiological/pathological stimulus they react to and 
regulate, and which intricate molecular mechanisms govern their opening to induce 
mitochondrial permeability transition and instigate the apoptotic cell death pathway. 
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G.2 Breaking the Silence –Insights Into the Scientific Challenges of 
Interpreting RNAi CKMT1 Phenotype Rescue Experiments and CKMT1 
Gene Product Analysis 
The break-through discovery of RNA interference (RNAi)(Fire, Xu et al. 1998) has 
revolutionized the field of molecular biology, genetic research and the development 
of medical therapies. In simplified terms, RNAi - the silencing of gene expression by 
double-stranded RNA molecules- offers a key experimental tool to elucidate the 
function of a gene by selective ablation of its expression(Novina and Sharp 2004). 
Genetic “loss-of-function-studies” have long been achieved through gene 
disruptions, i.e. the establishment of knock-out organisms/cells. However, 
traditional knock-out strategies are laborious, cost-intensive and not trivial in higher 
model organisms. Additionally, there is growing evidence that the role of 
developmental changes, compensatory changes, plasticity and environmental 
factors have been underestimated in the interpretation of phenotypic changes 
observed in knock-out organisms(Gingrich and Hen 2000). Therefore, RNAi has 
quickly become the method of choice for loss-of-function-studies.  
Our experiments were not aimed at further deciphering the RNAi phenomenon, but 
rather designed to use RNAi as a tool to explain the mechanisms involved in 
apoptosis regulation by CKMT1. Therefore, the molecular composition of the RNAi 
mediating complexes and their proposed physiological roles is not discussed in this 
thesis – for the detailed information on RNAi complexes and involved proteins refer 
to (Novina and Sharp 2004). However, it is essential to understand the principle 
mechanisms of action of RNAi in order to appreciate possible caveats of RNAi 
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experiments. Thus a brief introduction to the effects of RNAi will be given in the 
following paragraphs. 
Up to date, at least 3 clearly distinct mechanisms of the RNAi machinery have been 
described(Novina and Sharp 2004). The most-studied one is the silencing of 
cognate genes through double-stranded short RNAs(Sharp 1999; Bernstein, Caudy 
et al. 2001) at the post-transcriptional level. In this case, those double-stranded 
RNAs – typically 21/22 nucleotides in length – serve to instruct a multicomponent 
nuclease, the so-called RISC (RNA-induced silencing complex), to destroy exactly 
complementary mRNAs(Hammond, Bernstein et al. 2000; Bernstein, Caudy et al. 
2001). Although RNAi constructs are designed to be fully complementary to a single 
mRNA species, they may inadvertently show complementary stretches to other non-
target mRNAs – and data on specificity vary, ranging from reports that as little as 
11bp of perfect homology can result in significant mRNA downregulation(Jackson, 
Bartz et al. 2003) to observations that as little as 1-2 mismatches within the 21-23 
nucleotides disrupts degradation of the target mRNA(Elbashir, Harborth et al. 2001; 
Elbashir, Martinez et al. 2001; Dillin 2003). This can give rise to so-called off-target 
effects. Another source of these off-target effects is the activation of non-specific 
cellular innate immune responses induced by the presence of double stranded RNAs, 
e.g. the interferon response and induction of inflammatory cytokines, which can 
lead to global inhibition of protein synthesis(Bridge, Pebernard et al. 2003; Sledz, 
Holko et al. 2003; Hornung, Guenthner-Biller et al. 2005; Judge, Sood et al. 2005; 
Sioud 2005). 
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Recent studies report that siRNAs can be potent inducers of interferons (IFNs) and 
inflammatory cytokines both in vivo and in vitro raising questions about the 
specificity of RNAi. Much of the IFN response is caused by the activation of the 
dsRNA-dependent protein kinase R (PKR) leading to a global inhibition of protein 
synthesis. Additionally, transfected or expressed RNAi constructs might saturate the 
cell’s RNAi machinery thus preventing the processing of endogenous RNAi molecules 
(miRNA) which regulate cell physiology(Dillin 2003). There is also some evidence, 
that the crosstalk of the RNAi machinery and RNA editing pathways might have an 
effect on RNAi-mediated gene silencing as they compete for common substrate 
RNA(Nishikura 2006). 
However, and this is often overlooked when performing RNAi experiments, the RNAi 
machinery is not only associated with target mRNA cleavage, but also with the 
impairment of target mRNA translation(Novina and Sharp 2004) as well as – on the 
DNA level - the formation of heterochromatin in specific genetic loci (thus 
contributing to epigenetic gene silencing)(Wassenegger 2005). The RNAi machinery 
can direct epigenetic alterations to homologous DNA sequences to induce 
transcriptional gene silencing or, in extreme cases, DNA elimination(Matzke and 
Birchler 2005). The first mechanism, so-called translational silencing, is achieved by 
the assembly of RNA into a ribonucleoprotein complex, which binds to target mRNAs 
by partially complementary sequences (comparable to the mechanism of action of 
endogenous miRNA) and results in effective translational inhibition(Doench, 
Petersen et al. 2003). The action of RNAi on the DNA level can be explained through 
the formation of the RNA-induced initiation of transcriptional gene silencing (RITS) 
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complex. This complex mediates the formation of heterochromatin in genomic areas 
containing homologous DNA sequences through histone modification; thus resulting 
in epigenetic transcriptional gene silencing (Matzke and Birchler 2005). Additionally, 
RNAi-mediated programmed excision of DNA has also been observed(Mochizuki and 
Gorovsky 2004). 
Despite - or actually encouraged by - the apparent ease of RNAi techniques, the 
scientific community is facing an acute problem, since numerous publications 
display RNAi data without sufficient controls (Nature Cell Biology editorial 5, 489 - 
490(2003)). To a great extent, the data presented in this thesis relies on RNAi 
experiments, which reveal a certain phenotype after loss of the targeted gene. In 
essence, efficient RNAi against endogenous CKMT1 resulted in mitochondrial 
depolarization and apoptotic cell death (Fig.D.6, Fig.D.7 and Fig.D.8). Our study 
provides a plethora of controls that extensively validate the observed CKMT1 RNAi 
phenotype; however our data also gives a comprehensive insight into how these 
control experiments can drive a more detailed examination of gene products and 
their function, and gives an account of the intricate challenges of RNAi validation 
techniques, in particular the proclaimed gold standard of RNAi phenotype rescue 
experiments. 
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G.2.1 RNAi Against CKMT1 – Proving RNAi Specificity Considering RNAi-
Induced Transcriptional Silencing, RNAi-induced Post-transcriptional Gene 
Silencing, RNAi-induced Translational Gene Silencing and Other Off-Target 
Effects 
One of the best ways to increase confidence in data relating to an RNAi phenotype is 
the use of several independent RNAi sequences targeting the same gene - as 
effective RNAi constructs should result in comparable gene silencing and thus 
similar phenotypes. In our study, we used 7 distinct RNAi constructs in human cells 
and 6 distinct RNAi constructs in murine cells (11 distinct constructs in total) to 
efficiently downregulate the CKMT1 protein expression (Fig.E.11). One of these 
constructs was confirmed to result in complete degradation of CKMT1 mRNA levels 
from 48 hours post-transfection onwards (Fig.D.6), while the depletion of CKMT1 
protein levels lagged behind indicating a slow turnover of the CKMT1 protein 
(Fig.D.6). It can be statistically excluded that 11 distinct RNAi constructs share a 
common off-target effect/phenotype (mitochondrial depolarization) that is mediated 
by post-transcriptional gene silencing or translational gene silencing. As described 
above, post-transcriptional gene silencing refers to the degradation of mRNA species 
through RNAi, whereas translational gene silencing refers to the inhibition of mRNA 
translation by the presence of complementary (or partly complementary) RNA 
molecules(Novina and Sharp 2004). While the use of siRNA/shRNA, as used in our 
experiments, normally favours post-transcriptional gene silencing, more recent data 
established that siRNAs can also mediate translational silencing (comparable to 
micro RNAs)(Doench, Petersen et al. 2003). Again, considering the use of 11 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |338 
 
 
independent RNAi constructs resulting in mitochondrial depolarization, it is 
statistically highly unlikely that this is a common off-target effect of these RNAi 
constructs. 
Other off-target effects described for RNAi experiments include the unintentional 
activation of global translational repression through the interferon response (Nature 
Cell Biology editorial 5, 489-490(2003)) as well as the transcriptional gene silencing 
via RNAi effects at the chromatin level(Wassenegger 2005). It can be excluded that 
the CKMT1 RNAi phenotype is due to these mechanisms, as 8 constructs that are 
complementary to the CKMT1 mRNA target sequence but failed to mediate gene 
silencing (Fig.E.11) did not induce mitochondrial depolarization. Additionally usage 
of an RNAi construct encoding a scrambled control sequence did likewise not induce 
any phenotype adding to the evidence that the effects observed in our study are not 
due to the RNAi delivery method per se. Therefore, an unintentional activation of 
global translation repression can be ruled out. The RNAi constructs targeting CKMT1 
could potentially have a common effect via heterochromatin formation and induce 
transcriptional silencing of the affected area – thereby not only affecting CKMT1 
expression, but also the expression of genes located in close proximity of the 
CKMT1 loci. However, this can also be ruled out since 8 constructs that target the 
same genomic area are not sharing the CKMT1 RNAi phenotype. Additionally, the 
construct shCK1 TRC703, which downregulates CKMT1 and induced mitochondrial 
depolarization, does not target any genomic area associated with the CKMT1 gene 
as its sequence spans the exon2/exon3 junction (therefore only present on the 
processed mRNA level).  
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G.2.2 The “Gold Standard” of RNAi Data – Phenotype Rescue Experiments? 
Recently, it has been suggested that the “ultimate” control for RNAi data is the 
rescue of the RNAi effect by the expression of an siRNA-resistant version of the 
targeted gene(Nature Cell Biology editorial 5, 489-490(2003))(Lassus, Rodriguez et 
al. 2002; Cullen 2006; Chang, Marran et al. 2012). In our study, we wanted to use 
this kind of rescue experiment for two reasons – firstly, providing the ultimate 
control for the observed RNAi effect; and secondly – and maybe more importantly – 
gaining insight into which functional domains/residues of CKMT1 are vital for the 
cell. RNAi phenotype rescue experiments can be achieved by utilizing synonymous 
mutations in the third base pair of a codon (previously but misleadingly called 
“silent” mutations, refer to chapter G.2.2.2 for more details) within the targeted 
coding region; or, alternatively, by targeting the UTRs of the target mRNA while 
rescuing with a construct that lacks UTRs. These strategies have been used 
successfully in the past as demonstrated, e.g. by the establishment of a cross-
species RNAi rescue platform in drosophila(Kondo, Booker et al. 2009; Langer, 
Ejsmont et al. 2010), the RNA interference rescue by bacterial artificial chromosome 
transgenesis in mammalian tissue culture cells(Kittler, Pelletier et al. 2005) or the 
rescue of the siRNA phenotype by introduction of synonymous mutations in the 
coding sequence of a mammalian expression plasmid(Matuliene and Kuriyama 
2004). 
Our first round of attempted rescue experiments presented in this thesis used the 
transient as well as stable expression of the murine CKMT1 homologue, which 
cannot be downregulated by the RNAi constructs used to deplete the endogenous 
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human CKMT1 (Fig.E.1, Fig.E.2 and Fig.E.5). However, no RNAi rescue could be 
achieved by the murine homologue (Fig.E.7), despite the murine CKMT1 protein 
showing greater than 98% identity on the amino acid sequence level and 
approximately 92% base pair identity in the coding sequence. This was surprising, 
since the same murine construct showed a significant anti-apoptotic effect in 
previous experiments (Fig.D.4 and Fig.D.5). This could, in theory, point to the fact, 
that apoptosis regulation by CKMT1 through overexpression and downregulation are 
mediated via different mechanisms – while the murine construct can inhibit 
apoptosis, it is not functional when it comes to maintaining cell viability upon 
depletion of endogenous CKMT1. Additionally, the murine construct contained a C-
terminal HA-tag, which might have interfered with the physiological function of 
CKMT1, however this HA-tag did not impede apoptosis inhibition through 
overexpression (Fig.D.4 and Fig.D.5). 
The second and third approaches to RNAi CKMT1 phenotype rescue experiments 
used stable clones expressing a mutated human CKMT1, which was altered to 
contain several synonymous mutations in the RNAi target sequence, thus rendering 
it resistant to RNAi-mediated degradation (Fig.E.8, Fig.E.9 and Fig.E.10). The major 
difference between these two rescue attempts was the presence or absence of the 
C-terminal HA-tag, as this tag might affect the function of CKMT1. However, none of 
these codon-usage-modified CKMT1 constructs rescued the phenotype of 
endogenous CKMT1 RNAi. The attempt to interpret these results is non-trivial, and 
follows three main lines of argumentation, which will be discussed in the following 
three chapters.  
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G.2.2.1 “What is Taken out” by RNAi is not Identical to “What is put in” by 
Ectopic Expression – Alternative Gene Products of CKMT1A/B? 
We examined the expression of CKMT1 on the mRNA in more detail as the CKMT1 
gene is contained in a duplicated genomic area creating 2 copies, CKMT1A and 
CKMT1B, potentially giving rise to two full length mRNAs that can be distinguished 
by the presence of 2 synonymous mutations. Indeed, both CKMT1 gene copies are 
functional, as mRNA species containing these 2 mismatches can be amplified using 
primers spanning the published coding sequence. And the sequenced CKMT1A 
mRNA (as amplified by cDNA PCR) is 100% identical to the coding sequence of the 
CKMT1 plasmid used during the failed rescue experiments described above (except 
for the codon usage mutations). This could potentially point to the existence of 
other CKMT1 gene products that are vital for cell survival. Using our data on RNAi 
constructs that result in the phenotype of mitochondrial depolarization and the 
genomic alignment of publicly available mRNA sequences available at the AceView 
database, we identified one transcript that aligns to both CKMT1 genes and displays 
all functionally validated RNAi sites (Fig.E.13), but is different to the published full 
length CKMT1 coding sequence as used in the rescue experiments. Importantly, we 
could validate the existence of this particular transcript on the mRNA level in HeLa 
and 293T cells (Fig.E.14) 
 
This mRNA transcript encodes a 448aa (compared to 417aa for the published 
CKMT1) CKMT1 isoform (CKMT1(iso)) and is likely to be expressed in the 
mammalian kingdom as the extended sequence aligns to genomes across the 
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mammalian kingdom. We also suggest, that the “unnamed protein product [Homo 
sapiens], accession BAH14495” is the gene product of the CKMT1 loci as it is 100% 
identical to the translated alternative CKMT1 transcript observed in our study. 
Further supporting evidence for the existence of CKMT1(iso) comes from Western 
blots using a polyclonal CKMT1 antibody, as the CKMT1 antibody yielded at least 2 
distinct bands (Fig.E.16). However, this observation could also be due to the 
detection of the recently described unprocessed CKMT1 precursor (mitochondrial 
localization signal + mature CKMT1)(Cui, Yu et al. 2011), or post-translational 
modifications of the mature CKMT1. The physiological function and expression of the 
potential CKMT1 isoform described in this study is unknown and should be 
addressed in further experiments, especially since this isoform – upon ectopic 
overexpression - cannot contribute to the mitochondrial CKMT1 octamer (Fig.E.16), 
pointing to the notion that it could have a distinct cellular function. Interestingly, 
expression of the CKMT1(iso) construct resulted in 3 distinct bands of almost equal 
intensity when analysing by SDS-page and Western blotting with a CKMT1 antibody. 
These bands are all upshifted compared to the endogenous CKMT1 band at 42 kDa 
(Fig.E.16). In theory, one band could correspond to the uncleaved precursor 
(mitochondrial import signal still attached) and a second one to the mature protein. 
However, the existence of a third band cannot be explained by this procession, and 
could reflect a post-translational modification of CKMT1(iso).  
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Unfortunately, neither the RNAi-resistant CKMT1(iso) construct, nor a combination 
of RNAi-resistant CKMT1 and CKMT1(iso) could rescue the effect of depletion of 
endogenous CKMT1 (Fig.E.17). Of note, these RNAi rescue experiments were only 
conducted using transient overexpression of the RNAi-resistant constructs. Thus, 
the failed rescue could also be due to strong fluctuations in protein levels that 
negatively affect the pathway of interest. The problem of protein expression levels 
in the RNAi rescue experiment setting will be addressed separately in chapter 
G.2.2.3. Additionally, we cannot formally exclude that the CKMT1 loci encode for yet 
fully undescribed gene products that are affected by all the RNAi constructs used 
but vital for cell survival. As an example, these gene products could include other 
alternatively spliced mRNA transcripts or microRNAs encoded in the CKMT1 intron 
sequences (although the RNAi constructs target the exons, sequences encoded by 
introns would be affected by transcriptional gene silencing or by the potential 
degradation of pre-mRNA containing these sequencing prior to splicing(Bosher, 
Dufourcq et al. 1999)). 
In an attempt to perform an RNAi rescue experiment that would take into account 
the issues of alternative gene products as well as the existence of genomic 
rearrangements in the cell line used, we amplified the CKMT1 genomic locus from 
HeLa cells, subcloned it into a mammalian expression vector, and used it to 
successfully overexpress CKMT1 at the protein level (Fig.E.15). The whole 6.3kB 
genomic locus was sequenced (see I. Appendix) and two constructs that contained 
codon usage mutations mediating RNAi resistance introduced by a company 
(GenScript). These constructs did not result in phenotype rescue when endogenous 
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CKMT1 was depleted by RNAi (Fig.E.18 and Fig.E.19), although CKMT1 expression 
as detected by CKMT1 immunofluorescent staining was expressed. 
The amplified genomic locus of CKMT1 extends over 6.3kB, making it prone to 
errors during PCR amplification and thus introduced mutations. However, this is 
unlikely, as the Phusion high fidelity polymerase (fidelity of 4.4x10-7 in the buffer 
used) only yields approximately 6.9% erroneous products (calculated using the 
Thermo Scientific online tool available at 
http://www.thermoscientificbio.com/webtools/fidelity/). This number is even 
diminished taking into account that not all point mutations within the 6.3kB CKMT1 
genomic locus would have a biological effect. Full length sequencing revealed that 
the genomic locus amplified corresponds most likely to the human published 
CKMT1A locus with 6288 out of 6322 base pairs identical to “Homo sapiens 
chromosome 15 genomic scaffold, alternate assembly CHM1_1.0 Sequence ID: ref 
NW_004078084.1”.  
Of note, these genomic RNAi rescue experiments were only conducted using 
transient overexpression of the RNAi-resistant genomic constructs. As described 
before, the failed rescue could also be due to strong fluctuations in protein levels 
that negatively affect the pathway of interest (refer to chapter G.2.2.3). 
Additionally, genomic RNAi rescue experiments were only conducted using the 
CKMT1A genomic locus. Despite the expression of the full length CKMT1 mRNA from 
both genomic loci CKMT1A and CKMT1B respectively, it is also conceivable that only 
one genomic locus encodes the CKMT1 gene product that is vital for cell viability (all 
RNAi constructs used in this study target CKMT1A and CKMT1B). All previous CKMT1 
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RNAi rescue experiments used the coding sequence of CKMT1 corresponding to the 
CKMT1A locus (as identified by 2 synonymous mutations in the coding sequence). 
 
Additionally, the genomic CKMT1A and CKMT1B loci are complex, since – according 
to the AceView database, initially described in 2006 (Thierry-Mieg and Thierry-Mieg 
2006) but updated in 2010 – both CKMT1 loci contain a stretch >260bp, that is 
antisense to spliced gene CATSPER2, pointing to the possibility of regulated 
alternate expression. This also raises the possibility of transcriptional gene silencing 
effects in this genomic area, since long dsRNAs of similar sequence to genomic DNA 
might be produced by symmetrical transcription from opposing promoters, which 
often occurs when many gene copies or other repeated sequences are 
present(Novina and Sharp 2004). 
Another major pitfall of RNAi rescue experiments involving codon usage modified 
constructs is the modification of the codon usage in the gene itself, which will be 
discussed in the following chapter. 
 
 
G.2.2.2 Synonymous but not the Same - Are the “Silent” Mutations 
Conferring RNAi Resistance “Silent” After all? 
RNAi rescue experiments are considered the “gold standard” for confirming the 
specific effect of gene silencing. If the RNAi construct used targets the open reading 
frame of the mRNA, this approach involves the mutation of the mRNA, without 
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changing the encoded protein, by taking advantage of the redundancy of the 
genetic code(Cullen 2006). Due to the dogma that the physiological structure and 
function of proteins is determined by the amino acid sequence(Anfinsen 1973), 
synonymous mutations have, until very recently, been referred to as “silent”(Sauna 
and Kimchi-Sarfaty 2011). Synonymous mutations would be “neutral” during 
evolution as they would have no effect on the fitness of an organism(Kimura 1977). 
However, recent discoveries have led to a paradigm shift establishing that 
synonymous mutations could have functional consequences(Plotkin and Kudla 
2011). These functional consequences can arise from different mechanisms: 
Synonymous point mutations, especially at exon/intron junctions, can lead to 
aberrant mRNA splicing which can be associated to disease formation(Cartegni, 
Chew et al. 2002). Synonymous mutations can also affect mRNA stability as well as 
accessibility to regulation by endogenous miRNAs(Brest, Lapaquette et al. 2011) 
and thus protein expression levels(Nackley, Shabalina et al. 2006). Additionally, the 
mRNA structure/folding might change upon the introduction of synonymous 
mutations impacting on the ribosomal access to start protein translation as well as 
the speed of translation(Sauna and Kimchi-Sarfaty 2011). The speed of translation 
not only affects protein levels, but can also impact on the conformation of the 
protein via a mechanism called co-translational folding(Tsai, Sauna et al. 2008). 
According to this concept, the primary amino acid sequence does not provide all the 
information for the correct three-dimensional structure of a protein(Sosnick 2008). 
Different protein domains stabilize each other during the process of translation and 
exhibit cooperativity during tertiary folding. This co-translational folding seems to be 
governed by the choice and position of codons, as rare codons in strategic locations 
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limit the speed of translation and allow for more complex protein folding(Sauna and 
Kimchi-Sarfaty 2011). Thus synonymous mutation disrupt the synchronised process 
of protein folding, leading to misfolding, aggregation or lower levels of protein 
synthesis(Sauna, Kimchi-Sarfaty et al. 2007). 
The introduction of synonymous codon usage mutations in the CKMT1 open reading 
frame could therefore inadvertently have affected the structure/function of the 
CKMT1 protein(s), as the modified base triplets display distinct relative codon usage 
frequencies in human proteins (Fig.E.18). However, we also show that codon usage 
modified ectopically expressed CKMT1 can still form octamers, which is the only 
tertiary structure described for CKMT1 (Fig.E.16). Nevertheless, this is not a full 
proof of correct conformational folding. Additionally, two distinct RNAi sites have 
been used to modify codon usage and render transcripts RNAi resistant. Using 2 
distinct sites for those codon usage mutations decreases the risk of misfolding due 
to altered codon usage bias. Despite this precaution, both RNAi resistant genomic 
CKMT1 constructs failed to rescue the phenotype of RNAi against endogenous 
CKMT1 (Fig.E.18). 
Considering the new paradigm that the codon usage on the mRNA level can 
determine protein function, it is also conceivable that the two synonymous 
mutations distinguishing CKMT1A and CKMT1B, are mediating distinct protein 
functions. This adds unexpected complexity of RNAi rescue experiments using 
synonymous mutations conferring RNAi resistance. 
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G.2.2.3 Does the Altered CKMT1 Protein Level Account for the Lack of RNAi 
Rescue? 
All RNAi rescue experiments presented in this thesis used transient overexpression 
of RNAi-resistant CKMT1 constructs or stable clones expressing these. FACS analysis 
and Western blotting revealed, that these CKMT1 constructs are expressed at higher 
levels than the endogenous CKMT1 (Fig.E.2, Fig.E.3, Fig.E.10, Fig.E.15, Fig.E.17, 
Fig.E.18 and Fig.E.19). As discovered recently, phenotypic rescue experiments can 
fail when the rescuing protein is expressed at such a high level that it dominantly 
inhibits the pathway of interest(Morita, Arii et al. 2012). However, one could argue, 
that this cannot be the case with CKMT1 overexpression since transient CKMT1 
overexpression mediates apoptosis inhibition and protects against mitochondrial 
depolarization (Fig.D.4 and Fig.D.5). Furthermore, the viability of stable clones 
expressing the CKMT1 constructs was not negatively affected in any way by the 
long-term presence of elevated CKMT1 levels (data not shown) and the cellular 
system should have adapted the high CKMT1 level over time. One other group 
actually demonstrated that cell clones stably overexpressing CKMT1 show 
accelerated tumour growth in nude mice(Qian, Li et al. 2012). Therefore we argue 
that – albeit RNAi-resistant CKMT1 constructs are expressed at a higher level than 
endogenous CKMT1 in all our rescue experiments - elevated CKMT1 levels should 
not lead to the failure of RNAi rescue experiments. 
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G.2.3 Do Total CKMT1 Levels Act a Sensor That Induces Apoptosis Upon a 
Relative Drop of CKMT1 Levels? 
Another explanation for the failed RNAi rescue could be the hypothesis that CKMT1 
protein levels serve as a finely tuned and decisive sensor for detecting cellular 
stress and inducting apoptosis. Accordingly, a relative decrease in total CKMT1 
protein could constitute the trigger for apoptosis induction, without the need for 
total CKMT1 downregulation. Although this is an interesting hypothesis, several 
observations can be controversially discussed in this context: As mentioned earlier, 
all stable clones express the CKMT1 protein at a much higher level than the 
endogenous protein(Fig.E.2, Fig.E.3, Fig.E.10, Fig.E.15, Fig.E.17, Fig.E.18 and 
Fig.E.19). Therefore the RNAi mediated complete degradation of endogenous CKMT1 
only corresponds to a marginal overall CKMT1 protein decrease; and its kinetics are 
governed by the natural and gradual CKMT1 protein turnover, which is relatively 
slow (Fig.D.6). This decrease could not even be detected by Western blot analysis 
as stable clones expressing CKMT1 constructs do not show a significantly altered 
total CKMT1 level upon RNAi mediated depletion of endogenous CKMT1 (Fig.E.9, 
Fig.E.10 and Fig.E18). 
Unless the total level of CKMT1 is a very sensitive and finely tuned sensor, the 
marginal drop of total CKMT1 levels would not induce mitochondrial depolarization. 
The hypothesis that a relative drop in CKMT1 levels triggers apoptosis induction per 
se certainly does not hold true considering the transient overexpression of CKMT1. 
As can be seen in Fig.E.18, overexpression induced by transfection of the genomic 
CKMT1 construct leads to a massive increase of CKMT1 levels, which then decay 
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over the next 5 days. The relative drop in total CKMT1 levels in this experiment is 
dramatic compared to the marginal drop of CKMT1 levels upon RNAi against 
endogenous CKMT1 observed in the cells stably expressing RNAi resistant 
CKMT1(Fig.E.9, Fig.E.10 and Fig.E18). Despite the drop of total CKMT1 levels, cells 
do not induce mitochondrial depolarization. Of course, one could argue, that the 
total CKMT1 level serves as a sensor to induce apoptosis only when the level has 
been established in a homeostatic fashion over a long term, i.e. cells stably 
expressing high levels of CKMT1 establish this CKMT1 level as the point of 
reference, and the slightest relative downregulation would therefore signal for 
apoptosis induction; whereas cells transiently overexpressing CKMT1 still use their 
“normal” endogenous CKMT1 level as the point of reference, and thus the drop of 
total CKMT1 levels subsequent to the initial peak in expression does not signal for 
mitochondrial depolarization. 
If total CKMT1 levels truly serve as a finely tuned sensor, previous CKMT1 RNAi 
experiments could also be interpreted in this way (Fig.D.6). Subsequent to RNAi 
transfection targeting endogenous CKMT1, one can assume that most cells show an 
initially small relative downregulation of CKMT1 levels. This initial downregulation 
(without being complete) could already be sufficient to activate the sensor and 
signal for apoptosis induction. In this case, the subsequent complete degradation of 
CKMT1 protein would not be the cause, but rather an effect of sustained RNAi as 
well as degradation of CKMT1 during late apoptosis (Fig.D.15). However, it remains 
disputable, why the actual apoptosis execution would lag behind significantly – 
relative CKMT1 downregulation on the protein level could already be observed quite 
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early, at least 48 hours post transfection, while substantial apoptosis execution was 
only observed later, at 72 hours post transfection (Fig.D.6). 
Further experiments are required to address the questions whether it could indeed 
be the CKMT1 protein level that serves as a sensor and initiates the mitochondrial 
apoptosis pathway. 
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G.3 Apoptosis Regulation by Mitochondrial IκBα 
The experiments on the role of mitochondrial IκBα in mitochondrial permeability 
transition presented in this thesis formed part of a larger study on the role and 
mechanism of apoptosis regulation by IκBα at mitochondria. Please refer to the PhD 
thesis of Dr. Evangelos Pazarentzos (publicly available at the Imperial College 
library; submitted for publication to a peer reviewed journal) for further 
experimental findings and an exhaustive discussion thereof. Therefore, only the 
experiments performed as a contribution to this thesis will be discussed in greater 
detail here. Data that has been provided by Dr. Evangelos Pazarentzos or generated 
in collaboration is clearly marked throughout the results section. 
The role of IκBα, which is a key player in the NF-кB signalling pathway, was studied 
in the second part of the project. NF-кB is a transcription factor that can induce the 
transcription of target genes impacting on diverse cellular processes including cell 
cycle progression, cell adhesion, metastasis, and apoptosis, thus enabling not only 
malignant transformation and tumour progression, but also resistance to cancer 
therapy(Ravi and Bedi 2004). NF-кB has been shown to be constitutively active in 
numerous human cancers including breast cancer(Karin, Cao et al. 2002) – 
especially estrogen-receptor-negative breast cancer(Nakshatri, Bhat-Nakshatri et al. 
1997; Sovak, Bellas et al. 1997), colorectal cancer(Sakamoto, Maeda et al. 2009), 
prostate cancer(Suh, Payvandi et al. 2002), leukemia, lymphoma and ovarian 
cancer(Rayet and Gelinas 1999). Furthermore, its constitutive activation has been 
linked to treatment resistance of some of these tumours(Weldon, Burow et al. 
2001). NF-кB transcriptionally up-regulates genes that counteract apoptosis and 
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hence is required for the sustained proliferation(Pikarsky, Porat et al. 2004). IкBα is 
one of the best-known target genes of NF-кB located in the cytoplasm(Le Bail, 
Schmidt-Ullrich et al. 1993). However, recent studies have revealed another locale 
of IкBα: Its elution profile(Cogswell, Kashatus et al. 2003) and immunogold 
staining(Bottero, Rossi et al. 2001) indicated that IкBα localises to the 
intermembrane space of mitochondria and interacts with ANT1. This study aimed to 
identify the role of mitochondrial IкBα by constructing and overexpressing a 
mitochondrially targeted IкBα in order to determine whether mitochondrial IκBα 
could be responsible for the apoptosis resistant phenotype seen in tumours with 
constitutively active NF-кB. 
 
G.3.1 Targeting IкBα Specifically to Mitochondrial Subcompartments 
Preliminary data generated within our research group (unpublished data, Dr. Foy 
Osborne) had suggested that an N-terminal fusion of IкBα with the Mcr1 signalling 
peptide could be used to target IкBα specifically to mitochondria in order to 
investigate the role of mitochondrial IкBα. However, high-resolution confocal 
imaging (Fig.F.1 and Fig.F.2) showed that Mcr1-IкBα localized mainly to the ER. 
Although the detection limit of immunofluorescence microscopy might not be low 
enough to detect residual expression of IкBα in mitochondria, this construct could 
not be used as an ideal tool to study mitochondrial IкBα. Endogenous IкBα has not 
been described to be found in the ER so far – according to data obtained using 
immunogold electron microscopy(Cogswell, Kashatus et al. 2003). Although, 
formally, it cannot be excluded that IкBα could be found at the ER under certain 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |354 
 
 
conditions or in specific cell types. As it seemed unlikely that targeting IкBα to the 
ER has a physiological relevance, we did not proceed to further investigate the 
effects of reticular IкBα. Subsequent studies used an N-terminal fusion of IκBα with 
the mitochondrial localisation sequence of Smac/Diablo (SD-IκBα), and an N-
terminal fusion with the first 32 amino acids of MitoNEET (MEET-IκBα); for 
information on the MEET sequences please refer to (Wiley, Murphy et al. 2007). 
These constructs targeted IкBα efficiently to mitochondria (Fig.F.3) and 
submitochondrial compartments, the mitochondrial outer membrane and the 
mitochondrial inner membrane space (submitochondrial localization validated by Dr. 
Evangelos Pazarentzos). 
 
G.3.2 IкBα Acts as an Apoptosis Inhibitor at the Outer Mitochondrial 
Membrane 
As mitochondria occupy a prime role in the cellular regulation of apoptosis (chapter 
A.2.2), we examined whether overexpressed IкBα specifically targeted to 
mitochondrial subcompartments could contribute to apoptosis regulation. Previous 
studies conducted within our research group described ANT1 as an apoptosis 
inducer acting via the PT-pore(Bauer, Schubert et al. 1999). As recent data provides 
evidence of the interaction of ANT1 and IкBα(Bottero, Rossi et al. 2001; Cogswell, 
Kashatus et al. 2003), we applied the overexpression of ANT1 as an apoptotic 
stimulus. Surprisingly, wild-type IкBα and MEET-IκBα efficiently protected cells 
against mitochondrial depolarization whereas SD-IκBα did not have any effect on 
ANT1 induced loss of the mitochondrial membrane potential (Fig.F.4). Equally, these 
Imperial College London 2013 
 
Christoph DATLER – PhD Thesis  |355 
 
 
constructs prevented apoptosis induction as assessed by DNA fragmentation (data 
not shown). Therefore IкBα acts as an apoptosis inhibitor at the outer mitochondrial 
membrane by inhibiting mitochondrial depolarization. This finding is in stark 
contrast to the description of the pro-apoptotic function of IкBα: Overexpression of 
IкBα has been described to sensitize cells to TNFα induced apoptosis(Bradham, Qian 
et al. 1998; Muenchen, Lin et al. 2000). These studies used the IкBα super-
repressor (S34A, S36A mutant) which cannot be phosphorylated and targeted for 
degradation thus preventing NF-κB activation(Van Antwerp, Martin et al. 1996); this 
mutant has also been used by Dr. Evangelos Pazarentzos and was also shown to 
inhibit ANT1 induced apoptosis (data not shown). Generally IкBα had been assigned 
a pro-apoptotic function since it inhibits the anti-apoptotic NF-κB transcription 
factor(Wang, Mayo et al. 1996). However, our data is a strong indicator that 
mitochondrial IкBα acts as an apoptosis inhibitor. This reflects the apparently 
different roles of IкBα in the cytosol and mitochondria – accordingly, purely 
cytoplasmic IкBα (fusion with βActin to achieve cytosolic localisation – Fig.F.3) did 
not have any anti-apoptotic properties (Fig.F.4). Therefore, the new function of IкBα 
at mitochondria is fundamentally different from IкBα at other cellular locales. 
Interestingly, the anti-apoptotic properties of IкBα are specific for its localisation in 
a mitochondrial subcompartment, the outer mitochondrial membrane, as SD-IκBα 
did not inhibit apoptosis (Fig.F.4). Therefore, the anti-apoptotic activity of 
mitochondrial IκBα seems to be independent from the previously discovered 
interaction with ANT1(Bottero, Rossi et al. 2001; Cogswell, Kashatus et al. 2003), 
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which localizes to the inner mitochondrial membrane(Adrian, McCammon et al. 
1986) and is absent in the outer mitochondrial membrane. 
 
G.3.3 Mitochondrial IкBα Forms Part of the “PT-pore Complex” and 
Depends on VDAC1 for Apoptosis Inhibition 
Mitochondrial Depolarization can be mediated by the opening of the PT-pore, which 
spans the inner and outer mitochondrial membranes (chapter A.4). As IкBα 
inhibited mitochondrial depolarization when targeted to the outer mitochondrial 
membrane, we speculated that IкBα could be part of the PT-pore and regulate its 
function during apoptosis induction. This hypothesis was further corroborated by 
endogenous immunoprecipitations of IкBα in mitochondrial extracts, which co-
immunoprecipitated proteins previously implicated in PT-pore formation/function – 
namely ANT1, as described earlier (Bottero, Rossi et al. 2001; Cogswell, Kashatus 
et al. 2003), VDAC1, hexokinase II and CKMT1 (Fig.F.5). 
As our experiments revealed that IкBα exerts its anti-apoptotic activity at the outer 
mitochondrial membrane (Fig.F.4), the interaction with VDAC1 was of particular 
interest. Indeed, the ability of IкBα to inhibit apoptosis was dependent on the 
presence of VDAC1 since in VDAC1 knock-down cells, mitochondrial IкBα had no 
protective effect on the mitochondrial depolarization seen upon ANT1 
overexpression (Fig.F.6). One previous study had addressed the involvement of 
VDAC isoforms on apoptosis regulation, but observed no effect on cell death when 
VDAC1 and VDAC3 were genetically removed and VDAC2 was reduced by knock-
down with RNAi(Baines, Kaiser et al. 2007). In this scenario – theoretically – the 
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remaining VDAC2 could first compensate for the lack in the other VDAC1 and VDAC3 
isoforms, which are not required for cell viability(Anflous, Armstrong et al. 2001; 
Sampson, Decker et al. 2001). Additionally one could assume that VDAC2 knock-
down was not complete since VDAC2-null-mice are not viable(Cheng, Sheiko et al. 
2003), albeit transient knock-down of VDAC2 by RNAi has also been described to 
inhibit apoptosis(Li, Wang et al. 2012). Again, the knock-down might not have been 
complete or, alternatively, VDAC2 is indeed also dispensable for viability and only 
required during embryologic development. In our studies, knock-down of the VDAC1 
isoform was sufficient to abrogate the anti-apoptotic activity of mitochondrial IκΒα, 
as VDAC2 and VDAC3 were not targeted by RNAi; thus ruling out that other VDAC 
isoforms can compensate for the lack of VDAC1 in our study. Nevertheless, our 
results point to another interesting aspect: Loss of VDAC isoforms in the 
experiments performed by Baines et al. might have had a dual effect: 
Downregulation of VDAC might make the cells more resistant to cell death, but at 
the same time these cells lose the anti-apoptotic activity of mitochondrial IκΒα as 
this depends on VDAC1 expression. Therefore – on balance – there might not be 
any net effect on cell death observable in their study. 
VDAC1 expression is required for apoptosis regulation by mitochondrial IκΒα and 
mitochondria IκΒα might well be part of mitochondrial protein complexes forming 
the PT-pore. However, IκΒα does not universally regulate all stimuli that induce 
mitochondrial permeability transition, since the loss of the mitochondrial membrane 
potential through depletion of endogenous CKMT1 cannot be inhibited by its 
overexpression (Fig.D.10B). This observation supports the notion that the PT-pore 
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forming complexes could be flexible in their molecular make-up depending on the 
cellular requirements, actual stimuli and cell type used to examine their function. 
This idea is discussed in more detail in section G.1.6. 
 
G.3.4 Identification of the IκΒα Domain Responsible for Apoptosis 
Inhibition via VDAC1 Interaction 
Despite the well-known pro-apoptotic activity of IκΒα as an inhibitor of anti-
apoptotic NF-κB signalling(Wang, Mayo et al. 1996), our experiments revealed a 
novel anti-apoptotic activity of IκΒα at the outer mitochondrial membrane, which 
depends on VDAC1. Therefore, we investigated whether these distinct functions are 
corresponding to different domains of the IκΒα protein. As deletion mutants might 
lose the intrinsic ability of IκΒα to localize at the outer mitochondrial membrane, 
these experiments were conducted using IκΒα deletion mutants containing the N-
terminal MEET targeting sequence. Using 2 internal deletion mutants as well as an 
N-terminal and C-terminal deletion mutant (Fig.F.7), we mapped the anti-apoptotic 
activity to the N-terminus (aa 1-70) of IκΒα (Fig.F.9). The N-terminus is a 
regulatory domain for degradation of IκBα (Traenckner, Pahl et al. 1995) in the 
canonical NF-κB signalling but it does not mediate interactions with p65/p50 
heterodimers (Van Antwerp and Verma 1996; Baeuerle 1998). On the other hand, 
the C-terminus and the ankyrin repeats, which were dispensable for apoptosis 
inhibition in our experiments, are responsible for inhibition of NF-κB 
signalling(Haskill, Beg et al. 1991; Ernst, Dunn et al. 1995) – compare chapter 
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A.6.1.1. Therefore, the dual activities of IκΒα are not only functionally diverging but 
also structurally distinct. 
In addition to our previous finding, that apoptosis inhibition of IκΒα depends on the 
presence of VDAC1, we demonstrate that it is the protein-protein interaction with 
VDAC1 that is required to mediate its anti-apoptotic effect: The N-terminal IκΒα 
deletion mutant not only loses its anti-apoptotic properties but also loses the ability 
to interact with VDAC1 (Fig.F.10). 
In conclusion, our studies reveal a fundamentally new function of the NF-κB target 
gene IκΒα, which is distinct from its well-established inhibitory effect on NF-κB and 
the pro-apoptotic consequences thereof. It potently represses the intrinsic apoptosis 
pathway when targeted to the outer mitochondrial membrane where its N-terminus 
interacts with and its anti-apoptotic property depends on VDAC1. Therefore, IκΒα 
contributes to the intricate balance of both, cell survival and cell death signalling via 
its contribution to a mitochondrial multi-protein complex and NF-κB signalling, 
respectively. 
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H. CONCLUSIONS 
 
H.1 Apoptosis Regulation by CKMT1 
Our study provides evidence that the expression of mitochondrial creatine kinase 
CKMT1 is a key determinant of cellular fate. It functions as a crucial molecular 
regulator of mitochondrial permeability transition through a yet unidentified 
permeability transition complex that is distinct from the “classical” PT-pore. 
Although increased CKMT1 expression levels do not spur cellular proliferation or cell 
cycle progression (as initially expected), CKMT1 overexpression confers resistance 
against inducers of mitochondrial permeability transition and protects against 
mitochondrial depolarization and subsequent apoptosis induction. We demonstrate 
that this inhibiting effect on apoptosis is not due to the enzymatic kinase activity of 
CKMT1. Conversely, RNAi-mediated downregulation of CKMT1 results in highly 
significant induction of caspase-dependent apoptotic cell death, the extent of which 
is kinetically correlated with the extent of CKMT1 downregulation on the protein 
level. We provide evidence that CKMT1 is a functionally necessary gatekeeper of 
mitochondrial permeability transition and apoptosis execution, as depletion of 
CKMT1 induces mitochondrial depolarization and apoptotic cell death. This effect is 
universally observable in murine and human transformed/tumourigenic cell lines as 
well as in human primary cells. Additionally, the overexpression of the ankyrin 
repeat and suppressor of cytokine signalling (SOCS) box protein 9 ASB9, leads to 
the ubiquitination of mitochondrial CKMT1 octamers and degradation of CKMT1, 
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which is concomitant with mitochondrial depolarization and apoptotic cell death 
induction. 
Physiologically, CKMT1 protein degradation is not the initiation point of 
mitochondrial apoptosis. However, CKMT1 is downregulated in later stages of 
apoptosis induction suggesting that CKMT1 downregulation could act as a positive 
feedback loop to reinforce the commitment of cells to apoptosis execution.  
The locale of CKMT1 remains mitochondrial during apoptosis, even after the release 
of apoptogenic factors and the loss of mitochondrial outer membrane integrity. 
Mitochondrial permeability transition upon CKMT1 depletion does not depend on 
components of the “classical” PT-pore as the expression level/status or 
pharmacological inhibition of cyclophilin D and VDAC1 do not have any effect on 
mitochondrial depolarization observed upon CKMT1 downregulation. Thus, we 
conclude that VDAC1 and cyclophilin D are dispensable for CKMT1 depletion induced 
apoptosis. Furthermore, CKMT1 and VDAC1 interact equally under physiological as 
well as apoptotic conditions, ruling out that changes in the CKMT1/VDAC1 
interaction regulate mitochondrial disintegration. Additionally, the interaction of 
components of the “classical” PT-pore as assessed by the interactome of ANT1 does 
not change upon CKMT1 knock-down. Therefore, we conclude that the “classical” 
PT-pore is not involved in mitochondrial permeability transition induced by CKMT1 
depletion. 
MPT through CKMT1 depletion and subsequent apoptosis induction can efficiently be 
inhibited by bongkrekic acid – a pharmacological agent inhibiting mitochondrial 
membrane ion channels. Therefore, we conclude that mitochondrial channel proteins 
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other than VDAC1 and ANT1 are at the core of CKMT1-mediated apoptosis 
regulation. 
Our studies show that CKMT1 is present predominantly as an octamer in healthy 
cells. However, the dissociation of the octamer is dispensable for mitochondrial 
permeability transition to proceed in our experimental setup. Interestingly, a novel, 
as of yet undefined, larger CKMT1 complex (CKMT1*complex) was detected in 
native cell lysates and disappears upon treatment with cytotoxic drugs in a dose 
dependent manner, and its disappearance is correlated to mitochondrial 
depolarization. 
Mitochondrial permeability transition upon CKMT1 depletion cannot be abrogated by 
the supplementation with phosphocreatine, the end product of the enzymatic 
reaction catalysed by CKMT1. Therefore we conclude that depletion of CKMT1 is 
lethal by inducing mitochondrial depolarization, which is independent of the lack of 
mitochondrial creatine kinase enzyme activity and, as a consequence, the lack of 
phosphocreatine as the enzymatic product, but rather due to the intrinsic MPT 
inhibiting function of CKMT1. 
 
Our studies highlight that CKMT1 expression is crucial for the cellular fate and thus 
could be a promising therapeutic target since its altered expression is implicated in 
diverse pathological processes including apoptosis resistance in cancer or increased 
apoptosis in neurodegeneration. 
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H.2 Insights Into the Scientific Challenges of CKMT1 RNAi Validation 
Experiments and CKMT1 Gene Products 
RNA interference is an essential method in molecular biology to reduce the 
expression of target genes and thereby determine their function. Since this tool is 
known to also have unspecific effects, control experiments are needed, chiefly 
among them the reconstitution of the genes’ expression and the rescue of their 
cellular effects.  
Our studies show that the knock-down of CKMT1 RNAi causes the dissipation of the 
mitochondrial membrane potential. This was accomplished with 11 different RNAi 
constructs making unspecific off-target effects unlikely. However, all attempts failed 
to rescue the cells from the CKMT1 RNAi phenotype by the expression of CKMT1 
alleles not targeted by RNAi: Transient as well as stable expression of the murine 
CKMT1 homologue. Furthermore, stable ectopic expression of human CKMT1 alleles 
modified in their codon usage and thus resistant to specific RNAi constructs, could 
not rescue from cell death after depletion of endogenous CKMT1. 
The analysis of CKMT1 mRNA transcripts revealed that human CKMT1 is transcribed 
from two genetic loci (functional gene duplications) distinguished by synonymous 
mutations in their coding sequences. Additionally, we provide evidence that a novel 
alternatively spliced variant of CKMT1 is expressed in human cells, which has not 
been characterized previously. The biological function of this isoform and the 
existence of additional CKMT1 splice variants needs to be addressed in more detail 
by future experiments. 
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This novel CKMT1 isoform (made RNAi-resistant by codon usage modifications) also 
failed to rescue the cells from the CKMT1 RNAi phenotype. Finally, even the 
introduction of two distinct RNAi resistant genomic clones for CKMT1 did not prevent 
mitochondrial depolarization upon the knock-down of endogenous CKMT1. 
We give an account of all potential specific and unspecific RNAi effects (on-target 
and off-target effects) including RNAi induced post-transcriptional gene silencing, 
translational gene silencing, transcriptional gene silencing and other RNAi side 
effects (e.g. interferon response) observed in the context of CKMT1 RNAi. Our data 
also highlight the pitfalls of RNAi phenotype rescue experiments including 
discrepancies in protein expression level or the introduction of synonymous (but not 
silent) mutations. 
In conclusion, our results indicate that while off-target effects of RNAi can be 
addressed – as demonstrated by the experiments indicating the specificity of the 
CKMT1 RNAi phenotype – the rescue of the induced phenotype is not necessarily 
achievable. 
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H.3 Apoptosis Inhibition by IκΒα at the Outer Mitochondrial 
Membrane 
Our studies reveal a fundamentally new function of the NF-κB target gene IκΒα at 
the outer mitochondrial membrane, which is distinct from its well-established 
inhibitory effect on NF-κB signalling and the pro-apoptotic consequences thereof. 
The MEET-IкBα and SD-IκBα fusion constructs can be used to target IκBα 
specifically to mitochondrial sub-compartments, while the Mcr1-IкBα fusion 
construct is mostly expressed associated with the ER. Targeted to the outer 
mitochondrial membrane, IкBα (MEET-IкBα) potently represses the intrinsic 
apoptosis pathway by inhibiting mitochondrial membrane depolarization. This effect 
could not be observed when targeting IкBα to the mitochondrial inner membrane 
space (by SD-IκBα). 
Endogenous IкBα in mitochondrial extracts interacts with proteins previously 
implicated in “classical” PT-pore formation/function – namely ANT1, VDAC1, 
hexokinase II and CKMT1. Interestingly, the ability of IкBα to inhibit apoptosis when 
targeted to the outer mitochondrial membrane is dependent on the presence of 
VDAC1 as IкBα loses its ability to protect cells from mitochondrial depolarization in 
VDAC1 knock-down cells. The anti-apoptotic activity of mitochondrial IкBα maps to 
its N-terminus (aa 1-70), which is not responsible for the inhibition of NF-κB 
signalling, but is required for its interaction with VDAC1. 
In conclusion, we provide evidence for a novel function of the NF-κB target gene 
IκΒα: It potently represses the intrinsic apoptosis pathway when targeted to the 
outer mitochondrial membrane where its N-terminus interacts with and its anti-
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apoptotic property depends on VDAC1. Therefore, IκΒα contributes to the intricate 
balance of both, cell survival and cell death signalling via its dual contribution to NF-
κB signalling and the “classical” PT-pore, respectively. Considering that NF-κB 
dysregulation is a major culprit in disease formation, it is likely that the anti-
apoptotic activity of IκΒα at the outer mitochondrial membrane contributes to 
pathological mechanisms (e.g. the resistance of cancer cells to anti-neoplastic 
treatments), and further experiments examining the biological implications and the 
therapeutic applicability of our findings are promising avenues of research. 
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I. APPENDIX 
I.1 Sequencing of the Human Genomic CKMT1 Locus From HeLa Cells 
The human genomic CKMT1 locus from HeLa cells (as amplified and subcloned as 
described in Fig.E.15) was sequenced by GenScript (USA). The sequencing file 
shows the alignment of the human CKMT1B gene as published on the NCBI server 
aligned with the sequencing of genomic CKMT1 from HeLa cells. Variations are 
indicated in red. Using a blast search, the amplified locus shows 6288 identities with 
“Homo sapiens chromosome 15 genomic scaffold, alternate assembly CHM1_1.0 
Sequence ID: ref|NW_004078084.1|” over a total of 6322 base pairs with no gaps 
in alignment. 
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